

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number  
WO 02/064611 A1

(51) International Patent Classification<sup>7</sup>: C07H 21/02,  
21/04

San Francisco, CA 94081 (US). SUN, Yongming [US/US];  
869 S. Winchester Boulevard, Apartment 260, San Jose,  
CA 95128 (US). LIU, Chenghua [CN/US]; 1125 Ranchero  
Way #14, San Jose, CA 95117 (US).

(21) International Application Number: PCT/US02/04197

(22) International Filing Date: 12 February 2002 (12.02.2002)

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrrell  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/268,292 13 February 2001 (13.02.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 60/268,292 (CIP)  
Filed on 13 February 2001 (13.02.2001)

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SALCEDA, Susana  
[AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136  
(US). MACINA, Roberto, A. [AR/US]; 4118 Crescendo  
Avenue, San Jose, CA 95136 (US). HU, Ping [US/US]; 108  
Palmer Street, San Ramon, CA 94583 (US). RECIPON,  
Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA  
94115 (US). KARRA, Kalpana [IN/US]; 6511 Rainbow  
Drive, San Jose, CA 95129 (US). CAFFERKEY, Robert  
[IE/US]; 849 West Orange Avenue, Apartment 1030, South

Published:

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic breast cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast tissue, identifying breast tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered breast tissue for treatment and research.

1000-1000



-1-

## COMPOSITIONS AND METHODS RELATING TO BREAST SPECIFIC GENES AND PROTEINS

This application claims the benefit of priority from U.S. Provisional Application  
5 Serial No. 60/268,292 filed February 13, 2001, which is herein incorporated by reference  
in its entirety.

### FIELD OF THE INVENTION

The present invention relates to newly identified nucleic acid molecules and  
polypeptides present in normal and neoplastic breast cells, including fragments, variants  
10 and derivatives of the nucleic acids and polypeptides. The present invention also relates  
to antibodies to the polypeptides of the invention, as well as agonists and antagonists of  
the polypeptides of the invention. The invention also relates to compositions comprising  
the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists  
of the invention and methods for the use of these compositions. These uses include  
15 identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-  
cancerous disease states in breast tissue, identifying breast tissue and monitoring and  
identifying and/or designing agonists and antagonists of polypeptides of the invention.  
The uses also include gene therapy, production of transgenic animals and cells, and  
production of engineered breast tissue for treatment and research.

### 20 BACKGROUND OF THE INVENTION

Excluding skin cancer, breast cancer, also called mammary tumor, is the most  
common cancer among women, accounting for a third of the cancers diagnosed in the  
United States. One in nine women will develop breast cancer in her lifetime and about  
192,000 new cases of breast cancer are diagnosed annually with about 42,000 deaths.  
25 Bevers, *Primary Prevention of Breast Cancer*, in *BREAST CANCER*, 20-54 (Kelly K Hunt  
et al., ed., 2001); Kochanek et al., 49 Nat'l. Vital Statistics Reports 1, 14 (2001).

In the treatment of breast cancer, there is considerable emphasis on detection and  
risk assessment because early and accurate staging of breast cancer has a significant  
impact on survival. For example, breast cancer detected at an early stage (stage T0,  
30 discussed below) has a five-year survival rate of 92%. Conversely, if the cancer is not  
detected until a late stage (i.e., stage T4), the five-year survival rate is reduced to 13%.  
AJCC Cancer Staging Handbook pp. 164-65 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998).  
Some detection techniques, such as mammography and biopsy, involve increased

-2-

discomfort, expense, and/or radiation, and are only prescribed only to patients with an increased risk of breast cancer.

Current methods for predicting or detecting breast cancer risk are not optimal. One method for predicting the relative risk of breast cancer is by examining a patient's risk factors and pursuing aggressive diagnostic and treatment regimens for high risk patients. A patient's risk of breast cancer has been positively associated with increasing age, nulliparity, family history of breast cancer, personal history of breast cancer, early menarche, late menopause, late age of first full term pregnancy, prior proliferative breast disease, irradiation of the breast at an early age and a personal history of malignancy. Lifestyle factors such as fat consumption, alcohol consumption, education, and socioeconomic status have also been associated with an increased incidence of breast cancer although a direct cause and effect relationship has not been established. While these risk factors are statistically significant, their weak association with breast cancer limited their usefulness. Most women who develop breast cancer have none of the risk factors listed above, other than the risk that comes with growing older. NIH Publication No. 00-1556 (2000).

Current screening methods for detecting cancer, such as breast self exam, ultrasound, and mammography have drawbacks that reduce their effectiveness or prevent their widespread adoption. Breast self exams, while useful, are unreliable for the detection of breast cancer in the initial stages where the tumor is small and difficult to detect by palpitation. Ultrasound measurements require skilled operators at an increased expense. Mammography, while sensitive, is subject to over diagnosis in the detection of lesions that have questionable malignant potential. There is also the fear of the radiation used in mammography because prior chest radiation is a factor associated with an increase incidence of breast cancer.

At this time, there are no adequate methods of breast cancer prevention. The current methods of breast cancer prevention involve prophylactic mastectomy (mastectomy performed before cancer diagnosis) and chemoprevention (chemotherapy before cancer diagnosis) which are drastic measures that limit their adoption even among women with increased risk of breast cancer. Bevers, *supra*.

A number of genetic markers have been associated with breast cancer. Examples of these markers include carcinoembryonic antigen (CEA) (Mughal et al., 249 JAMA 1881 (1983)) MUC-1 (Frische and Liu, 22 J. Clin. Ligand 320 (2000)), HER-2/neu (Haris et al., 15 Proc.Am.Soc.Clin.Oncology. A96 (1996)), uPA, PAI-1, LPA, LPC,

RAK and BRCA (Esteva and Fritsche, *Serum and Tissue Markers for Breast Cancer*, in BREAST CANCER, 286-308 (2001)). These markers have problems with limited sensitivity, low correlation, and false negatives which limit their use for initial diagnosis. For example, while the BRCA1 gene mutation is useful as an indicator of an increased  
5 risk for breast cancer, it has limited use in cancer diagnosis because only 6.2 % of breast cancers are BRCA1 positive. Malone et al., 279 JAMA 922 (1998). *See also*, Mewman et al., 279 JAMA 915 (1998) (correlation of only 3.3%).

Breast cancers are diagnosed into the appropriate stage categories recognizing that different treatments are more effective for different stages of cancer. Stage TX  
10 indicates that primary tumor cannot be assessed (i.e., tumor was removed or breast tissue was removed). Stage T0 is characterized by abnormalities such as hyperplasia but with no evidence of primary tumor. Stage Tis is characterized by carcinoma in situ, intraductal carcinoma, lobular carcinoma in situ, or Paget's disease of the nipple with no tumor. Stage T1 is characterized as having a tumor of 2 cm or less in the greatest  
15 dimension. Within stage T1, Tmic indicates microinvasion of 0.1 cm or less, T1a indicates a tumor of between 0.1 to 0.5 cm, T1b indicates a tumor of between 0.5 to 1 cm, and T1c indicates tumors of between 1 cm to 2 cm. Stage T2 is characterized by tumors from 2 cm to 5 cm in the greatest dimension. Tumors greater than 5 cm in size are classified as stage T4. Within stage T4, T4a indicates extension of the tumor to the  
20 chest wall, T4b indicates edema or ulceration of the skin of the breast or satellite skin nodules confined to the same breast, T4c indicates a combination of T4a and T4b, and T4d indicates inflammatory carcinoma. AJCC Cancer Staging Handbook pp. 159-70 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998). In addition to standard staging, breast tumors may be classified according to their estrogen receptor and progesterone receptor protein  
25 status. Fisher et al., 7 Breast Cancer Research and Treatment 147 (1986). Additional pathological status, such as HER2/neu status may also be useful. Thor et al., 90 J.Nat'l.Cancer Inst. 1346 (1998); Paik et al., 90 J.Nat'l.Cancer Inst. 1361 (1998); Hutchins et al., 17 Proc.Am.Soc.Clin.Oncology A2 (1998).; and Simpson et al., 18 J.Clin.Oncology 2059 (2000).

30 In addition to the staging of the primary tumor, breast cancer metastases to regional lymph nodes may be staged. Stage NX indicates that the lymph nodes cannot be assessed (e.g., previously removed). Stage N0 indicates no regional lymph node metastasis. Stage N1 indicates metastasis to movable ipsilateral axillary lymph nodes. Stage N2 indicates metastasis to ipsilateral axillary lymph nodes fixed to one another or

-4-

to other structures. Stage N3 indicates metastasis to ipsilateral internal mammary lymph nodes. Id.

Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Simpson et al., 18 J. Clin. Oncology 2059 (2000). Generally, 5 pathological staging of breast cancer is preferable to clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred if it were as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of breast cancer would be improved by detecting new markers in cells, tissues, or bodily fluids which could differentiate 10 between different stages of invasion. Progress in this field will allow more rapid and reliable method for treating breast cancer patients.

Treatment of breast cancer is generally decided after an accurate staging of the primary tumor. Primary treatment options include breast conserving therapy (lumpectomy, breast irradiation, and surgical staging of the axilla), and modified radical 15 mastectomy. Additional treatments include chemotherapy, regional irradiation, and, in extreme cases, terminating estrogen production by ovarian ablation.

Until recently, the customary treatment for all breast cancer was mastectomy. Fonseca et al., 127 Annals of Internal Medicine 1013 (1997). However, recent data indicate that less radical procedures may be equally effective, in terms of survival, for 20 early stage breast cancer. Fisher et al., 16 J. of Clinical Oncology 441 (1998). The treatment options for a patient with early stage breast cancer (i.e., stage Tis) may be breast-sparing surgery followed by localized radiation therapy at the breast. Alternatively, mastectomy optionally coupled with radiation or breast reconstruction may be employed. These treatment methods are equally effective in the early stages of breast 25 cancer.

Patients with stage I and stage II breast cancer require surgery with chemotherapy and/or hormonal therapy. Surgery is of limited use in Stage III and stage IV patients. Thus, these patients are better candidates for chemotherapy and radiation therapy with surgery limited to biopsy to permit initial staging or subsequent restaging because cancer 30 is rarely curative at this stage of the disease. AJCC Cancer Staging Handbook 84, ¶. 164-65 (Irvin D. Fleming et al. eds., 5<sup>th</sup> ed. 1998).

In an effort to provide more treatment options to patients, efforts are underway to define an earlier stage of breast cancer with low recurrence which could be treated with lumpectomy without postoperative radiation treatment. While a number of attempts have

-5-

been made to classify early stage breast cancer, no consensus recommendation on postoperative radiation treatment has been obtained from these studies. Page et al., 75 Cancer 1219 (1995); Fisher et al., 75 Cancer 1223 (1995); Silverstein et al., 77 Cancer 2267 (1996).

5 As discussed above, each of the methods for diagnosing and staging breast cancer is limited by the technology employed. Accordingly, there is need for sensitive molecular and cellular markers for the detection of breast cancer. There is a need for molecular markers for the accurate staging, including clinical and pathological staging, of breast cancers to optimize treatment methods. Finally, there is a need for sensitive  
10 molecular and cellular markers to monitor the progress of cancer treatments, including markers that can detect recurrence of breast cancers following remission.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while  
15 indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

## 20 SUMMARY OF THE INVENTION

The present invention solves these and other needs in the art by providing nucleic acid molecules and polypeptides as well as antibodies, agonists and antagonists, thereto that may be used to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast; identify and monitor breast tissue; and identify  
25 and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered breast tissue for treatment and research.

Accordingly, one object of the invention is to provide nucleic acid molecules that are specific to breast cells and/or breast tissue. These breast specific nucleic acids  
30 (BSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the BSNA is genomic DNA, then the BSNA is a breast specific gene (BSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast. In a more preferred embodiment, the nucleic acid molecule encodes a

-6-

polypeptide that comprises an amino acid sequence of SEQ ID NO: 172 through 295. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 171. By nucleic acid molecule, it is also meant to be inclusive of sequences that selectively hybridize or exhibit substantial sequence

5 similarity to a nucleic acid molecule encoding a BSP, or that selectively hybridize or exhibit substantial sequence similarity to a BSNA, as well as allelic variants of a nucleic acid molecule encoding a BSP, and allelic variants of a BSNA. Nucleic acid molecules comprising a part of a nucleic acid sequence that encodes a BSP or that comprises a part of a nucleic acid sequence of a BSNA are also provided.

10 A related object of the present invention is to provide a nucleic acid molecule comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of a BSNA. In a preferred embodiment, the nucleic acid molecule comprises one or more expression control sequences controlling the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment  
15 of a BSP.

Another object of the invention is to provide vectors and/or host cells comprising a nucleic acid molecule of the instant invention. In a preferred embodiment, the nucleic acid molecule encodes all or a fragment of a BSP. In another preferred embodiment, the nucleic acid molecule comprises all or a part of a BSNA.

20 Another object of the invention is to provided methods for using the vectors and host cells comprising a nucleic acid molecule of the instant invention to recombinantly produce polypeptides of the invention.

Another object of the invention is to provide a polypeptide encoded by a nucleic acid molecule of the invention. In a preferred embodiment, the polypeptide is a BSP.

25 The polypeptide may comprise either a fragment or a full-length protein as well as a mutant protein (mutein), fusion protein, homologous protein or a polypeptide encoded by an allelic variant of a BSP.

Another object of the invention is to provide an antibody that specifically binds to a polypeptide of the instant invention..

30 Another object of the invention is to provide agonists and antagonists of the nucleic acid molecules and polypeptides of the instant invention.

Another object of the invention is to provide methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. In a

-7-

preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying, diagnosing, monitoring, staging, imaging and treating breast cancer and non-cancerous disease states in breast. In another preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying and/or monitoring breast tissue. The nucleic acid molecules of the instant invention may also be used in gene therapy, for producing transgenic animals and cells, and for producing engineered breast tissue for treatment and research.

The polypeptides and/or antibodies of the instant invention may also be used to identify, diagnose, monitor, stage, image and treat breast cancer and non-cancerous disease states in breast. The invention provides methods of using the polypeptides of the invention to identify and/or monitor breast tissue, and to produce engineered breast tissue.

The agonists and antagonists of the instant invention may be used to treat breast cancer and non-cancerous disease states in breast and to produce engineered breast tissue.

Yet another object of the invention is to provide a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences.

#### DETAILED DESCRIPTION OF THE INVENTION

##### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g.,* Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor

-8-

Press (2001); Ausubel *et al.*, Current Protocols in Molecular Biology, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel *et al.*, Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4<sup>th</sup> Ed., Wiley & Sons (1999); Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1999); each of which is incorporated herein by reference in its entirety.

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.

The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages



-9-

(*e.g.*, alpha anomeric nucleic acids, etc.) The term “nucleic acid molecule” also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated  
5 sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.

A “gene” is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround  
10 the nucleic acid sequence that encodes the polypeptide. For instance, a gene may comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term “exon” refers to a  
15 nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute a contiguous sequence to a mature mRNA transcript. The term “intron” refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be “spliced out” during processing of the transcript.

20 A nucleic acid molecule or polypeptide is “derived” from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.

An “isolated” or “substantially pure” nucleic acid or polynucleotide (*e.g.*, an  
25 RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a  
30 portion of a polynucleotide in which the “isolated polynucleotide” is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term “isolated” or “substantially pure” also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized

-10-

polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant

5 vectors present as episomes or as integrated into a host cell chromosome.

A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to  
10 occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression  
15 or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule,  
20 or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally  
25 comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others. Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35,  
30 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, e.g. for use as probes or primers, or may be double-stranded, e.g. for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

-11-

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of other methods, including *in vitro* recombinant DNA-mediated techniques and by  
5 expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as  
10 those that employ a kinase and ATP. The 3' end of a chemically synthesized oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other  
15 polynucleotide(s) prior to ligation.

The term "naturally-occurring nucleotide" referred to herein includes naturally-occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotide linkages  
20 such as phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate, phosphoroamidate, and the like. See e.g., LaPlanche *et al. Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al. Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al. Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical  
25 Approach, pp. 87-108, Oxford University Press (1991); United States Patent No. 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In  
30 addition, the left hand direction of a polynucleotide sequence in sense orientation is referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the

-12-

polynucleotide composition: for example, if the isolated nucleic acid is composed of RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally-occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence.

- 5 In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

- The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using
- 15 FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, *e.g.*, the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000);
- 20 Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998); herein incorporated by reference). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or
- 25 using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

- A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its
- 30 complementary sequence. The complementary strand is also useful, *e.g.*, for antisense therapy, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology"

-13-

interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned  
5 with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity,  
10 such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists when a nucleic acid or fragment thereof hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under selective hybridization conditions. Typically, selective hybridization will occur when there is at least about 55% sequence identity,  
15 preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% sequence identity, over a stretch of at least about 14 nucleotides, more preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt  
20 concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different  
25 physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, "stringent hybridization" is performed at about 25°C below the thermal melting point ( $T_m$ ) for the specific DNA  
30 hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular set of conditions. The  $T_m$  is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51, hereby incorporated by reference.

-14-

The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G + C}) - 0.63 (\% \text{ formamide}) - (600/l)$$

where  $l$  is the length of the hybrid in base pairs.

The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G + C}) + 11.8 (\text{fraction G + C})^2 - 0.35 (\% \text{ formamide}) - (820/l).$$

The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G + C}) + 11.8 (\text{fraction G + C})^2 - 0.50 (\% \text{ formamide}) - (820/l).$$

10 In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C  
15 would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

20 An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without  
25 formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a  
30 library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (e.g. 42°C and 6X SSC) and varying the formamide

-15-

concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well-known in the art. *See* Sambrook *et al.* (1989), *supra*, pages 8.46 and 9.46-9.58, herein incorporated by reference. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

- 5 Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see* Sambrook (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An  
10 exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

- As defined herein, nucleic acid molecules that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode  
15 polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid molecule is created synthetically or recombinantly using high codon degeneracy as permitted by the redundancy of the genetic code.

- Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (*e.g.*, for oligonucleotide probes) may be calculated by the formula:  
20  $T_m = 81.5^{\circ}\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/\text{N})$ ,  
wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See* Sambrook (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using  
25 mismatched probes, pools of degenerate probes or “guessmers,” as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-11.57.

- The term “digestion” or “digestion of DNA” refers to catalytic cleavage of the  
30 DNA with a restriction enzyme that acts only at certain sequences in the DNA. The various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the

-16-

purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.

The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, *e.g.*, Sambrook (1989), *supra*.

Genome-derived "single exon probes," are probes that comprise at least part of an exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies.

The term "microarray" or "nucleic acid microarray" refers to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Microarrays or nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical



Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). These microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are  
5 disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000).

The term "mutated" when applied to nucleic acid molecules means that nucleotides in the nucleic acid sequence of the nucleic acid molecule may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration  
10 may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment, the nucleic acid molecule comprises the wild type nucleic acid sequence encoding a BSP or is a BSNA. The nucleic acid molecule may be mutated by any method known in the art  
15 including those mutagenesis techniques described *infra*.

The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-  
20 33 (1992).

The term "oligonucleotide-directed mutagenesis" refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a  
25 PCR product from a mixture of small DNA fragments. A large number of different PCR reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

The term "sexual PCR mutagenesis" or "DNA shuffling" refers to a method of error-prone PCR coupled with forced homologous recombination between DNA  
30 molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g.*, Stemmer, *Proc. Natl. Acad. Sci. U.S.A.* 91: 10747-10751 (1994). DNA shuffling can be carried out between several related genes ("Family shuffling").

-18-

The term "*in vivo* mutagenesis" refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These "mutator" strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate random mutations within the DNA.

The term "cassette mutagenesis" refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide "cassette" that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.

The term "recursive ensemble mutagenesis" refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. See, e.g., Arkin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 89: 7811-7815 (1992).

The term "exponential ensemble mutagenesis" refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. See, e.g., Delegrave *et al.*, *Biotechnology Research* 11: 1548-1552 (1993); Arnold, *Current Opinion in Biotechnology* 4: 450-455 (1993). Each of the references mentioned above are hereby incorporated by reference in its entirety.

"Operatively linked" expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination, promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that

-19-

enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include the promoter, ribosomal binding site, and

- 5 transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

- The term "vector," as used herein, is intended to refer to a nucleic acid molecule
- 10 capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral
- 15 genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable
- 20 of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector.
- 25 However, the invention is intended to include other forms of expression vectors that serve equivalent functions.

- The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell
- 30 but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

-20-

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refer to that portion of a transcript-derived nucleic acid that can be translated in its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode  
5 the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the  
10 standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally-occurring proteins and polypeptides, polypeptide fragments and polypeptide mutants, derivatives and analogs. A polypeptide may be monomeric or polymeric. Further, a  
15 polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises a BSP encoded by a nucleic acid molecule of the instant invention, as well as a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide  
20 that by virtue of its origin or source of derivation (1) is not associated with naturally associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be  
25 "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single  
30 species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be indicated by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample,

-21-

followed by visualizing a single polypeptide band upon staining the gel with a stain well-known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

The term "polypeptide fragment" as used herein refers to a polypeptide of the  
5 instant invention that has an amino-terminal and/or carboxy-terminal deletion compared to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids  
10 long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40 or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" refers to polypeptides or fragments thereof that are substantially similar in primary structural sequence but which include, *e.g.*, *in vivo* or *in vitro* chemical  
15 and biochemical modifications that are not found in the native polypeptide. Such modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization,  
20 disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as  
25 arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as <sup>125</sup>I, <sup>32</sup>P, <sup>35</sup>S, and <sup>3</sup>H, ligands which bind to labeled  
30 antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer, stability requirements, and available instrumentation. Methods for labeling polypeptides

-22-

are well-known in the art. See Ausubel (1992), *supra*; Ausubel (1999), *supra*, herein incorporated by reference.

The term "fusion protein" refers to polypeptides of the instant invention comprising polypeptides or fragments coupled to heterologous amino acid sequences.

5 Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be  
10 produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

15 The term "analog" refers to both polypeptide analogs and non-peptide analogs. The term "polypeptide analog" as used herein refers to a polypeptide of the instant invention that is comprised of a segment of at least 25 amino acids that has substantial identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the  
20 same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

25 The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide of the instant invention. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce  
30 an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--,  
--CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>--, and --CH<sub>2</sub>SO--, by methods

-23-

well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (e.g., D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus  
5 sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992), incorporated herein by reference). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

A "polypeptide mutant" or "mutein" refers to a polypeptide of the instant  
10 invention whose sequence contains substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the  
15 sequence of the naturally-occurring protein, and/or truncations of the amino acid sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity,  
20 more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to the wild type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.

25 Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid  
30 substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not

-24-

substantially change the structural characteristics of the parent sequence (*e.g.*, a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H. Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991), each of which are incorporated herein by reference.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed., Sinauer Associates (1991), which is incorporated herein by reference. Stereoisomers (*e.g.*, D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as  $\alpha$ -,  $\alpha$ -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino acids may also be suitable components for polypeptides of the present invention. Examples of unconventional amino acids include: 4-hydroxyproline,  $\gamma$ -carboxyglutamate,  $\epsilon$ -N,N,N-trimethyllysine,  $\epsilon$ -N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other similar amino acids and imino acids (*e.g.*, 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

A protein has "homology" or is "homologous" to a protein from another organism if the encoded amino acid sequence of the protein has a similar sequence to the encoded amino acid sequence of a protein of a different organism and has a similar biological activity or function. Alternatively, a protein may have homology or be homologous to another protein if the two proteins have similar amino acid sequences and have similar biological activities or functions. Although two proteins are said to be "homologous," this does not imply that there is necessarily an evolutionary relationship between the proteins. Instead, the term "homologous" is defined to mean that the two proteins have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous protein is one that exhibits 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence similarity. Even more preferred are homologous proteins that exhibit 80%, 85% or 90%



-25-

sequence similarity to the wild type protein. In a yet more preferred embodiment, a homologous protein exhibits 95%, 97%, 98% or 99% sequence similarity.

When "sequence similarity" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. See, e.g., Pearson, *Methods Mol. Biol.* 24: 307-31 (1994), herein incorporated by reference.

For instance, the following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992), herein incorporated by reference. A "moderately conservative" replacement is any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from

-26-

different species of organisms or between a wild type protein and a mutein thereof. *See, e.g.,* GCG Version 6.1. Other programs include FASTA, discussed *supra*.

A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer

- 5 program BLAST, especially blastp or tblastn. *See, e.g.,* Altschul *et al.*, *J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997); herein incorporated by reference. Preferred parameters for blastp are:

- |    |                       |               |
|----|-----------------------|---------------|
|    | Expectation value:    | 10 (default)  |
|    | Filter:               | seg (default) |
| 10 | Cost to open a gap:   | 11 (default)  |
|    | Cost to extend a gap: | 1 (default)   |
|    | Max. alignments:      | 100 (default) |
|    | Word size:            | 11 (default)  |
|    | No. of descriptions:  | 100 (default) |
| 15 | Penalty Matrix:       | BLOSUM62      |

- The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number
- 20 of different organisms, it is preferable to compare amino acid sequences.

- Database searching using amino acid sequences can be measured by algorithms other than blastp are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.,* FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best
- 25 overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated by reference.

- 30 An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.,* a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv,

-27-

dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. An Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; an F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single arm of an antibody; and a dAb fragment consists of a VH domain. See, e.g., Ward *et al.*, *Nature* 341: 544-546 (1989).

10 By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

15 A single-chain antibody (scFv) is an antibody in which a VL and VH region are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. See, e.g., Bird *et al.*, *Science* 242: 423-426 (1988); Huston *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but  
20 using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. See e.g., Holliger *et al.*, *Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak *et al.*, *Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it  
25 an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one  
30 or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-

-28-

chain antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

10 A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

The term "epitope" includes any protein determinant capable of specifically binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than 1  $\mu$ M, preferably less than 100 nM and most preferably less than 10 nM.

The term "patient" as used herein includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

The term "breast specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the breast as compared to other tissues in the body. In a preferred embodiment, a "breast specific" nucleic acid molecule or polypeptide is expressed at a level that is 5-fold higher than any other tissue in the body. In a more preferred embodiment, the "breast specific" nucleic acid molecule or polypeptide is expressed at a level that is 10-fold higher than any other tissue in the body, more preferably at least 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide

levels may be measured by any method known to accurately quantitate protein levels, such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

5

*Nucleic Acid Molecules*

One aspect of the invention provides isolated nucleic acid molecules that are specific to the breast or to breast cells or tissue or that are derived from such nucleic acid molecules. These isolated breast specific nucleic acids (BSNAs) may comprise a cDNA,  
10 a genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to breast, a breast-specific polypeptide (BSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 172 through 295. In  
15 another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 171.

A BSNA may be derived from a human or from another animal. In a preferred embodiment, the BSNA is derived from a human or other mammal. In a more preferred embodiment, the BSNA is derived from a human or other primate. In an even more  
20 preferred embodiment, the BSNA is derived from a human.

By "nucleic acid molecule" for purposes of the present invention, it is also meant to be inclusive of nucleic acid sequences that selectively hybridize to a nucleic acid molecule encoding a BSNA or a complement thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may not encode a BSP. However, in a  
25 preferred embodiment, the hybridizing nucleic acid molecule encodes a BSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 172 through 295. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic  
30 acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 through 171.

In a preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under low stringency conditions. In a more preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under moderate stringency conditions. In a more preferred

-30-

embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding a BSP under high stringency conditions. In an even more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a yet more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1 through 171. In a preferred embodiment of the invention, the hybridizing nucleic acid molecule may be used to express recombinantly a polypeptide of the invention.

By "nucleic acid molecule" as used herein it is also meant to be inclusive of sequences that exhibits substantial sequence similarity to a nucleic acid encoding a BSP or a complement of the encoding nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding human BSP. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the similar nucleic acid molecule is one that has at least 60% sequence identity with a nucleic acid molecule encoding a BSP, such as a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding a BSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding a BSP.

In another preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a BSNA or its complement. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171. In a preferred embodiment, the nucleic acid molecule is one that has at least 60% sequence identity with a BSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1 through 171, more preferably at least 70%, even more preferably at least 80% and even more

preferably at least 85%. In a more preferred embodiment, the nucleic acid molecule is one that has at least 90% sequence identity with a BSNA, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid  
5 molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a BSNA.

A nucleic acid molecule that exhibits substantial sequence similarity may be one that exhibits sequence identity over its entire length to a BSNA or to a nucleic acid molecule encoding a BSP, or may be one that is similar over only a part of its length. In  
10 this case, the part is at least 50 nucleotides of the BSNA or the nucleic acid molecule encoding a BSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one  
15 that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 172 through 295 or demonstrates significant sequence identity to the nucleotide sequence of SEQ ID NO: 1 through 171. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid  
20 molecule from a human, when the BSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated species, e.g., dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, e.g., monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar  
25 nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In  
30 another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by directed mutation of a BSNA. Further, the substantially similar nucleic acid molecule may or may not be a BSNA. However, in a preferred embodiment, the substantially similar nucleic acid molecule is a BSNA.

-32-

By "nucleic acid molecule" it is also meant to be inclusive of allelic variants of a BSNA or a nucleic acid encoding a BSP. For instance, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes. In fact, more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001). Thus, the sequence determined from one individual of a species may differ from other allelic forms present within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein. Further, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the nucleic acid molecule comprising an allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes a BSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is a BSNA. In a more preferred embodiment, the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1 through 171. In a preferred embodiment, the allelic variant is a naturally-occurring allelic variant in the species of interest. In a more preferred embodiment, the species of interest is human.

By "nucleic acid molecule" it is also meant to be inclusive of a part of a nucleic acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is a BSP. However, in a preferred embodiment, the part encodes a BSP. In one aspect, the invention comprises a part of a BSNA. In a second aspect, the invention comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to a BSNA. In a third aspect, the invention comprises a part of a nucleic acid molecule that is an allelic variant of a BSNA. In a fourth aspect, the invention comprises a part of a nucleic acid molecule that encodes a BSP. A part comprises at least 10 nucleotides, more preferably at least 15, 17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.



-33-

By "nucleic acid molecule" it is also meant to be inclusive of sequence that encoding a fusion protein, a homologous protein, a polypeptide fragment, a mutein or a polypeptide analog, as described below.

Nucleotide sequences of the instantly-described nucleic acids were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (*e.g.*, reverse transcription and/or polymerase chain reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, CA, USA). Further, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined, unless otherwise specified.

In a preferred embodiment of the invention, the nucleic acid molecule contains modifications of the native nucleic acid molecule. These modifications include nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe, the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate. When the isolated nucleic acid is used as a therapeutic agent, the modifications will be limited to those that do not confer toxicity upon the isolated nucleic acid.

In a preferred embodiment, isolated nucleic acid molecules can include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. In a more preferred embodiment, the labeled nucleic acid molecule may be used as a hybridization probe.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $\alpha$ - $^{32}\text{P}$ -dATP,  $\alpha$ - $^{32}\text{P}$ -dCTP,  $\alpha$ - $^{32}\text{P}$ -dGTP,  $\alpha$ - $^{32}\text{P}$ -dTTP,  $\alpha$ - $^{32}\text{P}$ -3'-dATP,  $\alpha$ - $^{32}\text{P}$ -ATP,  $\alpha$ - $^{32}\text{P}$ -CTP,  $\alpha$ - $^{32}\text{P}$ -GTP,  $\alpha$ - $^{32}\text{P}$ -UTP,  $\alpha$ - $^{35}\text{S}$ -dATP,  $\alpha$ - $^{35}\text{S}$ -GTP,  $\alpha$ - $^{33}\text{P}$ -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA), fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade

Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY® TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP, tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY® FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA; biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA), digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp., Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA).

Nucleic acid molecules can be labeled by incorporation of labeled nucleotide analogues into the nucleic acid. Such analogues can be incorporated by enzymatic polymerization, such as by nick translation, random priming, polymerase chain reaction (PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules, and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for RNA molecules. Commercial kits are readily available for each such labeling approach. Analogues can also be incorporated during automated solid phase chemical synthesis. Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3' hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids. For example, fluorophores can be attached using a cisplatin reagent that reacts with the N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); see Alers *et al.*, *Genes, Chromosomes & Cancer* 25: 301- 305 (1999); Jelsma *et al.*, *J. NIH Res.* 5: 82 (1994);

-35-

Van Belkum *et al.*, *BioTechniques* 16: 148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally-coupled to the target nucleic acid using aryl azide chemistry; after reduction, a  
5 free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report  
10 specific hybridization through release of fluorescence quenching or to report exonucleotidic excision. See, e.g., Tyagi *et al.*, *Nature Biotechnol.* 14: 303-308 (1996); Tyagi *et al.*, *Nature Biotechnol.* 16: 49-53 (1998); Sokol *et al.*, *Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); Kostrikis *et al.*, *Science* 279: 1228-1229 (1998); Marras *et al.*, *Genet. Anal.* 14: 151-156 (1999); U. S. Patent 5,846,726; 5,925,517; 5,925,517;  
15 5,723,591 and 5,538,848; Holland *et al.*, *Proc. Natl. Acad. Sci. USA* 88: 7276-7280 (1991); Heid *et al.*, *Genome Res.* 6(10): 986-94 (1996); Kuimelis *et al.*, *Nucleic Acids Symp. Ser.* (37): 255-6 (1997); the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the invention may be modified by altering one or more  
20 native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside bonds. See Hartmann *et al.* (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science, Kluwer Law International (1999); Stein *et al.* (eds.), Applied Antisense Oligonucleotide Technology, Wiley-Liss (1998); Chadwick *et al.* (eds.), Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd  
25 (1997); the disclosures of which are incorporated herein by reference in their entireties. Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction. See Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000), the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation,  
30 phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having

-36-

normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U. S. Patents 3,687,808; 5 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by reference in their entireties. In a preferred embodiment, the modified internucleoside 10 linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include 15 those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; 20 and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S. Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 25 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced 30 with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S.

patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Automated PNA synthesis is readily achievable on commercial synthesizers (*see, e.g.*, "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The  $T_m$  of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the  $T_m$  of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the  $T_m$  by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the  $T_m$  by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases do not recognize the PNA polyamide backbone with nucleobase sidechains. *See, e.g.*, Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and modified PCR reactions, as further described in U.S. Patents 5,760,012 and 5,731,181, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acids of the present invention can include any topological conformation appropriate to the desired use; the term thus explicitly

-38-

comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001);

5 Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201

10 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

*Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as

15 hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably, detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

20 In one embodiment, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the gene of a BSNA, such as deletions, insertions, translocations, and duplications of the BSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. See, e.g., Andreeff *et al.* (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and

25 Clinical Applications, John Wiley & Sons (1999), the disclosure of which is incorporated herein by reference in its entirety. The isolated nucleic acids of the present invention can be used as probes to assess smaller genomic alterations using, e.g., Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that

30 include the nucleic acid molecules of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

In another embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect, characterize, and quantify BSNA in, and

-39-

isolate BSNA from, transcript-derived nucleic acid samples. In one aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>-selected RNA samples. In another aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g.,* Schwarczacher *et al.*, In Situ Hybridization, Springer-Verlag New York (2000), the disclosure of which is incorporated herein by reference in its entirety. In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to BSNA, including, without limitations, identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000), the disclosures of which are incorporated herein by reference in their entirety.

Thus, in one embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In a preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a BSP. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the probe or primer is derived from a BSNA. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171.

In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer

-40-

in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. *See, e.g.,* Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); 10 Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); McPherson *et al.* (eds.), 15 PCR 2: A Practical Approach, Oxford University Press, Inc. (1995); the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.,* in Siebert *et al.* (eds.), Gene Cloning and Analysis by RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; Siebert (ed.), PCR Technique: RT-PCR, Eaton Publishing Company/ BioTechniques Books 20 (1995); the disclosure of which is incorporated herein by reference in its entirety.

PCR and hybridization methods may be used to identify and/or isolate allelic variants, homologous nucleic acid molecules and fragments of the nucleic acid molecules of the invention. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules that encode homologous proteins, analogs, fusion 25 protein or muteins of the invention. The nucleic acid primers of the present invention can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.,* U.S. Patent 6,004,744, 30 the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.,* Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 (2001); U.S. Patents 5,854,033 and 5,714,320; and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by



-41-

reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g., Lizardi et al., Nature Genet.* 19(3): 225-32 (1998).

Nucleic acid molecules of the present invention may be bound to a substrate  
5 either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

In one embodiment, the nucleic acid molecule of the present invention is bound to  
10 a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon. The nucleic acid molecule of the present invention can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, *e.g.*, a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without  
15 limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including  
20 rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or  
25 some combination thereof. The nucleic acid molecule of the present invention can be bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, *e.g.* on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such  
30 as glass, these substrate bound collections of plural nucleic acids are colloquially termed microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

*Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention relates to vectors that comprise one or more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

5       The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids  
10 of the present invention *in vitro* or within a host cell, and for expressing polypeptides encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides (expression vectors). Vectors of the present invention will often be suitable for several such uses.

      Vectors are by now well-known in the art, and are described, *inter alia*, in Jones  
15 *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000);  
20 Sambrook (2001), *supra*; Ausubel (1999), *supra*; the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

      Nucleic acid sequences may be expressed by operatively linking them to an  
25 expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part  
30 of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

      A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for

example, may consist of segments of chromosomal, non-chromosomal and synthetic nucleic acid sequences.

In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred  
5 embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their  
10 derivatives, wider host range plasmids, such as RP4, phage DNAs, *e.g.*, the numerous derivatives of phage lambda, *e.g.*, NM989,  $\lambda$ GT10 and  $\lambda$ GT11; and other phages, *e.g.*, M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: *e.g.*, typical markers confer resistance to antibiotics, such as ampicillin, tetracycline,  
15 chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic genetic studies, due to the ease of targeting genetic changes by homologous  
20 recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, *e.g.* through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will typically, but not invariably, contain an origin of replication suitable for use in yeast and  
25 a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (*e.g.*, YIp5) and Yeast Replicating plasmids (the YRp and YEp series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2, 2 $\mu$  plasmids and derivatives thereof, and improved shuttle vectors such as those  
30 described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as *ura3-52*, *his3-D1*, *leu2-D1*, *trp1-D1* and *lys2-201*.

-44-

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and express SF™ cells (Protein Sciences Corp., Meriden, CT, USA)), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

In another embodiment, the host cells may be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway.

Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, e.g., in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A).

Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.

Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (e.g., vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.

Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.

-45-

It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

Any of a wide variety of expression control sequences may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the *trc* promoter, a hybrid derived from the *trp* and *lac* promoters; the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, or the *araBAD* operon. Prokaryotic expression vectors may further include transcription terminators, such as the *aspA* terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon; Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the *CYC1* promoter, the *GAL1* promoter, the *GAL10* promoter, *ADH1* promoter, the promoters of the yeast  $\alpha$ -mating system, or the *GPD* promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the *CYC1* or *ADH1* gene.

-46-

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 or the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the BSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include introns, such as intron II of rabbit  $\beta$ -globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (*e.g.*, ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

Expression vectors may be either constitutive or inducible. Inducible vectors include either naturally inducible promoters, such as the *trc* promoter, which is regulated by the *lac* operon, and the *pL* promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid *Plac/ara-1* promoter and the *PLtetO-1* promoter. The *PLtetO-1* promoter takes advantage of the high expression levels from the *PL* promoter of phage lambda, but replaces the lambda repressor sites with two

-47-

copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one aspect of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or visualization. Tags that facilitate purification include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverly, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion protein with glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that

carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or  
5 identification tags. Useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusion to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusion proteins for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, *e.g.*, the gene III  
10 protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. See Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996).  
15 Vectors for yeast display, *e.g.* the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the  $\alpha$ -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, *e.g.*, the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet  
20 derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring  
25 proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic  
30 fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. See Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of



-49-

protein fusions, are well-known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.*, Cormack *et al.*, *Gene* 173: 33-38 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)). Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.*, Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patents 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. See also Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred. Stable expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and

-50-

cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent  
5 antibiotic blasticidin.

Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-  
10 293, AmphoPack-293, and GP2-293 cell lines (all available from Clontech Laboratories, Palo Alto, CA, USA), allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally  
15 well to express the nucleic acid sequences of this invention. Neither will all hosts function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must  
20 be replicated in it. The vector's copy number, the ability to control that copy number, the ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into  
25 the host cell chromosome. Among other considerations, some of which are described above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation, and it is an aspect of the present invention to provide BSPs with such post-  
30 translational modifications.

Polypeptides of the invention may be post-translationally modified. Post-translational modifications include phosphorylation of amino acid residues serine, threonine and/or tyrosine, N-linked and/or O-linked glycosylation, methylation, acetylation, prenylation, methylation, acetylation, arginylation, ubiquitination and

-51-

racemization. One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational

5 modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-

10 anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.

General examples of types of post-translational modifications may be found in

15 web sites such as the Delta Mass database <http://www.abrf.org/ABRF/ResearchCommittees/deltamass/deltamass.html> (accessed October 19, 2001); "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. *Nucleic Acids Res.* 29; 332-335 (2001) and <http://www.glycosuite.com/> (accessed October 19, 2001); "O-GLYCBASE version 4.0: a

20 revised database of O-glycosylated proteins" Gupta et al. *Nucleic Acids Research*, 27: 370-372 (1999) and <http://www.cbs.dtu.dk/databases/OGLYCBASE/> (accessed October 19, 2001); "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. *Nucleic Acids Res* 27(1):237-239 (1999) and <http://www.cbs.dtu.dk/databases/PhosphoBase/> (accessed October 19, 2001); or <http://pir.georgetown.edu/pirwww/search/textresid.html> (accessed October 19, 2001).

25

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from

30 normal cells or tissues. A number of altered post-translational modifications are known. One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another

-52-

common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue.

- 5 Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

- Another post-translational modification that may be altered in cancer cells is  
10 prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signaling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).  
15

- Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to  
20 the corresponding polypeptides from noncancerous cells.

- Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is  
25 cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell  
30 compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).

Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method

-53-

known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.

In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website [www.expasy.org](http://www.expasy.org). The nucleic acid molecule is then be introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational

-54-

modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.

In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its  
5 controllability, and its compatibility with the nucleic acid sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture  
10 requirements, and the ease of purification from them of the products coded for by the nucleic acid sequences of this invention.

The recombinant nucleic acid molecules and more particularly, the expression vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention  
15 may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid sequences according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have biological activity.

Vectors of the present invention will also often include elements that permit *in*  
20 *vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell  
25 (*e.g.*, conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (*See*, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*). Bacterial, yeast, plant or mammalian cells are transformed or transfected with an  
30 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be

-55-

able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from breast are particularly preferred because they may provide a more native post-translational processing. Particularly preferred are human breast cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number of texts and laboratory manuals in the art. See, e.g., Ausubel (1992), *supra*, Ausubel (1999), *supra*, Sambrook (1989), *supra*, and Sambrook (2001), *supra*, herein incorporated by reference.

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well-known in the art; the choice of technique will depend primarily upon the specific vector to be introduced and the host cell chosen.

-56-

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA), and the packaged virus used to infect *E. coli*.

- 5 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, e.g., with  $\text{CaCl}_2$ , or a solution of  $\text{Mg}^{2+}$ ,  $\text{Mn}^{2+}$ ,  $\text{Ca}^{2+}$ ,  $\text{Rb}^+$  or  $\text{K}^+$ , dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent
- 10 strains are also available commercially (e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5α competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent *E. coli* Kit (Invitrogen, Carlsbad, CA, USA)). Bacterial cells can be rendered electrocompetent, that is, competent to take up exogenous DNA by electroporation, by various pre-pulse
- 15 treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols (BioRad, Richmond, CA, USA) ([http://www.biorad.com/LifeScience/pdf/New\\_Gene\\_Pulser.pdf](http://www.biorad.com/LifeScience/pdf/New_Gene_Pulser.pdf)).

- Vectors can be introduced into yeast cells by spheroplasting, treatment with
- 20 lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the action of hydrolytic enzymes such as snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus*, to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol
- 25 (PEG) and  $\text{Ca}^{2+}$ . Subsequently, the cells are resuspended in a solution of sorbitol, mixed with molten agar and then layered on the surface of a selective plate containing sorbitol.

- For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of
- 30 PEG and lithium acetate, and subsequently spread on plates containing ordinary selective medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).



-57-

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991).

- 5 The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

- Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be
- 10 coprecipitated with  $\text{CaPO}_4$  or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for  $\text{CaPO}_4$  transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN®
- 15 Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent, FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA). Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA) ([http://www.bio-rad.com/LifeScience/pdf/](http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf)
- 20 [New\\_Gene\\_Pulser.pdf](http://www.bio-rad.com/LifeScience/pdf/New_Gene_Pulser.pdf)); Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000); incorporated herein by reference in its entirety. Other transfection techniques include transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc. Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA*
- 25 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can optionally be followed by purification.

- Purification of recombinantly expressed proteins is now well by those skilled in the art. See, e.g., Thormer *et al.* (eds.), Applications of Chimeric Genes and Hybrid
- 30 Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology, Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press (2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.),

-58-

Protein Purification Applications, Oxford University Press (2001); the disclosures of which are incorporated herein by reference in their entireties, and thus need not be detailed here.

Briefly, however, if purification tags have been fused through use of an expression vector that appends such tags, purification can be effected, at least in part, by means appropriate to the tag; such as use of immobilized metal affinity chromatography for polyhistidine tags. Other techniques common in the art include ammonium sulfate fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high performance liquid chromatography (HPLC), and preparative gel electrophoresis.

#### 10 Polypeptides

Another object of the invention is to provide polypeptides encoded by the nucleic acid molecules of the instant invention. In a preferred embodiment, the polypeptide is a breast specific polypeptide (BSP). In an even more preferred embodiment, the polypeptide is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 172 through 295. A polypeptide as defined herein may be produced recombiantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification and using methods well-known to those having ordinary skill in the art.

In another aspect, the polypeptide may comprise a fragment of a polypeptide, wherein the fragment is as defined herein. In a preferred embodiment, the polypeptide fragment is a fragment of a BSP. In a more preferred embodiment, the fragment is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 172 through 295. A polypeptide that comprises only a fragment of an entire BSP may or may not be a polypeptide that is also a BSP. For instance, a full-length polypeptide may be breast-specific, while a fragment thereof may be found in other tissues as well as in breast. A polypeptide that is not a BSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing animals to prepare anti-BSP antibodies. However, in a preferred embodiment, the part or fragment is a BSP. Methods of determining whether a polypeptide is a BSP are described *infra*.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 81: 3998-4002 (1984) and U.S. Patents 4,708,871 and 5,595,915, the disclosures of

which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

5           Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize the proteins of the present invention. *See, e.g.,* Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al.*, *Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al.*, *Science* 219: 660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further  
10 described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic, meaning that they are capable of eliciting antibody for the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

          Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as  
15 competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Patents 5,539,084 and 5,783,674, incorporated herein by reference in their  
20 entireties.

          The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the protein of the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids,  
25 or 50 amino acids or more in length. Of course, larger fragments having at least 75 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

          One having ordinary skill in the art can produce fragments of a polypeptide by truncating the nucleic acid molecule, *e.g.*, a BSNA, encoding the polypeptide and then  
30 expressing it recombinantly. Alternatively, one can produce a fragment by chemically synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally-occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.,* Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992),

-60-

*supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a fragment of polypeptide of the invention, preferably a BSP, may be produced by chemical or enzymatic cleavage of a polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule encoding a

5 fragment of the polypeptide, preferably a BSP, in a host cell.

By "polypeptides" as used herein it is also meant to be inclusive of mutants, fusion proteins, homologous proteins and allelic variants of the polypeptides specifically exemplified.

A mutant protein, or mutein, may have the same or different properties compared  
10 to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native protein. Small deletions and insertions can often be found that do not alter the function of the protein. In one embodiment, the mutein may or may not be breast-specific. In a preferred embodiment, the mutein is breast-specific. In a preferred  
15 embodiment, the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 172 through 295. In a more preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to  
20 a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In yet a more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295.

25 A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical  
30 techniques. In a preferred embodiment, a mutein may be produced from a host cell comprising an altered nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid sequence of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino

-61-

acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is breast-specific, as described below. Multiple random mutations can be introduced into the

5 gene by methods well-known to the art, *e.g.*, by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo* mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. *See, e.g.*,

10 Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), U.S. Patent 5,223,408, and the references discussed *supra*, each herein incorporated by reference.

By "polypeptide" as used herein it is also meant to be inclusive of polypeptides homologous to those polypeptides exemplified herein. In a preferred embodiment, the

15 polypeptide is homologous to a BSP. In an even more preferred embodiment, the polypeptide is homologous to a BSP selected from the group having an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the homologous polypeptide is one that exhibits significant sequence identity to a BSP. In a more preferred embodiment, the polypeptide is one that exhibits significant sequence identity

20 to an comprising an amino acid sequence of SEQ ID NO: 172 through 295. In an even more preferred embodiment, the homologous polypeptide is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a yet more

25 preferred embodiment, the homologous polypeptide is one that exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In another preferred embodiment, the homologous polypeptide is one that exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%,

30 99.7%, 99.8% or 99.9% sequence identity to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the amino acid substitutions are conservative amino acid substitutions as discussed above.

In another embodiment, the homologous polypeptide is one that is encoded by a nucleic acid molecule that selectively hybridizes to a BSNA. In a preferred embodiment,

-62-

the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a BSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the BSNA is selected from the group consisting of SEQ ID NO: 1 through 171. In another preferred embodiment, the

- 5 homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes a BSP under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the BSP is selected from the group consisting of SEQ ID NO: 172 through 295.

- The homologous polypeptide may be a naturally-occurring one that is derived
- 10 from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, baboon or gorilla, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 172 through 295. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the BSP is a member of a family of
- 15 polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, *e.g.*, dog, cat, mouse, rat, rabbit, guinea pig, hamster, cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The
- 20 naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous polypeptide recombinantly. In another embodiment, the homologous polypeptide may be one that is experimentally produced by random mutation of a nucleic acid molecule and
- 25 subsequent expression of the nucleic acid molecule. In another embodiment, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of a BSP. Further, the homologous protein may or may not encode polypeptide that is a BSP. However, in a preferred embodiment, the homologous polypeptide encodes a polypeptide that is a BSP.
- 30 Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an antibody. It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the

-63-

binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well-known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, by "polypeptide" as used herein it is also meant to be inclusive of polypeptides encoded by an allelic variant of a nucleic acid molecule encoding a BSP. In a preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that encodes a polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295. In a yet more preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 171.

In another embodiment, the invention provides polypeptides which comprise derivatives of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is a BSP. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295, or is a mutein, allelic variant, homologous protein or fragment thereof. In a preferred embodiment, the derivative has been acetylated, carboxylated, phosphorylated, glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, *e.g.*, radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ . In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antigens that can serve as specific binding pair members for a labeled ligand.

Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983); Seifter *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

-64-

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), e.g., offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).



-65-

The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, *e.g.*, APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DFDNB, DMA, DMP, DMS, DPDPB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS, HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC, SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

The polypeptides, fragments, and fusion proteins of the present invention can be conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to the polypeptides, fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-BSP antibodies.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum half-life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); DeSantis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999), incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

In yet another embodiment, the invention provides analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred

-66-

embodiment, the polypeptide is a BSP. In a more preferred embodiment, the analog is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 172 through 295. In a preferred embodiment, the analog is one that comprises one or more substitutions of non-natural amino acids or non-native inter-residue bonds

5 compared to the naturally-occurring polypeptide. In general, the non-peptide analog is structurally similar to a BSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--,

--CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another embodiment, the non-peptide analog comprises substitution of one or more amino acids

10 of a BSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific three-dimensional conformations on the peptide. Other amino acid analogues commonly

15 added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com.* 209: 817-821 (1995)), and various halogenated phenylalanine derivatives.

Non-natural amino acids can be incorporated during solid phase chemical

20 synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000); Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford

25 Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer Laboratory), Springer Verlag (1993); the disclosures of which are incorporated herein by reference in their entireties.

Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added

30 using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (Fmoc biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The Fmoc and tBOC derivatives of dabcyL-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyL chromophore at selected sites in the peptide sequence during

-67-

synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyI quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from

5 Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl

10 side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially,

15 including, *e.g.*, Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid, Fmoc-3-exo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-

20 trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-

25 aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-

30 hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-

-68-

phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

#### *Fusion Proteins*

The present invention further provides fusions of each of the polypeptides and fragments of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide is a BSP. In a more preferred embodiment, the polypeptide that is fused to the heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 172 through 295, or is a mutein, homologous polypeptide, analog or derivative thereof. In an even more preferred embodiment, the nucleic acid molecule encoding the fusion protein comprises all or part of the nucleic acid sequence of SEQ ID NO: 1 through 171, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171.

The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

-69-

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP  
5 chromophore-containing proteins) are particular useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of  
10 recombinantly-expressed proteins. *See, e.g.,* Ausubel, Chapter 16, (1992), *supra*. Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so  
15 included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins — into the periplasmic space or extracellular milieu for  
20 prokaryotic hosts, into the culture medium for eukaryotic cells — through incorporation of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an  
25 epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.

30 Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. *See* Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et*

- al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); ; Colas *et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; Norman, T. *et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, Fabbizio *et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; Xu *et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; Yang, *et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; Kolonin *et al.*, (1998) Targeting cyclin-dependent kinases in *Drosophila* with peptide aptamers. *Proc Natl Acad Sci U S A* 95, 14266-14271; Cohen *et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; Uetz, P.; Giot, L.; al, e.; Fields, S.; Rothberg, J. M. (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; Ito, *et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl Acad Sci U S A* 98, 4569-4574, the disclosures of which are incorporated herein by reference in their entirety. Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The polypeptides and fragments of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, *diphtheria* toxin, *shiga* toxin A, *anthrax* toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST, immunoglobulins,  $\beta$ -galactosidase, biotin trpE, protein A,  $\beta$ -lactamase,  $\alpha$ -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast  $\alpha$  mating factor, GAL4 transcription activation or DNA binding domain,

-71-

luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. *See, e.g.,* Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art.

- 5 Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (*e.g.,* a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind the fusion protein to a plate or column through an affinity linkage for screening binding  
10 proteins or other molecules that bind to the BSP.

As further described below, the isolated polypeptides, muteins, fusion proteins, homologous proteins or allelic variants of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize BSPs, their allelic variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to  
15 assay for the polypeptides of the present invention, particularly BSPs, *e.g.* by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of BSPs, as for example by immunoprecipitation, and for use  
20 as specific agonists or antagonists of BSPs.

One may determine whether polypeptides including muteins, fusion proteins, homologous proteins or allelic variants are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine  
25 scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are  
30 available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-102S; EZ::TN™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

Purification of the polypeptides including fragments, homologous polypeptides, muteins, analogs, derivatives and fusion proteins is well-known and within the skill of

-72-

one having ordinary skill in the art. See, e.g., Scopes, Protein Purification, 2d ed. (1987). Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, e.g., by HPLC.

Accordingly, it is an aspect of the present invention to provide the isolated  
5 proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

Although high levels of purity are preferred when the isolated proteins of the  
10 present invention are used as therapeutic agents, such as in vaccines and as replacement therapy, the isolated proteins of the present invention are also useful at lower purity. For example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In preferred embodiments, the purified and substantially purified proteins of the  
15 present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

20 For example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, e.g. in serum, that bind  
25 specifically to the immobilized protein of the present invention.

As another example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, e.g. in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include  
30 polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.



-73-

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with  
5 sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction there between. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the  
10 surface-bound protein to indicate biological interaction there between.

#### Antibodies

In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid  
15 molecules of the invention, as well as antibodies that bind to fragments, muteins, derivatives and analogs of the polypeptides. In a preferred embodiment, the antibodies are specific for a polypeptide that is a BSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 172 through 295, or a fragment, mutein,  
20 derivative, analog or fusion protein thereof.

The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, e.g., by solubilization in SDS. New epitopes may be also  
25 due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on a BSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or visa versa. In addition, alternative splice forms of a BSP may be indicative of cancer. Differential degradation of the C or N-terminus of a BSP may also be a marker or target for anticancer therapy. For example, a BSP may  
30 be N-terminal degraded in cancer cells exposing new epitopes to which antibodies may selectively bind for diagnostic or therapeutic uses.

As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention

-74-

will discriminate over adventitious binding to non-BSP polypeptides by at least 2-fold, more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the  
5 antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human breast.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the  
10 present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$  M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

15 Human antibodies can, but will infrequently, be drawn directly from human donors or human cells. In this case, antibodies to the proteins of the present invention will typically have resulted from fortuitous immunization, such as autoimmune immunization, with the protein or protein fragments of the present invention. Such antibodies will typically, but will not invariably, be polyclonal. In addition, individual  
20 polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that express human immunoglobulin genes, which transgenic animals can be affirmatively immunized with the protein immunogen of the present invention. Human Ig-transgenic mice capable of producing human antibodies and methods of producing human  
25 antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patents 6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299; 5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825; 5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by reference in their entireties. Such antibodies are typically monoclonal, and are typically  
30 produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the antibodies of the present invention are to be administered to human beings as *in vivo* diagnostic or therapeutic agents, since recipient immune response to the administered

-75-

antibody will often be substantially less than that occasioned by administration of an antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention can also be obtained from other species, including mammals such as rodents (typically mouse, but  
5 also rat, guinea pig, and hamster) lagomorphs, typically rabbits, and also larger mammals, such as sheep, goats, cows, and horses, and other egg laying birds or reptiles such as chickens or alligators. For example, avian antibodies may be generated using techniques described in WO 00/29444, published 25 May 2000, the contents of which are hereby incorporated in their entirety. In such cases, as with the transgenic human-  
10 antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when  
15 conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

Immunogenicity can also be conferred by fusion of the polypeptide and fragments of the present invention to other moieties. For example, peptides of the present invention  
20 can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl. Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

25 Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From  
30 Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996), the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990).

-76-

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention. Antibodies from avian species may have particular advantage in detection of the proteins of the present invention, in human serum or tissues (Viking et al., *Biosens. Bioelectron.* 13: 1257-1262 (1998)).

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well-known in the art, Coligan, *supra*; Zola, *supra*; Howard *et al.* (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997), incorporated herein by reference in their entirety, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: *e.g.*, genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S. Patent 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant production of either whole antibodies, antibody fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein

-77-

(pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. See, e.g., Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths *et al.*, *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom *et al.*, *Immunotechnology*, 4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997);

5 Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994).

Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. See, e.g., Barbas  
10 (2001), *supra*; Kay, *supra*; Abelson, *supra*, the disclosures of which are incorporated herein by reference in their entirety.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length  
15 antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. See, e.g., Takahashi *et al.*, *Biosci.*  
20 *Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 201(1): 67-75 (1997);, Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998), the disclosures of which are incorporated herein  
25 by reference in their entirety.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. See, e.g., Li *et al.*, *Protein Expr. Purif.* 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997);  
30 and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entirety.

Antibodies and fragments and derivatives thereof of the present invention can also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavalondo *et al.*, *Biotechniques* 29(1): 128-38 (2000);

-78-

Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer *et al.*, *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma *et al.*, *Plant Physiol.* 109(2): 341-6 (1995), the disclosures of which are incorporated herein  
5 by reference in their entirety.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. *See, e.g.* Pollock *et al.*, *J. Immunol. Methods.* 231: 147-57 (1999); Young *et al.*, *Res. Immunol.* 149: 609-10 (1998); Limonta *et al.*, *Immunotechnology* 1: 107-13 (1995), the disclosures  
10 of which are incorporated herein by reference in their entirety.

Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells.

Verma *et al.*, *J. Immunol. Methods* 216(1-2):165-81 (1998), herein incorporated  
15 by reference, review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.

Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk *et al.*, *J. Biochem. (Tokyo)* 125(2): 328-33 (1999) and Ryabova *et al.*, *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic  
20 animals, as further described in Pollock *et al.*, *J. Immunol. Methods* 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entirety.

The invention further provides antibody fragments that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present  
25 invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful fragments are Fab, Fab', Fv, F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).  
30

It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively

-79-

inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

Among such useful derivatives are chimeric, primatized, and humanized  
5 antibodies; such derivatives are less immunogenic in human beings, and thus more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

Chimeric antibodies typically include heavy and/or light chain variable regions  
10 (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g.,* United States Patent No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al.*, *Nature* 309(5966): 364-7 (1984); Takeda *et al.*, *Nature* 314(6010): 452-4 (1985), the disclosures of which are incorporated herein by reference in  
15 their entireties. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162): 323-7 (1988); Co *et al.*, *Nature* 351(6326): 501-2 (1991); United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886;  
20 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties.

Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

25 It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. The present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be  
30 prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco *et al.*, *Proc. Natl.*

-80-

*Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to  
5 provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments  
10 encoded by the isolated nucleic acids of the present invention.

The choice of label depends, in part, upon the desired use.

For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label is preferably an enzyme that catalyzes production and local deposition of a detectable product.

15 Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase,  $\beta$ -galactosidase, glucose oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl  
20 phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue  
25 tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are luminescent. For example, in the presence of hydrogen peroxide ( $H_2O_2$ ), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate  
30 reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. See, e.g., Thorpe et al., *Methods Enzymol.* 133: 331-53 (1986); Kricka et al., *J. Immunoassay* 17(1): 67-83



-81-

(1996); and Lundqvist *et al.*, *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995), the disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

5 As another example, when the antibodies of the present invention are used, *e.g.*, for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

10 For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

15 Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568,  
20 BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5,  
25 Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, *e.g.*, for Western blotting  
30 applications, they can usefully be labeled with radioisotopes, such as <sup>33</sup>P, <sup>32</sup>P, <sup>35</sup>S, <sup>3</sup>H, and <sup>125</sup>I.

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be <sup>228</sup>Th, <sup>227</sup>Ac, <sup>225</sup>Ac, <sup>223</sup>Ra, <sup>213</sup>Bi, <sup>212</sup>Pb,

-82-

$^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

As would be understood, use of the labels described above is not restricted to the application for which they are mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, diphtheria toxin, shiga toxin A, anthrax toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998), the disclosures of which are incorporated herein by reference in their entireties.

The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to paramagnetic microspheres, typically by biotin-streptavidin interaction, which microspheres can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

-83-

As noted above, the antibodies of the present invention can be produced in prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the

5 antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by

10 one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the

15 antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody molecule, or to alter it in any other way that may render it more suitable for a particular application.

#### Transgenic Animals and Cells

20 In another aspect, the invention provides transgenic cells and non-human organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding a BSP. In a preferred embodiment, the BSP comprises an amino acid

25 sequence selected from SEQ ID NO: 172 through 295, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise a BSNA of the invention, preferably a BSNA comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 171, or a part, substantially similar nucleic acid molecule, allelic variant

30 or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human BSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric

-84-

homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson *et al., Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press (1999).

5 *A Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol.* 40: 691-698 (1994); Carver *et al., Biotechnology* 11: 1263-1270 (1993); Wright *et al., Biotechnology* 9: 830-834 (1991); and U.S. Patent 4,873,191 (1989 retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (*see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA* 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (*see, e.g., Thompson et al., Cell* 56: 313-321 (1989)); electroporation of cells or embryos (*see, e.g., Lo, 1983, Mol. Cell. Biol.* 3: 1803-1814 (1983)); introduction using a gene gun (*see, e.g., Ulmer et al., Science* 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (*see, e.g., Lavitrano et al., Cell* 57: 717-723 (1989)).

Other techniques include, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campell et al., Nature* 380: 64-66 (1996); Wilmut *et al., Nature* 385: 810-813 (1997)). The present invention provides for transgenic animals that carry the transgene (*i.e., a nucleic acid molecule of the invention*) in all their cells, as well as animals which carry the transgene in some, but not all their cells, *i. e., mosaic animals or chimeric animals.*

25 The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, *e. g., head-to-head tandems or head-to-tail tandems.* The transgene may also be selectively introduced into and activated in a particular cell type by following, *e.g., the teaching of Lasko et al. et al., Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to

-85-

verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR  
5 (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding  
10 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to  
15 both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited  
20 to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are  
25 also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus  
30 inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science* 265: 103-106 (1994). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature* 317: 230-234 (1985); Thomas *et al., Cell* 51: 503-512 (1987); Thompson *et al., Cell* 5: 313-321 (1989).

-86-

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable  
5 marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications  
10 to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g., Thomas, supra* and *Thompson, supra*. However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

15 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from an animal or patient or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells,  
20 blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably  
25 vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve  
30 expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft;

-87-

genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patents 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.

When the cells to be administered are non-autologous or non-MHC compatible  
5 cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

10 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

15 Computer Readable Means

A further aspect of the invention relates to a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 1 through 171 and SEQ ID NO: 172 through 295 as described herein, as the complete set  
20 of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences meeting a set of criteria, and the like.

25 The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical characteristic of a polynucleotide or polypeptide of the invention that is or may be  
30 reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

-88-

This invention provides computer readable media having stored thereon sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence comprising the sequence of an amino acid of the invention in a computer readable



-89-

medium; and comparing said an amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the  
5 steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence.

#### Diagnostic Methods for Breast Cancer

10

The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by comparing expression of a BSNA or a BSP in a human patient that has or may have breast cancer, or who is at risk of developing breast cancer, with the expression of a  
15 BSNA or a BSP in a normal human control. For purposes of the present invention, "expression of a BSNA" or "BSNA expression" means the quantity of BSG mRNA that can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of a BSP" or "BSP expression" means the amount of BSP  
20 that can be measured by any method known in the art or the level of translation of a BSG BSNA that can be measured by any method known in the art.

The present invention provides methods for diagnosing breast cancer in a patient, in particular squamous cell carcinoma, by analyzing for changes in levels of BSNA or BSP in cells, tissues, organs or bodily fluids compared with levels of BSNA or BSP in  
25 cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of a BSNA or BSP in the patient versus the normal human control is associated with the presence of breast cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing breast cancer in a patient by analyzing  
30 changes in the structure of the mRNA of a BSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing breast cancer in a patient by analyzing changes in a BSP compared to a BSP from a normal control. These

-90-

changes include, *e.g.*, alterations in glycosylation and/or phosphorylation of the BSP or subcellular BSP localization.

In a preferred embodiment, the expression of a BSNA is measured by determining the amount of an mRNA that encodes an amino acid sequence selected from  
5 SEQ ID NO: 172 through 295, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the BSNA expression that is measured is the level of expression of a BSNA mRNA selected from SEQ ID NO: 1 through 171, or a hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acids. BSNA expression may be measured by any method known in  
10 the art, such as those described *supra*, including measuring mRNA expression by Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g.*, Ausubel (1992), *supra*; Ausubel (1999), *supra*; Sambrook (1989), *supra*; and Sambrook (2001), *supra*. BSNA transcription may be measured by any method known in the art including using a reporter  
15 gene hooked up to the promoter of a BSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*, aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, BSNA expression may be compared to a known control, such as normal breast nucleic acid, to detect a change in expression.

20 In another preferred embodiment, the expression of a BSP is measured by determining the level of a BSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 172 through 295, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for  
25 instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of BSNA or BSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of breast cancer. The expression level of a BSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the BSP expression level may be  
30 determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g.*, Harlow (1999), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. Alterations in the BSP

-91-

structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*

5           In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An antibody specific to a BSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-BSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a protein such as bovine serum albumin. A sample of interest is incubated with the  
10       antibody on the solid support under conditions in which the BSP will bind to the anti-BSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-BSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the BSP to the labeled antibody will occur. After  
15       binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of a BSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

20           Other methods to measure BSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-BSP antibody is attached to a solid support and an allocated amount of a labeled BSP and a sample of interest are incubated with the solid support. The amount of labeled BSP detected which is attached to the solid support can be correlated to the quantity of a BSP in the sample.

25           Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is  
30       perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of a BSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example,

5 reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

10 Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more BSNAs of interest. In this approach, all or a portion of one or more BSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the  
15 RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid  
20 molecule or a secondary molecule designed to detect the hybrid.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any  
25 other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of BSNA or BSP includes, without limitation, breast tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, breast cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment,  
30 especially when metastasis of a primary breast cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and colon. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy,

bone marrow biopsy and bone marrow aspiration. See Scott, *supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in BSNAs or BSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples is disclosed in Franklin, *supra*.

- 5 All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of a BSNA or BSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the one or more other cancer markers include other BSNA or BSPs as disclosed herein.
- 10 Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular BSNA or BSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even more preferred embodiment, at least three, more preferably at least five, even more
- 15 preferably at least ten additional cancer markers are used.

#### *Diagnosing*

- In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a sample from a patient suspected of having breast cancer. In general, the method comprises the steps
- 20 of obtaining the sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP and then ascertaining whether the patient has breast cancer from the expression level of the BSNA or BSP. In general, if high expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times
- 25 higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of breast cancer, a diagnostic assay is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least
- 30 five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

-94-

The present invention also provides a method of determining whether breast cancer has metastasized in a patient. One may identify whether the breast cancer has metastasized by measuring the expression levels and/or structural alterations of one or more BSNA and/or BSPs in a variety of tissues. The presence of a BSNA or BSP in a certain tissue at levels higher than that of corresponding noncancerous tissue (*e.g.*, the same tissue from another individual) is indicative of metastasis if high level expression of a BSNA or BSP is associated with breast cancer. Similarly, the presence of a BSNA or BSP in a tissue at levels lower than that of corresponding noncancerous tissue is indicative of metastasis if low level expression of a BSNA or BSP is associated with breast cancer. Further, the presence of a structurally altered BSNA or BSP that is associated with breast cancer is also indicative of metastasis.

In general, if high expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the BSNA or BSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

The BSNA or BSP of this invention may be used as element in an array or a multi-analyte test to recognize expression patterns associated with breast cancers or other breast related disorders. In addition, the sequences of either the nucleic acids or proteins may be used as elements in a computer program for pattern recognition of breast disorders.

### *Staging*

The invention also provides a method of staging breast cancer in a human patient. The method comprises identifying a human patient having breast cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more BSNA or BSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and the expression level of one or more BSNA or BSPs is determined for each stage to obtain a

-95-

standard expression level for each BSNA and BSP. Then, the BSNA or BSP expression levels are determined in a biological sample from a patient whose stage of cancer is not known. The BSNA or BSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the BSNA and BSPs  
5 from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations of a BSNA or BSP to determine the stage of a breast cancer.

### *Monitoring*

Further provided is a method of monitoring breast cancer in a human patient.  
10 One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, *e.g.*, chemotherapy, radiotherapy or surgery, has decreased or eliminated the breast cancer. The method  
15 comprises identifying a human patient that one wants to monitor for breast cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for expression levels of one or more BSNA or BSPs, and comparing the BSNA or BSP levels over time to those BSNA or BSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in a BSNA or  
20 BSP that are associated with breast cancer.

If increased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of a BSNA or BSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively.  
25 One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or failure to progress to a neoplastic lesion. If decreased expression of a BSNA or BSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of a BSNA or BSP  
30 indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of BSNA or BSPs are determined from the same cell type, tissue or bodily fluid as prior patient samples.

-96-

Monitoring a patient for onset of breast cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of a BSNA and/or BSP. The present invention provides a method in which a test sample is obtained from a human patient and one or more BSNAs and/or BSPs are detected. The presence of higher (or lower) BSNA or BSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly breast cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more BSNAs and/or BSPs of the invention can also be monitored by analyzing levels of expression of the BSNAs and/or BSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

#### *Detection of Genetic Lesions or Mutations*

The methods of the present invention can also be used to detect genetic lesions or mutations in a BSG, thereby determining if a human with the genetic lesion is susceptible to developing breast cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing breast cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion and/or substitution of one or more nucleotides from the BSGs of this invention, a chromosomal rearrangement of BSG, an aberrant modification of BSG (such as of the methylation pattern of the genomic DNA), or allelic loss of a BSG. Methods to detect such lesions in the BSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

#### Methods of Detecting Noncancerous Breast Diseases

The invention also provides a method for determining the expression levels and/or structural alterations of one or more BSNAs and/or BSPs in a sample from a patient suspected of having or known to have a noncancerous breast disease. In general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of a BSNA and/or BSP, comparing the



-97-

expression level or structural alteration of the BSNA or BSP to a normal breast control, and then ascertaining whether the patient has a noncancerous breast disease. In general, if high expression relative to a control of a BSNA or BSP is indicative of a particular noncancerous breast disease, a diagnostic assay is considered positive if the level of  
5 expression of the BSNA or BSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of a BSNA or BSP is indicative of a noncancerous breast disease, a diagnostic assay is considered positive if the level of expression of the BSNA  
10 or BSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether a BSNA and/or BSP  
15 is associated with a particular noncancerous breast disease by obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining which BSNAs and/or BSPs are expressed in the tissue at either a higher or a lower level than in normal breast tissue. In another embodiment, one may determine whether a BSNA or BSP exhibits structural alterations in a particular noncancerous breast disease state by  
20 obtaining breast tissue from a patient having a noncancerous breast disease of interest and determining the structural alterations in one or more BSNAs and/or BSPs relative to normal breast tissue.

#### Methods for Identifying Breast Tissue

25 In another aspect, the invention provides methods for identifying breast tissue. These methods are particularly useful in, *e.g.*, forensic science, breast cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a  
30 sample is breast tissue or has breast tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising breast tissue or having breast tissue-like characteristics, determining whether the sample expresses one or more BSNAs and/or BSPs, and, if the sample expresses one or more BSNAs and/or BSPs, concluding that the sample comprises breast tissue. In a preferred embodiment, the BSNA encodes a  
35 polypeptide having an amino acid sequence selected from SEQ ID NO: 172 through 295,

-98-

- or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from SEQ ID NO: 1 through 171, or a hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses a BSNA can be accomplished by any method known in the art.
- 5 Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether a BSP is expressed. Determining whether a sample expresses a BSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the BSP
- 10 has an amino acid sequence selected from SEQ ID NO: 172 through 295, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two BSNAs and/or BSPs is determined. In a more preferred embodiment, the expression of at least three, more preferably four and even more preferably five BSNAs and/or BSPs are determined.
- 15 In one embodiment, the method can be used to determine whether an unknown tissue is breast tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into breast tissue.
- 20 This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new breast tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium. Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH,
- 25 aqueous:air interface and various other culture conditions.

#### Methods for Producing and Modifying Breast Tissue

- In another aspect, the invention provides methods for producing engineered breast tissue or cells. In one embodiment, the method comprises the steps of providing cells,
- 30 introducing a BSNA or a BSG into the cells, and growing the cells under conditions in which they exhibit one or more properties of breast tissue cells. In a preferred embodiment, the cells are pluripotent. As is well-known in the art, normal breast tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered breast tissue or cells comprises one of these cell types. In another

-99-

embodiment, the engineered breast tissue or cells comprises more than one breast cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the breast cell tissue. Methods for manipulating culture conditions are well-known in the art.

5       Nucleic acid molecules encoding one or more BSPs are introduced into cells, preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode BSPs having amino acid sequences selected from SEQ ID NO: 172 through 295, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected  
10   from SEQ ID NO: 1 through 171, or hybridizing nucleic acids, allelic variants or parts thereof. In another highly preferred embodiment, a BSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

15       Artificial breast tissue may be used to treat patients who have lost some or all of their breast function.

#### Pharmaceutical Compositions

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, antibodies, antibody derivatives,  
20   antibody fragments, agonists, antagonists, and inhibitors of the present invention. In a preferred embodiment, the pharmaceutical composition comprises a BSNA or part thereof. In a more preferred embodiment, the BSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 171, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity  
25   thereto. In another preferred embodiment, the pharmaceutical composition comprises a BSP or fragment thereof. In a more preferred embodiment, the BSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 172 through 295, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the  
30   pharmaceutical composition comprises an anti-BSP antibody, preferably an antibody that specifically binds to a BSP having an amino acid that is selected from the group consisting of SEQ ID NO: 172 through 295, or an antibody that binds to a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

-100-

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

Pharmaceutical formulation is a well-established art, and is further described in  
5 Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. (2000), the disclosures of which are incorporated herein by reference in their entireties,  
10 and thus need not be described in detail herein.

Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation,  
15 topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Solid formulations of the compositions for oral administration can contain  
20 suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium  
25 carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and  
30 alginic acid.

Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone<sup>TM</sup>), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

-101-

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

5 Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

10 Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or  
15 suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral)  
20 administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and  
25 flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

For intravenous injection, water soluble versions of the compounds of the present  
30 invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.

-102-

Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and  
5 administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate,  
10 isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the  
15 suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as  
20 polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

25 The pharmaceutical compositions of the present invention can be administered topically.

For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops,  
30 tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid

-103-

ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, *e.g.*, 5 to 10%, in a carrier such as a pharmaceutical cream base.

For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases  
5 as ointments, creams, lotions, paints or powders.

For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

Inhalation formulations can also readily be formulated. For inhalation, various  
10 powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for  
15 reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts  
20 tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

The active compound will be present in an amount effective to achieve the  
25 intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example BSP polypeptide, fusion protein, or fragments thereof, antibodies specific for BSP, agonists, antagonists or inhibitors of BSP, which ameliorates the signs or symptoms  
30 of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model

-104-

can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age, weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (e.g., 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to



-105-

the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

#### Therapeutic Methods

5           The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of breast function. As used herein, "treating" includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term "treating" encompasses any  
10 improvement of a disease, including minor improvements. These methods are discussed below.

#### *Gene Therapy and Vaccines*

          The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be  
15 driven from a vector, typically a viral vector, often a vector based upon a replication incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further  
20 described in U.S. Patents 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; and 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g.*, Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).

25           In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of a BSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of a BSP are  
30 administered, for example, to complement a deficiency in the native BSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g.*, Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid

-106-

molecule encodes a BSP having the amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express a BSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in BSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode a BSP having the amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, fusion protein, allelic variant or homolog thereof.

10 *Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of a BSG antisense nucleic acid, are administered to downregulate transcription and/or translation of a BSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

15 Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of a BSG. For example, oligonucleotides derived from the transcription initiation site, *e.g.*, between positions -10 and +10 from the start site, are preferred.

Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to BSG transcripts, are also useful in therapy. *See, e.g.*, Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995), the disclosures of which are incorporated herein by reference in their entireties.

25 Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the BSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. *See, e.g.*, Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9 (2000), the disclosures of which are incorporated herein by reference. Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

-107-

In a preferred embodiment, the antisense molecule is derived from a nucleic acid molecule encoding a BSP, preferably a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule  
5 having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a BSP, a  
10 fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant BSP defect.

Protein compositions are administered, for example, to complement a deficiency in native BSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to BSP. The immune response can  
15 be used to modulate activity of BSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate BSP.

In a preferred embodiment, the polypeptide is a BSP comprising an amino acid  
20 sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Antibody, Agonist and Antagonist Administration*

In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is administered. As is well-known, antibody compositions are administered, for example,  
30 to antagonize activity of BSP, or to target therapeutic agents to sites of BSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred

-108-

embodiment, the antibody specifically binds to a BSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

The present invention also provides methods for identifying modulators which  
5 bind to a BSP or have a modulatory effect on the expression or activity of a BSP. Modulators which decrease the expression or activity of BSP (antagonists) are believed to be useful in treating breast cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of a BSP can  
10 also be designed, synthesized and tested for use in the imaging and treatment of breast cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the BSPs identified herein. Molecules identified in the library as being capable of binding to a BSP are key candidates for further evaluation for use in the treatment of breast cancer. In a preferred embodiment,  
15 these molecules will downregulate expression and/or activity of a BSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of BSP is administered. Antagonists of BSP can be produced using methods generally known in the art. In particular, purified BSP can be used to screen libraries of pharmaceutical  
20 agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of a BSP.

In other embodiments a pharmaceutical composition comprising an agonist of a BSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

25 In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP comprising an amino acid sequence of SEQ ID NO: 172 through 295, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, a BSP encoded by a  
30 nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 171, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Targeting Breast Tissue*

The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the

-109-

breast or to specific cells in the breast. In a preferred embodiment, an anti-BSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if breast tissue needs to be selectively destroyed. This would be useful for targeting and killing breast cancer cells.

- 5 In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting breast cell function.

In another embodiment, an anti-BSP antibody may be linked to an imaging agent that can be detected using, *e.g.*, magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring breast function, identifying breast cancer tumors,

- 10 and identifying noncancerous breast diseases.

### EXAMPLES

#### Example 1: Gene Expression analysis

BSGs were identified by mRNA subtraction analysis using standard methods. The sequences were extended using GeneBank sequences, Incyte's proprietary database.

- 15 From the nucleotide sequences, predicted amino acid sequences were prepared.  
DEX0306\_1, DEX0306\_2 correspond to SEQ ID NO.1, 2 etc. DEX0157 was the parent sequence found in the mRNA subtractions.

	DEX0306_1	DEX0157_1	DEX0306_172
	DEX0306_2	flex DEX0157_1	
20	DEX0306_3	DEX0157_2	DEX0306_173
	DEX0306_4	flex DEX0157_2	
	DEX0306_5	DEX0157_3	DEX0306_174
	DEX0306_6	flex DEX0157_3	
	DEX0306_7	DEX0157_4	DEX0306_175
25	DEX0306_8	flex DEX0157_4	
	DEX0306_9	DEX0157_5	DEX0306_176
	DEX0306_10	flex DEX0157_5	
	DEX0306_11	DEX0157_6	DEX0306_177
	DEX0306_12	flex DEX0157_6	
30	DEX0306_13	DEX0157_7	DEX0306_178
	DEX0306_14	DEX0157_8	DEX0306_179
	DEX0306_15	DEX0157_9	DEX0306_180
	DEX0306_16	flex DEX0157_9	
	DEX0306_17	DEX0157_10	DEX0306_181
35	DEX0306_18	flex DEX0157_10	DEX0306_182
	DEX0306_19	DEX0157_11	DEX0306_183
	DEX0306_20	flex DEX0157_11	
	DEX0306_21	DEX0157_12	DEX0306_184
	DEX0306_22	flex DEX0157_12	
40	DEX0306_23	DEX0157_13	DEX0306_185
	DEX0306_24	flex DEX0157_13	
	DEX0306_25	DEX0157_14	DEX0306_186
	DEX0306_26	flex DEX0157_14	
	DEX0306_27	DEX0157_15	DEX0306_187
45	DEX0306_28	flex DEX0157_15	
	DEX0306_29	DEX0157_16	DEX0306_188

-110-

DEX0306\_30 DEX0157\_17 DEX0306\_189  
DEX0306\_31 flex DEX0157\_17 DEX0306\_190  
DEX0306\_32 DEX0157\_18 DEX0306\_191  
DEX0306\_33 flex DEX0157\_18  
5 DEX0306\_34 DEX0157\_19 DEX0306\_192  
DEX0306\_35 DEX0157\_20 DEX0306\_193  
DEX0306\_36 flex DEX0157\_20 DEX0306\_194  
DEX0306\_37 DEX0157\_21  
DEX0306\_38 DEX0157\_22 DEX0306\_195  
10 DEX0306\_39 flex DEX0157\_22  
DEX0306\_40 DEX0157\_23 DEX0306\_196  
DEX0306\_41 flex DEX0157\_23  
DEX0306\_42 DEX0157\_24 DEX0306\_197  
DEX0306\_43 DEX0157\_25 DEX0306\_198  
15 DEX0306\_44 flex DEX0157\_25 DEX0306\_199  
DEX0306\_45 DEX0157\_26 DEX0306\_200  
DEX0306\_46 DEX0157\_27 DEX0306\_201  
DEX0306\_47 flex DEX0157\_27  
DEX0306\_48 DEX0157\_28 DEX0306\_202  
20 DEX0306\_49 flex DEX0157\_28  
DEX0306\_50 DEX0157\_29 DEX0306\_203  
DEX0306\_51 flex DEX0157\_29  
DEX0306\_52 DEX0157\_30 DEX0306\_204  
DEX0306\_53 flex DEX0157\_30 DEX0306\_205  
25 DEX0306\_54 DEX0157\_31 DEX0306\_206  
DEX0306\_55 flex DEX0157\_31  
DEX0306\_56 DEX0157\_32 DEX0306\_207  
DEX0306\_57 flex DEX0157\_32  
DEX0306\_58 DEX0157\_33 DEX0306\_208  
30 DEX0306\_59 flex DEX0157\_33  
DEX0306\_60 DEX0157\_34  
DEX0306\_61 flex DEX0157\_34  
DEX0306\_62 DEX0157\_35 DEX0306\_209  
DEX0306\_63 DEX0157\_36 DEX0306\_210  
35 DEX0306\_64 flex DEX0157\_36  
DEX0306\_65 DEX0157\_37 DEX0306\_211  
DEX0306\_66 flex DEX0157\_37 DEX0306\_212  
DEX0306\_67 DEX0157\_38 DEX0306\_213  
DEX0306\_68 DEX0157\_39 DEX0306\_214  
40 DEX0306\_69 flex DEX0157\_39 DEX0306\_215  
DEX0306\_70 DEX0157\_40 DEX0306\_216  
DEX0306\_71 flex DEX0157\_40 DEX0306\_217  
DEX0306\_72 DEX0157\_41 DEX0306\_218  
DEX0306\_73 flex DEX0157\_41 DEX0306\_219  
45 DEX0306\_74 DEX0157\_42 DEX0306\_220  
DEX0306\_75 flex DEX0157\_42  
DEX0306\_76 DEX0157\_43 DEX0306\_221  
DEX0306\_77 flex DEX0157\_43  
DEX0306\_78 DEX0157\_44 DEX0306\_222  
50 DEX0306\_79 flex DEX0157\_44  
DEX0306\_80 DEX0157\_45 DEX0306\_223  
DEX0306\_81 flex DEX0157\_45 DEX0306\_224  
DEX0306\_82 DEX0157\_46 DEX0306\_225  
DEX0306\_83 DEX0157\_47 DEX0306\_226  
55 DEX0306\_84 DEX0157\_48 DEX0306\_227  
DEX0306\_85 DEX0157\_49 DEX0306\_228  
DEX0306\_86 flex DEX0157\_49 DEX0306\_229  
DEX0306\_87 DEX0157\_50 DEX0306\_230  
DEX0306\_88 flex DEX0157\_50 DEX0306\_231  
60 DEX0306\_89 DEX0157\_51 DEX0306\_232  
DEX0306\_90 flex DEX0157\_51  
DEX0306\_91 DEX0157\_52 DEX0306\_233

-111-

DEX0306\_92 DEX0157\_53 DEX0306\_234  
DEX0306\_93 flex DEX0157\_53 DEX0306\_235  
DEX0306\_94 DEX0157\_54 DEX0306\_236  
DEX0306\_95 flex DEX0157\_54  
5 DEX0306\_96 DEX0157\_55 DEX0306\_237  
DEX0306\_97 DEX0157\_56 DEX0306\_238  
DEX0306\_98 flex DEX0157\_56 DEX0306\_239  
DEX0306\_99 DEX0157\_57 DEX0306\_240  
DEX0306\_100 DEX0157\_58 DEX0306\_241  
10 DEX0306\_101 flex DEX0157\_58  
DEX0306\_102 DEX0157\_60 DEX0306\_242  
DEX0306\_103 flex DEX0157\_60 DEX0306\_243  
DEX0306\_104 DEX0157\_61 DEX0306\_244  
DEX0306\_105 flex DEX0157\_61 DEX0306\_245  
15 DEX0306\_106 DEX0157\_62 DEX0306\_246  
DEX0306\_107 flex DEX0157\_62 DEX0306\_247  
DEX0306\_108 DEX0157\_63 DEX0306\_248  
DEX0306\_109 flex DEX0157\_63  
DEX0306\_110 DEX0157\_64 DEX0306\_249  
20 DEX0306\_111 flex DEX0157\_64 DEX0306\_250  
DEX0306\_112 DEX0157\_65 DEX0306\_251  
DEX0306\_113 DEX0157\_66 DEX0306\_252  
DEX0306\_114 DEX0157\_67 DEX0306\_253  
DEX0306\_115 DEX0157\_68 DEX0306\_254  
25 DEX0306\_116 flex DEX0157\_68 DEX0306\_255  
DEX0306\_117 DEX0157\_69 DEX0306\_256  
DEX0306\_118 flex DEX0157\_69 DEX0306\_257  
DEX0306\_119 DEX0157\_70 DEX0306\_258  
DEX0306\_120 flex DEX0157\_70  
30 DEX0306\_121 DEX0157\_71 DEX0306\_259  
DEX0306\_122 flex DEX0157\_71  
DEX0306\_123 DEX0157\_72 DEX0306\_260  
DEX0306\_124 flex DEX0157\_72 DEX0306\_261  
DEX0306\_125 DEX0157\_73 DEX0306\_262  
35 DEX0306\_126 flex DEX0157\_73 DEX0306\_263  
DEX0306\_127 DEX0157\_74 DEX0306\_264  
DEX0306\_128 flex DEX0157\_74  
DEX0306\_129 DEX0157\_75 DEX0306\_265  
DEX0306\_130 DEX0157\_76 DEX0306\_266  
40 DEX0306\_131 flex DEX0157\_76 DEX0306\_267  
DEX0306\_132 DEX0157\_77 DEX0306\_268  
DEX0306\_133 flex DEX0157\_77  
DEX0306\_134 DEX0157\_78 DEX0306\_269  
DEX0306\_135 flex DEX0157\_78 DEX0306\_270  
45 DEX0306\_136 DEX0157\_79 DEX0306\_271  
DEX0306\_137 flex DEX0157\_79 DEX0306\_272  
DEX0306\_138 DEX0157\_80 DEX0306\_273  
DEX0306\_139 DEX0157\_81 DEX0306\_274  
DEX0306\_140 flex DEX0157\_81 DEX0306\_275  
50 DEX0306\_141 DEX0157\_82 DEX0306\_276  
DEX0306\_142 flex DEX0157\_82  
DEX0306\_143 DEX0157\_83 DEX0306\_277  
DEX0306\_144 flex DEX0157\_83  
DEX0306\_145 DEX0157\_85 DEX0306\_278  
55 DEX0306\_146 flex DEX0157\_85  
DEX0306\_147 DEX0157\_86 DEX0306\_279  
DEX0306\_148 flex DEX0157\_86 DEX0306\_280  
DEX0306\_149 DEX0157\_87 DEX0306\_281  
DEX0306\_150 flex DEX0157\_87  
60 DEX0306\_151 DEX0157\_88 DEX0306\_282  
DEX0306\_152 flex DEX0157\_88  
DEX0306\_153 DEX0157\_89 DEX0306\_283

-112-

DEX0306\_154 flex DEX0157\_89  
 DEX0306\_155 DEX0157\_90 DEX0306\_284  
 DEX0306\_156 flex DEX0157\_90 DEX0306\_285  
 DEX0306\_157 DEX0157\_93 DEX0306\_286  
 5 DEX0306\_158 DEX0157\_94 DEX0306\_287  
 DEX0306\_159 flex DEX0157\_94  
 DEX0306\_160 DEX0157\_95 DEX0306\_288  
 DEX0306\_161 flex DEX0157\_95  
 DEX0306\_162 DEX0157\_96 DEX0306\_289  
 10 DEX0306\_163 DEX0157\_97 DEX0306\_290  
 DEX0306\_164 flex DEX0157\_97  
 DEX0306\_165 DEX0157\_98 DEX0306\_291  
 DEX0306\_166 DEX0157\_99 DEX0306\_292  
 DEX0306\_167 DEX0157\_100 DEX0306\_293  
 15 DEX0306\_168 flex DEX0157\_100  
 DEX0306\_169 DEX0157\_101 DEX0306\_294  
 DEX0306\_170 DEX0157\_102 DEX0306\_295  
 DEX0306\_171 flex DEX0157\_102

## 20 Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation  
 detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The  
 method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5'  
 reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity  
 25 of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected  
 by the laser detector of the Model 7700 Sequence Detection System (PE Applied  
 Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to  
 standardize the amount of sample RNA added to the reaction and normalize for Reverse  
 Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate  
 30 dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this  
 endogenous control. To calculate relative quantitation between all the samples studied,  
 the target RNA levels for one sample were used as the basis for comparative results  
 (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard  
 curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence  
 35 Detection System).

The tissue distribution and the level of the target gene are evaluated for every  
 sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer  
 tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently,  
 first strand cDNA is prepared with reverse transcriptase and the polymerase chain  
 40 reaction is done using primers and Taqman probes specific to each target gene. The  
 results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute  
 numbers are relative levels of expression of the target gene in a particular tissue  
 compared to the calibrator tissue.



-113-

One of ordinary skill can design appropriate primers. The relative levels of expression of the BSNA versus normal tissues and other cancer tissues can then be determined. All the values are compared to a normal tissue (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the BSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values are compared to a normal tissue (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, BSNAs show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results obtained with normal pooled samples.

Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1 through 171 being diagnostic markers for cancer.

#### **Example 2B: Custom Microarray Experiment**

Custom oligonucleotide microarrays were provided by Agilent Technologies, Inc. (Palo Alto, CA). The microarrays were fabricated by Agilent using their technology for the *in-situ* synthesis of 60mer oligonucleotides (Hughes, et al. 2001, Nature Biotechnology 19:342-347). The 60mer microarray probes were designed by Agilent, from gene sequences provided by diaDexus, using Agilent proprietary algorithms. Whenever possible two different 60mers were designed for each gene of interest.

All microarray experiments were two-color experiments and were performed using Agilent-recommended protocols and reagents. Briefly, each microarray was hybridized with cRNAs synthesized from polyA+ RNA, isolated from cancer and normal tissues, labeled with fluorescent dyes Cyanine3 and Cyanine5 (NEN Life Science Products, Inc., Boston, MA) using a linear amplification method (Agilent). In each experiment, the experimental sample was polyA+ RNA isolated from cancer tissue from

-114-

a single individual and the reference sample was a pool of polyA+ RNA isolated from normal tissues of the same organ as the cancerous tissue (*i.e.* normal breast tissue in experiments with breast cancer samples). Hybridizations were carried out at 60°C, overnight using Agilent *in-situ* hybridization buffer. Following washing, arrays were  
5 scanned with a GenePix 4000B Microarray Scanner (Axon Instruments, Inc., Union City, CA). The resulting images were analyzed with GenePix Pro 3.0 Microarray Acquisition and Analysis Software (Axon). A total of 36 experiments comparing the expression patterns of breast cancer derived polyA+ RNA (9 stage 1 cancers, 23 stage 2 cancers, 4 stage 3 cancers) to polyA+ RNA isolated from a pool of 10 normal breast tissues were  
10 analyzed.

Data normalization and expression profiling were done with Expressionist software from GeneData Inc. (Daly City, CA/Basel, Switzerland). Gene expression analysis was performed using only experiments that meet certain quality criteria. The quality criteria that experiments must meet are a combination of evaluations performed  
15 by the Expressionist software and evaluations performed manually using raw and normalized data. To evaluate raw data quality, detection limits (the mean signal for a replicated negative control  $\pm 2$  Standard Deviations (SD)) for each channel were calculated. The detection limit is a measure of non-specific hybridization. Arrays with poor detection limits were not analyzed and the experiments were repeated. To evaluate  
20 normalized data quality, positive control elements included in the array were utilized. These array features should have a mean ratio of 1 (no differential expression). If these features have a mean ratio of greater than 1.5-fold up or down, the experiments were not analyzed further and were repeated. In addition to traditional scatter plots demonstrating the distribution of signal in each experiment, the Expressionist software also has  
25 minimum thresholding criteria that employs user defined parameters to identify quality data. Only those features that meet the threshold criteria were included in the filtering and analyses carried out by Expressionist. The thresholding settings employed require a minimum area percentage of 60% [(% pixels > background  $\pm 2$ SD)-( % pixels saturated)], and a minimum signal to noise ratio of 2.0 in both channels. By these criteria, very low  
30 expressors and saturated features were not included in analysis.

Relative expression data was collected from Expressionist based on meeting the quality parameters described above. Sensitivity data was calculated using an analysis tool. Up- and down- regulated genes were identified using criteria for percentage of valid values obtained, and the percentage of experiments in which the gene is up- or

-115-

down-regulated. These criteria were set independently for each data set, depending on the size and the nature of the data set. Results for several BSNA's are shown in the following table. The first three columns of the table contain information about the sequence itself (Oligo ID, Parent ID, and SEQ ID NO), the next 3 columns show the results obtained. '%valid' indicates the percentage of 36 unique experiments total in which a valid expression value was obtained, '%up' indicates the percentage of 20 experiments in which up-regulation of at least 2.5-fold was observed, and '%down' indicates the percentage of the 36 experiments in which down-regulation of at least 2.5-fold was observed. The last column in Table 1 describes the location of the microarray probe (oligo) relative to the sequence.

OligoID	Parent ID	Patent # SEQ ID NO	Sensitivity of up and down regulation			Oligo Seq location in original seq.	Oligo Seq location in FLEX seq
			% valid	% up	% down		
16052	8056	DEX0157_74, DEX0131_52 SEQ ID NO: 127/128	100	11.1	33.3	75-134	1928-1987
24688	5998	DEX0167_22, DEX0157_95, DEX0133_22, DEX0131_78 SEQ ID NO: 160/161	94.4	2.8	58.3	437-496	1093-1152
24689	5998	DEX0157_95, DEX0131_78 SEQ ID NO: 160/161	97.2	2.8	61.1	397-456	
27873	8713	DEX0157_74, DEX0131_52 SEQ ID NO: 127/128	100	13.9	30.6	101-160	1954-2013
33090	5973	DEX0157_73, DEX0131_56 SEQ ID NO: 125/126	97.2	2.8	44.4	408-466	2142-2200
33091	5973	DEX0157_73, DEX0131_56 SEQ ID NO: 125/126	100	2.8	41.7	368-427	1221-1280

### Example 3: Protein Expression

The BSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the BSNA is subcloned in pET-21d for expression in *E. coli*. In addition to the BSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of BSNA, and six histidines, flanking the

-116-

COOH-terminus of the coding sequence of BSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be observed on a Coomassie blue stained polyacrylamide gel. This protein band is  
5 confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of BSP was achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that had been separated from total cell lysate were incubated with a nickle chelating resin. The column was packed and washed with five column  
10 volumes of wash buffer. BSP was eluted stepwise with various concentration imidazole buffers.

#### Example 4: Protein Fusions

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also  
15 should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a  
20 polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the  
25 vector can be modified to include a heterologous signal sequence. *See, e. g.*, WO 96/34891.

#### Example 5: Production of an Antibody from a Polypeptide

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such  
30 cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The

-117-

splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT

- 5 medium, and then cloned by limiting dilution as described by Wands *et al.*, *Gastroenterology* 80: 225-232 (1981).

The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

- Alternatively, additional antibodies capable of binding to the polypeptide can be  
 10 produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the  
 15 hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies. Using the Jameson-Wolf methods the following epitopes were predicted. (Jameson and  
 20 Wolf, CABIOS, 4(1), 181-186, 1988, the contents of which are incorporated by reference).

The predicted antigenicity for the amino acid sequences is as follows:

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_ 172			Myristyl 28-33; 53-58; 60- 65; Pkc_Phospho_ Site 67-69;	26, .882, .574
DEX0306_ 173			Myristyl 13-18; Pkc_Phospho_Site 19-21;	
DEX0306_ 174		1,120-420		
DEX0306_ 175	11-21, 1.07, 11		Pkc_Phospho_Site 4-6; 12-14;	
DEX0306_ 176	52-69, 1.16, 18 9-18, 1.16, 10		Asn_Glycosylation 82-85; Ck2_Phospho_Site 7-10; Myristyl 79-84;	

-118-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			Pkc_Phospho_Site 4-6;	
DEX0306_177			Asn_Glycosylation 7-10;55-58; Ck2_Phospho_Site 22-25;57-60; Pkc_Phospho_Site 57-59; Tyr_Phospho_Site 46-52;	
DEX0306_178	10-47,1.07,38 80-141, 1.03, 62		Myristyl 33- 38;129-134; Pkc_Phospho_Site 116-118;147-149;	
DEX0306_179			Myristyl 3-8;	
DEX0306_180	59-74,1.04,16		Ck2_Phospho_Site 4-7;49-52; Myristyl 45- 50;50-55;80- 85;86-91;95-100; Pkc_Phospho_Site 60-62;65-67;69- 71;	
DEX0306_182			Myristyl 22-27;	
DEX0306_184	12-36,1.22,25		Asn_Glycosylation 32-35; Camp_Phospho_Site 26-29; Ck2_Phospho_Site 9-12; Pkc_Phospho_Site 25-27;	
DEX0306_185	6-39,1.13,34		Asn_Glycosylation 64-67; Ck2_Phospho_Site 37-40;65-68; Glycosaminoglycan 48-51; Myristyl 14-19;49-54;51- 56; Pkc_Phospho_Site 18-20;42-44;	
DEX0306_187		1,025-47i	Ck2_Phospho_Site 70-73; Myristyl 7-12; Pkc_Phospho_Site 42-44;	
DEX0306_188		3,i5-22o32- 54i61-83o	Myristyl 27- 32;141-146;144- 149; Pkc_Phospho_Site 17-19;55-57;90- 92;111-113;	17, .989, .91
DEX0306			Ck2_Phospho_Site	

-119-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
190			73-76; Myristyl 12-17;17-22;66- 71; Pkc_Phospho_Site 91-93;	
DEX0306_ 192			Pkc_Phospho_Site 6-8;	
DEX0306_ 193			Myristyl 4-9;	
DEX0306_ 194	415-439, 1.14,25 242-251, 1.13,10 459-528, 1.11,70 159-197, 1.09,39 777-810, 1.09,34 632-669, 1.07,38 1034-1044, 1.04,11 1077-1103, 1.03,27		Asn_Glycosylation 12-15;19-22;23- 26;151-154;513- 516;873-876;886- 889; Camp_Phospho_ Site 107-110; Ck2_Phospho_Site 72-75;260- 263;283-286;319- 322;463-466;807- 810;975-978; Glycosaminoglycan 125-128;905- 908;913-916; Myristyl 13- 18;28-33;30- 35;52-57;53- 58;58-63;61- 66;62-67;126- 131;179-184;372- 377;529-534;699- 704;716-721;717- 722;721-726;837- 842;845-850;889- 894;906-911;910- 915; Pkc_Phospho_Site 129-131;160- 162;188-190;189- 191;356-358;613- 615;822-824;825- 827; Prokar_ Lipoprotein 44- 54;	
DEX0306_ 195			Pkc_Phospho_Site 6-8;	
DEX0306_ 196			Pkc_Phospho_Site 24-26;33-35;	
DEX0306_ 197			Pkc_Phospho_Site 7-9;	
DEX0306_ 198	39-55,1.09,17 25-34,1.05,10		Ck2_Phospho_Site 92-95; Pkc_Phospho_Site 107-109;	
DEX0306_ 199	97-113, 1.09,17		Ck2_Phospho_Site 150-153;193-	

-120-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
	83-92, 1.05, 10		196; 200-203; Myristyl 11- 16; 178-183; Pkc_Phospho_Site 165-167; Tyr_Phospho_Site 53-61;	
DEX0306_200		1, i12-34o	Asn_Glycosylation 20-23; Myristyl 18-23;	
DEX0306_201			Myristyl 16-21; Pkc_Phospho_Site 24-26;	24, .944, .7 79
DEX0306_202	25-37, 1.17, 13		Ck2_Phospho_Site 12-15; Myristyl 27-32; 31-36; 53- 58;	
DEX0306_203			Asn_Glycosylation 28-31; Myristyl 8-13; 62-67; 63- 68; 64-69;	
DEX0306_204			Pkc_Phospho_Site 2-4;	
DEX0306_205			Ck2_Phospho_Site 60-63; 77-80; Myristyl 14-19; Pkc_Phospho_Site 57-59;	
DEX0306_206		1, o5-24i	Myristyl 4-9;	
DEX0306_207			Ck2_Phospho_Site 64-67; 75-78; Myristyl 71- 76; 81-86; 85-90;	
DEX0306_208			Asn_Glycosylation 53-56; 62-65; Myristyl 72-77; Pkc_Phospho_Site 63-65; 64-66;	
DEX0306_209			Asn_Glycosylation 47-50; Pkc_Phospho_Site 28-30; 38-40; Tyr_Phospho_Site 29-36; 30-36;	
DEX0306_211			Asn_Glycosylation 33-36; Ck2_Phospho_Site 17-20; Pkc_Phospho_Site 26-28;	
DEX0306_212	30-39, 1.06, 10		Ck2_Phospho_Site 76-79; Myristyl 19-24; 31-36; 92- 97; Pkc_Phospho_Site	17, .97, .82 9



-121-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			12-14;76-78; Pkc_Phospho_Site 29-31;	
DEX0306_213			Myristyl 43-48;48-53;	
DEX0306_214			Myristyl 90-95;101-106;104-109;	21,.973,.8 2
DEX0306_215	104-118, 1.16,15		Ck2_Phospho_Site 5-8;	
DEX0306_216		1,i11-33o	Myristyl 42-47;54-59;67-72; Pkc_Phospho_Site 4-6;37-39;	33,.982,.8 23
DEX0306_217			Asn_Glycosylation 12-15; Ck2_Phospho_Site 8-11; Myristyl 3-8; Pkc_Phospho_Site 23-25;	
DEX0306_218			Asn Glycosylation 21-24; Ck2_Phospho_Site 43-46; Pkc_Phospho_Site 23-25;	
DEX0306_219			Amidation 19-22; Pkc_Phospho_Site 23-25;	
DEX0306_220	14-32,1.13,19		Pkc_Phospho_Site 18-20;	
DEX0306_221			Pkc_Phospho_Site 2-4;	
DEX0306_223			Ck2_Phospho_Site 31-34;38-41;57-60;79-82;85-88; Pkc_Phospho_Site 7-9;	
DEX0306_224		1,i7-26o	Asn_Glycosylation 34-37; Ck2_Phospho_Site 36-39;	
DEX0306_225			Pkc_Phospho_Site 34-36;	15,.918,.7 44
DEX0306_226	52-72,1.19,21	1,i73-95o	Amidation 66-69; Ck2_Phospho_Site 6-9; Myristyl 74-79;78-83;	
DEX0306_227		1,i20-42o		
DEX0306_228		1,o22-44i	Prokar_ Lipoprotein 23-33;	
DEX0306_230			Camp_Phospho_Site 3-6; Myristyl 31-	
DEX0306_231				

-122-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			36;90-95;	
DEX0306_232		1,015-32i	Myristyl 47-52; Pkc_Phospho_Site 2-4;	
DEX0306_233			Asn_Glycosylation 4-7;	
DEX0306_234	24-39,1.2,16		Myristyl 8-13; Pkc_Phospho_Site 65-67;	
DEX0306_235	560-572, 1.27,13 509-519, 1.23,11 1126-1153, 1.19,28 861-873, 1.18,13 794-804, 1.16,11 964-976, 1.16,13 880-901, 1.16,22 812-828, 1.11,17 588-612, 1.09,25 41-77, 1.07,37 461-489, 1.07,29 735-751, 1.07,17 978-1011, 1.06,34 535-558, 1.04,24 1081-1.04,17 620-644, 1.03,25 654-671, 1.01,18 354-382,1,29		Amidation 281- 284;403-406;721- 724; Asn_Glycosylation 633-636;655-658; Atp_Gtp_A 507- 514; Camp_Phospho_Site 54-57;479-482; Ck2_Phospho_Site 132-135;144- 147;181-184;209- 212;217-220;244- 247;310-313;332- 335;345-348;546- 549;558-561;560- 563;593-596;617- 620;622-625;635- 638;651-654;656- 659;697-700;739- 742;740-743;745- 748;969-972; Glycosaminoglycan 482-485;719-722; Myristyl 110- 115;130-135;142- 147;159-164;230- 235;254-259;277- 282;341-346;400- 405;510-515;572- 577;582-587;645- 650;721-726;823- 828;842-847;843- 848;846-851;872- 877;922-927;940- 945;954-959; Pkc_Phospho_Site 72-74;83-85;148- 150;155-157;156- 158;209-211;627- 629;635-637;656- 658;660-662;661- 663;736-738;739- 741;745-747;766- 768;802-804;813- 815;913-915;965- 967;973-975;	

-123-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			Tyr_Phospho_Site 55-62;426-433; Zinc_Finger_C2h2 36-56;176- 197;250-270;278- 298;337-357;517- 537;	
DEX0306_ 236	11-29,1,19	1,o32-54i		
DEX0306_ 237			Glycosaminoglycan 80-83; Myristyl 14-19;54-59;58- 63; Pkc_Phospho_Site 68-70;80-82;	
DEX0306_ 238		1,o62-84i	Asn_Glycosylation 30-33; Pkc_Phospho_Site 31-33;	
DEX0306_ 239	42-63,1.12,22		Asn_Glycosylation 145-148; Ck2_Phospho_Site 4-7;63-66;151- 154; Euk_Co2_Anhydrase 126-142; Myristyl 25-30;33-38;125- 130; Pkc_Phospho_Site 280-282;	
DEX0306_ 240	20-34,1.08,15		Asn_Glycosylation 53-56; Camp_Phospho_Site 41-44; Pkc_Phospho_Site 39-41;	
DEX0306_ 242			Myristyl 49-54; Pkc_Phospho_Site 33-35;	
DEX0306_ 243			Ck2_Phospho_Site 23-26;24-27; Pkc_Phospho_Site 9-11;23-25;	
DEX0306_ 244			Asn_Glycosylation 4-7;	
DEX0306_ 245	45-55,1.15,11		Camp_Phospho_Site 51-54; Ck2_Phospho_Site 60-63; Pkc_Phospho_Site 22-24;	
DEX0306_ 246			Pkc_Phospho_Site 7-9;35-37;	
DEX0306_ 247			Myristyl 86-91; Pkc_Phospho_Site 17-19;	22,.929,.6 52

-124-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_248				18,.993,.9 14
DEX0306_249			Asn_Glycosylation 2-5; Ck2_Phospho_Site 54-57; Pkc_Phospho_Site 54-56;	28,.911,.7 4
DEX0306_250	142-180, 1.03,39 9-21,1,13		Asn_Glycosylation 13-16;132-135; Ck2_Phospho_Site 97-100; Pkc_Phospho_Site 17-19;55-57;113- 115;134-136;153- 155;	
DEX0306_251	113-123, 1.14,11 37-60,1.09,24		Camp_Phospho_Site 50-53; Ck2_Phospho_Site 88-91; Pkc_Phospho_Site 39-41;49-51;88- 90; Prokar_Lipoprotei n 59-69; Tyr_Phospho_Site 87-95;	
DEX0306_252			Pkc_Phospho_Site 10-12;	
DEX0306_253		1,i12-43o	Myristyl 30-35; Prokar_Lipoprotei n 12-22;	30,.996,.8 62
DEX0306_254			Ck2_Phospho_Site 16-19; Myristyl 31-36;36-41; Pkc_Phospho_Site 32-34; Rgd 25-27;	
DEX0306_255			Asn_Glycosylation 386-389;516- 519;536-539;626- 629;638-641;883- 886; Camp_Phospho_Site 61-64; Ck2_Phospho_Site 147-150;201- 204;205-208;252- 255;394-397;435- 438;462-465;491- 494;511-514;524- 527;552-555;632- 635;646-649;756- 759;839-842;867- 870;887-890; Myristyl 25- 30;263-268;751-	

-125-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			756;879-884; Pkc_Phospho_Site 29-31;107- 109;147-149;201- 203;506-508; Tyr_Phospho_Site 467-473;	
DEX0306_ 256	65-75,1.02,11 25-50,1.02,26		Asn_Glycosylation 56-59; Myristyl 14-19; Prokar_ Lipoprotein 8-18;	
DEX0306_ 257	179-203, 1.18,25 527-569, 1.15,43 422-464, 1.11,43 20-39,1.06,20 335-367, 1.06,33 43-117, 1.01,75		Amidation 267- 270; Asn_Glycosylation 176-179; Camp_Phospho_Site 71-74;324-327; Ck2_Phospho_Site 42-45;54-57;75- 78;99-102;109- 112;161-164;197- 200;206-209;223- 226;228-231;273- 276;283-286;336- 339;447-450;482- 485;497-500;567- 570; Glycosaminoglycan 246-249; Myristyl 24-29;38-43;86- 91;124-129;249- 254;262-267;278- 283;290-295;332- 337;410-415;430- 435; Pkc_Phospho_Site 12-14;18-20;28- 30;35-37;54- 56;69-71;296- 298;336-338;411- 413;434-436; Tyr_Phospho_Site 23-29;137- 144;310-318;	
DEX0306_ 258			Ck2_Phospho_Site 34-37;	
DEX0306_ 259			Asn_Glycosylation 31-34;	
DEX0306_ 260			Camp_Phospho_Site 6-9; Myristyl 54- 59;	
DEX0306_ 261	96-105, 1.19,10		Ck2_Phospho_Site 71-74;101-104; Glycosaminoglycan 55-58; Myristyl 52-57;54-59;58-	

-126-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			63;67-72; Pkc_Phospho_Site 17-19;137- 139;146-148;197- 199;215-217; Prokar_Lipoprotei n 164-174;	
DEX0306_ 262	30-41,1.02,12		Asn_Glycosylation 86-89; Ck2_Phospho_Site 21-24; Myristyl 96-101; Pkc_Phospho_Site 18-20;	
DEX0306_ 263	239-249, 1.13,11		Amidation 72-75; Asn_Glycosylation 119-122;120-123; Camp_Phospho_Site 107-110;216-219; Ck2_Phospho_Site 28-31;43-46;63- 66;160-163;169- 172;187-190; Myristyl 69- 74;158-163; Pkc_Phospho_Site 17-19;24-26;35- 37;52-54;59- 61;106-108;122- 124;184-186; Prokar_ Lipoprotein 248- 258;	
DEX0306_ 264			Myristyl 35-40; Pkc_Phospho_Site 21-23;22-24;	
DEX0306_ 265		1,i7-29o	Camp_Phospho_Site 47-50; Ck2_Phospho_Site 54-57; Myristyl 37-42; Pkc_Phospho_Site 72-74;	
DEX0306_ 266			Asn_Glycosylation 7-10;17-20; Pkc_Phospho_Site 2-4;	
DEX0306_ 267			Amidation 43-46; Ck2_Phospho_Site 79-82; Pkc_Phospho_Site 11-13;89-91;	
DEX0306_ 268			Pkc_Phospho_Site 8-10;45-47; Prokar_Lipoprotei n 32-42;	

-127-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
DEX0306_269			Camp_Phospho_Site 66-69; Ck2_Phospho_Site 12-15;34-37;56-59; Myristyl 30-35; Pkc_Phospho_Site 34-36;56-58;	
DEX0306_270	49-134,1,86		Asn_Glycosylation 46-49; Ck2_Phospho_Site 65-68;84-87;93-96;109-112; Myristyl 4-9;59-64; Pkc_Phospho_Site 60-62;89-91;104-106;115-117;116-118; Tyr_Phospho_Site 92-99;117-124;118-124;	
DEX0306_272	235-299,1.1,65 369-406, 1.07,38 99-109, 1.01,11		Asn_Glycosylation 37-40;69-72;284-287; Ck2_Phospho_Site 85-88;141-144;149-152;192-195;204-207; Glycosaminoglycan 433-436; Myristyl 43-48;44-49;96-101;118-123;402-407;406-411;432-437;438-443; Pkc_Phospho_Site 48-50;433-435; Rgd 278-280; Tyr_Phospho_Site 50-56;	
DEX0306_273			Pkc_Phospho_Site 6-8;15-17;	
DEX0306_274			Asn_Glycosylation 44-47;	
DEX0306_275			Asn_Glycosylation 78-81; Ck2_Phospho_Site 17-20; Myristyl 13-18;	
DEX0306_276			Ck2_Phospho_Site 58-61; Glycosaminoglycan 93-96; Myristyl 28-33;48-53;50-55;67-72;71-76; Pkc_Phospho_Site	

-128-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
			5-7;18-20;44-46;57-59; Rgd 59-61;	
DEX0306_277		1,037-59i	Ck2_Phospho_Site 22-25; Myristyl 71-76; Pkc_Phospho_Site 12-14;	
DEX0306_279			Myristyl 15-20;	
DEX0306_280			Ck2_Phospho_Site 76-79; Pkc_Phospho_Site 16-18;	27,.985,.682
DEX0306_281	17-29,1.07,13		Myristyl 5-10;9-14; Pkc_Phospho_Site 24-26;	
DEX0306_282		1,015-32i		
DEX0306_283			Asn_Glycosylation 35-38; Ck2_Phospho_Site 37-40; Myristyl 3-8; Pkc_Phospho_Site 57-59;	
DEX0306_284	28-37,1.09,10		Ck2_Phospho_Site 46-49; Pkc_Phospho_Site 32-34;	21,.958,.821
DEX0306_285	226-245, 1.37,20 489-501, 1.22,13 1271-1284, 1.21,14 1192-1203, 1.11,12 745-755, 1.09,11 929-940, 1.08,12 1039-1051, 1.08,13 1133-1150, 1.05,18 547-576, 1.05,30 89-98,1.04,10 22-53,1.03,32 1073-1086, 1.03,14 1243-1253, 1.03,11 1418-1461,		Amidation 473-476; Asn_Glycosylation 512-515;726-729; Camp_Phospho_Site 475-478;571-574;646-649; Ck2_Phospho_Site 29-32;143-146;176-179;228-231;230-233;232-235;263-266;294-297;388-391;447-450;493-496;506-509;517-520;581-584;664-667;890-893;929-932; Gram_Pos_Anchorin g 670-675; Myristyl 49-54;56-61;125-130;152-157;185-190;214-219;677-682;708-713;840-845;921-926;	



-129-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
	1.01, 44		Pkc_Phospho_Site 21-23; 29-31; 143- 145; 388-390; 415- 417; 443-445; 530- 532; 539-541; 552- 554; 565-567; 581- 583; 748-750; 802- 804; 925-927; 931- 933; 987-989; 996- 998; Tyr_Phospho_Site 867-874; Amidation 473-476; Asn_Glycosylation 512-515; 726-729; Camp_Phospho_Site 475-478; 571- 574; 646-649; Ck2_Phospho_Site 29-32; 143- 146; 176-179; 228- 231; 230-233; 232- 235; 263-266; 294- 297; 388-391; 447- 450; 493-496; 506- 509; 517-520; 581- 584; 664-667; 890- 893; 929-932; Gram_Pos_ Anchoring 670- 675; Myristyl 49- 54; 56-61; 125- 130; 152-157; 185- 190; 214-219; 677- 682; 708-713; 840- 845; 921-926; Pkc_Phospho_Site 21-23; 29-31; 143- 145; 388-390; 415- 417; 443-445; 530- 532; 539-541; 552- 554; 565-567; 581- 583; 748-750; 802- 804; 925-927; 931- 933; 987-989; 996- 998; Tyr_Phospho_Site 867-874;	
DEX0306_286		2, i13-30o35-54i	Asn_Glycosylation 15-18; Ck2_Phospho_Site 41-44; Myristyl 2-7; Pkc_Phospho_Site 6-8;	
DEX0306			Asn_Glycosylation	

-130-

DEX ID	ANTIGENICITY Position, AI Ave, Length	TRANSMEMBRANE Predicted Helix, Topology	PTM PTM	SIGNAL PEPTIDE Position, Max Score, Mean Score
287			43-46; 51-54; Ck2_Phospho_Site 34-37; Pkc_Phospho_Site 70-72;	
DEX0306_ 288			Asn_Glycosylation 42-45; Camp_Phospho_Site 12-15; Myristyl 4-9;	
DEX0306_ 290	20-31, 1.14, 12		Pkc_Phospho_Site 6-8; 21-23;	
DEX0306_ 291			Glycosaminoglycan 31-34; Myristyl 30-35;	
DEX0306_ 292			Camp_Phospho_Site 8-11; Ck2_Phospho_Site 11-14;	
DEX0306_ 293			Ck2_Phospho_Site 36-39; Myristyl 2-7; 94-99;	
DEX0306_ 294	31-52, 1.01, 22		Pkc_Phospho_Site 47-49;	
DEX0306_ 295			Myristyl 56-61;	

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

- 5 RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using protocols known in the art. See, Sambrook (2001), *supra*. The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1 through 171. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds;
- 10 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). See also Sidransky *et al.*, *Science* 278(5340): 1054-9 (1997).

- PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies).
- 15 The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then cloned and sequenced to validate the results of the direct sequencing. PCR products is

-131-

cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are  
5 nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Mannheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium  
10 iodide, producing a combination of C-and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical  
15 Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological  
20 Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 µg/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells  
25 are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate,  
30 at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl

-132-

phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

#### Example 8: Formulating a Polypeptide

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 ,  $\mu\text{g/kg/day}$  to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g/kg/hour}$  to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

-133-

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, I. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate,

succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e. g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

#### **Example 9: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form.

-135-

Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

- 5           For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100  $\mu\text{g/kg}$  of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

**Example 10: Method of Treating Increased Levels of the Polypeptide**

- 10           Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

- For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0  
15           and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided above.

**Example 11: Method of Treatment Using Gene Therapy**

- One method of gene therapy transplants fibroblasts, which are capable of  
20           expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room  
25           temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

- At this time, fresh media is added and subsequently changed every several days.  
30           After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf

-136-

intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

#### **Example 12: Method of Treatment Using Gene Therapy-*In Vivo***

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.



This page is not part of  
the pamphlet!

**WO 02-064611**

**2/5**

Date: 22 aug 2002

Destination: Agent

Address:



-137-

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, W0 90/11092, W0 98/11779; U. S. Patent 5,693,622;

- 5 5,705,151; 5,580,859; Tabata H. et al. (1997) *Cardiovasc. Res.* 35 (3): 470-479, Chao J et al. (1997) *Pharmacol. Res.* 35 (6): 517-522, Wolff J. A. (1997) *Neuromuscul. Disord.* 7 (5): 314-318, Schwartz B. et al. (1996) *Gene Ther.* 3 (5): 405-411, Tsurumi Y. et al. (1996) *Circulation* 94 (12): 3281-3290 (incorporated herein by reference).

- The polynucleotide constructs may be delivered by any method that delivers  
10 injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

- The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell,  
15 including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et al. (1995) *Ann. NY Acad. Sci.* 772: 126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85 (1): 1-7) which can be prepared by methods well known to those skilled in the art.

- 20 The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target  
25 cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

- The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow,  
30 thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue

-138-

ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They

5 are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

- 10 For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 µg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of
- 15 injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation
- 20 particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for

25 polypeptide of the present invention is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by

30 intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about

-139-

0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e. g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

10 The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

#### **Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i. e., polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology (NY) 11: 1263-1270 (1993); Wright et al., Biotechnology (NY) 9: 830-834 (1991); and Hoppe et al., U. S. Patent 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., Science 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., Cell 57: 717-723 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115: 171-229 (1989), which is incorporated by reference herein in its entirety.

-140-

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810813 (1997)).

5       The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a  
10 particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89: 6232-6236 (1992)). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous  
15 gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus  
20 inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science 265: 103-106 (1994)). The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant  
25 gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples  
30 obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

-141-

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in  
5 order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or  
10 homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant  
15 expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

#### **Example 14: Knock-Out Animals**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see  
20 Smithies et al., Nature 317: 230-234 (1985); Thomas & Capecchi, Cell 51: 503-512 (1987); Thompson et al., Cell 5: 313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions  
25 of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such  
30 approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the

-142-

recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i. e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e. g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U. S. Patent 5,399,349; and Mulligan & Wilson, U. S. Patent 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function



-143-

of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

All patents, patent publications, and other published references mentioned herein  
5 are hereby incorporated by reference in their entireties as if each had been individually  
and specifically incorporated by reference herein. While preferred illustrative  
embodiments of the present invention are described, one skilled in the art will appreciate  
that the present invention can be practiced by other than the described embodiments,  
which are presented for purposes of illustration only and not by way of limitation. The  
10 present invention is limited only by the claims that follow.

-144-

## CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising
  - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes  
5 an amino acid sequence of SEQ ID NO: 172 through 295;
  - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID  
NO: 1 through 171;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid  
molecule of (a) or (b); or
  - 10 (d) a nucleic acid molecule having at least 60% sequence identity to the nucleic  
acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid  
20 molecule is a mammalian nucleic acid molecule.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid  
molecule is a human nucleic acid molecule.
- 25 6. A method for determining the presence of a breast specific nucleic acid  
(BSNA) in a sample, comprising the steps of:
  - (a) contacting the sample with the nucleic acid molecule according to claim 1  
under conditions in which the nucleic acid molecule will selectively hybridize to a breast  
specific nucleic acid; and
  - 30 (b) detecting hybridization of the nucleic acid molecule to a BSNA in the  
sample, wherein the detection of the hybridization indicates the presence of a BSNA in  
the sample.
7. A vector comprising the nucleic acid molecule of claim 1.

-145-

8. A host cell comprising the vector according to claim 7.

9. A method for producing a polypeptide encoded by the nucleic acid molecule  
5 according to claim 1, comprising the steps of (a) providing a host cell comprising the  
nucleic acid molecule operably linked to one or more expression control sequences, and  
(b) incubating the host cell under conditions in which the polypeptide is produced.

10. A polypeptide encoded by the nucleic acid molecule according to claim 1.

10

11. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence with at least 60%  
sequence identity to of SEQ ID NO: 172 through 295; or

(b) a polypeptide comprising an amino acid sequence encoded by a nucleic  
15 acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 171.

12. An antibody or fragment thereof that specifically binds to the polypeptide  
according to claim 11.

20 13. A method for determining the presence of a breast specific protein in a  
sample, comprising the steps of:

(a) contacting the sample with the antibody according to claim 12 under  
conditions in which the antibody will selectively bind to the breast specific protein; and

(b) detecting binding of the antibody to a breast specific protein in the sample,  
25 wherein the detection of binding indicates the presence of a breast specific protein in the  
sample.

14. A method for diagnosing and monitoring the presence and metastases of  
breast cancer in a patient, comprising the steps of:

30 (a) determining an amount of the nucleic acid molecule of claim 1 or a  
polypeptide of claim 11 in a sample of a patient; and

(b) comparing the amount of the determined nucleic acid molecule or the  
polypeptide in the sample of the patient to the amount of the breast specific marker in a  
normal control; wherein a difference in the amount of the nucleic acid molecule or the

-146-

polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of breast cancer.

15. A kit for detecting a risk of cancer or presence of cancer in a patient, said  
5 kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 11 in a sample of a patient.

16. A method of treating a patient with breast cancer, comprising the step of  
administering a composition according to claim 12 to a patient in need thereof, wherein  
10 said administration induces an immune response against the breast cancer cell expressing the nucleic acid molecule or polypeptide.

17. A vaccine comprising the polypeptide or the nucleic acid encoding the  
polypeptide of claim 11.

15

1

## SEQUENCE LISTING

<110> diaDexus, Inc.  
 Salceda, Susana  
 Macina, Roberto  
 Hu, Ping  
 Recipon, Herve  
 Karra, Kalpana  
 Cafferkey, Robert  
 Sun, Yongming  
 Liu, Chenghua'

<120> Compositions and Methods Relating to Breast Specific Genes and Proteins

<130> DEX-0306

<150> 60/268,292

<151> 2001-02-13

<160> 295

<170> PatentIn version 3.1

<210> 1

<211> 591

<212> DNA

<213> Homo sapien

<400> 1

```

gctcttctctg tctacaaagg ggactgctca cagtggcctc agcttggtgg ttttgagggg      60
ccgcccccccg gccctccata agggatcctt gggcctgaga attctgcata tgccattgga      120
tggatgtaca gcctcaaattg gaagtgaagc ccacgggaga tgggtccgag gtccaggctg      180
tggccatcca gccccctgtg gcttgtccag cctctgtgca cccctggtgt cttcactcca      240
ggggcagaca gtagccactg cagttccttt cttcgtgaga taacagtagt gatagcagct      300
ggggctaaca ggctaggctt agtgctctgc gcatttggtc agcttctcac tcgacccctc      360
ctaaagcaat ggggaggccc ccactagccc agttttcagg aagtcaactg ggagggttaga      420
tggggggccag aggtcccaca gctactgatg gcccagagcca ggttgagctt tcctggatgt      480
ccagtccgga tcccacttgc agatctcatg ctctcagata ggtgggacaa gttcttttgt      540
cacagtgtctg gctctgtcct gaggcctcat tgctggtctg tgtgctctgc t          591

```

<210> 2

<211> 2754

<212> DNA

<213> Homo sapien

<400> 2

```

gccagaagca gcctcagctt ggcaagggtg ggagatgact gctgttcctt tcgcatttgg      60

```

ggaaaacagg ctccctcggg agctcgatga tcctcttttg atcttggtg acctcctgga 120  
 gagtggatga cgctgggtggc cttagctttt ctagacagtg taaattgcac tgggcgatgt 180  
 ccccagagca gggcaaggtc tctagagcgg gtctcccaca tgactggctt cacacaggca 240  
 ctccgctcg ggttgcatgc tctgtgcat cttaccggtc cagggttgca ggtaggaaat 300  
 gtttgtagcc tcttctgatt gccacctcct tcccatcgcc ccttagggac agggcttgag 360  
 ggccagttag gcgctgggtca ggcaccccag gcctccttgg gacctgccc ggggcaccct 420  
 gagagctcct gaaaccccc cttagcttcc agacctttct gcaaaagctc ctcttggtt 480  
 tcctccctcc cccaatctat gggtcacagc taacagatct gagggcaact gctgtgctag 540  
 tggccagggc tgcacctgcc atccccggct ctgccacttt agggccttct agaggcagtg 600  
 tccttaggaa gtagctctga ggcattgggt ttctgtcct gtgcaggga gctgatggga 660  
 taagggtggg aaggacggtc agtgcttggg cccagctgg ccagcctggc gatggggaaa 720  
 ccaaaccatg tccccagcg aagggccaga gtgggaacct gtctcatgc ccttcgtcct 780  
 gaggagccct gaggtgggca gcaggggcca ggggaagttt tcaggccttc atcaaagaga 840  
 acaacatcct cagctccgca cccctcatcc tgtatcagca cttaccggtg tgtgactgcc 900  
 cttgtcagct agcatagcgt gggccacact ggccactgg ctgtttatgc cactgattta 960  
 tgatagggaa tattatcttt gaacccaatg aagtgtttt tccccatca caaaaaaaaa 1020  
 aattcttatt tttagtagac atgtatttac caaaaatatg tactcaatta ttgtattttg 1080  
 gatcttatca atttaaaat tgtggaaatt tgtttgctct tacgccaca taatattgat 1140  
 tttgcctctt ggctctgaaa gcccaaaata tttaccgtct agcccgttac agaaaaagtc 1200  
 tgctgactac tgagccagac ctccattacc tccatccctg ttggattatt taaagaaagc 1260  
 ctccagacagt aagggtcttt ttaaaagaat aaaatgactt ggtttgcgct tgggaagcagg 1320  
 ggaagcattc agatgagcgg tttctgcatt aaccctgcct atcacgcac tcgtgtcctg 1380  
 tgtggctggc gagccccct tggaaaggtc tgggtgcttca gctggctcct gcagagtcca 1440  
 ccccgctcg tgggtgggaat gcagagccct ttgctttcct tcttgccgcc tgcttctgt 1500  
 tcctggggac ccgctgggcc tttggtctgc atccccggc caggteccctc agggttgatg 1560  
 cgtggagaag gactttgagc agtggtgggc agcagtggcc tcctggccag ctccactct 1620  
 tgtcctggga ggggcagcct gatctcact ccacctagta ccttggggac tgaggacctt 1680  
 ttggcttctc tggagcctgc aagcctcttc ccatgtgtcc agctgctctt cctgctacaa 1740  
 aggggactgc tcacagtggc ctccagcttg tggttttgag gggccgcccc ccggccctcc 1800  
 ataagggtat cctgggcctg agaattctgc atctgccatt ggaggatgga cagcctcaaa 1860

tggaaggagt cccacgggag atgggtccga ggtccggctg tggccatcca gccccctgtg 1920  
 gcttgtccag cctctgtgca cccctgggtg cttcactcca ggggcagaca gcagccactg 1980  
 cagttccttt cttcgtgagt aacagtagtg atagcagctg gggctaacag gctaggcttt 2040  
 gtgttctgcg catttggtca gcttctcact cgatcctccc taaagcaatg gggaggcccc 2100  
 cactagccca gttttcagga agtcaactgg gaggttagat gggggccagg gtcccacagc 2160  
 tactgatggc ccgagccagg ttgagcttcc tgggtgccag tccggatccc acttgcagat 2220  
 ctcatgctct cagatagggt ggacaagttc ttttgtcaca gtgctggctc tgtcctgagg 2280  
 cctcattgct ggctgggtgt gctctgctgg gaaaagcttt gcggggcttg cttggttaac 2340  
 cacagaagag aaggggactg tttggggtgc ctctctgcag cctccccgtg ctgggtggaa 2400  
 gcacgggttac tgtgttctct aatgttcatg tatttaaaat gatttctttc taaagatgta 2460  
 acctccacac ctttctccag attgggtgac tcttttctaa aggtgggtgg agtatctgtc 2520  
 ggggtggtgt ggcccttggg tgggtcaggt ggggtgaga ggtcctgggg aggtgggcgt 2580  
 tgagctcaaa gttgtcctac tgccatgttt ttgtacctga aataaagcat attttgcact 2640  
 tgttactgta ccatagtgcg gacgagaagt ctgtatgtgg gatctgtgct tgggttagaa 2700  
 tgcaataaaa actcacattt gtaagaaaaa aaaaaaaat aaaaagatgc ggcc 2754

<210> 3  
 <211> 856  
 <212> DNA  
 <213> Homo sapien

<400> 3  
 acgttaaaat taagaactta ggctttggtt taaaaaacaa taaatgaagt gaaaaaaca 60  
 agccacagag taaaagaaga tacttgcagc aagtataaa ggattagtat ccaggatata 120  
 taaagactgt tattgagtca atgtgaaagg gagaaaaaca cctgaagcaa agaattggatg 180  
 ccggcattaa ataggcactt caaagaggaa ccatgaacga ccaaaatcaa gtgagtaggt 240  
 gaccagtcc cattagtaat taggaaatag caaattaaga ccacaaagag ggagtgagg 300  
 gtggctcaca cacctctaatt ctcagcggct tgggagtcca ggcccagagg atcccttgag 360  
 gccaggaggt ggagtctagc ctgggaaaca tagcaagacc ctgtctctac aaaaaataa 420  
 ataaataaaa taagaaaaa gtaaacaca aggagatgac ttaccaccag gcaaaaatat 480  
 taaagtatgc taataccaag tatcaagaag aatgaagcaa gatagctcaa atatgctttt 540  
 gaaggaaata tactgggctt ccattcattc tgaaataccc cttatttaag atactctatt 600  
 atattaaata cagttccaaa acaaaagaaa tccaaagaac aaaaaactaa cccaatactt 660

4

ttatcacttg taattgtata ttacaccata ttgaaagata tattttacga cttatttagag	720
aacgattttt aaattggata tcaactctgtg catacaaata aaataaagtg attaagggttc	780
taacaaaaaa acaaaccaca acaccaaagg ctttttaagg gggggaggaa taaggaaagg	840
ggcccaaaaa agggac	856

<210> 4  
 <211> 1580  
 <212> DNA  
 <213> Homo sapien

<400> 4	
gtcccttttt tgggccctt tccttattcc tccccctt aaaaagcctt tgggtgtgtg	60
gtttgttttt ttgttagaac cttaatcact ttattttatt ttgtatgcac aagagtgata	120
tccaattaaa aatcgttctc taataagtct aaaatatatc tttcaatatg tgtaataatac	180
aaattacaag tgataaaagt attgggttag ttttttggtc tttgatttct tttgttttgg	240
aactgtattt aatataatag agtatcttaa ataaggggta tttcagaatg aatgaagccc	300
agtatatttc cttcaaaagc atatttgagc tatcttgctt cattcttctt gatacttggg	360
attagcatac tttaatattt ttgcctgggtg gtaagtcac tccttggtgtt ttactttttt	420
cttattttat ttattttatt tttttagtag acagggctct gctatgtttc ccaggctaga	480
ctccacctcc tggcctcaag ggatcctctg ggcctggact cccaagccgc tgagattaga	540
ggtgtgtgag ccacctcac tgcctcttt gtggtcttaa tttgtattt cctaattact	600
aatgggaact ggtcacctac tcacttgatt ttggtcgttc atggttcctc tttgaagtgc	660
ctatttaatg ccggcatcca ttctttgctt cagggtgttt tctccctttc acattgactc	720
aataacagtc tttatatatc ctggatacta atcctttatc acttgctgca agtatcttct	780
tttactctgt ggcttgttt tttcacttca tttattgttt tttaaaccaa agcctaagtt	840
cttaatttta acgtacttga actgacattt tctaccctgg cccctccca cccttagttc	900
ccagacacct cttatgatct ggggtcgagg agccgcctt cctggcggtc tcagctgggg	960
cctggggagc gaaggcgcg ggcgctcgcg ggaggagctg cgcgattcgg atgctgggga	1020
ggtgaagctc gcggggccgc caggccgccg gggttaaggaa ggccgggagg ccgcgggggt	1080
ccacggcgcg gagggagccg caggcaccgg gcacagccct cgcctatcgc cgagacccgg	1140
caggcccagg agccagaggg cggcggcgtg agagggaaac gcctccaaag gacgcctcg	1200
ccctcccgca ggcatagtcg caggcgccag tcccggtccg agccagctgg ggggtggctcc	1260
ggggagctga gccgggggag ggccgggccc cccaacggat caataggggg gtttctccca	1320



5

gggtgcccgtt tctctggccc gcgacgcctt acccgccgga gccgcccac cgcaagcccc 1380  
 gccccgaagg cgggtgcagc caggaaggcg gggcctgggtg gcctctgggc gctggcgcca 1440  
 agttcagagc cgcgccctgg gctgggcggt ggcggccgcg tctgcacttc cccccctgcg 1500  
 cgcctctgga gagcccgga gagacgcacc ctcaggctcg ccaagaccga gaacaagcgg 1560  
 gcgcgggcag cggagcccat 1580

<210> 5  
 <211> 800  
 <212> DNA  
 <213> Homo sapien

<400> 5  
 tggtcgcggc cgaggtacaa aggctttgag gtccatggac tatacttgtc ccatttatca 60  
 tcccagggtgg tgctttgacc ctagggatac cctggctatt aagataaaaa gatttgtgga 120  
 cattaaaatt atgaatatgt cagtaataat ccagcacaca ttgaaatatt gacacagatt 180  
 accataatth gtgcaacatc ttataaacia tgtcatttcc acagtagtct aaggcttcac 240  
 cagcctggcc cactgtatct agactttagg ttcattttaa ttaattatgc tttccttctc 300  
 tgtatcattt gggaagttga taaatatcac ttccttagat accttcattc agtgatatat 360  
 ctggctttta caattaaatt ggaaaaggta agtttctctt tggtaggggtg agagttggac 420  
 catcaattct aatctacaaa aggaaattca tgatttcact ctgacgccta ggatctagcc 480  
 aaggctggtc tgcagtatca gatgtccaaa ctcatctact attagccata ttttgtgagt 540  
 cgtttgtcta aactttgtca aaaatgcctt tgccatgatt ttgttgctat ctggatttca 600  
 aacatggaca gtttaggaaga tgtgcattga agtaggaaaa tttgtttcag catctgctgt 660  
 tattttatth ttaccacttc aaaaatggcc actgtctttt taacaaacac caacgacaac 720  
 aacacacaaa acaaaaaaaaa acaccctgcg gcttaccctg gccctccttt tccctgttga 780  
 attgtttccc cccaatcac 800

<210> 6  
 <211> 956  
 <212> DNA  
 <213> Homo sapien

<400> 6  
 atttataagg ccottcaaht ttgtggcttc ctttctcata cttctcaagt ataataaag 60  
 ggggagaaaa accccaccat caacacaaaa gaaggctata aagactgtgc accttttaac 120  
 aagtcaatth gtagtcagtc cctgggcctg tctttttttt tttttaatth tgaagctacc 180

6

tgagggttag aattccttca gccctagctg cttttattct gctttttatt taaacaaaaa 240  
 gagggggagg atctgaagga aactagtttt ctgtacaaag gctttgaggt ccatggacta 300  
 tacttgctcc atttatcacc ccagggtggtg ctttgaccct gccataccct ggctattaag 360  
 ataaaaagat ttgtggacat taaaattatg aatatgtcag taataatcca gcacacattg 420  
 aaatattgac acagattacc ataatttggt caacatctta taaacaatgt catttccata 480  
 gtagtctaag gcttcaccag cctggcccac tgtatctaga ctttaggttc attttaataa 540  
 ttatgctttc cttctctgta tcatttggtg agttgataaa tatcacttcc ttagatacct 600  
 tcattcagtg atatatctgg cttttacaat taaattggaa aaggtaagtt tctctttggt 660  
 ggggttagag ttggaccatc aattcctaac tacaaaagga aattcatgat ttcactctga 720  
 cgcctaggat ctagccaagg ctggtctgca gtatcagatg tccaaactca tctactatta 780  
 gccatatttt gtgagtcggt tgtctaaact ttgtcaaaaa tgcctttgcc atgattttgt 840  
 tgctatctgg atttcaaaca tggacagtta ggaagatgtg cattgaagta ggaaaatttt 900  
 gttcagattt gctgttattt attttttaaa ttaaaaatgg aaatgtaaaa aaaaaa 956

<210> 7  
 <211> 489  
 <212> DNA  
 <213> Homo sapien

<400> 7  
 actatgtgtt aacataatcc caccttctta gagctttgtt ccttctgaag gtgtatagat 60  
 acagcttgct ttgaaatgtc tttctccaca taatgaagca tgctgaatgc tgggaatctg 120  
 gagcagcagc cctgggagcc ctgagttttg aagtgttttg gtttgcttca aaggtagaa 180  
 gaacttgata tgtatggcaa acaactttag aatactagtt actcactaac atgaggcggg 240  
 taatgttgct ctagattcta tattccagta aagccagctt ttcttattat tggagtaggc 300  
 aaatgaatgg cattagaatt agtgggtggc ttgtaagttg tagttatagg cactttacca 360  
 cttctgccca ttagcaggca tccttgtttt ttcttctttt cctcttttgt tccttctttt 420  
 cctttctccc ttatacattt tctttctcta ctttaattct ccttctcctt tactgtagat 480  
 cccaagctt 489

<210> 8  
 <211> 3190  
 <212> DNA  
 <213> Homo sapien

<400> 8  
 ctctcattag cctgttcaga gtcttggggg aaattgagat ttttgagatt ttttttaaaa 60

actcaaatat tttactagtt tgcctgccat tttatttctt ttacaaagca gaagcatata	120
ccaatttatc acagtatttt agtaaatact gcaacattca tccttaaagc ttcaccaaga	180
aaagcatctt tgtagtagtg ctggaaaact attcagaata tacagataaa aatgctgttc	240
tttaattgct tacattgctt cttcccataa aaagcaaaaa ggaatcagtg cttgctattg	300
ctcctttcct tgaagttgta acaattgata catatattat gagttgactg gtcgattctg	360
tacctggccc atcctttaga atgttcttgt catgtagcag tcctacgtac tcttttcatg	420
agcagtctgt gatctcactc tgtgagttca gctattactc gtcgtggga gcttaatctt	480
ttcaaaatga agttgattta aaaagtcttc aggcagagta atcatgttag aggtggtatt	540
cgatggaaga aagtttagag agttaggagt gggggtagaa ttctagaatt tataagagtc	600
caggaagcat agcagtcagg ggcaaaaatt agcgtaatat ggagtaggca atagaggagc	660
tactggagtc agaagtcact gcagagtgcac acataggaag atggactcct agcttacatg	720
agattccctg cagctgtaat atagacaatt cccacatggc tgttctacac agaattacct	780
gctaagattt tttgtttatt tttgtttgag tgggtatttc actccaattg tataatggaa	840
atcagtggga aaataggggt taccttatat tcatgagttc tagtttctac tgttctgcta	900
tgtgtttcta agcaagagca aaggatactt catacttttt tcgttatatg attgatcttc	960
aaattgggat ttaccttttt caatatgttt taaagtagtc ttattcctct tttgatttgt	1020
taaacaagca ttttagttca gctattgaat agccttccaa aaaattaatt cagccttgca	1080
ggtaagtacc atactaagac tttaaaccaa tagtttttaa tcattctgcc tttattccaa	1140
actgtaaate tgtacacata agataaaaca tactaagtat tgcataaatt gttaacgtta	1200
cagtaaattg ttatctgcag ggctgacaga cataatgttg gtgggcaact gtgatcctat	1260
acatacatat atgcaaaagg ggattttaaa agtgcagatt atagagtaga ttgacaaatt	1320
ttattttata ttcagttgtc ctctctgctt ccatctgtgt tgctctctta gttgagagag	1380
agttagccat ttgacgattt taagtcagtg ggaacttatt tttagttact caataaaatt	1440
aatattttat ttgtatttta acttacagag taggttggtata ataacagctg aactgtgtaa	1500
cattgttget tcaaattgaa gtttatatta tgaacattca gaatcaatgc tcatgtagca	1560
gcatattatt gagctatttt gagtttgaaa tgtggagaaa cgctaaacca tgtactatgt	1620
gttaacataa tcccaccttc tttagacttt gtctctcttg aaggtgtata gatacagctt	1680
gtcttgaaat gtctttctcc acataatgaa gcatgctgaa tgctgggaat ctggagcagc	1740
agcctgggga gccctgagtt ttgaagtgtt ttgggttgct tcaaagggtta gaagaacttg	1800

8

atatgtatgg caaacaactt tagaatacta gttactcact aacatgagggc gggtaatggt 1860  
 gctctagatt ctatattcca gtaaagccag cttttcttat tattggagta ggcaaataa 1920  
 tggcattaga attagtgggt ggcttgtaag ttgtagttat aggcaacttta ccacttcctg 1980  
 ccattagcag gcatccttgt tttttcttct tttccctctt tgttccttct tttcccttct 2040  
 tccttataca ttttcttct ctactttaat tctccttcct ccttactgta gatcccaagc 2100  
 ttctagctta ggtttgcaag tcatattgct tggccctcca cattcactga gaggtgaaga 2160  
 taggctgacc ccctgtctc ttacatttga gggatcatag actgctgtgt gaattctgga 2220  
 aagtctcagg tccctaccag ggcactgaat ggcttctcaa tggctgtaga gacagtacag 2280  
 ttttccaaag cagcctaatt catctggaca gctaccaggc actttggaaa gttgggttcag 2340  
 ttactactat gaggccataa tatatttgct ggtattaaaa ttcttcagaa ttggaattac 2400  
 tatttgaaat aatattttgg ttgacttaag ttttgagaga caattctaaa attgatctag 2460  
 agactcatte aatagcaatg tgaccttta aatacttaca ttaagtaaaa ctgccagtag 2520  
 attaaatcat atatatatat atatatatat atatatatgt aagagcttcc tctatttact 2580  
 actgttgaaac ttcagtaatt tttagaggct aaataatggc cagaatgttt ttaagtgtgc 2640  
 tcttttatta catgcttgtg caggttttgt aattcagtag agaaaagtgt aacctgtac 2700  
 atttttgtat gtaaaaagtc ttttaagtag tcttatcctt atttaataa acagaataaa 2760  
 attaccttga gtaggtctgt tattcttatt aaaatggaaa aatgctctgt aatgacttga 2820  
 tctgttttta tttgagtga caattttgga aagtattctt tatagtacaa ctttctatac 2880  
 ctggattgat taagatcaga tgtgattcga gtagtccagc catatcttgt agcccttctt 2940  
 tgaatgagag ggtggctgga gtggtctggt gctgggatat cacggtgcta cagagcctga 3000  
 catgttgact gtcactacat gttgagggat ggaaatagaa gtctctgaac ttcccatgta 3060  
 atattaaagc tcttaacaaa atgagacaaa ctagagattc agttgagaga ttttatgtta 3120  
 gagtgatctg aaaaaagtt aatttctaaa ctgctatctt aatattatta tatttgagaa 3180  
 ctgatgctgt 3190

<210> 9  
 <211> 672  
 <212> DNA  
 <213> Homo sapien

<400> 9  
 ggtcggggcc gaggtactat tgctctggct cctggccctc tccttctat gggcttacc 60  
 ctcaagtcgc tctgtgattc aaagatgaac tgccaatcaa atgttctct aatgaaagat 120

9

```

ccaatcactc tacagcatgt gtgtattcaa agaacctatc taagactttc ttttggtcat 180
gggtgggaggc tgttgctgaa aacataccag agcccattgt ggaggtcagc tgacaggccg 240
catgaccttg gcaatggact actggtcac c tgggactgct taggactgtg caatggaact 300
tgggggcaaa actgatggag acagccaatg ggccttaa at ccagcaggca aagacagagt 360
aagttcttat ttgtgtagcc cagggcttat caaagtgtgg ttcttgacc acgtgcatca 420
gtatcagctg taagtatttg gcaaaatgca gattcccggg ccctgcacca aacagattga 480
ctttgaatct ctgggggttg ggctaaaaaa aaagaaaaaa aaaccctaca ttttaacaa 540
gctcttcaga tgacccttgt gtaagtttga gagcatctgc tggaaaacca ctagaatttg 600
caaacggcac tcaaaatact ccagccagtc cactagccaa agaccagatc tgagaccgga 660
tgggaaatta tc 672

```

```

<210> 10
<211> 997
<212> DNA
<213> Homo sapien

```

```

<400> 10
ggtcgcggcc gaggtactat tgctctggct cctggccctc tccttgctat gggctttacc 60
ctcaagtgc tctgtgattc aaagatgaac tgccaatcaa atgttcctct aatgaaagat 120
ccaatcactc tacagcatgt gtgtattcaa agaacctatc taagactttc ttttggtcat 180
gggtgggaggc tgttgctgaa aacataccag agcccattgt ggaggtcagc tgacaggccg 240
catgaccttg gcaatggact actggtcac c tgggactgct taggactgtg caatggaact 300
tgggggcaaa actgatggag acagccaatg ggccttaa at ccagcaggca aagacagagt 360
aagttcttat ttgtgtagcc cagggcttat caaagtgtgg ttcttgacc acgtgcatca 420
gtatcagctg taagtatttg gcaaaatgca gattcccggg ccctgcacca aacagattga 480
ctttgaatct ctgggggttg ggctaaaaaa aaagaaaaaa aaaccctaca ttttaacaa 540
gctcttcaga tgacccttgt gtaagtttga gagcatctgc tggaaaacca ctagaatttg 600
caaacggcca cctcaaaata ctccagccag tccactaag ccaaagactt tcttttggtc 660
atgggtgggag gctgttgctg aaaacatacc agagcccatt gtggaggtea gctgacaggc 720
cgcatgacct tggcaatgga ctactggtca tctgggactg cttaggactg tgcaatggaa 780
cttgggggca aaactgatgg agacagccaa tgggccttaa atccagcagg caaagacaga 840
gtaagttctt atttgtgtag ccagggctt atcaaagtgt ggttcttgga ccacgtgcat 900
cagtatcagc tgtaagtatt tggcaaatg cagattcccg ggcctgcac caaacagatt 960

```

10

gactttgaat ctctgggggt tgggctaaaa aaaaaa 997

<210> 11  
 <211> 696  
 <212> DNA  
 <213> Homo sapien

<400> 11  
 gpcgcccggg caggtagaaa tggtagccat gccattcatt tgactgtggg tggccctcta 60  
 gtctagggct ctcttagtga atggttgtgg aaatatgatt tttctaagtt ccttcctttt 120  
 ccttttgata gatgagtttg agatgatgga gtaggagtga gggccctcagg cacttctggg 180  
 aaagacattc cacctgcaag cagcattttg agtaaagcac tgctgtgggt tgccgattta 240  
 tgggtccattt aatgttaggc taaagcacct ttaatcattt ttgttgtttt aagataatgt 300  
 atttgtgaag tggataaaca ctggaaatag ggtgcttctt ctggaaagtt cagtgtaaaa 360  
 cactaacaag gctttggcgg gtttatctgg ctttataaac aagtctgaaa aatggatgaa 420  
 agctaaatat ataaagcagt tggttgtcta tcttttatca ttttttactc agatctgtat 480  
 ttaacactta tttatttggt agtttttaca ttcaaaagaa actacacttg gaactttggc 540  
 taacattgta ggatattttt taattgttcc tacattttta agcatgattc atcatttttg 600  
 taacttagat catttttaat ggtcttttct ttcaataacc agttacatca tgttttggga 660  
 actctttggg tccatataag gtgaattggg gcaaaa 696

<210> 12  
 <211> 3233  
 <212> DNA  
 <213> Homo sapien

<400> 12  
 aacggtccta aggtagcgag agaatactac caggtagctag tttttccagt attgacttct 60  
 gattactatt tccttttctc atcttttagtt tttcaagatt tgctttacca aaatagtaaa 120  
 gcccttatca tcagcttata ttgaataatg ttgtaattgg tttcaatcaa agtttctcct 180  
 caggtagctg ggggccccta gccttctaag gaactcccag gcacctactt aacaaggcca 240  
 gctacacact cagtatgtga taagcccat gatggatgca ggtagaatt caaagacctg 300  
 gttggagtcc tagatgtgga gacaggatca tcaggtcaca cttgttagat gactaacact 360  
 atcagtagaa gctcttgaga gattttccta acgcagcaag atttctgtga gtagaggtat 420  
 cctgggaggt atcctgggag gcagcctatt gacttgacca agtaagctga tcagggtggc 480  
 tcctctaccc actaaagaaa tgtgtaaaaca ctagcaataa ttgctttatc ttaaactcct 540  
 ggacatactc agttcctcca ttccactgtt ctattgcca tacctttgtt gttttcttca 600

cactcctctt ggcagcaaat gtctgaaagt atttcaattg tgtaatgtta aggagttttt	660
tcatagcttc agaaaagagg gcagcaaata tgaagcctta agttcaaaat aagtcattct	720
acctagaaat acagacccca gagcacattg catgaaaata cctgtactct gcagttcctc	780
aaagcagtat tcttcctgaa aagccaaaca ccacacctat tttcctatct gctaagaatc	840
agaataagca cgttgtaaata agtatccaaa gcagattcta aaatgacata gtaagaagcc	900
agattcaaat tgtaacccaa gaagacaata gaaatccac tttacccac tgtcatcagt	960
tagaacaccc ttgcaaaaac tgtaaccact taagcaattc atctgatccc agaagatcat	1020
accttctttt gaaagtatag gacagatata agtgggaaac gtcggcgctt tgagcaacac	1080
aggataaatg taggagggcc ttaaaaaata aatctcaatt catacactgg agcagcaaaa	1140
aactgagcag gaaaggaaac agaatccaaa gtcatttttc atatagctgt tgtcaaatag	1200
tataaccttg gtgtcttctt tgagttgcct ggacagtatt tatgaaacaa aaaactaat	1260
gccccccatt tggggacggg ggggggggtt cagaccteta acctggattc agagccttag	1320
aggccgagag ggaatctgga atctgggtatt actgagatcc taggtaaaag aaccagcctg	1380
gcagtctttc ccacctcatt ggtccgtgct tttattttta aacccaaaaa aaaaaaaaaa	1440
acacaccctc ttatgtagga atttcctttt tacaataat ttgacctggt agaaataaac	1500
ttgcctgcct gctcttaaat gccagacagt tggaagcaaa tgccgaggga aaggtgcccc	1560
gagccatgct tgataggact ttgaatattt tctccttaat taaagtacgt tgcttgtatt	1620
tagactataa gatgctatgg aggtctatcc catgccatgc caatgtgaat tgctttgctt	1680
cagtaacaat cagaagacca gtccaacaga aaataacttg tcataattcc accttagatt	1740
ctagacctct catacctgca gtgtacagaa tatgtacatg ttccaatgga attcactatt	1800
tttggtttta gtgtcaaaga gattgggtct acaagggtca tctgatttcc cataacaagt	1860
aaattttata atcctatgat tctaaattca atccccaata tagattctaa gcatcaaata	1920
aaaatcacag acaaagggga actggctgag aggggtctta gttatttcaa atccatgacc	1980
aaagtgtcca aagacatgaa actcttatac ctgctgagca tttcaactta ctatacaaaa	2040
tgtcagctac ccagttgcat cctgtgacat gatcagactg tcaatgtgga ccagtggcca	2100
ggagcatatt tatgggcat ttctgttcat cattctttac agagcattga ggtttccac	2160
tgaaacagct tctttagtca gacgtctata gattttacat aaatttacat ttaaatgcat	2220
taagttagat ggccaattg agcatctgaa tgaatatagt gggggttggt ggtggtgcaa	2280
attctgctgg ctttatgtta tggttttctt cgtgtttttt cttggttttg tctggcttct	2340

12

tctggcaagt gccctaaaag actggaacac tgtataaagt catagacata gaaccatattg 2400  
 ggaaagccca gatgaaaaaa tggaagaata aaatcaagtt gtcaaagtcc cagcaacagc 2460  
 cctgacttct tcaggaatcc aagcaaattg aaagccaaga caaaatgtac aaatgggtgcc 2520  
 catgccattc atttgactgt ggggtggcct ctagtctagg gctctcttag tgaatggttg 2580  
 tggaaatatg atttttctaa gttccttcct tttccttttg atagatgagt ttgagatgat 2640  
 ggagtaggag tggggccctc aggcacttct ggtaaagaca ttccacctgc aagcagcatt 2700  
 ttgagtaaag cactgctgtg gtttgccgat ttatggcca tttaatgtta ggctaaagca 2760  
 cctttaatca tttttgttgt ttttaagataa tgtattttgt aagtggataa aactggaaa 2820  
 taggggtgctt cttctggaaa gttcagtgtg aaacacaaac aaggcttttg cgggtttatc 2880  
 tggcctttata aacaagtctg aaaaatggat gaaagctaaa tatataaagc agttggttgt 2940  
 ctatctttta tcatttttac tcagatctgt atttaacact tatttatattg ttagttttta 3000  
 cattcaaaag aaatacactt tgaactttgg ctaacattgt aggatatttt ttaattgttt 3060  
 ctacattttt aaagcatgat tcatcatttt tgtaaactta gatcattttt taattgtctt 3120  
 ttcttttcca atagaccagt taccactcat gtgtctgcag aacctcttta ttgtattcct 3180  
 ataataaatg taaaatattt gtagcaaaaa aaaaaaaaaa aaaaaactcg gtc 3233

<210> 13  
 <211> 847  
 <212> DNA  
 <213> Homo sapien

<400> 13  
 atagactat gatatggact taccctcttg gtgccagccc tacaagctgc atgaccgtaa 60  
 tcagcctgtg aactacgac atgcgccact cagcctgtgc cactcttggc ctgagccttc 120  
 ggctctttat gactgaggcg gacaactcac gctcaacaat ggcaaagact gctgcacat 180  
 tgctagatca catcaatggg gccaccaact actctcttct tcacctacca atagtggact 240  
 gactggtctc tatgactcct atccacctca tctgctcccc tagtcacgaa ctacaagaca 300  
 ccacacaccc ccagccgcag cggaatgcc aaagggtcag cacacacggt gcgcaacaa 360  
 cccaatgcgc gacctatcat catccatata tatctggcgc tgctacgcgg acctacctac 420  
 gccatgtcgc tctgactac tctgctccac tgatggctcc tcctaaccaac acgcgcttgg 480  
 ctctgccag cctgcagccc acacacctgc gccctccctt ggcacgacac ccaactaccg 540  
 ccgactgccg aacgcaccag ctgacggaca cacgtccact ccacccgcgc ccaatcacct 600  
 cgcgacgccc ccagcccttg cctcccata ccacggcct acaccacag cgcccacctc 660



## 13

aactgcgac cggctgcca tatctctcca cgtcccgccc tctgcccccc ctccacacac 720  
 gcagcatcca cccagacaac ccacactgca cgacccctca tcacagcccc tcaaagccct 780  
 ccaccaccac acaccagcag tccccgccc caacacctaa taaacccac ccccgccgag 840  
 cctcaca 847

<210> 14  
 <211> 267  
 <212> DNA  
 <213> Homo sapien

<400> 14  
 actgtagcag tgagctcaag tgttgggtgt atcagctcaa aacaccatgt gatgccaatc 60  
 atctccacag gagcaatttg tttaaccaaga atctaagaat taaatcttag aatgtattaa 120  
 tgttaaattt ctgtgagatt atattgtagt cacgtagaat gtcttgactt gtaggaatac 180  
 ccactaagga aatcagaaat cacggtagag cgtcagcaat ttactctcaa atgggttcaga 240  
 gaaagaaagt tctttgtagt aaagctt 267

<210> 15  
 <211> 824  
 <212> DNA  
 <213> Homo sapien

<400> 15  
 tggctcgcggc cgaggtacag tgggtggaaa gggcatttgg agctcattag aatgagacat 60  
 agttaagagt cccattctca tcagtgtatt ccagactgag gaagaaatgg ggcagcagtc 120  
 aggagagctc gggattttga gtatagcaga atttaagtga aatggaaact acactcttta 180  
 atttgttctt ccatggaatt gctttttcta tgcaagggct gagccccag gagagccctt 240  
 gtgaagggaa tgctgatttg tgtgaatata ttaggtgag taggtatcta gtgaggatga 300  
 gttgggagga tgagttgggt aaggcgtgcc cctctgacac tgttctgggt ataaaagaca 360  
 acatcatgat gagatcttca tctgaataaa actatgccct ggccctttca gaaactgcgg 420  
 gcactgcagg tcccacagtg tgatggagtc caagctggga tcaactgcag atgaggagtc 480  
 agaggagtgg cttcggcagg catgggagct tcaggccctg agagagaaga cagaaattca 540  
 gaaaacggag tggaaaagaa aaacgtgaag gaactgcatg aagagcacat ggctgagaag 600  
 aaagagctac aggaggagaa ccagaggctc cagggcctcc ctgtctcagg atcagaagaa 660  
 ggcaggctgc cagttccaag tgccagatca agcaccctcc gtgccagctg caggaacgag 720  
 ctaggatcat tgcttccagg aggagagacc agccttggtc tcaaggaagg gcaccggacc 780  
 aaaggggcaa gggggggaca cagagaggat ccacaggaaa aatg 824

<210> 16  
 <211> 1998  
 <212> DNA  
 <213> Homo sapien

<400> 16  
 ttacttttta ttaaagtata ggaatcaaac tggataccaa attctcagtg cagttgggta 60  
 gtcattttgt taatgtattt ttaaaaaatt ttaagggtaa aaaccagcaa gattccattt 120  
 agaatgattg tgaaaaaac actgtaagac gtccattttc aaaatgcaaa aaatgattct 180  
 tcctgatgtt aggaaggcca atgaaaacta tatgtatatt gaaaatattt tttcctcaaa 240  
 actttttccc tgatacagaa gtctgagagc ttactttggc tacattacct gactaaagag 300  
 agaactttag attagacctg gggtaaattg agatgccaa ggagtgtcta gctaaatgga 360  
 aataccacga aggtttgtta tgccaagaaa gtcagctctg tgggtgtgtca taagcagcat 420  
 atggaaacca ggagtgcac attagaacct gggagttgtg catacatctg atcaagcatt 480  
 tgactctgaa aatattcagg gagtttagaa attgttaacc tttggaacca gtattgttta 540  
 gcaatagttg agaagtgtta gcaagaatga tatcaagtta aacttaggca cttggagtta 600  
 catccttaaa gccttaatag ggcttatgag ttttatacag tcatacagat agaaatatgt 660  
 tgcttttggt actacgacag tcatatatta taagaaataa tcaaagggtg gtggaaggc 720  
 atcctctctt tgatccaatt ttctgtacct ttttcttcag gtcacacaca ctgctagccc 780  
 aggaatcact aggtattgat gactctactt caagctgtgc aaagcccttt ctggagacag 840  
 ccaggatgtt ttgtaggag agaggcagga gtccctcagg agtggcctgg ggtgagaccc 900  
 tcccataggc tctaagagtc tcattctcat cagtgtattc cagactgagg aagaaatggg 960  
 gcagcagtca ggagagctcg ggatttatga gtatagcaga atttaagtga aatggaaact 1020  
 acactcttta atttgttctt ccatggaatt gctttttcta tgcaagggtg gagccccag 1080  
 gagagccctt gtagaaggga atgctgattt gtgtgaatat ctgtagggtga gtaggtatct 1140  
 agtgaggatg agttgggagg atgagttggg taaggcgtgc ccctctgaca ctgattctgg 1200  
 gataataaaa gacaacatca tgatgagatc ttcattcatga aataaaacta tgccctggcc 1260  
 ttttcagaaa ctgcgggcac tgcaggtccc acagtgtgat ggagtccaag ctgggatcac 1320  
 tgcgagatga ggagtgcagag gagggtcttc ggcaggcatg ggagcttcag gccctgagag 1380  
 agaagacaga aattcagaaa acggagtgga aaagaaaaac gtgaaggaa tgcatgaaga 1440  
 gcacatggct gagaagaaag agctacagga ggagaaccag aggctccagg gcctccctgt 1500  
 ctcaggatca gaagaaggca ggctgccag tcccagtgcc agatcagcac cctccgtgcc 1560

15

```

cagctgcagg aacaagctag gatcattgcc tcccaggagg agatgatcca gtccttgtct 1620
ctcaggaagg tggaagggat ccacaagggtg ccaaaggctg tggacacaga ggaggactct 1680
ccagaggaag agatggagga ctcccaggat gaacagcaca aggtgctggc agctctgagg 1740
cgtaacccca ctttgctgaa gcacttcaga ccaatcctgg aggacacctt ggaagagaag 1800
ctcgaaagca tggggataag gaaggatgca aagggaatct cgattcagac tctcagacac 1860
ctggaatccc tgctgagagt ccagcgggag cagaaggccc ggaagttttc tgaatttctg 1920
agtctgaggg gaaagcttgt caaggaagtc accagcagag cgaaggagag acaggagaat 1980
ggcgctgtgg tgtcccag 1998

```

```

<210> 17
<211> 653
<212> DNA
<213> Homo sapien

```

```

<400> 17
gcgtggtcgc cggcgaggta catggccgca agcagactaa cgcgttgacg ctaatttaat 60
gtattttacc tcacactaag gtcattgcttg ataaagacgt taaactcaac ttgtaaaatg 120
gtagcccagt gctatgcaca gagtgggtgc tcattagtgt tgaatgaaca catttgtaat 180
actacatgta attccatctg actgctttgt taaattttca gttagaacgt agatactgta 240
aagtccacac acacattaaa tcttgttttc ctgaaagtat ggcatcaaaa atacttgtag 300
aaaaaccttg tcacaactga tttgaatgtt cctattttct ttgactttga tattggcttg 360
taatgtctct tttcatcata tgtaatatca gtggaacagg cagcgctact caagtcctaa 420
ggattcctca gtgatcagt atccagggcc gttcatgaac cactgggctg gatttgactg 480
ttgagtgtgg cagttaatgc cctcaagaa atcaaaggat gtcttataag tgtcttccaa 540
aaaaaagcaa atgctgaaat cctattggca aagtaaactg aaattggctg ctatatttta 600
tataatcatt tctgcaaate ccattttttg aatactaata tttgacatgg tta 653

```

```

<210> 18
<211> 1498
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (29)..(29)
<223> a, c, g or t

```

```

<400> 18

```

16

ttattcagtg catagcttta agccagtgtt ggattcacta agtggacagc cagtctccca 60  
 gctctctgcc ttccccaaaa gggtcgtagt aggtcaccct tctacagcag ctaactagag 120  
 tcctaactaa tgggatccag cagggccatt tctccagagg gccagtatcc tattaggaga 180  
 ctcttggaat tcttaggttc tactcaagag tgggaaggacc aatcacctct gatattctgt 240  
 ggaaggtttg gggtcaaatt ctgccctctg cattctgtgc aacttgata aaagtcaagt 300  
 tagtattaca tgaattgggg tagggtagt gctttgaaaa aatgttgaa cggctgggcg 360  
 cggtggtca cgtctgtaat ccagcactt tgggaggccg aggcgggtgg atcatgaggt 420  
 caggagtctg agaccagcct ggccaacata tagttgcttt ggacctcatt tggaaaaata 480  
 atctgccttt ctaattgttc tgcataaggtt aaaatgataa atttacattc tttgaaccta 540  
 taccagattg tgggtgccga gtgaccggca cactgtctga cacacagtca gtgtgcacgt 600  
 atttgtctga gtgaatgagg agacctgaga aaccggtgac gtggcacagg gaagccagct 660  
 ggcccaggat tccgtacatg gccgcaagca gactaacgcg ttgacgctaa tttaatgtat 720  
 tttacctcac actaagggtca tgcttgataa agacgttaa ctcaacttgt aaaatggtag 780  
 ccagtgcta tggcaggagt ggggtgctcat tagtggtgaa tgaacacatt tgaataacta 840  
 catgtaattc catctgactg ctttggttaa ttttcagtta gaacgtagat actgtaaagt 900  
 ccacacacac attaaatctt gttttcctga aagtatggca tcaaaaatac ttgtagaaaa 960  
 accttgtcac aactgatttg aatgttccta ttttcttga cttagatatt ggcttgtaat 1020  
 gtctcttttc atcatatgta atatcagtg aacaggcagc gctactcaag tcctaaggat 1080  
 tcctcagtga tcagtgatcc agggccgttc atgaaccact gggctggatt tgactgttga 1140  
 gtgtggcagt taatgccct caagaaatca aaggatgtct tataagtgtc ttccaaaaaa 1200  
 aagcaaagtc tgaaatccta ttggcaaagt aaactgaaat tggctgctat attttatata 1260  
 atcatttctg caaatcccat tttttgaata ctaatatgtg acatgggttaa ttcttattaa 1320  
 tttgttgga ttgtttattg ttaataatgc aaatagataa tttttaatta tccacaactg 1380  
 atttgaatgt tcctattttc tttgactttg atattggctt gtaatgtctc ttttcatcat 1440  
 atgtaatatc agtggaacag gcagcgctac tcaagtccta aggattcctc agtgatca 1498

<210> 19  
 <211> 171  
 <212> DNA  
 <213> Homo sapien

<400> 19  
 gccgcccggg caggtagta atgaacata atatttatat ataaaagtgt gtagattgtt 60

17

aaatcacaaa aagagtgccta tgaccattat gtatgaggaa acaggccttt gacctcctgg 120  
 aaagcactgc tcaaaagtca ttagtgccca tttttgaatt ccccaaacag a 171

<210> 20  
 <211> 1820  
 <212> DNA  
 <213> Homo sapien

<400> 20  
 gaatttcgta atccttgaaa ttgaaaaaaa aaaaattgtg tttttaaaga gtgaaaacag 60  
 ttaggaaaca agtagaactg taatcagaac gctgcttcaa ttgatattaa aaataacctc 120  
 aataataatg taaaggttcc tttctcttgt gtcagttata ttcttaggga tagcctagaa 180  
 ggaatatatg gttagaacta agtgtgacta atcatctgag ccttgaagag aaacttcagt 240  
 gcctctaaac agatcatcta caaaacaaca ggtaaacatt tatgccagtt aagtgggtca 300  
 tgtttttgtt tcttgggttt ttcctaaatt taagtgaggt tgggcttacc ttgtagataa 360  
 aattatgttt tcttttttgt aaatacttga atgtggataa cgtcaaatca gaatattttg 420  
 tgaggaggtg atgatttgaa attaagctag atttctaggg aggtgttggt tccaatgaag 480  
 gatgggaaga aattaaaata gtcttcaaac ttcttctta ttatatttggt ttgctttgga 540  
 aaagatttgt cctatctca atctaattta ttactatta atattttaaa aacattcctg 600  
 agatacttaa aaagaccac ttagcgatta tagttgtca atgaaacaag aatttattta 660  
 tgcatagatt tttctctgta tcttaccaaa atccacttta cttagataac actaaattgt 720  
 tcttaaagac tactcatttc ccaataatcc tttatgattt caaaatttct agtggctcag 780  
 aagtgaattt tattttattt gtctttcact tgaataaatg agaaccaga aattaataat 840  
 gttgtttatt gcttactgtc aggactattt caaagactaa gaagagtttc ttctaacccc 900  
 tccctctcaa aggaatccta aattattagt tgtagataa gttttgtatg ctaagatatt 960  
 caggtttata gtttatgtat gtgtgtatat atataaatat atatgtatat ataaatatta 1020  
 tgttcagttt ggagtctggc acaactccat tatgtggatt agagagtaag atattatgga 1080  
 tgataaagta ctaaagaaa cataatattt atttataaaa gtgtgtagat tgttaaatca 1140  
 caaaaagagt gctatgacca ttatgtatga ggaacaggc ctttgacctc ctggaaagca 1200  
 ctgctcaaaa gtcattagtg cccatttttg aattcccaa acagaaagct tcttagaaaa 1260  
 cacgctgaga ttttatttac aggaattctt ttgacacatt tcaattggtg tgtagtcaag 1320  
 tatagcaagt acttaataat gactgaattt catgttccca cagtcataca tattcattag 1380  
 aagttttatg ttgttggtct gatctgattc ttctttgttt gtgggtggaa cggcactgag 1440

18

agaagtatat ttttttaaac ttgaacatgt tcagtagtta cattgcctta gaaaacccag 1500  
 acacatagca gtggaaatga aagaaatggc atcagaagtg acttaattta gcaattgtga 1560  
 ttcctcttgt aaaacaaaac aaaaaaaca tgccatattt tttggagaaa agttggcaat 1620  
 atagggggtt cgttgtctgt ttcacaagaa gactcatttg ttcttttggg ggaaccagtg 1680  
 ccttacagat tttgtatata ctgtaattat tcaggactag ggaacaaaca attgtattgt 1740  
 atttgttaca gattgtatat ggctttgttt taacattccc ctaaataaaa tggcttcatt 1800  
 ctccccttgg aaaaaaaaaa 1820

<210> 21  
 <211> 611  
 <212> DNA  
 <213> Homo sapien

<400> 21  
 acccaagaca ggttctgaac catgcttatg cagagctttt agtattaaag agggagagta 60  
 aaagaagtgt cagagtccag atttatcact gaaccaata ctttcttact ccctggggca 120  
 tctcctaata ctgatcctaa aatgctcctg tttctgagaa gctagggcaa gacctgcctt 180  
 acaaagacca gccatttgcc ttattcatag gatcataagc aagagaactg cattccagga 240  
 agaatgaagg aagaaggaag gctgctcaca gtagcagaag ggaggcaggg gccgagctgt 300  
 tcaagtcaca taaactctaa gaagcccagt cagcaaaata agtctatctt caattctagt 360  
 tgagtccagg actctgagga gctgtgattc acccagtttt tcctgcaaaa ggcacagtcg 420  
 ctaaaactaaa ttggtgcaat tcacttcctc ttgcctctct ggttcattcc accaattgtg 480  
 gttgagaaac acatcttagg gaagaaacag tatctaagca ttaaagagaa aatatccac 540  
 tttgctcctc ttctccta aaccogaact gctcttacat acaagataat ttttaaatca 600  
 taagattggt a 611

<210> 22  
 <211> 1885  
 <212> DNA  
 <213> Homo sapien

<400> 22  
 catgaacatt tgaggctgat tccctgtggg aaaaatcatt caaatctatt cactcatctg 60  
 atggctgttg cttgttttat tttttgtcca agagaggtgg tgttggaccg aggtagagaa 120  
 gacagtggta caccagaaat aacccaaagg attgcccctt ctgtagaagg cccttagact 180  
 ccatgatgcc tttcagctgg gtgctatact tgcacctaac tctgggggct tcactttcta 240  
 tccctacaat tactcaaaca gataaaaggc tggatgttaa catgtagtta taaggggcgt 300

```

gatctaataag taaggaatat cacttcccac aagtccttca aacaagattt gtgaggagct 360
ggatttgtca gcatgtcaga tctttttgaa aaccagagag tagaatgtaa gcaataccct 420
tgtcgtaatt aaagaccaga ctccatcctt ataccactga tgcctctggg accttaatcc 480
ttaaaatatt tagtgaccct tgccttctaa ttcttgacac aaatatataa tgaccatttt 540
agatcgggga actccctttc tttgaaggca gtttagggat tccacagatg ggctttgaac 600
ctgctaaatg tgtatggaaa actgagttaa ttacaaatgt ctttttctca aaagtgcgtt 660
tctggtttct gtcagattca acaggtctgt acccaagaca ggttctgaac cactgcttat 720
gcagagcttt tagtattaaa gagggagagt aaaagaagtg tcagagtcca gatttatcac 780
tgaacccaat actttcttac tccctggggc atctcctaact actgatccta aaatgctcct 840
gtttctgaga agctagggca agacctgcct tacaagact agccattttg ccttattcat 900
aggatcataa gcaagagaac tgcattccag gaagaatgaa ggaagaagga aggctgctca 960
cagtagcaga agggaggcag gggccaagct gttcaagtca cataaactct aagaagccca 1020
gtcagcaaaa taagtctatc ttcaattcta gttgagtcca ggactctgag gagctgtgat 1080
tcacccagtt tttcctgcaa aaggcacagt cgctaaacta aattggtgca attcacttcc 1140
tcttgccctc ctggttcatt ccaccaattg tgggttgagaa acacatctta gggaagaaac 1200
agtatctaag cattaaagag aaaatatccc actttgctcc tcttctccc taacccgaa 1260
ctgctcttac atacaagata atttttaaat tataagattg gtattaacac aattattgat 1320
aaagagaaac aatgaccaac tcattagcta acgatgctag aatacttatg caagccctag 1380
agttaagggt cttagtgtgg acacctttcc agaattggaa ggaaaacca ccagaaagct 1440
tattaccctg catcagctga aaagctaagc cacagccatt ttccctaaag ttctgtttct 1500
gggagaatga gatcttcaag aataactctt gcccttgat gaggcagtca aattcaaacc 1560
agtgatggca acaacttgca aacacgtaat tcctgcccta attttccagc acttaaaaca 1620
aaatcccac tcaatacaaa gtttctatgt gcctcttgcc tgaaatcaac aagaacagc 1680
tcacctgcc aaagactcct ctttctctgc cagggcaaaa gcaatctgca gccagagat 1740
tcaaacctag acatacacat ccacaattgt cttaatctca gcagtactgg gaaagctttg 1800
tactcaactt aacctgtcat ttaaccttt ccactagttc tcccttaacc agactgcttc 1860
ctgtcttgaa acaaagaaaa aaccc 1885

```

<210> 23  
 <211> 494  
 <212> DNA

20

&lt;213&gt; Homo sapien

&lt;400&gt; 23

```

aagcgcgcgc attgtgatgg atctatatatt taccctgtgc ttttctatag ctgtcctcaa      60
agcgtaaacc attccaaatt attttccaac gtagtggtat atgtgtgcag cagagctatt      120
tctgcctggg cattgccagt ccctgagcag gagggtctca cagtgaggtc tgcaggactg      180
taagtttggg gtctgactcc ctggccaccc tgtgtgggct gtgactgtct ctccagagcta      240
taccgcacct ttctctgctg gcagcccgac agagctggct caaccatcgg aggtcgcagg      300
ccaccagcca cgtggcacca ccatggcagc cttccagggt aaggtgagac acacaaggca      360
tgacctgggg gccgaccgga tccccatcac aaacgccaca aacaccataa acacaaccca      420
ccctgatcag agactaagca gagaaagcag ggagaggacc tagagttact cagtaatgac      480
tcaggaagga gacc                                         494

```

&lt;210&gt; 24

&lt;211&gt; 1692

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 24

```

gtccccacc atggaagagg cggggccac ccactgcaag tcttctctga gccacgttct      60
caagtcttct ctgagccgcg ttctccagggt tgtgtctctg gagtcagttg gcatttcctc      120
caagcctgaa agtgtagtca gattcagaat gggcttttct agattccctt gtaagatctt      180
tcccctgctc ctggcaggag caccacacca tgggaacccc agggcccacg cagctgcccg      240
ggactggggg accaggacgt ggcacttctc acatgggtgg aaagatgggt ttacagaatg      300
gtggcatgga gacgctgtgg cctggcaagg atcaatgggg tggcatctgg cattagccat      360
caggaagact taaggctgaa gggacattgg gcagggagct ctccaggctg ctccacccgc      420
ccccagggtg acagcccata gtatcactta ggggtgggact gagagtcacc tgggggagag      480
gagagaaggg gcccaacttc ccagcccct agtatcactt aggggtgggac tgagagtcac      540
ctgggggaga ggagagaagg gacccaactt cccagcccc tggcaccttc cctgccttct      600
ccagtctttt accagagtca taagatgggt cttggctctg ggcaggcatg tggcctggg      660
gagctctggg gtcagaggtc aagggtgctt gcatgtcagg caggcttgac ttttgctgt      720
agaaagacta tagaaagatg gcaagctagg cctcttttct ggaaaagtgc caacagctga      780
taatttttagg aaataatgtt ttgaatgtga agtgtgactt tttagaataa aaagacagga      840
agctcttaga aactgcaaga ttctaaatct aagcaaaagg ctatatctta ccctgtgctt      900
ttctatagct gtccctcaaag cgtaaaccat tccaaattat tttcaactag tgttatatgt      960

```



21

gttcagcaga gctatttctg cctgggcatt gccagtcctt gagcaggagg gtctcacagt 1020  
 gaggtctgca ggactgtaag tttggggctt gactccctgg ccaccctgtg tgggctgtga 1080  
 ctgtctctca gagctatacc cgccctttct ctgctggcag cccgacagag ctggctcaac 1140  
 catcggaggt cgcaggccac cagcccgtgg cccacctggc agccttccag gtgaagggtga 1200  
 gacaaacaag gcatgacctg gggggccgcc ggctcccat cacaaacgcc acaaacacca 1260  
 caaacacaac ccaccctgat cagagactaa gcagagaaag caggagagg acctagagtt 1320  
 actcagtaat gactcaggaa ggagacccta agcttctacc acatgccaga ctctgtgccc 1380  
 agtgcagcat aaacgtcctc agaaccagcc tgggtccagc ctggccgagc cggacgttcc 1440  
 tgggaaaggt tacaggagga gcagggccag gccacagca cttttagaag cccatgaaaa 1500  
 tgtcttcatt tctcttcaa tcacaacaa aacgtgcaa acccattctg gagtgcattct 1560  
 tttcactggc gaccaacca gtcctaagat aaccttctta atagttctat ggaggaagct 1620  
 gcaaaggcag aagtgactac aaccacaaa agtcatgat gagcctgac gtgtgtgtac 1680  
 acacacacta ca 1692

<210> 25  
 <211> 430  
 <212> DNA  
 <213> Homo sapien

<400> 25  
 acccagcgtc ccctggccag agccaccaga ggacagagct cccaatgagc ccagctgcta 60  
 gaaaagaagg tggagtcca ggcagaagag ttcttcaggc tgaacggaaa tgattccaga 120  
 gggaaatgca gatatgaaga aggagataaa gagctccaga aatggcaa at agcagggtga 180  
 gcctacgcga cttctctaac ggaagaaatt acctttaaaa cacacgtgca ggcttagagc 240  
 aaaagaaacc gtgccataag gtgtgagtaa gtgaagtgcc tgtgacacct acagatcaga 300  
 gaagcagagg cctccgggat ggcaaggcaa ggttgccgca tttcatatga agtgcacaat 360  
 catcataaaa gaatgcatta aatatacata tgtatgcatt caaattacac taacatcaca 420  
 tatatccatt 430

<210> 26  
 <211> 2603  
 <212> DNA  
 <213> Homo sapien

<400> 26  
 tgtttggtcc agtgaatctg cccaccaaca ccccgctct caccatccac cagcccttgg 60

accctagca ctgagctcac agtgaaaggg aatatttgct tgtaaataga aatagacgct	120
ggtagaaac caactggaaa gaatctttcg ttgaatagga gttaaaaaac aaggaaatta	180
accactcct gggtatttct gaaactggca atctatgctt gtctaggacg gccagacta	240
accctaactg ccccgtcac aacacagcag cacagcgttt cctccaggag aaacaccaag	300
atctcacgtc ccatccacag gctgaggetg ctgctcctgc aggaacctgg tgcagtgtag	360
caattccaca tcttgaaatt gctcatcaaa actcctatta aagtgtcaaa cagtgaatag	420
ctaaaaatac actttgcttg aacagtgaag aggttggaag gaaaacgtta actgtatcag	480
agaatatgga ctctaacaat acagggagtc aggttcattt tgaagtcact cttcttccaa	540
cagattcact aaggctcttt gtcaacacaa attgaaaacc gttaaaaaaa aaagtaatta	600
tgatgcttcc tgccctccat gaaaggacca catacagaca ccacgctcat atctgaggcc	660
ctggggtagc ctttaatggc ccagcagaat ggccagaacc gttagaggaa acatttaata	720
aagtctggag tcagagccct gcgggtctag ctggattcct ggaggtgcgg ccagagaagcc	780
agcgggaggg aattggaggc cggaggctca aactgtcccc acttccacca agggccctc	840
ctccaacagc ttccaggctg ccaaagcccc tgcatacct ccagggtccc ctgggtccag	900
cctcatgctt ccataatga gtttttaaac cacaacgctg catcagggtga catctcttct	960
gcaggctgtg cgcgtctcca gggggaaggg ggctgtgtct ttgggacagt ttgtgctctc	1020
aatcacttga ctgctgacag gcacctcagc tgaatgggtg gatattatgca aagattgtgc	1080
tgaattattt aaagcattct ctatttaaag aacagagaat atttaattag cattctgctg	1140
tgcttaattg aagactcaca aatcaattaa aactgcttac cttttggcag ttcagtaact	1200
tcacagaaac ctcccaggaa atgcatccta ttcacagctg gggtcatcct ataccagcg	1260
acctgtggcc agtgtggcgc tgtgattaga ggcggtcag cgccttcaga ggagcggcct	1320
ggctgtgcgc acattagaga aaggcttcca tcgtcgttgg tcctctttct cacagggact	1380
ctggggtctt ggtgccggga gatgcaaccg cctctggcag cccggcttca ttttagggac	1440
agtgactatg gagaaacca ggtctgacct attttctcca gaggggaggg agccacaggg	1500
aaaggccctt tgttgcctg ttggccctga gtgcctccca ggaaaggta gagcacagac	1560
tcagccctgg gagggccgag agatcccgct ggacctgcc ctctcgaca ctctggacaa	1620
gatgcagaga gtgggtcct ggcagcaaga tcccggtgga gtggggcctt ggagctcagg	1680
gccagaccga gggggtgctc attgctggct ctggcctaca gacacgttga cattggcacc	1740
acacggggcca actgaaaccc taagagaaaa ccagcgtcc cctggccaga gccaccagag	1800
gacagagctc ccaatgagcc cagctgctag aaaagaaggt ggagtcaccg gcagaagagt	1860

23

tcttcaggct gaatggaaat gattccagag ggaaatgcag atatgaagaa ggagataaag 1920  
 agctccagaa atggcaaata gcaggggtgag cctacgcgac ttctctaacg gaagaaatta 1980  
 cctttaaaac acacgtgcag gcttagagca aaagaaaccg tgccataagg tgtgagtaag 2040  
 tgaagtgcct gtgacacca cagatcagag aagcagaggc ctccgggatg gcaaggcaag 2100  
 gttgccgcat ttcatatgaa gtgcacaatc atcataaaag aatgcattaa atatacatat 2160  
 gtatgcattc aaattacact aacatcacat atatccatta gactttatca aaattaaaat 2220  
 cttctgttca tccacataaa acgatgtcac ttactgcaa aaatattctc aaatatttat 2280  
 ccaagtgtg agatccagaa taagtaacc ctaaaatttc ataataaac aacttggtga 2340  
 aacaacggtc aaaggatttg aacacttcgc caaatgatgg caaataaaca caagaaaaag 2400  
 tgctcgacag actcgagcac caggaagatg cgctgtaaac accaacaata accaccacac 2460  
 acaccacag tagccaaaat ctataaaact ggtggcacca aacgtgaggg aggatgtggc 2520  
 ccaccagca ctgttgctgt gcattcttgg tgagaacacc taagacgtcc cctcaatggg 2580  
 attagaaaac cacaaggcag gca 2603

<210> 27  
 <211> 614  
 <212> DNA  
 <213> Homo sapien

<400> 27  
 acatatattt aaaggaaga tggatacaat ttgtttttat tatataaatc taggtaaggt 60  
 gaaatgcttt tgtcaacaaa aatacagtg agtgaatttt atatttgtcg cttgattagg 120  
 taaactgaaa actaacaata gaaatattat ttactgcat tgaataacca tgaactttca 180  
 gacttgtag ttctacaagc agttgtgcta ccttaatttt gtgtttccag aaataaaaat 240  
 taaccttagt tatgctgtca tttttaacta ataaaaaag tataattcat aaaacttttg 300  
 gctttataag ataattataa aattatata tttttctgt tttgtgggg ttgggaaac 360  
 attttcttat ttctattcac ttttcaaatg caggctctcat aatatgtgtc aatgatataa 420  
 gatgatggaa gacttctgta ataaaaacat atgtcattat cttcaatttg ttcaataaat 480  
 aatttaactg tgaaacaaca aaaaaaaaaa ccaaaaaaaaaa aaaaaaaaaa acaaaaaacg 540  
 gggggggggc accggggcaa agggggcccc gggggaaggg ttcccgggca aatccccata 600  
 agagcaaaaa acat 614

<210> 28  
 <211> 1134

24

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 28

```

gcacgaggat tgggtcaaagt agtattctct tgaagttcta gtcaatttaa tttgatccaa      60
taagtttttc tgaatctcct ttttaagttc caagaaattc tattataaat aagtgtactt      120
ttaccaattc cattgtataa gcaaacagac accttttaga aaaggataag taatcatcaa      180
tttggttttt ttaaaaaaaaa acaattttcca gactactaaa tttggcataa gaataattct      240
tttaaaatgc aacatacttt aattagtttt tttggtatat gcataagatg tgaactttcc      300
tattgatatc actttatatt aatagagatg tacatttctt tctatgccgt ggctagagca      360
aaagttaata atgattatct acacaattga ttttaattct taggatattg ataattattg      420
atattatata tgatttaaaa atactattcc atacattttt tttttcagga gataaaacat      480
agggaaaggt tttcatgtga attctttgta tcactttgaa gtacatatat ttaaagggaa      540
gatggataca atttgttttt attatataaa tctaggttaag gtgaaatgct tttgtcaaca      600
aaaatacagt gtagtgaatt ttatatattg cacttgatta ggtaaactga aaactaacia      660
tagaaatatt attttactgc attgaaatac catgaacttt cagacttggt agttctacaa      720
gcagttgtgc taccttaatt ttgtgtttcc agaaataaaa attaacctta gttatgctgt      780
catttttaac taataaaaaa agtataattc ataaaacttt tggctttata agataattat      840
aaaattatat atttttttct gtttttgtgg ggttgggaaa acattttctt atttctattc      900
actcttcaaa tgcaggcttc ataatatgtg tcaatgatat aagatgatgg aagactttgt      960
aataaaaaaa tatgtcatta tcttcaattt gttcaataaa taatttaatg tgaaaaaaaa      1020
aaaaaaaaaa ccaaaaaaaaa aaaaaaaaaa acaaaaaacg gggggggggc accggggcaa      1080
agggggcccc gggggaaggg ttcccgggca aatccccata agagcaaaaa acat          1134

```

&lt;210&gt; 29

&lt;211&gt; 1139

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 29

```

cgaggtaccc attataatta ctaaactgtg aagtcactat tattagtatc tgaccagcta      60
tacaaaaacat catcaatttt acttttgaca caaaaggtag taaaaatcgc aaacgataaa      120
gaagacacta ctcatataaa gtcatgttta ctaatccagc accataattc cagtctcaga      180
acctcccatg cagattggaa agggattatg ggaacgaggt gagtatgtag gacatgtcgg      240
cgctagtaac atcaaattga cggccccata tttgctcgct tcacaagaca aaaaacacag      300

```

25

```

ggtcctccca aagtaagcag aagatgacat gacggcatgg agacgaaaaa caaaacgcta 360
gcgcgctaaa tcaatgggtca atagctgcaa aaccatctga tgacaactag ggtaacttcc 420
cgtgtcaacc aaaaattcac aaacaagtaa gcactacctg tagaacagac acgaagtcac 480
gcaaacctac actttgagca cgcctgacca gagatccgag cacactcccc gaccaccaa 540
cacacagcag gccacgcggt agagagaaca agaatacaaa ggacaagcga gtagctgtag 600
aagcgatgag agagagcgta cgtagagatg ggggaggaac accacgtagg agcagaactg 660
ctgcactgcg tgcacacgcg acgcgaacag acgaaactac acgaagacaa aaggaaaagg 720
aaaggatggg accagagggg agagccaagc atgagagaca caccaaaagg caccgcacg 780
ctgcatggcg aagcgagaag aacagcagat aaccacaaaa aaaagcacac acggtgggac 840
atacacacca gagggggagc atcagacaca gggacaaaacc actaaagcag gagaacatgg 900
cgcgaaagga ctgaactaaa cagcaciaaac acgcaacgag cagcgaacag ccgatcatag 960
gcgtgacacc cgactacagc aaaagaaacg gagaagtatt cgacacaagg gatgacaagg 1020
aaacaggcta atggccaag gagaggaaca ataagatgga tgagcacagt agggcgaaca 1080
agggataacc caagtgaaga aacagtgaag aagaggaatg cacacaataa gaacgcaaa 1139

```

```

<210> 30
<211> 235
<212> DNA
<213> Homo sapien

```

```

<400> 30
agtgtttgca acagcaccat ttgtcaaatt caaagatgct caaaagggtg tccctacttt 60
gcatgagagg gagagctttg taacaggaaa ttgtataagg caaactctct attcattcct 120
aaggcctctg ttcatctcta atgtttacat ggttctctac tctgaagggc accaacatgg 180
acctcacctt cttaacatgg aaaatcaaaa tctaaatgaa ttaccattaa aagga 235

```

```

<210> 31
<211> 2171
<212> DNA
<213> Homo sapien

```

```

<400> 31
ctgcattttt ctgtcattct cttcatttgt tttaagggtg aaaattttct tacagttgat 60
gcaaagtatc aackacttta cctaccttc tccctttta gatgggttct tctgagttt 120
tggagtcttg tatgattatc agtattcccc tgtcaaaatc aaatctattc aggtttcttc 180
actgttgaga acacctaaat gtttttattt ttgagaagtg gggacagagt ctcactatgt 240
caccaggtt ggagtgaat ggcatgatct cagctcactg caaccttcgc ctctgggkt 300

```

caagcgattc tectgcctcc gcctcctgag tagctgggat tataggcacg caccaccacg	360
cccagytwwt tttttgtatt tagtagagac agagtttcac catgttggcc aggctggtct	420
tgaactcctg accttgtgat ccacccacct cggcctcccg aggggtgctgg gattacaggc	480
atgagccacc acgcttggtt aagaacacct aaatttttat gtttcttggc tcaaaaacca	540
gttccatttc taatgttgtc ctcacaagaa ggctaattgg tggtagagaca gcaggggagg	600
aggaagagct gtggtttgta acttgttcaa ctcaggcaat aagcgatttt agctttattt	660
aaagtcttct gtccagcttt aagcactttg taagacatgg ctgaaagtat cttttctatc	720
agaattgcag atagtcatgt tgggctaaca gtcaattgga tatattcctt tacctcacat	780
gacccagca actgtggtgg tatctagagg tgaaacaggc aagtgaatg gacacctctg	840
ctgtgaatgt tttagagaag gaaattcaaa aaatgttgta actgaaagca ctgttgaata	900
tgggtatcgg ctttcttttt cactttgact cttaacatta tcagtcaact tccacattaa	960
tgaaagttga ccatagttat ttccaaataa aaagaaacca actcttacca ggtcttggac	1020
tgtgatgtca tattattcag ttttatgctt gttcctgagc agaactcata agagtgcacat	1080
agtcagctgc tgacggcacc tcagccacgc cactcttact cagttcagtg ggtgtgcttg	1140
cgtggtagga tgtggtgcag ccctctctac gctcttctat ttttgggtata tttctatct	1200
aaccttcaaa tagcttccaa ttcttttttt cttggactgg cttcattctg aatttgtgct	1260
aaaataatct ttcataaaga gacctcagtt tatagcgtaa cagactacac aatgcactga	1320
tgttttcata atgtttaagg gacctctgc aagaagcttg ctgcctcctt ttaattgtat	1380
tcatttagat tttgattttc catgttaaga aggtgaggtc catgttggtg cccttcagag	1440
tagagaacca tgtaaacatt aggaatgaac agaggcctta ggaatgaata gagagtttgc	1500
cttatacaat ttcctgttac aaagctctcc ctctcatgca aagtagggaa caccttttga	1560
gcatctttga atttgacaaa tgggtgctgtt gcaaacactt tttttttgag atgaagtctc	1620
gcggttgta cccgggctgg agtgagtggt cgtgatctcg gctcactgca acttccacct	1680
cctgggttcc agccagttct cctgcctcag cctcccaagt agctgagatt acaggcgcct	1740
gccacccac ctggctgatt tttgtaattt tagtagagac ggggtttcac catgttggcc	1800
aggctgatta actcctgacc tcaggtgatc cacctttctc ggctcccaaa gtgcttgga	1860
ttacgggtgt gagccaccgt gcccggcctg caaacacatt ttaattgaca acactagggc	1920
tgttgtacaa aatagtaatg atagccatgg aagttttacc ttattctgtg agaagtgttc	1980
ttaaacttat taaagtgtct aaaactaagg ttagtgcttc taaaggaagt ggccggttct	2040

27

cctaagaagc aattatcact gtcctgact ttgtctggtt ggtttggttc cccctgtccc 2100  
 cgattggctc tgggtgctctg ctttgccgcg gttcttttaa gccagcgcg gttatttttt 2160  
 gaaaacctcg g 2171

<210> 32  
 <211> 192  
 <212> DNA  
 <213> Homo sapien

<400> 32  
 gcgtggcgcg gccgaggtac tgtctctaca gccattgaga agccattcag tgccctggta 60  
 gggacctgag actttccaga attcacacag cagtctatga tccctcaa at gtaagaggac 120  
 aggggggtcag cctatcttca cctctcagtg aatgtggagg gccaaagcaat atgacttgca 180  
 aacctaagct ag 192

<210> 33  
 <211> 2641  
 <212> DNA  
 <213> Homo sapien

<400> 33  
 tttttttttt ttcttttcca agttatttaa ttacagcat cagtctcaa atataataat 60  
 attaagatag cagtttagaa attaactttt ttccagatca ctctaacata aaatctctca 120  
 actgaatctc tagtttgtct ctttttgta agagctttta tattacatgg gaagttcaga 180  
 gacttctatt tccatccctc aacatgtagt gacagtcaac atgtcaggct ctgtagcacc 240  
 gtgatatccc agcaccagac cactccagcc accctctcat tcaaagaagg gctacaagat 300  
 atggctggac tactcgaatc acatctgac ttaatacaatc caggatataga aagttgtact 360  
 ataaagaata ctttccaaaa ttgttcactc aaataaaaac agatcaagtc attacagagc 420  
 atttttccat ttaataaga ataacagacc tactcaaggt aattttatc tgtttattta 480  
 aataaggata agactactta aaagactttt tacatacaaa aatgtacaag gttaaacttt 540  
 tctgtactga attacaaaac ctgcacaagc atgtaataaa agagcacact taaaaacatt 600  
 ctgaccatta ttagcctct aaaaattact gaagttcaac agtagtaaat agaggaagct 660  
 cttacatata tatatatata tatatatata tatatgattt aatctactgg cagttttact 720  
 taatgtaagt atttaaaagg tcacattgct attgaatgag tctctagatc aattttagaa 780  
 ttgtctctca aaacttaagt caacaaaat attatttcaa atagtaattc caattctgaa 840  
 gaattttaat accagcaa atattatggc ctcatagtag taactgaacc aactttccaa 900  
 agtgctgggt agctgtccag atgaattagg ctgctttgga aaactgtact gtctctacag 960

ccattgagaa gccattcagt gccctggtag ggacctgaga ctttccagaa ttcacacagc 1020  
 agtctatgat ccctcaaatg taagaggaca gggggtcagc ctatcttcac ctctcagtga 1080  
 atgtggaggg ccaagcaata tgacttgcaa acctaagcta gaagcttggg atctacagta 1140  
 aggaggaagg agaattaaag tagagaaaga aaatgtataa ggagaaaggg aaaagaagga 1200  
 acaaagaggg aaaagaagaa aaaacaagga tgcctgctaa tggcaggaag tggtaaagtg 1260  
 cctataacta caacttacaa gcccccact aattctaatag ccattcattt gcctactcca 1320  
 ataataagaa aagctggctt tactggaata tagaatctag agcaacatta cccgcctcat 1380  
 gttagttagt aactagtatt ctaaagttgt ttgccatata tatcaagttc ttctaacctt 1440  
 tgaagcaaac caaaacactt caaaactcag ggctcccagg gctgctgctc cagattccca 1500  
 gcattcagca tgcttcatta tgtggagaaa gacatttcaa gacaagctgt atctatacac 1560  
 cttcagaagg aacaaagctc taagaagggtg ggattatggt aacacatagt acatggttta 1620  
 gcgtttctcc acatttcaaa ctcaaaatag ctcaataata tgctgctaca tgagcattga 1680  
 ttctgaatgt tcataatata aacttcaatt tgaagcaaca atgttacaca gtacagctgt 1740  
 tattaccaac ctactctgta agttaaaata caaataaaat attaatTTTA ttgagtaact 1800  
 aaaaataagt tcccactgac ttaaaatcgt caaatggcta actctctctc aactaagaga 1860  
 gcaacacaga tgggaagcaga gaggacaact gaatataaaa taaaatttgt caatctactc 1920  
 tataatctgc acttttataaa tccccttttg catatatgta tgtataggat cacagttgcc 1980  
 caccaacatt atgtctgtca gccctgcaga taacaattta ctgtaacgtt aacaatttat 2040  
 gcaataacta gtatgtttta tcttatgtgt acagatttac agtttggaaat aaaggcagaa 2100  
 tgattaaaaa ctattgggtt aaagtcttag tatggtagctt acctgcaagg ctgaattaat 2160  
 tttttggaag gctattcaat agctgaacta aaatgcttgt ttaacaaatc aaaagaggaa 2220  
 taagactact ttaaaacata ttgaaaaagg taaatcccaa tttgaagatc aatcatataa 2280  
 cgaaaaaagt atgaagtatc ctttgctctt gcttagaaac acatagcaga acagtagaaa 2340  
 ctagaactca tgaatataag gtaaacccta ttttcccact gatttccatt atacaattgg 2400  
 agtgaaaata cactcaaac aaaaataaac aaaaaatctt agcaggtaat tctgtgtaga 2460  
 acagccatgt gggaattgtc tatattacag ctgcagggaa tctcatgtaa gctaggagtc 2520  
 catcttctta tgttgcactc tgcagtgact tctgactccc agtagctcct ctattgccta 2580  
 ctccatatta cgctaatttt tgcccctga ctgctatgct tcctgggact cttattaaat 2640  
 t 2641



29

<210> 34  
 <211> 434  
 <212> DNA  
 <213> Homo sapien

<400> 34  
 atttccttat acacacaccg aatcagaata tactttcagt tctacaattt gacaatacac 60  
 atagctgatt tatagcaagt gtgccatgaa ctgagggttt gtttagtttg tttttgcagg 120  
 gctgccaata tgctgtcttc acgggacggg aaagaaagta tcacttgggc cgcattctaat 180  
 atgaaatact gaaggtgggt gtagagaggg tgctagggct ttgaacagcg gcacttcctt 240  
 tctgagagag agaaaacatc atgctcccc cgcgccgaac tcattttaca gggtgattgg 300  
 gtgaacaatt cttggcaggc cctgagctag tctgggtatc ctgagtcaag agagaggccc 360  
 tgcctctgag gtaaagtgtc tctcatctgc ctaagtttgc ttagaaactt tggcttatga 420  
 aagattaacc taag 434

<210> 35  
 <211> 197  
 <212> DNA  
 <213> Homo sapien

<400> 35  
 tctgagacaa tagggcatgg gtcctctaata tcatctcgag cggegcattg gatggatagc 60  
 ggcgoccggg cagggaaacc cctactggac cctgtgtgtc tgccagcctg gaggccttgt 120  
 ctccagccct gcctttatc ctccttgcc ccacaccagc ctccccttgc ttctccttac 180  
 agactatcca agaagtg 197

<210> 36  
 <211> 3414  
 <212> DNA  
 <213> Homo sapien

<400> 36  
 atgggggatt tcgcagcccc cgctgctgcc gcgaatggca gtagtatttg catcaacagt 60  
 agcctgaaca gcagcctcgg cggggccggg atcggtgtga ataatactcc caatagtact 120  
 cccgctgctc cgagtagcaa tcacccggca gccggtggat gcggcggtc cgggggcccc 180  
 ggcggcggtt cggcgccgt tcccaagcac agcaccgtgg tggagcggct ccgccagcgc 240  
 atcgagggtt gccgtcggca ccacgtcaac tgcgagaaca ggtaccagca ggctcaggtg 300  
 gagcagctgg agctggagcg ccgggacacc gtgagcctct accagcggac cctggagcag 360  
 agggccaaga aatcgggcgc cggcaccggc aaacagcagc acccgagcaa accccagcaa 420

gatgcggagg ctgcctcggc ggagcagagg aaccacacgc tgatcatgct acaagagact	480
gtgaaaagga agttggaagg agctcgatca ccacttaatg gagaccagca gaatggtgct	540
tgtgatggga atttttctcc gactagcaaa cgaattcgaa aggacatttc tgcggggatg	600
gaagccatca acaatttgcc cagtaacatg ccactgcctt cagcttctcc tcttcaccaa	660
cttgacctga aaccttcttt gcccttgag aacagtggaa ctcacactcc tgggettcta	720
gaagatctaa gtaagaatgg taggctccct gagattaaac ttcctgtcaa cggttgcagt	780
gacctggagg atagcttcac catcttgag agcaaagacc tcaaacaaga acctctcgat	840
gaccctactt gcatagacac atcagaaaca tctctttcaa atcagaacaa gctgttctca	900
gacattaatc tgaatgatca ggagtggcaa gaattaatag atgaattggc caacacgggt	960
cctgaggatg acatacagga cctgttcaac gaagactttg aagagaagaa ggagccagaa	1020
ttctcgagc cagcaactga gacccctctc tcccaggaga gtgcgagcgt gaagagcgac	1080
ccctctcact ctcccttcgc acatgtctcc atgggatctc ccagggcgag gccttctctt	1140
tctggtcctc ccttttctac tgtctccag gccactagt taccttctgt tgccagcact	1200
cccgagctc caaacctgc aagctcacca gcaaactgtg ctgtccagtc ccctcaaact	1260
ccaaaccaag ccacactcc aggccaaagt ccacctcggc ctggaaatgg ttatctcctg	1320
aatccggcag cagtgacagt ggccgggtca gcgtcagggc ctgtggctgt gccagctct	1380
gacatgtctc cagcagaaca gctcaaacag atggctgcac agcagcaaca aagggccaaa	1440
ctcatgcagc agaagcagca acagcaacag cagcagcagc agcagcagca gcagcagcag	1500
cagcaacagc agcagcagca gcagcaacag cactcaaact agacttcaaa ttggtctccc	1560
ttaggacctc cctctagtcc atatggagca gcttttactg cagaaaaacc aaatagccca	1620
atgatgtacc cccaagcctt taacaaccaa aacctatag tgctccaat ggcaaacaac	1680
ctgcagaaga caacaatgaa taactacctc cctcagaatc acatgaatat gatcaatcag	1740
cagccaaata acttgggtac aaactcctta acaaacagc acaatattct gacttatggc	1800
aacactaaac ccctgacca cttcaatgca gacctgagtc agaggatgac accaccagt	1860
gccaaaccca acaaaaaccc cttgatgccg tatatccagc agcagcaaca gcagcagcaa	1920
cagcaacagc agcagcagca gcagcagcag ccgccacctc cacagctcca ggcccccagg	1980
gcacacctga gcgaagacca gaaacgcctg cttctcatga agcagaaagg agtgatgaat	2040
cagcccatgg cttacgtgc acttccatcc cacggtcagg agcagcatcc agttggactt	2100
ccccgaacca caggcccat gcagtcctcc gtgccccag gctcaggtgg catggtctca	2160
ggagccagtc ccgcaggccc cggttctctg ggcagccagc cccaagcagc catcatgaag	2220

cagatgctca ttgatcagcg ggcccagttg atagagcagc agaagcaaca gttcctgcgg 2280  
 gagcaaaggg agcagcagca gcagcagcag cagcagatth tggcggaaca gcagttgcag 2340  
 caatcacatc taccocggca gcacctccag ccacagcggga atccataccc agtgcagcag 2400  
 gtcaatcagt ttcaaggttc tcccaggat atagcagccg taagaagcca agcagccctc 2460  
 cagagcatgc gaacgtcacg gctgatggca cagaacgcag gcatgatggg aataggaccc 2520  
 tcccagaacc ctgggacgat ggccaccgca gctgcgcagt cggagatggg actggcccct 2580  
 tatagacca cgcctaccag ccaaccagga atgtacaata tgagcacagg catgacccaa 2640  
 atgttgacgc atccaaacca aagtggcatg agcatcacac ataaccaagc ccagggaccg 2700  
 aggcaacctg cctctgggca ggggggttga atggtgagtg gctttggtca gagcatgctg 2760  
 gtgaactcag ccattacca gcaacatcca cagatgaaag ggccagtagg ccaggccttg 2820  
 cctaggcccc aagcccctcc aaggctgcag agccttatgg gaacagtcca gcaaggagca 2880  
 caaagctggc aacagaggag cttgcagggc atgcctggga ggactagtgg agaattggga 2940  
 ccattcaaca atggcgccag ctaccctctt caagctgggc agccgagact gaccaagcag 3000  
 cacttcccac agggactgag ccagtcagtc gtggatgcta acacgggcac agtgaggacc 3060  
 ctcaaccag ctgccatggg tggcagatg atgccatgc tcccggggca gcaaggcacc 3120  
 agccaggcga ggccaatggt catgtctggc ctgagccagg gagtcccagg catgccagcg 3180  
 ttcagccagc ccccagcaca gcagcagata cccagtggca gctttgctcc aagcagccag 3240  
 agccaagcct atgagcggaa tgcccctcag gacgtgtcat acaattacag tggcgacgga 3300  
 gctggggggt ccttccctgg cctcccggac ggtgcagacc ttgtggactc catcatcaaa 3360  
 ggcggggccag gggacgagtg gatgcaggag cttgatgaat tggttggtaa cccc 3414

<210> 37  
 <211> 678  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (310)..(611)  
 <223> a, c, g, or t

<400> 37  
 tcataatgct gtcgagcggc ccgagtggt gatggatcgg ccgcccggga ggtacctgct 60  
 gtgtggcagg ctctgggctg ggggctttat tcagcttcct cagcctgctt cgacttcccg 120  
 attagagagc taatgtgaat caccaacct gtgatgcctc ttgagatgag agttcagatt 180

tcccaagaag atctaagcag ttggtccaaa ttgtagttca ctagcaaag acccagtgct 240  
 gtccctgtgg tgtgtttatg acatgatgga agatgctgcc ttcaaaagtg tccacttgta 300  
 agaagatgtn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 600  
 nnnnnnnnnn nacacacaaa aaaaaggtgg gggaaccagg gcaagcggtc ccgggggaaa 660  
 tggtttccgc acattcca 678

<210> 38  
 <211> 461  
 <212> DNA  
 <213> Homo sapien

<400> 38  
 gtgcggccga ggtaccaact gacatttcag tttttctgtt tgaagtccaa tgtattagt 60  
 actctgtggc tgcctctctc acctgcccct tgtggcctgt ctacaattct aaatggattt 120  
 tgaactcaat gtcgtcgctt ctggtttcct gcatatacca atagcattac ctatgacttt 180  
 ttttttctg agctattttc actgagctga gctaataaac taaaactgag ttatgtttaa 240  
 tatttgtatc aaatacataa aaggaatact gctttttcct tttgtggctc aaaggtagct 300  
 gcattttaaa atatttgtga aaataaaaac ttttgttatt agaaaaaaa aaaaaaaa 360  
 aaaaaaaa ggcttggggg aaaccgggg ccaaaagcgg tgtccgggg gggaattgg 420  
 ttctccggtc caaattcccc aaaaaaatcg agaagaaaag t 461

<210> 39  
 <211> 633  
 <212> DNA  
 <213> Homo sapien

<400> 39  
 caacaccatc tttttttttt tttttttttt ttgagacaga ttcttactct gactccagc 60  
 ctgggtgacag agcgagattc catctcaaaa aaaaaaaaac agtatgcacg tacaaatttc 120  
 ttaacctgtt atcaatgtct gagctacata attatctttc tagttggagt ttgttttagg 180  
 tgtgtaccaa ctgacatttc agtttttctg tttgaagtc aatgtattag tgactctgtg 240  
 gctgctctct tcacctgcc cttgtggcct gtctacaatt ctaaatggat tttgaactca 300

33

```

atgtcgtcgc ttctggtttc ctgcatatac caatagcatt acctatgact ttttttttcc 360
tgagctatth tctctgagct gagctaata actaaaactg agttatgttt aatatttgta 420
tcaaatacat aaaaggaata ctgctttttc cttttgtggc tcaaaggtag ctgcatttta 480
aatattttgt gaaaataaaa acttttggtta ttagaaaaaa aaaaaaaaaa aaaaaaaaaa 540
aaggcttggg ggaaaccggt ggccaaaagc ggtgtcccggt gggggaattg gtttctccgg 600
tccaaattcc ccaaaaaaat cgagaagaaa agt 633

```

```

<210> 40
<211> 536
<212> DNA
<213> Homo sapien

```

```

<400> 40
ggggcgcccc gggcaggtag ttgacagtgt tatctgtcac ttatttaaaa aaaaaacaca 60
aaaggaatgc tccacatttg acgtgtagtg ctataaaaca cagaatattt cattgtcttc 120
attagggtgaa atcgcaaaaa atatttcttt agaaacataa gcagaatctt aaagtatatt 180
ttcatataac ataatttgat attctgtatt actttcactg ttaaattctc agagtattat 240
ttggaacggc atgaaaaatt aaaatttcga tcatgtttta gagacagtgg agtgtaaattc 300
tgtggctaatt tctgttggtc gtttgtatta taaatgtaaa atagtattcc agctattgtg 360
caatatgtaa atagtgtaaa taaacacaag taataaatga agtgtttggt ataaaaaaaa 420
aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gtggggggaa cccggggcca aaaggggttc 480
cgggggggaa attggtttcc ggccaaaat ttccaacaat ttggggagaaa aaaggt 536

```

```

<210> 41
<211> 1206
<212> DNA
<213> Homo sapien

```

```

<400> 41
gtactctccc aaatgcagcc taatcttagt aaccttgaag tttatcattc tttaaaacta 60
aatagaatac caatgggtta gatattccaa caaagaatgc tagaaacaaa tgtctaattc 120
cgattattag ctttaccac cctgtgaaca ctgaggttgc agaactgccg ggttaattcc 180
tgtggcctag actactgagg attctgatag cacatgtaag actaagcact cttcaagctg 240
taataaagca tccacatgta tctgtgatga ttttcattgc tttagcattg cagccatgta 300
acaactgcag aaagaaggta tttttaaaaa tacaatagac tacacttttt ggatcacaga 360
gaaatacaga tgcactctga gactgcctat gtttataaac atgttgtgtc ccctaactga 420
agtgacaggt cttctggaat tgacattaag aagtggtgat agtcatatca cagcgaatgt 480

```

34

atttgttttc agcagtgagc agaccgtaca ggagcagcac accaggagcc atgagaagtg 540  
 ccttggaac caacagggaa acagaactat cttatacac atccccctcat ggacaagaga 600  
 tttatttttg cagacagact cttccataag tcctttgagt tttgtatgtt gttgacagtt 660  
 tgcagatata tattcgataa atcagtgtac ttgacagtgt tatctgtcac ttatttaaaa 720  
 aaaaaacaca aaaggaatgc tccacatttg acgtgtagtg ctataaaaca cagaatattt 780  
 cattgtcttc attaggtgaa atcgcaaaaa atatttcttt agaaacataa gcagaatctt 840  
 aaagtatatt ttcataaac ataatttgat attctgtatt actttcactg ttaaattctc 900  
 agagtattat ttggaacggc atgaaaaatt aaaatttcga tcatgtttta gagacagtgg 960  
 agtgtaaatc tgtggctaatt tctgttggc gtttgattta taaatgtaaa atagtattcc 1020  
 agctattgtg caatatgtaa atagtgtaaa taaacacaag taataaatga agtgtttgtt 1080  
 ataaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaagg gtggggggaa cccggggcca 1140  
 aaaggggttc cgggggggaa attggtttcc gggccaaaat ttccaacaat ttgggagaaa 1200  
 aaaggt 1206

<210> 42  
 <211> 209  
 <212> DNA  
 <213> Homo sapien

<400> 42  
 ccgggcagggt ggaacttagt gggcagcatt acgggcagcg ctaaggaacc atttaaagta 60  
 agacaagtcc acacagctgt ggtgcttttc tacgagtctt gttccaactg ctgcataaca 120  
 atagaatgtt ggaagcagga attagtttta aagtaagact tcagaagtgg aaacaaattt 180  
 gatattttatt ttataatga tataatagc 209

<210> 43  
 <211> 706  
 <212> DNA  
 <213> Homo sapien

<400> 43  
 gaaccctcca aaacatctga aaagcaaatt tgggggggatg aggaagtgag atgatgactt 60  
 gattctcctt ctaggaagaa tagaggaacc cttctggcaa aatttcaagc atctacaaga 120  
 ggaggttttc cagaaaataa agacactggc tcagctctca aaggatgttc aggatgtcat 180  
 gttctacagt atcctggcca tgctcagaga cagaggggct ctacaggacc tgatgaacat 240  
 gctggaattg gacagctcag gtcatttggg tggccctggt ggtgccatcc taaagaaact 300

35

tcaacaggat tcaaaccatg catggtttaa cccaaaggac cccattcttt atctccttga 360  
 agccataatg gtgctgagtg acttccaaca cgatttgctg gcctgttcca tggagaagag 420  
 gatcctgctt cagcaacagg agctggtaag gagcatcctg gagccaaact tcagataccc 480  
 ctggagcatt cccttcaccc tcaaacctga gctcctcgcc ccactccaga gtgagggttt 540  
 ggcacacact atggctgctg gaggagtgtg gccttaggac ggagctggat aaccccaggt 600  
 caacctggga tgtagaagca aagatgccct gtctgtcctc tatgggactc tctcgttgct 660  
 gagcagtggg tgaaggctaa gcctccctga tgggagcagt cagaaa 706

<210> 44  
 <211> 1298  
 <212> DNA  
 <213> Homo sapien

<400> 44  
 atatgaagtt aaaaccagag ctatttctga cacagcaatt tttgagcggg catttgccaa 60  
 aatacgaaca agttcacatc ctcccagtag gtgagtgtga gtttgctgga ggtgggggtg 120  
 gggatcccat cctgcacaca tggggtaagt agggcagatt gccctgcct cgcctttgcc 180  
 accaccgcc tagggcctgg cgtttggtca tgtggaatgg gaagggtcca gaaagctgag 240  
 aacatggagg atgaatggga atgggggcag gaagaagttg agtaagaggg aggaggtggt 300  
 aggagagcag aaccctccaa aacatctgaa aagcaaattt ggggggatga ggaagtgaga 360  
 tgatgacttg atttccttc taggaagaat agaggaaccc ttctggcaaa atttcaagca 420  
 tctacaagag gaggttttcc agaaaataaa gacactggct cagctctcaa aggatgttca 480  
 ggatgtcatg ttctacagta tcctggccat gtcagagac agaggggctc tacaggacct 540  
 gatgaacatg ctggaattgg acagctcagg tcatttgat gccctgggtg gtgccatcct 600  
 aaagaaactt caacaggatt caaacatgc atggtttaac ccaaaggacc ccattcttta 660  
 tctccttgaa gccataatgg tgctgagtga cttccaacac gatttgctgg cctgttccat 720  
 ggagaagagg atcctgcttc agcaacagga gctggtaagg agcatcctgg agccaaactt 780  
 cagatacccc tggagcatte ccttcacctt caaacctgag ctctcgcgcc cactccagag 840  
 tgagggtttg gccatcacct atggcctgct ggaggagtgt ggccttagga cggagctgga 900  
 taaccccagg tcaacctggg atgtagaagc aaagatgcc ctgtctgccc tctatgggac 960  
 tctctcattg ctgcagcagc tggctgagge ctaagccctc cctgatgggc agtcagteca 1020  
 gagatgctgg cctcgcacca gtctatgctg tgagtgtcct tatgggtgca agagataggg 1080  
 ctgtgcctct ctgcgtttcc aggtggagta gagacagtaa tgggtagaga ctttaggaaa 1140

36

tggtttgggg tggtggaata ctctatatat tgacaagagt ttatatattg acaagagttt 1200  
 atatatttgt caaaactcct caaatagtat gttaaagacg taagcgtttc actatgtata 1260  
 aattttactt caaaataata aaaacaaata ctgactct 1298

<210> 45  
 <211> 531  
 <212> DNA  
 <213> Homo sapien

<400> 45  
 acaacattca acaaccagt ggtgaggttg taaatcaa at gagagaggag gaactgatcc 60  
 gggtagcagg aacacatttc caagtaaaat ttgcaacaga gcatgttgag atcatggttt 120  
 taatttatga atggcattat tatctttaa ctattatttt ccaagctcat atatggcctt 180  
 tttgaagggt ttccgaatgt tacatttgat ttaagatct aatccaaat gaaatataga 240  
 atgtgcttag tttctataa aaatgccaat gactatctct taaattagtc aaggaaagac 300  
 aaattacca aattcaaact tatttgaatt atttttaagt gattccaggc aataaatata 360  
 tagaacccat ggaaagtttt agcttcaa at caaaaattg caaaaaaaaa aaatggtaaa 420  
 tggctaaca taaggggggt tatggaaa at attgggtcac ctttaattata ggtttaaatg 480  
 ccacaaacaa tataataata gttttaactt actttttctg attactaagc a 531

<210> 46  
 <211> 469  
 <212> DNA  
 <213> Homo sapien

<400> 46  
 taacgccatc agctcgctgc ttaaagccgt gtttgcgtct cattttctca aagaaatctg 60  
 ctttagtttg agattacagt ttatcaa atg ttaaggcttt gaccccaaaa tctgggtcca 120  
 gaaagacagg aaggccagct aagaggaggt tttcagagt cgtagaaagg ctgctctgtg 180  
 cttcggcatt tgttctggaa gtgcttcttc ggttggcaaa gattcctagc aaaacctttg 240  
 actggaggct ttacagggcc atacaccaa tatcactaat gacagtgttg taaaatagct 300  
 tttgtgcacc atgcttagga ttcaaggagg ataaagtata tctttctaaa gttatacttt 360  
 agaaactgtc attccatgtt gaaatgata acattccatg tttatctttt gtgtaagaag 420  
 taaaaaagca aaaattcatt gcatcaa atg aggtcaggca ctgctaaag 469

<210> 47  
 <211> 483  
 <212> DNA  
 <213> Homo sapien



37

<400> 47  
 aaaccgagtt ctggagaacg ccatcagctc gctgcttaaa gccgtgtttg ctctcatttt 60  
 ctcaaagaaa tctgttttag tttgagatta cagtttatca aatgttaagg ctttgacccc 120  
 aaaatctggg cccagaaaga caggaaggcc agctaagagg aggttttcag agtgcataga 180  
 aaggctgctc tgtgcttcgg catctgttct ggaagtgctt ctctcggttg caaagattcc 240  
 tagcaaaacc tttgactgga ggctttacag ggccatacac ccaatatcac taatgacagt 300  
 gttgtaaaat agcttttgtg caccatgctt aggattcaag gaggataaag tatactcttc 360  
 taaagttata ctttagaaac tgtcattcca tgttgaaatg ataaacattc catgtttatc 420  
 ttttgtgtaa gaagtaaaaa agcaaaaatt cattgcatca aagtaggtca ggcactgcta 480  
 aag 483

<210> 48  
 <211> 600  
 <212> DNA  
 <213> Homo sapien

<400> 48  
 tccatttctc atggcttgct catcttcagg ctccagctc tgacttcac tcaggatggg 60  
 atcgggtgtgt gtctgttttc atagatccac tacatcagaa gtatctttac atctctgtat 120  
 ctttacatcc caaggtcaag gccctggcaa cctcagaggt tcccatagct tcagtcttcc 180  
 ccaaaccatg ccacttcctc ccatttcttt gggtcaggaa tctggctttt gttttccata 240  
 tttctttttc ccaagacatt gggaggcatc tggatgaaca caccaataaa acagttctct 300  
 ccccaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaac aaaaaacgaa 360  
 gaacaaagaa cagagaaaaa aaaaaacaag aaacaccaa aaacaaaaaa gaaaacgcgg 420  
 ccgccagcgc acgcgcgagg gcgcgcgagc acaccctgtg gccagcccgc gagcgagaag 480  
 ggagcggggcg gggcggggcg gaccggagac ccaaggaggc cgcagggagc aacgaacggg 540  
 agccggagga gcgcgacact gcacgcagga gagcagacgg gaggggagac agcgcgggga 600

<210> 49  
 <211> 1098  
 <212> DNA  
 <213> Homo sapien

<400> 49  
 aacctcttca acaataaatt gctctttggg gacattttat gcacagaact gtgcaccctc 60  
 ctcagaacag caggctctta atggcccatg tgatgagaag ggcccatca aggcagcagg 120  
 aatgggccac tctccacac cccatgggcc aggcactgc cactcctgct gccctgcatc 180

38

```

cccagggttta tggctgcatg gtagaagtca cttctgtaag aaattcacct ttctaaaata 240
aagtatgtct ttttttctga gacatctata gaataacttg tggcagagtg ttttaaaaac 300
tgatttggat tttttttatc ctttaaccgt gtgaaaggat ggaagggatt ttaggtggaa 360
gagaagttaa gaacagaaag atagagcagg tttttagagt gggagaatta atcccaaaga 420
aaaagagggc atggaaacaa atgtggatgc catgggctct gtgccagact tgccagtgtc 480
gactggaaca ggccgggctc ctcaactcagc ggctcctgcc tcagctgtgg ttcccgcagc 540
ctctgggtct cacggaaccc ttcttgga gttccatttc tcatggcttt gctcatcttc 600
cggcttcagg ctctgacttc atctcaggat gggatcggtg tgtgtctgtt ttcatagata 660
cactacatca gaagtatctt tacatctctg tatctttaca tcccaaggtc aaggccctgg 720
caacctcaga ggttcccata gcttcagtct tcccaaacc atgccacttc ctcccatttc 780
tttgggtcag gaatctggct tttgttttcc atatttcttt tcccaagac attgggaggc 840
atctgtgaa caacaccaat aaaacagttc tctccccacg gtcattccagg tcaactctct 900
aactcattcc tgcacacaca gcacacgtgg aatttgctg ttagtctat gttcttgact 960
tgatcacaga cgctgtaca ataaagcccc ttttcaacaa ggtgctgcag aatgataatg 1020
ctttcccaa aatctgaaac tgatttgtat cattgaagtt ttttctgta ttaaaaataa 1080
agcaaaatta aaaataaa 1098

```

```

<210> 50
<211> 540
<212> DNA
<213> Homo sapien

```

```

<400> 50
ggtcgcggcc gaggtactcc cgctcctgg agcggccgac ccacatgga ttctcaacag 60
gtggccggca catcttctga gctcgctct ctcatctgaa agtggagtgt aagtccaaga 120
agattcattt agacaaagaa ggtggaaaaa aaggactttc tgggccagca agtcggatga 180
ccaccctcca aggggcagag gagggcccat tttgtgaaga agaaatcaac taccgggaaa 240
acgccacagg aggacatgtt tctgcagatg tagttgcct agaaacagaa gagtatgggg 300
gtgtgaatgt cttctctttt gggggcaaac actatgtcct tttctttttc tagatacagt 360
taattcctgg aaatttttagc gagtttgttc ttgtggatat ttgaacaat aaagagttaa 420
aatcaaaaaa aaaaaaaaaa aaaaaaaaaa accctgggcg gtacccatgg cgcaaagcct 480
ggccccctgg ggggacactg ggttaccg ccccaattc ccacaattg cggagcaacg 540

```

39

<210> 51  
 <211> 1028  
 <212> DNA  
 <213> Homo sapien

<400> 51  
 cggccgcggc atgaaaggcg gcgaggagag gcagcactgc tgcctcttgac ttctgagcag 60  
 ggcttagaga gcctgccccg gcttaagccg agctgctggg gctgaccctg agcgccgagt 120  
 ccgcgagctc tgagtccgga gctctccagc cgtggagccg tgggatgagg ggggcgttgg 180  
 gggacagggc aaagtcgac ttggttgtag agccgcccga tcctagcgcg gagctgcgag 240  
 cctgaccggc cgcgtctggc atggtcagag aaagaatctt cttttcccaa ctccggcttt 300  
 tggttttgtg tgtccacctt gcgcaactcc ggagccagcc gaccccatat ggattctcaa 360  
 cagggtggccg gcacatcttc tgagcctcgc tctctcatct gaaagtggag tgtaagtcca 420  
 agaagattca tttagacaaa gaaggtggaa aaaaaggact ttctgggcca gcaagtcgga 480  
 tgaccaccct ccaaggggca gaggagggcc cattttgtga agaagaaatc aactaccggg 540  
 aaaaagccac agggaggacat gtttctgcag atgtagttgc cctagaaaca gaagagtatg 600  
 ggggtgtgaa tgtcttctct tttgggggca aacactatgt ccttttcttt ttctagatac 660  
 agttaattcc tggaaatctt agcgagtttg ttcttggtga tattttgaac aataaagagt 720  
 gaaaatcact ttggagtcac ttaatcttcg ttagaagggc agtttcttcc agggccatct 780  
 tctttcacca gatattgttt tcctcgttcc caaatgaggt agttttaaaa atcaaagtcc 840  
 acttgctaac tcacctggga aagagactgc gacagaagga agagaagtaa atagacatca 900  
 ctctcaaact aaaagtgtaa ctttcattcc tggcagctga gattcagaac acaaagaac 960  
 aaactcgttt acctttgagt atttcccccg tatgggtaat ttatctagag ctttcccaac 1020  
 aattaatc 1028

<210> 52  
 <211> 541  
 <212> DNA  
 <213> Homo sapien

<400> 52  
 acagattggg aaggtgacat tgtatcacia agctagtctt tgagtccaaa gttttgtggg 60  
 tttatgttat gatatacttt tatcatggaa ttgtcttatt aaatgttttg ccagtgggtc 120  
 ttaaagtgtg tttctgacac cagtagcatt gacttcactt agaaacctgt tagaaataca 180  
 aattatttgg cccaccccaa cacttgagtc acaaactttg cagatggggc tcaatctgtt 240  
 ttaacaagcg cttcatgtaa ttttgatgca ggcctaagtt tttagccgc tgcagtatgc 300

40

```

atttctatTT ttaagcaaag atcttggTct ttctTTTTtg acattgtaga aataacatga 360
acttgtctTT ttgtttgtTT ggttttgtTT tgttttaagc tcttgatctt tgttggttat 420
gttgcaaaag attgtatcag gagaagcctc agcatggaca ttggcatcct gacataaccc 480
ccattaatTT agtattctTT ctgaaactca aatggattct caagtccaag agactatgga 540
a 541

```

```

<210> 53
<211> 261
<212> DNA
<213> Homo sapien

```

```

<400> 53
atgccatcag tggcacaggg ccctgtgccc tggcatctgg gttcacgctc tgctgttgct 60
gtcttcgaat tcttagtgat gtttgaacaa aggcctatg ttgcatttt gcactgggcc 120
ccacaaatca catggcccat cctgagaaga ggagtctcac acctccagtc tctaaatca 180
cctctggaag tttttctcaa cgaaagaact gaagctttcc tcaaaagttc cgtaggggag 240
acagttcatc accataccca a 261

```

```

<210> 54
<211> 325
<212> DNA
<213> Homo sapien

```

```

<400> 54
gctctgtttt gtgttttggt tggattgtgc tggttgtggt ttgtgtttgt ggaagggtgtg 60
tgtgtggggt tggcgagtac atgtcgcccg ggaccgctat ggctctgggt gcgcccacgc 120
tttttttttt tttttttttt tttttttttt ataatacaacc tataagggat ttatcaataa 180
ataaaccttt atttattata aggaattggc ttacacaata atggaggccg agaaggcccc 240
aagtctgctg tccgaaggtc tgagaaccag gagcactgat ggtgtcagtc ccagttcaag 300
ggcaggagaa gatgggtgtc ccagc 325

```

```

<210> 55
<211> 2461
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (356)..(393)
<223> a, c, g or t

```

```

<400> 55

```

41

gcctgaatag agctgtgcag cccaaggggt ggactgagcc agcagtgat atgcaccact	60
gagatctctt gctgtggaac gtaattgact ggggggggtcc cgcctactgc tctctgaatc	120
cattgatata gtcatgcca ggctacattt cccatgggtt gttcccataa gaataacaat	180
aactgaatga agaaggtata ctaataatgc aggcctattc ctgtgaggtg gggggctcct	240
ccaatgggag actttgggtt gagtggttct catcagctga ccttaaactt tattggaatt	300
gtgctacagc ctaagctttc tgctactcaa cccgccttcc ttcctctctt ccttcnnnnn	360
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnaaaccta tggctctatc aatcaattaa	420
taaggattta taatcaacct ataaggattt atcaataaat aaacccttat ttattataag	480
gaattggctt acacaataat ggaggccgag aaggcccca gtctgctgtc cgaaggctctg	540
agaaccagga gcactgatgg tgtcagtcct agttcaaggg caggagaaga tgggtgtccc	600
agcgccacag tcaggcagaa aattcaagct tcctccacct attttatttg ggtccttaga	660
agactggatc aagcccatcc aactgggga ctgcaatctg ctttattcag tccatcaatt	720
caaatgcgaa tttcctccag aaaaagcttc atgaacacaa ccagaaataa tgttcgatca	780
tatatggggc atcctgtggc ccagcgaagt tgacatgcat aaaattaacc atcacacctc	840
catggaggcc agaaatttta tgtattctga ggactctgtc tctctggctt cctctccatt	900
tcaaccctca ggcattcttt ttttcccaa ataaatgtct tgtaaacta tttttttttt	960
acatgtgttt tttttggagt actggaacta ataaatttg actttgttct gcaggtagtt	1020
tagttactta cagatcagct ttatactatt gaggcctgtt ttttaagctt ttgtgggggt	1080
gaggagcaag tgtagttag tttttagtca ggatagttta gccctacgta tgtaacacac	1140
aacctttctg ggatctttag cgaatgctg gttttcagtc aggactctcc actgtggctg	1200
gatggaaatt agatatttcc caatctcacg ctaattttga gaattgttag gcttagtggt	1260
ccgcaatgta cacaatgggg tctctacata gatttctgga tttttttgtc taccttctc	1320
cttggtgata ctttgtcctg aaaattcaag ctatctcagt atcaactcca atcttctct	1380
cctcaactca gcaagactct gatctcctgc gatgggatcc agagtgtca cctcagaaag	1440
gcagggcgat cggaggctc actttgttcc cctgcctcag cgatcaaatt gtataaactt	1500
tttccctggc ttctggaaac actgatagcc aacctttcgg taaaatttct aacatatgta	1560
cttagagctt taatatgcta agtatttaaa tgctaagtat tttctttaaa attcatttca	1620
aaatattttt gcaattttgc cgtgatttat tttttggctc atgggtcatg aggtgtatgt	1680
tccttaaatt aatgcatttt ggaaattttt tgttaccttt atgtacttga tttctgggtt	1740
aattcatact ctatatgatt tcaatctttt gaaatttctt gagacttgat ttgtgatcca	1800

42

```

gcctaacatg cgccccagaa cacatggtaa atgttttggg gtatacttta aaagaacatg 1860
tattctgatg tttttgaatg taatatctta tgtcttattc atatttatag taccaataca 1920
cagcacatag tagaaactta acatatattg agttaaataa ttcaaagggt ttatccgatt 1980
gggtggcaatt caagacccaa taagagagga tgatgatgac atcactatct ctgttaagac 2040
agggcctcat acaacataca ggaatgtcca gttgtcaagt catgcagttt ctcccctatt 2100
ctaaccaatg ttaatgcca tactttgtga tgaaaattat ccagtatctt ttctctctat 2160
gtttccacca gttttccctt cattgattgt taagatttat atcactagag ctatttgaca 2220
gtaggaaaca attaccttag gaaaagttgg tgacattggc ctataaaggc cacggagaca 2280
taagaaatgg ttattttttc atttttcacc aaacaattca cgattgtttc taagattaca 2340
aaagattaga cgatagctaa tttttctatg caatgggtcaa atttttcaag tagaatcatt 2400
tttaaatttt ccaagttcca atgtcacttt ctcttgaac acgactcaag gtcaaaactt 2460
a 2461

```

```

<210> 56
<211> 643
<212> DNA
<213> Homo sapien

```

```

<400> 56
ccgcccgggc aggtacacat gagtgcgtgt atgccccag gctgggtcag ctcttctgtg 60
gattgcatgg cgtgtgatta aaagcccatg tgttccaca catccacatc atgggaaggc 120
taatgtgtgc ctcttgga ctgggtgttg gtgtccatgg aacttctct ctgtatctca 180
ggtcagtagg cgcagaaacg cctcatgatg aagattcttg agccccattt ccaagacccc 240
tcacatccaa tctgtcctg taacatccat caaggatttc cataggggtg actggtgccc 300
accaagact gcaccagtgc ctgctcattg aggagagtaa ctgctggcca ggcagaaaga 360
atatgggctc tgcaatgaga cagacctgga ggggactctc ccgttgagca ctagcagctg 420
gaggagtggg gagttcatgg ctatcatggc tgtgttcaat cgattgtggg gatgacatgt 480
cattgtgtat ggaaggcggg gctcatggct gattggccaa taaaatggcg gctgccgttg 540
tcattgaaaa aacacaccac accacaacca aaaccgctgg ggcacacccg ggcacaaggc 600
ccccgggga aacgggttcc ccgccaaat tctccaaatt aga 643

```

```

<210> 57
<211> 1611
<212> DNA
<213> Homo sapien

```

&lt;400&gt; 57

```

ctcctcccga ggaaccagtg gtgacagctg aggccatgtg agtaggatcc tgaatgaggc      60
tttatctctg gctgttcgtc ccatcgteca ccgtggcacc agctccctca gccagccggg      120
atgggaccag cgactgagag agccagaggc agagaggtga gggtgaccat atcctggact      180
gtgagaggaa tgggactctg ggctgtagc tgccaagcag gtggcaggtg ctccaggctg      240
tgatctgcac cctctgacct ctgacattga cctectacct tgacctctgc ctgaccaagc      300
catgtctgaa caggaggctc aagccccagg gggccggggg ctgcccccg acatgctggc      360
agagcaggtg gagctgtggt ggtccagca gccgcggcgc tcggcgctct gcttcgtcgt      420
ggccgtgggc ctcgaggcag gctgtggcgc gggcgggcgtg gcactgctgt caaccaccag      480
cagccgctca ggtgaatggc ggctagcaac gggcactgtg ctctgtttgc tggtctgct      540
ggttctggtg aaacagctga tgagctcggc tgtgcaggac atgaactgca tccgccaggc      600
ccaccatgtg gccctgctgc gcagtgggtg aggggcccgc gccctcgtgg tgctgctcag      660
tggcctcgtg ctgctgggtc ccggcctgac cctggccggg ctggccgcgc cccctgcccc      720
tgctcggccg ctggccgcca tgctgtctgt gggcattgct ctggctgcct tgggctcgt      780
tttgctgctg ggctgctgc tgtatcaagt ggggtgtgagc ggacactgcc cctccatctg      840
tatggccact ccctccacct acagtggcca tggcggccat ggcagcatct tcagcatctc      900
aggacagttg tctgctggcc ggcgtcacga gaccacatcc agcattgcca gcctcatctg      960
acggagccag agccgtcctt cttctcacag cggcctcagc gtccccagag ccgagccagg      1020
gtgtgagtgc atgtgaacgt tgagtacaca tgagtgcgtg tatgccccca ggctgggtca      1080
gctcttctgt ggattgcatg gcgtgtgatt aaaagcccat gtgttccac acatccacat      1140
catgggaagg ttaatgtgtg cctccttga actgggtgtt ggtgtccatg gaacttcctc      1200
tctgtatctc aggtcagtag gcgcagaaac gcctcatgat gaagattctt gagccccatt      1260
tccaagacct ctcacatcca atcctgtcct gtaacatcca tcaaggattt ccataggggt      1320
gactggtgcc caccgaagac tgcaccagtg cctgctcatt gaggagagta actgctggcc      1380
aggcagaaag aatatgggct ctgcaatgag acagacctgg aggggactct cccgttgagc      1440
actagcagct ggaggagtgt ggagttcatg gctatcatgg ttgtgttaat cgattgtggg      1500
gatgaaatgt cattgtgtat ggaaggcggg gctcatggct gattggcaat aaaatggcgg      1560
ctgccgttgt cattgtctcc aaaaaaaaaa aaaaaaaaaa aaaccgcgga c      1611

```

&lt;210&gt; 58

&lt;211&gt; 617

44

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 58

```

actgtgaagt cttcaggctc ttagaaggct ccagcctgag agagcccttt attattgcc 60
tctctgtcct tctcaaggc ctggtgacct gtgacctttc gctctgggca gggcccaggt 120
agatgggccc tcatccgggc ctgtaagccg tactatgatt tctgcattga ttacatatt 180
ttttactgtg atcttggttc caaacacaga atcgtcaccc cattctccct tgaatgtgcc 240
ggatccttgt aaatttctcat tcacctactt gttcttaggt gtgtatgtgt gtgcgaaact 300
ctatgttcaa gaaagaaatc atacaaagag taacgaacca tggttctgtt ggccattgga 360
cgaaacttgg tttttggact ttcttaccta acattaattt tgctcttgcc tcggtttaca 420
cacacacaca cactacaaca aacacaacac aaacaacgtt ctggggccaac accacgcggc 480
gccagcgccg gctccctggg ttgaaacttg gatctcttcc cgcgccacaa ttctcccaac 540
aactataatg agcacaagga ccacaaccat acacaagaac aacacaaacc agcgacacaa 600
cagagacaac acacaac 617

```

&lt;210&gt; 59

&lt;211&gt; 913

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 59

```

caaaaccaca cccatgcaca cacataccct cagccccac acacaccccg ttgaaccctg 60
gagtcctatca gggcatccta aaactccgtg agttgacatt tcagtaattt caggggaagg 120
tgttttccag ggatggggtc tcccagggtc agatagtgcc tttggctgca aatgctcctt 180
tagctaaaact tttcctcagg aagaattcat tattctagac attatgtgat atatctgtta 240
ggaataaaaag gtgcttaacc ttctccctg ggatgtggga gaagggtgctg gaggtgtac 300
tgtgaagtct tcaggctctt agaaggctcc agcctgagag agccctttat tattgacatt 360
cctgtccttc ctcaaggcct ggtgacctgt gacctttcgc tctgggcagg gccaggtag 420
atgggccgtc atccgggcct gtaagccgta cttgatttct gcattgattt acatattttt 480
tactgtgatc ttggttccaa acacagaatc gtcaccccat tctcccttga atgtgccgga 540
tcttgtaaa ttctcattta cctacttgtt cttagtgtgt atgtgtgtgc gaaactctat 600
gttcaagaaa gaaatcatc aaagagtaac gaaccatggt tctgttggcc attggacgaa 660
acttggtttt tggactttct tacctaacat taattttgct cttgcctcgg ttacacaca 720
cacacacact acaacaaaca caacacaaac aacgttctgg gccaacacca cgcggcgcca 780

```



45

gcgcccggctc cctgggttga aacttggatc tcttcccgcg ccacaattct cccaacaact 840  
 ataatgagca caaggaccac aaccatacac aagaacaaca caaaccagcg acacaacaga 900  
 gacaacacac aac 913

<210> 60  
 <211> 554  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (304)..(430)  
 <223> a, c, g or t

<400> 60  
 tggaaaataa agtttaaaac cagattgccc agagcaagac tctaattgtc ccaacggtga 60  
 tgacatctag ggcagaatgc tgccattttg agggggcaggg ggtcagctga tttctcatca 120  
 agataataat gtatggtttt tacactaagc aactgataaa tggacaattt atcactggac 180  
 aatctccctc tgcttcttta atggggccag ctttgcagcc ctgcagcctg ggtagtcgca 240  
 cacatttcca tgcattccaag gcccccgctg ttggggagaat gatctgctag tgccatttta 300  
 aatnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420  
 nnnnnnnnnn tcaactgtgtc cggcataaag tagaacattc ttacaagaaa taaatatattc 480  
 gtagtcatgg agaagaacgc gaaaaaaaaa aaaacaaaaa aaaggctggg ggtaaccagg 540  
 gcccaagcgg ttcc 554

<210> 61  
 <211> 1401  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (803)..(929)  
 <223> a, c, g or t

<400> 61  
 aattattttg ggtctctgtt caaatgagtt tggagaatgc ttgacttggt ggtctgtgtg 60  
 aatgtgtata tatatatata cctgaatata ggaacatcgg agacctatc actcccacac 120  
 actctgctat agtttgctg cttttgtgga caccctcat gaacaggctg gcgctctagg 180  
 acgctctgtg ttcaactgat atgaagaac ctagaactcc aagcctgttt gtaaacacac 240

46

taaacacagt ggcctagata gaaactgtat cgtagtttaa aatctgcctc gcgggatgtt 300  
 actaaactcg ctaatagttt aaaggttact tacaatagag caagttggac aattttgtgg 360  
 tgttggggaa atgttagggc aaggcctaga ggttcatttt gaatcttggg ttgtgacttt 420  
 agggtagtta gaaactttct acttaatgta cctttaaaat agtccatttt ctatgttttg 480  
 tataatctga aactgtacat ggaaaataaa gtttaaaacc agattgccca gagcaagact 540  
 ctaatgttcc caacgggatg gacatctagg gcagaatgct gccattttga ggggcagggg 600  
 gtcagctgat ttctcatcaa gataataatg tatggttttt acactaagca actgataaat 660  
 ggacaattta tcaactggaca atctccctct gcttctttaa tggggccagc ttgcagccc 720  
 tgcagcctgg gtagtcgcac acatttccat gcaccaagg ccccatgct tgggagaatg 780  
 atctgctagt gccattttaa atnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 840  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 900  
 nnnnnnnnnn nnnnnnnnnn nnnnnnnnt cactgtgtcc ggcataaagt agaacattct 960  
 tacaagaaat aaatatttcg tagtcatgga gaagaacgct cctaaaatga tgaacgcacg 1020  
 acggaaaaga gtagggaaca ttttgcctga tgagaaaatc cgccagcaag gatgttgggc 1080  
 tctaagcaga actgaagctc tggaattaag aacacagcca aggaagagct ctggactctg 1140  
 agtttaaaga agctgactga cttgtaaggc aattccaggt aagattggtg aatcaagtta 1200  
 agaatcaaaa gcaactgaga tcaacgtgga ggcttgaag gtaaggcca tattttacct 1260  
 agatactagc ttagagactt gctacattgg cactgtattt taagtatgtt atttagtagt 1320  
 attgtgaaat caactgggtt caacattgaa aaggataaaa atagcttatg aaaacaaaac 1380  
 ggtttttttt ttttttttaa a 1401

<210> 62  
 <211> 568  
 <212> DNA  
 <213> Homo sapien

<400> 62  
 agatgctgcc gagcggcgca gtgtgatgga tagtccaaaa aaaaaaagta ttaaaatgtg 60  
 attgatgtaa ttaccatgt ttactttatg catgcatttt attggggagg ggacgtgtca 120  
 gaataataca cccaaatcta gtggtctaatt ttcatagtgc taatctgggt tatattggca 180  
 ttaaacgata ctgcgaagga gctagatcat ttacaagag ttgtaggttt gtcttatgtt 240  
 ggaaaagcag tcctctatta atatcatgtg tgaagagtat ctgttcacaa gatttatgag 300  
 attatgacgt gtttcagaga atgtctacta gtatatcttt acagtatttg cctgttgaac 360

47

tccctgcaca aactggaatt actttccaga agacttaggg aatgcaaata tgttactcat 420  
 aagatgcatt ggagtatggt aaataaaaca aaccattttg gattgggtta aattggctcg 480  
 ttacagtctt cttgtgggga gggactttgt cagtcatttt ggcatcttaa gctagactaa 540  
 actttttggt gttgttttcc taaaacca 568

<210> 63  
 <211> 791  
 <212> DNA  
 <213> Homo sapien

<400> 63  
 tggctatgg taatttttta tagcagtcac agccaagaca gtgcgctcat ttactacata 60  
 ccatttatat tattatatag gctcctttca gaaacccatg ttcaaataag agataagata 120  
 ctgaaacaca taacaccttc actagttttt agtatacaaa tattgagaaa tagttgttat 180  
 taactatctc atccaagaaa tgcagattca tgttgtttct aaatttttta tatatattga 240  
 ccaaaatgaa gaaacttaac accatcctag attttagctg ccaaagaat gaaaagaatg 300  
 aaaaaaaaaat cttgtgaaaa ccacaagtg atatggatct aatttatggt taaatagata 360  
 tagataacaa acagaatacg cctgtttaaa actgttaaaa tgacattggt tctaattata 420  
 cttttattta aattgaaaga caaggcattt atatggatct tctaaccatc acaactttgg 480  
 tgtgacaaaa agaaattatc accaaaatac acctccttaa gtaagtgtct gatttcacac 540  
 ttccagaaaa agtgctcttt ctggtcaagg ccagcaagaa ttgagaaaga ttaagaaagt 600  
 gcttcaaaga tgtttattac aaagtgtgca taaaaactgt gaagtagatg tagacatcaa 660  
 gcataccaaa taaagtaaaa actgtcctcc ggcaaaacaa caacccaaaa aaaaaagcgg 720  
 gggggggacc gggggcaaaa cgggtcccgg ggggaatggt tccgccaatc accccaacaa 780  
 aaaaaaagg a 791

<210> 64  
 <211> 1523  
 <212> DNA  
 <213> Homo sapien

<400> 64  
 gggagatgct gccacctagg ttacttgtag gaccctatac ggcaacctcc tttgccagga 60  
 actatttata aacatcctgc aggaaaatgc agtgaagtag aagagacagg gatatcccag 120  
 aaggttatgc aaaacatcaa gagaagatga gaggagtcta tatgtcagaa tacacatttc 180  
 ccaccttgcc caacagtaga aaaacataag aagagaaaaa cattaaaaaa tgacaaggaa 240

48

gttaaatggaa gtcagcaatg tgatgggtgtt tggaggtgga gccttcagaa ggtaattaat 300  
 gcccttgtaa gaagaggcca gagagcttgc gcaccttctt cctgccatgt gaggagccaa 360  
 gaagccggct gtctgcaacc tgcaagagga ccctcactag aagctagcca tactggcatc 420  
 ctcatcttgg ctttccaact tccagaactg tgagaagtat atgttgtggt ttagtcaatg 480  
 gtctatggta atttttttat agcagtccca gccaaagacag tgcctcattt actacatacc 540  
 atttatatta ttatataggc tcctttcaga aacctatggt caaataagag ataagatact 600  
 gaaacacata acaccttcac tagtttttag tatacaaata ttgagaaata gtttgttatt 660  
 aactatctca tccaagaaat gcagattcat gttgtttcta attttttata tataattgac 720  
 aaaatgaaga aacttaacac catcctagat tttagctgcc caaagaatga aaagaatgaa 780  
 aaaaaaatct ttgaaaaccc acaagtata tggatctaata ttatgggttaa atagatatag 840  
 ataacaaaca gaatacgcct gtttaaaact gttaaaatga cattgggtct aattatactt 900  
 ttatttaaata tgaaagacaa ggcatttata tggatctctt aacctacaca acttttgtgt 960  
 gacaaaaaga aattatcacc aaaatacacc tccttaagta agtgtctgat ttcacacttc 1020  
 cagaaaaagt gctctttctg gtcaagccag caagaattga gaaagattaa gaaagtgctt 1080  
 caaagatggt tattaaaaag ttgtcataaa aatgtgaagt agatgtagca tcaagcatc 1140  
 caaataaagt aaaactgtca tcaagaagt tcaacagcta tgaaaagagt tcttcaaaat 1200  
 atgatatggt tttctagatg ataataaaat ttatcaattc caaatgtcca cattagtctt 1260  
 tcataaagac accaatgagt cacaggaaaa aaattaaaaa taacaaaacc ctatctcagg 1320  
 gaatcatgct aacaacctga tgtgttttct tccacatatt tatgtctgct tataagtatt 1380  
 tacaacata tattegcata tatgcatttt gaattttttc tgttgctgca cttaaatttt 1440  
 tttcataata aaacaagact cctgcaattt gcttttttag gtagactatg tatccctgac 1500  
 aacctccag gtcagcttga tga 1523

<210> 65  
 <211> 377  
 <212> DNA  
 <213> Homo sapien

<400> 65  
 ggtcgcggcc gaggtacaaa agtgcaaaaca aggttagtga ttaacaactt accatcaata 60  
 taccacttca acatacttta cattcagcca aatactgaag gtttcaccgt ggaaaaacac 120  
 ttttatcact tttaaagtaa cttgactatg ttcaccctga gtgctcttgc ctgagtatgg 180  
 caactgatta tgagttcagg ttaagagcaa caccagggaa tacagaaacc caggttaagt 240

49

tggccattct gacatgaatc tatacttgaa aatgaaaaca atcccaaaga aaacctgtat 300  
 gtcaaaaaca gaactgttcc tgcctttcac cccaaaatat ttaaaactaa atctaagcca 360  
 cttttaaaat gcatgct 377

<210> 66  
 <211> 1703  
 <212> DNA  
 <213> Homo sapien

<400> 66  
 ccaggctgga gtgcagtggg gtgatctcca ctactgcaa cctccacctc ccagcttcaa 60  
 gtgattctcc tgcctcaacc ttccaagtag cttggattac aggcgtgcgc caccacagct 120  
 ggctaataatt tgtattgtta gtagagacag ggtttcacca gtgttgctca ggcttgctga 180  
 acttctgacc tcacgtgatc cacctgcctc agcctcccaa agtgctagat tataggcgtg 240  
 aaccactgcg ccgggccagc atgcatttta aaagtggctt agatttagtt ttaaatattt 300  
 tggggtgaaa ggcaggaaca gttctgtttt tgaaatacag gttttctttg ggattgtttt 360  
 cattttcaag tatagattca tgtcagaatg gccaaactta cgtgggtttc tgtattccct 420  
 ggtgttgctc ttaaactgaa ctcataatca gttgccatac tgaggcaaga gcactcaggg 480  
 tgaacatagt caagttactt taaaagtgat aaaagtgttt ttccatgggtg aaaccttcag 540  
 tatttggtcg aatgtaaagt atgttgaagt ggtatattga tggtaagttg ttaatcacta 600  
 accttgtttg cacttttgta caccactgct tgcactagga tcttggtgtg aattttcaat 660  
 tgttttacag tgtatacaga ttattaagga taatttatat aaagatgttt ctgtttaact 720  
 ttgtgtgttt tacaacaaag agctataata gatgggttaa cgtttttgaa ttgtgtttat 780  
 atgttagttt gattagtatt ttatttttcc ctctctaaca ctcaaattca tggcaggtga 840  
 aaagataata gaacataatc aaactaacat ataaacacaa ttcaaaaacg tttaaccatc 900  
 tattatagct ctttgttgta aaacacacag agttaaacag aaacatcttt atataaatta 960  
 tccttaataa tctagtatac actgtaaaac aattgaaaat tcacaccaag atcctagtgc 1020  
 aagcagtggg gtacaaaagt gcaacaagg ttagtgatta acaacttacc atcaatatac 1080  
 cacttcaaca tactttacat tcagccaaat actgaagggt tcaccatgga aaaacacttt 1140  
 tatcactttt aaagtaactt gactatgttc accctgagtg ctcttgctc agtatggcaa 1200  
 ctgattatga gttcagggtta agagcaacac cagggatac agaaaccac gttaagttgg 1260  
 ccattctgac atgaatctat acttgaaaat gaaacaatc ccaagaaaa cctgtatgtc 1320  
 aaaaacagaa ctgttcctgc ctttcacccc aaaatattta aaactaaatc taagccactt 1380

50

ttaaaatgca tgctggccgg gcgcagtggg tcacgcctat aatctagcac tttgggaggc 1440  
 tgaggcaggt ggatcacgtg aggtcagaag ttcgacaagc ctggacaaca tggtgaaacc 1500  
 ctgtctctac taacaatata aatattagcc agctgtgggt cgcacgcctg taatccaagc 1560  
 tacttggaag gttggtgagg cagcagaatc gcttgaacct ggggaagcaga ggttgcaagt 1620  
 agtggagatc acaccactgc actccagcct ggggtgacaaa gcaagactcc atctcaaaaa 1680  
 aaaaaaaaaa aaatgagcgg tcg 1703

<210> 67  
 <211> 456  
 <212> DNA  
 <213> Homo sapien

<400> 67  
 atctctttaa ataattagca agaagggaga caagatgcag gagttcactt ggctctttga 60  
 aaaggaaaac tttaaagtca gtggttgac tgagtcccat gaagccagat cacttctgac 120  
 tgcaaggagc ttggaaaagc aagtatctgg atcttttacc agctaaattg ggaggaacta 180  
 taaaatgaga aaagattgat gaatattaag tagaagagt agatgggtcat ctttgcat 240  
 aaaaaagatc atttgctgta gttgtatgga aaatgaattg gagcaggcga tgaggcttcc 300  
 tctttgaaga tcacaggtga gaagattagg tgctttctca gaagcccagc aacctgatgg 360  
 gagtgtggag tgagcaagac ccaaactcga gcttcatccc tgcattggtc attttgctta 420  
 tttggcaaac ttgccctgca gaatctactc aagctt 456

<210> 68  
 <211> 380  
 <212> DNA  
 <213> Homo sapien

<400> 68  
 ccgcccgggc aggtagaggt tgtagtgagc cgggatcacg cactgcact ctaggcctgg 60  
 gcaacagaga gagagactgt ctaaaaaagg aaaagaaaaa aatttatacg ccaaaaaaga 120  
 tattctgaga taacctgtag ttaccactaa ctttgtgaca aaattataaa aatccacagc 180  
 catctatgaa tctgtaggca gacctgaagt ttgaacgact ggtgaagaca tctgcatttt 240  
 ctttatagcc aagttaggat acaaaaaatg caaacaagtc attaatattt actatatgca 300  
 agatacagaa acgatgaacg gaaggagtaa gaagttatcc ttcgtggaac tatttaaagc 360  
 aaaaatgcaa aataccaggg 380

<210> 69  
 <211> 2177

51

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 69

ttccaacatc tcatttctcc catgaactat ttggaaaaag ctgcaggcgt aatattggat	60
ccctaaatac ttatttctcc ttataccatt atcagaccca agtatcatct aatagtccat	120
aatcaaactg cctaaacagt ttctacactg tctttttaac tatttcaaac tatcaaggtc	180
cgcattttct tccttagaac ttttagtctt tttcttcccc aaaatatttg agtccatgcc	240
agttgccttt agttgtaccc aaataatggg ttgtctatct cctaaaagta gtactcttaa	300
atttaaattt agtggtatct ttgttgctat cgttccttct tcctcatgtg gttgtgcagg	360
cagagcttga gcatccagat ttcaaaatta aaaaaataaa gataatctag tttaatatat	420
agtagttgaa tcaccttaag tctagactgc tgtatgagca cccattatct ttcactatat	480
tccatcatcc cctccccca tgaactatct ggaaaaagct gcaggcgtaa tattggatcc	540
ctaaatactt tattctcctt ataccattat cagacccaag tatcatctaa tagtccataa	600
tcaaactgcc taagcagttt ctacactgtc tttttaacta tttcaaacta tcaaggttcg	660
cattttcttc cttagaactt ttagtctttt tcttcccaa aatatttgag tccatgccag	720
ttgccttttag ttgtacccaa ataatggttt gtctatttcc taaaagtagt actcttaaat	780
ttaaatttag tggtattttt gttgtcattg ttccttcttc ctcatgtggg tgtgcaggca	840
gagcttgagc atccagattt caaaattaaa aaataaaaga taatctagtt taatatatag	900
tagttgaatc accttaagtc tagactgctg tatgagcacc cattatcttt cactatatct	960
catcatcccc caacatatcc acagtagatg aagggcagtt tgctcaaaca ttgttttgat	1020
cctgtcatgt ctgttcagaa atgcctgtct attcagaaac ccacgtctaa taacaaaatc	1080
ttggactggg tactatcaaa acccaacaac atacagactc ctgagctagg ccttagggat	1140
atttttctac cttgatttcc aaatgttcat tgaaagaatg cttaattcta atttgaaaaa	1200
aagtttttg cttcccactt ctgctttaca cgttcatctt tcttgaaatc aaatccaatc	1260
caatctatat tctaagaacc tgctcaaatc ttgggtcttc aaagctttcc ctgggtatttt	1320
gcatttttgc tttgaatagt tccacgaagg ataacttctt actccttctt tcatctttct	1380
gtatcttgca tatagtaaatt attaatgact tgtttgcatc ttgttatcct aacttggtta	1440
taaagaaaat cagatgtctt caccagtcgt tcaaacttca ggtctgccta cagattcata	1500
gatggctgtg gatttttata attttgtcac aaagttagtg gtaactacag gttatctcag	1560
aatatctttt ttggcgtata aatttttttc ttttcctttt ttagacagtc tctctctctg	1620
tcgcccaggc tagagtgcag tggcgtgatc ccggctcact acaacctctg cctcctgggt	1680

tcaagagatt cttaggcctc agcctcccga gtagctaggg ttacaggcgc gcaccacctc 1740  
 catgcccagc tcttttgtat ttttaagtag agacagggtt tcaccatggt ggtcaggctg 1800  
 gtctcgaact tctgacttca ggcaatccgg ccgcctcggc ctcccaaagt gctgggatta 1860  
 caggcacaag ccactgcacc cagccttatt accataaatc atcttgatgc tggtagctga 1920  
 taagattcta tttgcttttc tttattcata gagaccacaa acagatcgca gatccagggt 1980  
 tctcaaaactg gagcatctgc ttaattttcc cataaaatca gtcttattct ttctgacagc 2040  
 tctgagactc ctccggccac gactaggtgc tgtcctggag gaaacggtgg aggacggccg 2100  
 cacaaaaacc aatctacctg atgaaaactc cgttcccttc tcgccagaaa cataaaatgc 2160  
 gatggagacg ctctgtgc 2177

<210> 70  
 <211> 226  
 <212> DNA  
 <213> Homo sapien

<400> 70  
 tctcatgccc attcaatatg gaatgttctt cgcttgetga atttaagcct gtattttaag 60  
 gttttgtggg tctcggcca caatgggtga tgtcactgat agaacgaagc tgagtttcta 120  
 aggggttggg gctgtgcaag agtaaacact agagcttgag ttgttatcca gctggcaagc 180  
 acggaagtct ttgaagaatg taatgtaaaa agggaacaag aatgta 226

<210> 71  
 <211> 2554  
 <212> DNA  
 <213> Homo sapien

<400> 71  
 gcgggagagc cctgtcctta aacacattag gacaagtagt taaaacaggg ccaagaagta 60  
 tggctgtgta gtgatcactg tacaagcaca cctggctgaa taaaccagtg ggggataaaa 120  
 tccagctcac ctgccgtgg ctatgctttg tgcctcagga caagggtgtg ctcccttget 180  
 aattgacagg aaccatcttc ctgcccaact gcattccac tgcgtaggca ccttatctgc 240  
 ccaatggggc tgtgaacct aattggaagc tttgcaattc ttaacactat atcttcttga 300  
 gctgggtttg agtccctatc caatcaagat gaaggcctga gaggactact caagttctaa 360  
 catgatgtgg gggcaaggca tagtagtcca gatccgggac atgaggcagc ttttggetta 420  
 gtatgacaat ctaatagttc ctaaaataga attatcccag gatggagctc cgtatgacag 480  
 aagggtctt cataggtagt tggtaggggg aattgtgtat catgtaagaa gtaggaccag 540



53

atgtctttaa aaagaccttc caactctaata gctacatgag tctgtctagt tgttatgttc	600
caacagggac agctcttaaa atagtgtggc aaagcaagag atgagatttc cagtgtctgac	660
tcggtgggtg aatgacttta gggcaggtat ttaacctcca cttccccaag tacacaagtt	720
atttcacaac tcttggcaaa aacagtgtctg taaaaatcgt aagttttattt gttaaaaaaa	780
atactgtatt tgaaaagtac cttccttctg ggattttcaa ataatttgta cactacattt	840
tattcatcta cacattggaa atgagtaaac tggatgaacat atagcttttt atacatttaa	900
cacaaccagt gcaaattctc ctgcctctga gaaggcagag aagcccttta ctcagaaggt	960
cttcaattct agcattactc caactcctag ggaaatttcg ggtgggtgcc tatggctgta	1020
tgaccatctg attcctcagg gacaggacag gaattcagca agggagctta aaatatttta	1080
agtaattgtc aacattccat ggtgactctc cccaaaaatc tagtggtagg aaaataatct	1140
gtacttattc ctctttctgc acacaaagcc ctcatttaaa tttgtgagcc tgcttgggat	1200
ccattaccta gccattcaga gatcctgtca aatgcacagc agattggata ctcaccatcc	1260
caaaggggtt cctccacact ggatggggcc aatctctagt tgacagtgcc cctcagagt	1320
caccatggag atggaatgtc ccttcacagag agacttttac acagggaaaa gcatttgttg	1380
gctgggtccc aactctcatt tggatcaaaa agctttacat tcttttccct ttttacatta	1440
cattcttcaa agacttccgt gcttgccagc tggataaaa ctcaagctct agtggttact	1500
cttgacagc cccaaaccct tggaaactca gcttcgttct atcagtgaca tccccattg	1560
tggccgagga accacaaaac cttaaaatac aggcctaaat tcagcaagcg aagaacattc	1620
catattgaat gggcatgaga tatgcctatc agattgtgtg tgtgtgcgcg ttttttaaag	1680
acagccaatt acatcgtatc tagtcaaatg agcggattct aaagcagcct gctgggatgt	1740
tccacttagt ctaatgctgt tgccactgta cgccacagca ccggacagtg ttctttggga	1800
catctctggg aaatgctctg gaacatgctc cttgatggaa aacactaatt tttgaaagaa	1860
gtagatgtct ggaggcaggt ctggtgaata aactgaatag tactgccttg gacccagct	1920
gaggggtggc agtaagcaat gaggatgggc tataaagctg ttaactggct aagggccatc	1980
cttgggcagg catttcagac acatctgtag agagggcagt agcatctccg ataggccagc	2040
tctgaaggaa gcttaatgct taatacagtc aactgcata aattagctta gaatgctctc	2100
ttgggtaaaa aatattaata gtgtatatgc acttgaaaag caaaattcct caagaaaaaa	2160
agtttaatag caaggagttt ccatcagtc cgtctttgtg gaggattacc acaacaacaa	2220
cttaaaagga tacaacaggt acttattaaa tgctgccttg ctttttacct cttccttttt	2280
tttttttttt tgagatggag tctcgtctctg ctgcccagcc tgaagtgcag tgggtgtgatc	2340

54

tcggctcact gcaacctccg ccttccaggt ttaggtgatt ctcttgctc ggccctccga 2400  
 gtagctggga tggactacag gcacatgtca ccatgcccag ctaatttttt gtatttttag 2460  
 tagagacggg gtttctgtgt tagccaggac ggtctggatc tcctgatttc atgatccgcc 2520  
 cgcctcggcc tccctaccct cgtgccgaat tctt 2554

<210> 72  
 <211> 583  
 <212> DNA  
 <213> Homo sapien

<400> 72  
 cagatcatga agcaattatc ttcttggaag ggttttttagc tatgctctcc agttgcctca 60  
 gcagcttttg ctctgatgcc acagtgagcc caaggtggaa ggtgatggaa cagcatcaca 120  
 tctgcaggct cagtgtgtcg taaggtagg gtaaggggag ggcaagtgt gacggatgaa 180  
 gaagatttct ccctattgct tccattttga ttttcttta acttcacatt tcatccatca 240  
 ttcttagaca gttgcctagt tatagaggat ttcttttate ttttttatca gaggcattgcc 300  
 aggtggaagt gaggctgctg ctggcctaca actccagtgc tcgcattcca aaatgccctt 360  
 ggatggaggg tggtagatg tcaacacagg tggaaaacag atccgagggc accataccca 420  
 tacagacaac ctgtaaaagt cataataaag cccacactg cacggagcta aggcacaaac 480  
 aacgcttccc aaccgatggc taagggccaa ctaggcggca gatgagcaag ccgaagcatc 540  
 accgaaatga agcagctcag aagaggacct aagccccggg aca 583

<210> 73  
 <211> 981  
 <212> DNA  
 <213> Homo sapien

<400> 73  
 gaaagaatga gatgttttca gacatttttag gtccctgaga catgttcctg ttcattggcc 60  
 agaaactttt tggcgaacca cttcctattc aaaggcttcc tctccactaa taaagtagtc 120  
 tgtggtacat gcagccctga ggcttgagat ggaactgcgc aggaagagcc caactgggta 180  
 tcagaataag ccacatgcac cttctgaaac tgcccaaate cacacctgca taagaatttg 240  
 agcccagttc ataaagcaga tcatgaagca attatcttcc tggaagggtt tttagcttgc 300  
 tctccagttg cctcagcagc tttggctctg tgccacagtg agcccaaggg gaaggtagt 360  
 gaacagcatc acatctgcag gctcagtgtt ttgtttggtg agggtaaggg gagggaatgt 420  
 agacggatga agaaatttct ccctactgct tccattttga ttttcttta acttcacatt 480

55

```

tcatectcat tcctagcagt tgcctagtta tagaggattt cttttatctt tttttcagag 540
gcatgccagg tggaagtgag gctgctgctg gcctacaact ccagtgtctg cattccaaaa 600
tgccctgga tggagggtgg tgagatgtca ccacagggtg aaaccagcat cgagggcacc 660
attcccttca gcaagcctgt aaaagtttat ataatgccca aacctgcacg gcgctaaggc 720
aaaaacagtc ttcccaaccg tggcctagag ggcccttctt aggtgtcaga atgagccaag 780
cctgaagcac ttcacctgga attgatgtgt aggcttaagg agtatgtgac ccttacagtc 840
tcatctggta tcaaacacag gataaattgt ttcttcatta aaaaataaaa aaccttcaag 900
tctacttacc cttctcctgt ccacaataaa gttgagaaaa caaaaaaaaa aaaaaaaaaa 960
aagatcttta attaagcggc c 981

```

<210> 74  
 <211> 401  
 <212> DNA  
 <213> Homo sapien

```

<400> 74
gccgccggg caggtaccag gcagaggag gagcaccaag gtgggggata tttaggggac 60
ctctttcctt caggaccaca cccttctagg tgaaagcacg aacacttgat tactttgcat 120
tccatctgca aaaacaaatt taggttttga atatggtgaa aaacgaagaa aggaaaatat 180
aaaactctgt attttatata cagtaaggaa taatggaggc tgataatgat cttgtgatca 240
gctaagacaa tgtcagtaag caggtgaggt aggggtgctt ctatgggcaa aagggtgaat 300
atcttgaatg accagaaatg actcgaagag ctgcattact atcatggtag catgcatgaa 360
gtgatacatc taaacctttg ctaacctaac attattactc t 401

```

<210> 75  
 <211> 1847  
 <212> DNA  
 <213> Homo sapien

```

<400> 75
gccgatcttt tttttttttt ttttttattt ataaatttat tgcctgtttt attataacaa 60
cattatactg tttatgggtt aatacatatg gttcaaaatg tataatacat caagtagtac 120
agtttttaaaa ttttatgctt aaaacaagt ttgtgtaaaa aatgcagata cattttacat 180
ggcaaatcaa tttttaagtc atcctaaaga ttgatttttt tttgaaattt aaaaacacat 240
ttaatttcaa tttctctctt atataacctt tattactata gcatgggttc cactacagtt 300
taacaatgca gcaaaattcc catttcacgg taaattgggt ttaagcggc aaggttaaaa 360
tgctttgagg atcctgaata cacctttgaa cttcaaatga aggttatggt tgttaattta 420

```

accctcatgc ataagcagag gcacaagtta gctgcatgtg ctctagactg tagagcgagc 480  
 caccgttgag aagcaaagga cagcagcagg aagagcaatg gaacctcctc aggacttacc 540  
 aggetgctgc acaggatcta gcttctocca cctaagatgg gcacattgaa agccttggtg 600  
 cagcagcacc cccatctgtg gaagcacagg ctgcctgcac ttctccagct gctctagcac 660  
 ctgacttctt ggtagtcagg gtaccagggg gagggaggag caccagggtg ggggatattt 720  
 aggggacctc ttcccttcag gaccacaccc ttctaggtga aagcacaac acttgattac 780  
 tttgcattcc atctgcaaaa acaaathtag gttttgaata tggtgaaaaa cgaagaaagg 840  
 aaaatataaa actctgtatt ttatatacag taaggaataa tggaggctga taatgatctt 900  
 gtgatcagct aagacaatgt cagtaagcag gtgaggtagg gtgctttcta tgggcaaaag 960  
 gggaataatc ttgaatgacc agaatgact cgaagagctg cattactatc atggtagcat 1020  
 gcatgaagtg atacatctaa acctttgcta acctaacatt attactctca agctttatta 1080  
 tctcaaggc ttaaatggct gtagctgttt aatttaaaag caaggcttaa aaaatagagg 1140  
 ttactcataa ttccctttcc atatcccttt ttgacttgaa aattatttca ccaactactt 1200  
 ttctggaatg ctgcttataa tacatattca cagattgccc tatgtgttat tctagtcatt 1260  
 ggcccgtttt gcttataaaa aaggccatgt tttgtattcc tacaaaatct gcagacattg 1320  
 ttaacataat acacgtcatt atacatcata tgtatgctac atctactcac tgacatttaa 1380  
 aaaatgagct attttcaaag actaacacag gatctgttac tgagacgtgt aggaaggagc 1440  
 tcagtgtaaa atattttctt tggatagatc ccttcaaagg gattaaaaca cacaaaatat 1500  
 tattttatact aaactttctt aatgtttcta tgatatttct atttcaaat tctcttattg 1560  
 tgagaatatg tgaaatatag atgtagcaaa ttcaacacat aagcttatac cccttagctt 1620  
 gagtaaaaga cacatatatg gcttcccagc accaagaaga tggagaagaa tctactgcaa 1680  
 ctacttccct ttttccaagc agctcaaat gctttagcaa atacctgtg attctttttt 1740  
 tttttttttt ttttgagacg gagtctcgct ctgtcgccca ggccggactg cggactgcag 1800  
 tggcgcaatc tcggctcact gcaagccgcc ctgctgccga attctat 1847

<210> 76  
 <211> 522  
 <212> DNA  
 <213> Homo sapien

<400> 76  
 attttactct agtattaatg tggttttata aatgattata tgccttatat tctgggggga 60  
 aagaaatgtg aaaatgtgct aacgtagaca gaaacagaat atataagtcg ttttgaatgt 120

57

tatttctttt ttaaaaaatt tgcttggtgt catatagcca aaactattca tggtgacagt 180  
 ttcattgcta tactttttat atgatttcag cgaattgaaa acatgtatat aatagcaaaa 240  
 aactggactt catgctgagt atagatgata catataaaaag aagtcaaaat ttggagaaaa 300  
 aatttaaaaa gataagtaga aaaaatgaagt aactgtagaa accataactta ctctttgatc 360  
 tcaaatgctc aaaaactgaa tgaaaatgtg aatttaggcc gaccaggtag tcttgtcaat 420  
 aaactaaaag caaaaacagg aaaattgaga aatatgttac aactataaca acacaaaaca 480  
 gcatagtttt gaaacacttg cagttcttaa atataaaagc tt 522

&lt;210&gt; 77

&lt;211&gt; 1643

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 77

actgtcaatc atcaattgac attaacatgg tcaattaagt aatgtttctc acccaacttt 60  
 aaatttccat agtcataacc atggaaacat acaaaaaaca aacatgcaa taaaatgtca 120  
 aaataattga gctgagtact ttgcatgctt taggaaataa gatgtagggt gggtctttgt 180  
 gccaatatat tcaagtaatt ggtttatctt cccatgtttt gctgctctaa acatgatcta 240  
 atataactct cattcatggt gacatagcag agagctgcta ggagtaaacc tgttttctac 300  
 acattaatca agctgttctt tcaaagtatt gtttgacaca ttgaatgttt tttattctgg 360  
 aatattatca cagcaaaacc tcattaattg gatgctatca aaattatgaa aggaaatctg 420  
 agtgagcaca cttgttttga aaagaaattg gtaaatactt ctatgatgca gttttaagtt 480  
 atacaattaa ctgctatttg gaatttaata agtcactat aagcaatgtg cctgcacacc 540  
 aattaaagggt tggatctgtc tcttcttgac aattttttag aagccattat ttcggtacca 600  
 aataaacctg aagttaagaa atatttatat ttacatctat ttatatctgt tggagaatat 660  
 ttcataactc agacttgggt gttttacaca gacttctccc cattatccaa catagtgaga 720  
 tttttctata gttctatatt ttactctagt attaatgtgg ttttataaat gatttatatgc 780  
 cttatatctt ggggggaaag aaatgtgaaa atgtgctaag tagacagaaa cagaatatat 840  
 aagttgtttt gaatgttatt tcttttttaa aaaatttgtc tgggtgcata tagccaaaac 900  
 tattcatggt gacagtttca ttgcttactt tttatatgat ttcagcgaat tgaaaacatg 960  
 tatataatag aaaaaactgg acttcatgct gagtatagat gatacatata aaagaagtca 1020  
 aaatttggag aaaaaattta aaaagataag tagaaaaatg aagtaactgt agaaaccata 1080  
 cttactcttt gatctcaaat gcccaaaaac tgaatgaaaa tgtgaattta ggccgaccag 1140

58

gtagtcttgt caataaacta aaagaaaaac aggaaaattg agaaatatgt tacaactata 1200  
 acaacacaaa acagcatagt ttgaaacac ttgcagttct taaatataaa agctttttatt 1260  
 agttaatttt ttaaaaggat ctcataggat tgacactgaa tcaggttggg aggtggaata 1320  
 aggggtgatgg catattcttt ctgaattact tattataaca ttcttagaat cattaggtca 1380  
 gtgctacttt gttgtcgtca atgtacaata aaggaatcac aaattgatct tagtgataat 1440  
 tttacagagg cagacattgc acataggtat gactgcaaaa atgggtggct aactctggga 1500  
 agatacttgt gttaaacttt atatgacatt taataaccct tcatcataag gcaatgtttt 1560  
 ttacaaaaag attgcacaaa atcatgttag tcatttactc tgcaaaaatg gcacattagt 1620  
 ggggggtcca aaatccataa tga 1643

<210> 78  
 <211> 755  
 <212> DNA  
 <213> Homo sapien

<400> 78  
 cgaggataaa aaactacgtc actctaaaat gttacaaata ggtcatctac ttagtatgca 60  
 tagccttgat aaaaacattg gtcaagtcgg gatgtagtcg gccaccaact agaaatgtgt 120  
 taagattttt ttaagcagac ttgcttaata aggcaaggag tggggtcagg ttgttctagg 180  
 ggccagcaga aggggtctaaa atacagggtg gtgaaaagag attacgagac tagtgagttt 240  
 cctttaaatg cttaactagt cattattaag acagccacat ttcagtggg ctgagccaaa 300  
 ctgctgagct tggaatagca tatgcttgga atctgaatat gaataaggcc cagggtgccac 360  
 actttacacc acagatcctt tgctaaagag gcactatttt gtctaacagg caaggaccag 420  
 gctggcagtc aggaaggctg ggtttcgggtg ctgatcttgt caccaactat gcactcttga 480  
 acaagtcact tcaattcact atcctaagcc tggtatctca tctgaacaaa taacaggggt 540  
 tagacttagc cttttacaat gacattttgt atatatctac tgagctctaa caattattac 600  
 aacatatcta tgtctgacag ataggatagt cctacatatt caggaaactc cacgtatagc 660  
 tctcctaaaa ctgattgttg cgtgttacca cacaacacaa caacatacaa acctgggcac 720  
 tggcaacacg accggtcaat tctcccaaca caacc 755

<210> 79  
 <211> 1002  
 <212> DNA  
 <213> Homo sapien

<400> 79

59

tatttcatct ttataggga tttgctccca aggtatatcc ggcacgagaa aaaacctcat 60  
 atttaaaac tacgtcactc taaaatgtta caaataggtc atcttcttag tatgcatagc 120  
 cttgataaaa acattggtca agtcgggatg tagtcggcca ccaactagaa atgtgttaag 180  
 atttttttaa gcagacttgc ttaataaggc aaggagtggg gtcaggttgt tctaggggcc 240  
 agcagaaggg tctaaaatac agggtagtga aaagagatta cgagactagt gagtttcctt 300  
 taaatgctta actagtcatt attaagacag ccacatttca gtggggctga gccaaactgc 360  
 tgagcttga atagcatatg cttggaatct gaatatgaat aaggcccagg tgccacactt 420  
 tacaccacag atcctttgct aaagaggcac tatttgtcta acaggcaagg accaggctgg 480  
 cagtcaggaa ggctggggtt tgggtgctgat cttgtcacca actatgcact cttgaacaag 540  
 tcacttcact tcactatcct aagcctgttt tctcatctga aaaataaagg ggtagactt 600  
 agccttttaa atgacatttt tgtatatatt tactggctat aaaattatta caaatatcta 660  
 tgtctgacgg taagatagtc taaatattca ggaaaactcc aagtatagct ctctaaaaa 720  
 tgatatgttg cgtgttaaaa aaagaaaaaa aagaaaagaa gaagggggag gaaaaataa 780  
 aatgaaaaaa acttcaaaaa tgcacggctg agttggtagc aaagaaggaa attctttgga 840  
 ggccaaaaag atctagaaag tttaaatcca atgtgcagga gctggcattg cctagctaata 900  
 cctcatgat tgagaacctc agattataga cactcatggg gaccaagaga taaggcctgg 960  
 ggctcaaaa aggccagagc cgaggctgga tcaaagaatc cc 1002

<210> 80  
 <211> 374  
 <212> DNA  
 <213> Homo sapien

<400> 80  
 tcttttctaa aactttaatt tccactatgg ctcttttgaa accattttta tcaagtcaca 60  
 tttcttagaa aaaattcact cagggttctg aaggaattag ttattttcta caagcaactc 120  
 tgtcatgagt gatagagttg tagctctctt agaagttttt ttcccttttc aaagagaatg 180  
 agaaatatgc agagatttcc ttactgactc actaaatgta aagattaaga ggacataata 240  
 aaatttgga ctacagtagc atataggttt tcagtttatt tactactaac tagctataac 300  
 ttagacaagt catttaacat gctgtgcttt agtttcatct ttgaaaccaa agagattcga 360  
 accagaaatc tctt 374

<210> 81  
 <211> 399  
 <212> DNA

60

&lt;213&gt; Homo sapien

&lt;400&gt; 81

atggggaatt ccattgacac agtcagatat ggcaaagaat cagatttagg ggatgttagt 60  
gaagaacatg gtgaatggaa taaggaaagc tcaaataacg agcaggacaa tagtctgctt 120  
gaacagtatt taacttcagt tcaacagctg gaagatgctg atgagaggac caattttgat 180  
acagagacaa gagatagcaa acttcacatt gcttgtttcc, cagtacagtt agatacattg 240  
tctgacggtg cttctgtaga tgagagtcacat ggcatatctc ctcctttgca aggtgaaatt 300  
agccagacac aagagaattc taaattaaat gcagaagttc aagggcagca gccagaatgt 360  
gattctacat ttcagctatt gcatgttggt gttactgtg 399

&lt;210&gt; 82

&lt;211&gt; 517

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 82

gaaagtatat tgacgtaggt agtggagacg ccatgagttc ataactgtc cagagtcgca 60  
gtatgatgta tccggcaccg gacaggtaa gaaagaacta cttgtttcta ggaagaacat 120  
atgaagtgtc taatttataa gcgggctgtc gaattattac caatatagtt tcttctgaaa 180  
agtgaagggt gatcatctat tggtagatta gggggctctg gaaactttt gaaaattcga 240  
atcagtggac caatgtacat gtgaaaacta aagagggcag ggggtaaaat agggcttgaa 300  
tttctcattc tgtatagacc agcaaacttc cctgtgcaag gcaagtttac atcaciaaac 360  
caagaatgtt tgcacacctaa atgctagttt gcttcagccc ctagttaacc tcaggacttg 420  
gtttgcatat aaaaggtaga cagctgatat gttttcatga ataaatattg tcagccagaa 480  
aaggttgggt tcaggtaatg catatttttt taagctt 517

&lt;210&gt; 83

&lt;211&gt; 619

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 83

acacaatgat acccattttt gcatgttaat gtattattaa atatcagtgg gaatagtctg 60  
catgctatctt cacatctcag gcacacttaa ggaagacctt gtgatgtgca tgttgctcat 120  
ttaatctaga aaggatacca agattcattt agaacttctt tatgcacagt ttttttttga 180  
gtatgttatg tcttgaggca ttaaggggtat tactaaagca agcagcggga cttctcagag 240  
aaattaaagg tttcatatca accacacggt gtcaaaatct tcactttgaa taggattaaa 300



61

```

tgatgtttca tcagtattct tggcacacat gacattgttt ttaaaataac agttttatta 360
ctctgggctg tgacagtttc tcagactttc cttaatatca tacaattctc caatttaaac 420
tggatatagtc agttttacaa tattttaatt accctgtatt cattagcact ttcctcattt 480
tctactacct cctccccagc tggccctacc ctaggcaatg ccaaactctac tttctgtota 540
tatatttgcc tattcttgaa atttcaaata aatggaatcg tataatacaa acaaaaaaca 600
ggaaaaaaaa aaaaaaaag 619

```

```

<210> 84
<211> 646
<212> DNA
<213> Homo sapien

```

```

<400> 84
aatgatccat ataggcgaat ggtcatctaa atcatgctcg agcggcgagcag tgtgatggat 60
cggcgcgggg caggtaactc accccccagg atagagaagt gtttgtagg gagagaagag 120
ggagaggcag gagccggccc aagcccaggg tccctgcttg ggccccagaa agcacttaac 180
caggcccaa gccttcaagg gaaaccaagg cctcaaccag acaatcttga ggaagggaaa 240
agccagactt tgggtttgtt ttttggggga attattggtt tttttttttt tatgtttctt 300
ttggaatttt gtttggtggc aaattctgtg tgatcttttt tcataaaaaa aaagacaaag 360
aatttacatt ggacaaaatt aaaaaaaac aaaaaaaca aacaaaaca acaggcgtgg 420
gcggtctacc tcagggtggc atatgccggt gtgtcccgtt ggtggtgaaa catgtggtgt 480
tatctccggc ctcaacaaat tctccccac acaattccg tccaccgcac caagccgat 540
ctaacaacag gacatcatat agcaacctat atacgagcac ctcaacagca ccaacgacag 600
ccaagcgaga cgaacgacca acagacacac cactcacaac caaagc 646

```

```

<210> 85
<211> 419
<212> DNA
<213> Homo sapien

```

```

<400> 85
cgccgcggcg gcaggtactt tcgttgatac aggcgtggaa gaccttgagt tcccctgtgg 60
ctaccccatc atagttcctc ctaaggctat accagataag ccatacggag cagatgacca 120
gcaagaacct ttccagaatt attattctaa ctagaatctt agccaagaga atggaatcac 180
cacaaatgtt atcatgaaaa tcctctcaag taaatttcct attccattca taccgttaag 240
ttgaggctcg atgatatacg aaaactttta ctgaattgac ttcataaagg cttaatggtc 300
ttcaaaatta tgctggttat atgaattctt aaattcaagc tcttttccaa ataataaatg 360

```

ataaaacaac attttaatta gtattttacg taaaaatata tattaaaaag taaatcaag 419

<210> 86

<211> 2133

<212> DNA

<213> Homo sapien

<400> 86

ggaagtacag gataatatta aagtcaaata gaggacagtt cttcagcatc ataaatcaaa 60

attcaattgc tacaaaaatc aaaacttggtc agacttttttg ctttaataca aatagttgga 120

atttctgagc aatcagggtt atcttttaaat atgttttttt ctgagctttt ttacttcaaa 180

aacgatgaga attatcaatt tttcagtact actgacttgt tccttggtgga aggagggaac 240

attaagtatt taaatcaatt tcttaagtct tcgagtatca aatttatatt gtttaattctt 300

tgatttaattg ttttaacatgg gcacttttta tattctctta cctgagtttag ttttgaattc 360

ctagaacatg tccattttaa cagtgggtgt gatattattt agttaatact actgtctgga 420

ttatttttaa atcttggtac aatttggtata aaacaacata acacttggtta acttgccagt 480

cctctaggaa cttgtttcct ttccttactc tgaatagact agtggttagct gtccattatc 540

ttttacctta attacgattg tttgaaccac atttaaattc caaaatctat attattgggt 600

taaaagcttc aacttgacaa gatattatta acagtctaca tgaaatcctc aaattatata 660

tgaattttca aacattgata tcagctcctt gatttacttt ttaatatata tttttacgta 720

aaatactaatt taaaatgttg ttttatcatt tattatttgg aaaagagctt gaatttaaga 780

attcatataa ccagcataat ttggaagacc attaagcctt tatgaagtca attcagttaa 840

agttttcgta tatcatcgag cctcaactta acggtatgaa tggaatagga aatttacttg 900

agatgatttt catgataaca tttgtggtga tccattctc ttggctaaga ttctagtttag 960

aataataatt ctggaaagggt tcttgctggt catctgctcc gtatggctta tctggtatag 1020

ccttaggagg aactatgatg gggtagccaa aggggaactc aaggctctcc acccctgtat 1080

caacgaaagt actctaattg ctgttttaca tactgggatt atttgtaaga tttcatttga 1140

aaggaagggt ctttagacca agaaagaaaa ggaaaaagggt tgaaaccaat gacctgctcc 1200

aatctcttag aaactgaatc tcagagaagt taacttcaag gtaaaagcat ttgttagtgc 1260

tagaggtaag atgaaaattc aagttttttt attccttggtc ttcataataa tataattatt 1320

gtgatgtctt ttgtacaatt tgcataatac tatgtatata ttcacatgta gtatttaagt 1380

tacataagtg atgggtacta tgaaattact attgatcaag aatgactatt agattttaat 1440

taagattaca ctttatttct tgtaaaagggt gatttaaaat gcacattcct taccaatcta 1500

```

.atttgaatca tgattagcct cagtttaatt atccttacia aaatatatttt gagtggttgg 1560
gatcagtttt aagttgagct cctagatttg ttgaatagga aaggatacta ataactgttc 1620
taggggaaat gattttgtaa tatttcacct tgaatttttg aactgaacct tataaactag 1680
tcttcagaat gactaagcag gttaaagtgt ttagcattta aatgtcaaat agagaaatca 1740
atctgacttt tggaaaaaag aaagatgttt aatttaaaat atgtaaagca aacttcctaaa 1800
tttcttccat cagtaagagt aactaactgt ctgaatgtag ttattattat tgtgtcaagt 1860
taaatgattg tacatacttt cctttacaga tttggataag tgaagacagt aataacattg 1920
aagcagtga cagtggaag gagacagtaa taaatccaga aaagggttgtt atcaggtggc 1980
acaaattaaa tccatcttga agacttcaca cattaatttg gtgaagaact tgacattctt 2040
ttagaagact tatgatttca atttgctacc aatgagaaga ggcaaatcaa caaatttgtc 2100
aatattatggg ggctataatt atggtatata atg 2133

```

```

<210> 87
<211> 493
<212> DNA
<213> Homo sapien

```

```

<400> 87
gcggccgccc ggcaggtctt cgatctcccg ggggtgctggg attacaggtg tgagccacag 60
cacctagcct taccttcaaa ttctaaacca agctatttaa atagccactg tttgattatt 120
tgaattaaca tggagcatct tctgggatat tggtcagga aatatgagta gatcaaggta 180
ttttggggat gtaaaccctc atgtttgata aaataaatga tattttgagc tactgtttgc 240
tgggaacaga aagtaagaag ggaaaaggag cgaccatata ggaaagtaaa aataataaaa 300
gaaaatttag aaaactagag gaaaaggat gaaaggataa atcctccatc ccatactgat 360
aatggccttt gagcatcact aagccccttt gcttctccca ttaagcaaag gatgatgact 420
gaggaggaac aaacaaaaat agacatcatt ataaaaaata cccaagactt ttagatgttt 480
ctctaacatt tgg 493

```

```

<210> 88
<211> 1412
<212> DNA
<213> Homo sapien

```

```

<400> 88
tgaattagcc atacaaaaaa aataaaaaat tactgttagt caccctacag tgcaaggtaa 60
cactagaatt tatctttcca tctagtaacc actgtttttt aaagagacag agtatctccc 120

```

64

```

tggtgcccc gctggagtgc agtggcacia tcatagttca ccacaccctg gaactcctgg 180
gctaagggat cctccttagc ctcagcctcc caagtagcta ggtatacagg catgtgctac 240
catgcctggc taattaaaaa agattttttt agagatgagg tcttgctgtg ttgccaggc 300
tggtctcaaa ctctgggct caaacaatcc tcccaccttg gcctcccaa gtgctgggat 360
tacagggtgtg agccacagca cctagcctta ctttcaaatt ctaaaccaag ctatttaaatt 420
agccactggt tgattatttg aattaacatg gagcatcttc tgggatattg ttcaggga 480
tatgagtaga tcaaggatatt ttggggatgt aaacctcat gtttgataaa ataatgata 540
ttttgagcta gtgtttgctg ggaacagaaa gtaagaaggg aaaaggagcg accatacagg 600
aaagtaaaaa taataaaaga aaatttagaa aactagagga aaaggatga aaggataaat 660
cctccatccc atactgataa tggccttga gcatcactaa gccctttgc ttctccatt 720
aagcaaagga tgatgactga ggaggaacaa acaaaaatag acatcattag aaaaaatacc 780
caagactttt agatgtttct ctaacatttt ggggtcattt tcagattacc agtgttcatt 840
tgctgaggta tattaacgga tatttgact taatttgaaa aatagcagga tccaaaccag 900
aggtctgtat aagagcaggc ggcatgcgtg tctggagagc tgctgcctcc acaagtattc 960
tgacagcact gggctgctag tgagacctgg atggccaccc tccccatgtc atggccatgg 1020
gttttcggga accgtttcct ctttttactg catcacagtt gcaaactcgt ctatttattt 1080
ttctcttgat taacaactgc actctgacat tgcagcagtg ttgatgaaga caatttaact 1140
catgtttttg ttaacataat aattgtctgt cgtaactaaa atataagttt cttgaaagct 1200
ataatcaggt atagagaaaa tctttgttat gcacaatacc agggcaggta atatctgtaa 1260
tatgtattaa cagcaattca ctaaacttg aatgtctctg tatgtctggca cctgtgctaa 1320
agatttgctg tataaagata aataggaaat tgcctcttct cccacgaaac tcaaaacatt 1380
tattgaatga ataaataata ggtgaattaa ta 1412

```

<210> 89  
<211> 624  
<212> DNA  
<213> Homo sapien

```

<400> 89
ggtaacttgag gtgtttctca ggttcagaa catccgtgtc atcttaccag atccttcaag 60
gattcagctt aaagatcagc tccaccagga agccttcctg gatttccctt cttagtttcc 120
aacaagaatc eggctcttcc gttctctgcc caccttgagg tagcagtagc gtccagctgt 180
gagactctcc gtgtttttcc cgttacagtc gtttggttagc gtgcacctc ttctgactga 240

```

This page is not part of  
the pamphlet!

**WO 02-064611**

**3/5**

Date: 22 aug 2002

Destination: Agent

Address:



65

attagttaga tgtgagaccc taggactctc ttgttttctt cgttacagtc tttgttgctg 300  
 catcctctct cactgaattg ttgaattgtg agaccctgtg agggtcggca ccctgtgata 360  
 ctggccagga aagggttgtt gcaaggggat catgggattg ttgaatgggt tttgatctgg 420  
 attttgatgt tggaaatcaa gttcccaaat gttttcaacc ttgggtaaag gaacatgtaa 480  
 tgggtgtttt taacaaaaca aaaaattaaa aaaaaaaaaa aacaaacata aaaaacaacc 540  
 aacggctggg ggcaccggg ggcaaagggg gcccgggggg acattgtttt tcccggtaaa 600  
 atccccaat tgggaaaaaa aagt 624

<210> 90  
 <211> 659  
 <212> DNA  
 <213> Homo sapien

<400> 90  
 accacgctg tagcctctgt ctagagtagt tcacacatgg atgctgtctc tctggtactt 60  
 ggggtgtttct caggttccag aacatccgtt catcttacca gtccttcaag gttcagctta 120  
 aagatcagct ccaccaggaa gccttctctg atttcccctc ttagtttcca acagaatccg 180  
 tctcttccgt tctctgccc a cttgagtag cagtagcttc agctgtagac tctcctgttt 240  
 ttccttaca gtctttgttg ctgcctctc tttcactgaa ttgttgatgt gagaccctag 300  
 actctcctgt tttttcgta cagtctttgt tgctgcatcc tctctcactg aattgttgaa 360  
 ttgtgagacc ctgtgagggt cggcaccctg tgatactggc caggaaaggg ttgttgcaag 420  
 gggatcatgg gattgttgaa tgggttttga tctggatttt gatgttgaa atcaagttcc 480  
 caaatgtttt caaccttggg taaaggaaca tgtaatgggtg ttttttaaca aaacaaaaaa 540  
 ttaaaaaaaa aaaaaaaca acataaaaaa caaccaacgg ctggggggcac ccggggggcaa 600  
 agggggcccg gggggacatt gtttttcccg gtaaaatccc caaattggga aaaaaaagt 659

<210> 91  
 <211> 556  
 <212> DNA  
 <213> Homo sapien

<400> 91  
 aattttcaac tggcccatatc tttatagtga tggaaagcgc ataacactac ttgtaaatca 60  
 ttaaaatagg gtgataactg tgataatagt gtttcttgca ttctagaaaa ttattttatt 120  
 aactacattc aaaaccagc atttcacagg ttccatcatt agaaacagta tagttctagt 180  
 taacatgatt ggagagtttc aggggaaagg ttacatttt ctgaaactgt atttggtatg 240  
 tgactcaatg tggatatttca gtcttgtag tcacttacat gactgacgtt tgcaaggatt 300

66

tattgccaaag taaaatttga tcagagtgcg ctgagaatag ctacataagg ggaaatctct 360  
 caaaattcct tctgttcaact ttaattogga gcatatgttt caactcattt tcacacatct 420  
 gtcccacagt tgaagcatta acacacatct tcacgacaca atgaacacat acacattagc 480  
 aaacataagt ctcttaatgc aaaattacta gttgactaca ataatagctac cttaaaagca 540  
 gagcttgcta taattc 556

<210> 92  
 <211> 635  
 <212> DNA  
 <213> Homo sapien

<400> 92  
 acaaaatata atgttataaa tgtattttta aaaaagaaat acaaattcta tggctcttttg 60  
 cattttactg cctcaaagca gaattagcaa agctgatgaa gaatgaacat tttcccttgg 120  
 gcgggtggcc cttggtcact cccacaggca cgttaccggg ctccggcgtg tgctcccacc 180  
 aaccacggca aacaaaggcg tcctcctcac ttgaagtcct ggcctgtggg tgtttcatct 240  
 gtttttttgc tcagtgaaca aaacgttctg aaattagaac tcaccaaagt taaaagcagt 300  
 aaaacaacat atgctactta agacattttg aagcgggaaag taaagctatg tgaatgccgt 360  
 ccttccttcc ttcttttttc tacagcttgg aaacctctga gaatttgctg gcgggtggca 420  
 gaggagggct tcgtctagct cttgaacgga caggaactgt ctggctagac agctctccag 480  
 accacgaaag cccaggaggt gccctcttcc acacaacaga ctaagcactg caccactttt 540  
 ctttgatcca gaaagcatcc ctactgaccc tgtaacctac accctctctg tccaaagaac 600  
 agaggccgac cagagtagcc agcctggaga ggcac 635

<210> 93  
 <211> 8156  
 <212> DNA  
 <213> Homo sapien

<400> 93  
 cggggcgtgc gcgtcctcct cccagggccc gccgcctccc tgccaagaat ctgagagagg 60  
 ccgagtggag ttcggtcctt ctctgaacag ttttagctga gaggaccagc atccaactgg 120  
 gagcgttgtc attgcatttc cacattccca ggaaagccca ggtgctgggt gccagctgct 180  
 gcgcccccca tgtagaagggt gcacctctcg ggagcaggca cgtcttttgg ctcttctgac 240  
 catggagaga taggacggtc cctgcagccc gcgcgacaga aagctgtgcc gccaccaccg 300  
 gccgcgtccg tccttcggat ggatcgcaac agagaggccg agatggagct gaggcgaggc 360



67

cccagcccca ccagggccgg ccggggccac gaggtggatg gggacaaggc tacctgccac	420
acctgctgca tctgcggcaa gagcttcccc ttccagagct cgctttcgca gcacatgcgc	480
aagcacacgg gcgagaagcc ctacaagtggt ccctactgcg accaccgggc ttcccagaag	540
ggcaacctga agattcacat ccggagccac cgcacgggga ctctgattca gggacacgag	600
ccggaggcgg gcgaggcgcc gctgggtgag atgcgcgcct ccgagggcct ggacgcctgc	660
gccagcccca ccaagagcgc ctctgcctgc aaccggctgc tgaacggggc ctgcgaggcc	720
gacggcgcca gggtcctgaa cggggcctcg caggccgaca gcggcagagt cctgctgcgg	780
agcagcaaga agggggcaga ggggtccgca tgcgccccgg gggaggccaa ggcagcggtc	840
cagtgtcctt tctgcaagag ccagttcgag cgtagaagg acctggagct gcacgtgcac	900
caggcgcaca agccgttcaa gtgcaggctg tgcagctacg cgacgctgcg ggaggagtcg	960
ctgtgagacc acatcgagag ggaccacatc accgcgcagg ggcccggcag cggcgaggcc	1020
tgcgtggaga acggcaagcc cgagctgagc cccggggagt tcccgtcga ggtgtgtggc	1080
caggccttca gccagacctg gttcctgaag gcgcacatga agaagcaccg gggctccttc	1140
gaccacggct gccacatctg cggccgtagg ttcaaggagc cctggttcct caagaaccac	1200
atgaaggcgc acggcccca gacgggcagc aagaacaggc ccaagagtga gctggacccc	1260
atcgccacca tcaacaacgt ggtccaggag gaggtgatcg tcgccggcct gaggctctac	1320
gaggtctgcg ccaagtgcgg gaacctgttt acaaacctgg acagcttgaa cgcccacaat	1380
gccatccacc gcagagtcca ggccagccgc acgcgcgccc cggccgagga gggggcgag	1440
gggcctcgg acaccaagca gttctttctc cagtgcctga acctgaggcc gtcggcggcc	1500
ggcgactcgt gccctggcac gcaggccgga cggcggggtg ctgagctgga cccggtcaac	1560
agctaccagg cctggcagct ggccacgcgg ggtaagggtg ccgagccggc cgagtacctc	1620
aagtacgggg cctgggacga ggcgctggcc ggggacgtgg ccttcgacaa ggacaggcgc	1680
gagtacgtcc tggtagcca ggagaagcgc aagcgtgagc aggatgcacc agccgcgcag	1740
gggccccgc ggaagcgcgc gagcgggcct ggggacccc cgcccggcg ccacctcgat	1800
ccccgctcgg ccgcgcgccc caaccgcagg gccgcagcca ccaccggcca gggcaagtcc	1860
tccgagtgtc tcgagtgcgg caagatcttc cgcacctatc atcagatggt gctgcactca	1920
cgcgtgcata gccgcgcgcg ccgcgagagg gacagtgacg gggacagggc ggcgcgggcc	1980
cgctgcggat cactcagtga gggtagctcg gcctcccagc ccagcagccc tggctccgcc	2040
tgtgccgtg ctgactcccc gggctctggc ctggccgacg aggctgccga agacagtgggt	2100
gaggagggcg cccctgaacc tgcaccaggg ggacagccgc gccgctgctg cttttccgaa	2160

gagggtgactt cgaccgagct ctccagtgga gaccagagtc acaagatggg agataacgcc 2220  
tcggaaagag acaccggcga gtccaaggca gggatcgag cttctgtgtc cataacttgaa 2280  
aacagtagca gagagacttc tagaaggcaa gagcagcaca gattttctat ggacttaaag 2340  
atgccagcat ttcaccccaa gcaggagggt cccgtccctg gtgatgggtg ggagttccct 2400  
tccagtacgg gagcggaggg ccagacgggt caccctgcag aaaagctgtc cgatttgcac 2460  
aacaaggaa actctggggg agggaagcgg gcgctggccc cagacctcat gccgctagat 2520  
ttaagtgcga ggtcgacgcg ggatgacccc agcaataagg agacggcctc ctccctgcag 2580  
gcggctttag tcgttcaccc gtgtccttac tgcagccaca agacctacta ccccgaggtc 2640  
ctgtggatgc acaaacgcat ctggcacggt gtcagctgca actccgtggc tcccccgtag 2700  
attcagccca atggttataa aagcatcaga agcaatttgg ttttcctttc ccggagcgga 2760  
cgcacggggc ccccgctgc cctcggtagg aaagaatgcc agcctttgct ccttgctcgg 2820  
ttcacccgca ctcaggtgcc aggggggatg cgggggtcca aaagtggctc ttctcccctg 2880  
ggagtggta caaaagccgc tagcatgcct aagaataagg agagccattc cggaggtccc 2940  
tgcgctctgt gggcgcccgg ccctgacggg tatcgacaga ccaaaccttg tcacggccag 3000  
gagccacatg gcgcgccac acagggggcc ctggccaagc ccaggcagga ggctagctcc 3060  
aaaccggtgc ctgccccggg tggcgggggc ttcagcagga gcgccacccc tacgcccacc 3120  
gtcatcgccc gggctggcgc gcagccctcg gccaatagca agcctgtgga gaagtttggg 3180  
gtccccccag cgggggctgg ctttgcccc acaaataagc acagtgcccc ggactccctg 3240  
aaagccaaat tcagtgtca gcctcagggt ccacctcctg caaagggcga agggggcgct 3300  
cctcctctac ctccccgca gccccctcg aaggcagccc aggagctgag gactctggcc 3360  
acctgtgctg cgggggtccag gggcgacgcg gccttgagg cccagcccg cgtaggctggg 3420  
gcgccccccc gtcctacact ccatacaaca ggagccagtg gccgaggggc atgagaagcg 3480  
cctggacatc ctcaacatct ttaagacgta cattccaaag gactttgcga ccctctacca 3540  
gggatggggg gtcagcggcc ctgggttggg gcacagaggg aactccgga cgcaggcccc 3600  
gccaggagag ttggtctgca tcgagtgcgg aaagagcttc caccagcccc gccacctcag 3660  
ggcccacatg cgggcacact cagtgggtgt tgagtccgat gggcctcggg gttctgaagt 3720  
tcataccacc tccgcagacg ccccaaaaca agggagagac cattctaaca caggtaccgt 3780  
ccagacagtg cctctgagaa agggaaaccta aaggcgtgtt tccgacgcac ccaggtccc 3840  
cgtaacggcc attagcagta ccctcacgat gtcccagcag cctccacact gtgacctggc 3900

cgctccatgg aagaacagcc ggggaactcc tgagcagaca cctcacatcc cgagccgctg 3960  
 cgctggagtg gaaactgaag gcagatgcct ctccttggtta aacgttcaga aataaatgaa 4020  
 gatgctatat tctagaaata catgtagata ctatatacgc atttacgtgc tcatcgtcca 4080  
 tagtcccata ttttcttata ataaacagta gtactggcag gcacagtagg ggcacaaggc 4140  
 atctgtctta ttcaagacaa gtttgagaca ctggaaaaaa agatacttgt tgtgtgtgtt 4200  
 ggacagagtg gcgaggctga gcactgtcac aggggcctcc catgttaaga gggactgtgg 4260  
 ggatgatgtc agaacaagac gtgggtgatt tgaggttgat cgagtattaa tactactgcc 4320  
 tctccttgtc ttagtgggta tttaaaatag taaataagag agaggaagga ggtgacgttc 4380  
 aggtgctgtg ggaagcaggc ttggcggagg ggtatgatga tgagaccctc attgttcact 4440  
 ggctccatcg cactcctccc tggggccgtg tgctgttcc attcttccca ccattcgaac 4500  
 tgagcgaatc tggcaaagga gacacgtctg tgggaatgcg tagattccgc ctcggaagag 4560  
 agctagcgca aactaagaa aagcaggctt cttgtttatt ctcaggacct ttttgtaaca 4620  
 gggctacatt ctgcaaactg cttacaaagg aagactatac gtcttaacaa attatttagc 4680  
 cactgagtc tcccgattcg gacctgtttt agtaatggca gaagaatccc tgagcaggtt 4740  
 caggtgccct agatgactag ggtgctgagc tctggcgctt tctgtcccca ctctttgcct 4800  
 ccccgccctt tccctgagcc accccagcaa gtgggtgtct tttctccctg ggcctggtga 4860  
 cctccacagg atgagtgact ttgttcataa aggggtggga tcaccagccc cttgggtggg 4920  
 ggacggcttc atatacctct tctcagtaa tgcaaatgcg agtttttggt gtgggggtta 4980  
 aggcccataa caaaggatct taaaccatgc agtgtacgca attgaaatgg tattccacag 5040  
 atataaatat tttcttttcc cattgccgtg aactatgtg tgatggtaat atttctgaga 5100  
 gtttcagatt tttgcacata tgattttatg cattatcaaa agttactgct gccttgaatg 5160  
 aaaatgttct gtgaaatttt ttgcaaaagc ttactaggt ttttttttaa ttgtgaaatt 5220  
 ttgtaaaggc aggaaatgga ttaaaacgag catgctaaat atatttttca aaaaagcaat 5280  
 aattttacat gtacagaaat taccctaacc ttaatactg gcgagagcaa cagtttactt 5340  
 aatacggtaa tggactagt cagtttttgt agacagtggg cttctgatac aaagtcttgt 5400  
 ttaaacacag acacacacac acacaaacac acacacacac cctaaagtgt gggtttctg 5460  
 ttctaataat ttgttgaata ttattatatt attattatta ttattattat tattgttatt 5520  
 gttattagta atgtttgggt ctggattcta cttgttactg agtttaaatt acttgacggt 5580  
 tcaggttact ttgcaacact ttcaaacgat gcaatgtaac tggctagctt atatatatat 5640  
 atatatatat atatatatat attttttttt ttttttactt atttttttct gatattctta 5700

caccagatat gtacgaaaat gatctgtcct gttggtgtaa ttaggaatgt ccatgcagat 5760  
 acagttaaac aactgtaatt gactgttctg taaagttatt ttgggcaaag ttgcggagac 5820  
 acattcctct gtccacctaa gaaatcagaa gactcttctg ttgatttatg tttaatcatt 5880  
 tcagtagttt cccacagtg atcatttctg ctttttctgg cttttgtttt cttggctgaa 5940  
 agtgaatggt gactgttagg aatgtcaggg actagtgacc cagtccgtgt tctctgtgtt 6000  
 ttagttatta aaaagaaatt ctgtacccaa agtgacacga aagtgtagtc tacattttta 6060  
 ctgtttcaga agcggcatgg aaaagtgcag ttggcctttg gagctggaag tgtcttgctg 6120  
 gtgaggctcc atcctggagg ctctggtggg gagtgggctg gcgctggggc cctgccggcc 6180  
 gcgtgctgga tccttcctgg cttgcaggag agcaggcgtg gaggacagtc agcttgccggg 6240  
 gccgcgcagg gtgcacagag tgcaggagga aggttttcac ccagttaaac agactgggga 6300  
 gccccccaa gaacgccatc ccttgaggcc agctgtgggc aggcctggat gtgtggtccc 6360  
 ttcttccac ccacgtcag tattgtgttg gtttgtaaat ttgttgattt ggtcatagta 6420  
 tttaatatga tttgtgttcc cttatttatt tagccaccgt ttgattgcc ttttttttc 6480  
 cgaatggtaa tttctgcatg atacacttct gtacgttgtc ttctgactgt tacagacttt 6540  
 ctactacctc tcccgatctg ctgtttcctt gtttcttaac aggatttttt acagtgttgc 6600  
 gtctaatagt acttagacaa taaagggttt ggttgcttac actgcagctt ctccgtgtct 6660  
 ctccctgct ttccgctcgc tgcttccgc tctgccctg ctggggcctg gctgcacct 6720  
 ggctgcctt cctatactct cctgtttccc gctcatatct ctctctcatt tttgcgttca 6780  
 aataacacac agctaataag cttctaaaaa tcttttcagg ttgttcactt gtattcctta 6840  
 atttgaagaa tgaatattta aattctctca aaagtcagat attgaggatc ttctctggga 6900  
 aattggccac tgtacctgcc caccttctg cctggttccc tggaaggctt tattgtcatc 6960  
 ttagacggac agatttcatt ctacgacca tacagatttg gcttcaaagc caggtgaatt 7020  
 ttgcctttga ggctctgaaa agtattaagt gttttaagag gtccccaat atttacttat 7080  
 ttatttttta aaccaagaaa gacactggtt ccctgaaaag caggtgcttc aggaagtagc 7140  
 aattgggagt tgcatacagt tacttcgtca gagaaaggag cggccagtat gacaggcccc 7200  
 caccctgat ccggccactg tgcacaggtc gctgagggtg tgagaacacc tctgcagggg 7260  
 ctccggcaca tgtgggtttc atcgtctcac actccttcag gctgcagggg ttgagtgcag 7320  
 aaagggaag cttcatctcc atggtgcctc tccaggctgg caactctggt cggcctctgt 7380  
 tctttggaca gagagggtgt aggttacagg gtcagtaggg atgcttctg gatcaaagaa 7440

71

```

agtgggtgca gtgcttagtc tgttggtggt aagagggcac ctctgggct ttcgtggctg 7500
gagactgtct accaacattc ctctcttcaa actagacaaa cctctctctg ccacccccag 7560
caaattctca gaggtttcca agctgtagaa aaaggaagga aggaaggacg gcattcacat 7620
agctttactt tccgcttcaa aatgtcttaa gtagcatatg ttgttttact gcttttaact 7680
ttggtgagtt ctaatttcag aacgttttgt tcactgagca aaaaaacaga tgaaacaacc 7740
acaggccagg acttcaagtg aggaggacgc ctttgtttgc cgtggttggt gggagcacac 7800
gccggagccc ggtaacgtgc ctgtgggagt gaccaagggc caccgcacca agggaaaatg 7860
ttcattcttc atcagctttg ctaattctgc tttgaggcag taaaatgcaa aagaccatag 7920
aatttgtatt tcttttttta aaatacaatt tataacatta tattttgtac tctttatatt 7980
agaatttgta actagattga tgtatttaac tatttctgaa aaagtaattc aatgttttag 8040
ttgtgtgata aaaatattta gataaaacat attcattcta ttggaatttg aaataaataa 8100
aaacatcttg gagttctgaa aaaaaaaaaa aaaaaaagat cttaattaa gcggca 8156

```

```

<210> 94
<211> 668
<212> DNA
<213> Homo sapien

```

```

<400> 94
tggtcgcggc cgaggtatcc cttagaaatt gacagcttct atgaaattta caatcaagaa 60
ggcataagaa caactgctgc agcttcagaa ctatgcagaa aataaaatgt caacagctgg 120
gagaaaaaat tctcagttag caacagagcc agtgaaaaat atcaccagta gagcaggcac 180
ctgagacagg gaaatggcac ccactaagtg caggtctaca ggggctgacc ttgcagacca 240
tttatggatc ccaagttacc aaaaccctta tttgattatg aactgcatag tagataccaa 300
tacatcagag cattgtctca atgttaatat ctatctgtgc tgattgtatt gtggatcatgt 360
aacagaatga atgcccttgt tcttaagtga tacgtgggaa aatatttgag ggggtgaagtg 420
tcatgatgtt tgctacttac tctcacatgc tttggcaaaa ataaaacatc tctctctctc 480
caggcaaaat atagtaatca gtaaaatatt aacaatctgt aaaaccacac cacaacaaa 540
caaaaaaggt tgggggacaa ccaagggcaa aaggggtgtc ccggggtgaa atttgttttc 600
gggccaaaat tccccacat ctccgcaca aagcgggagc aaaaaaacc acaaaaaaca 660
cacatata 668

```

```

<210> 95
<211> 746
<212> DNA

```

72

&lt;213&gt; Homo sapien

&lt;400&gt; 95

gactaagaca cctttctaga cagagaggag gccgatggca gacatttctca gataggtttg	60
tagctattga cctggctgca tcaaaggaga tgaaatccct tagaaattga cagcttctat	120
gaaatttaca atcaagaagg cataagaaca actgctgcag cttcagaact atgcagaaaa	180
taaaatgtca acagctggga gaaaaaatc tcagtgcagca acagagccag tgaaaaatat	240
caccagtaga gcaggcacct gagacaggga aatggcaccc actaagtgcg ggtctacagg	300
ggctgacctt gcagaccatt tatggatccc aagttaccaa aacccttatt tgattatgaa	360
ctgcatagta gataccaata catcagagca ttgtctcaat gttaatatct atctgtgctg	420
attgtattgt ggtcatgtaa cagaatgaat gcccttgctt ttaagtgata cgtgggaaaa	480
tatttgaggg gtgaagtgtc atgatgtttg ctacttactc tcacatgctt tggcaaaaat	540
aaaacatctc tctctctcca ggcaaaaatat agtaatcagt aaaatattaa caatctgtaa	600
aaccacacca caaccaaaca aaaaaggttg ggggacaacc aaggggcaaaa ggggtgtccc	660
ggggtgaaat ttgttttcgg gccaaaatc ccccatctc cccgcacaaa gcgggagcaa	720
aaaaaaccac aaaaaacaca cataca	746

&lt;210&gt; 96

&lt;211&gt; 978

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 96

cggccgaggt accctgtgcc aactagggga ggagaactgt tgctgctaa gttggtggca	60
ggaaccagct tcctgaagga tataaattcg ctggaagaaa gaccttggtt tatgttccag	120
tgctgttttc ccatctctag agcagtggct ggcagacatg tggctactca agaattggtc	180
ccagatgaat gaatgcagga aacagttccc tcctccaatg agattaacag ctgatccatg	240
cttataatga ctgaactctg taaagagggg aaccctctgc caatggggga tcaaatggt	300
taatgagagc cctgctgtgg agagaggtag gacagcaagc acagaagcac ctgaccccat	360
gcagaggacg ggaggcagaa gcaggggcca gactggaggg agtgatctcc atatgccccat	420
atagcatcca tctgtcttgc caagcaccct tctgggggtcc tctaccttta ccagagcata	480
gtctcttgtg cagatcaatg aaacgaagcg aagctggata gactatggcg agagcacttc	540
cctctctgcc tcccccaaga tgaatggcta cttgtggaga ggagctgtgg catataaaca	600
ctttcatcct taccgaaggc ccccatctc cctcaaattg cataacaggc agacgagcgg	660
ccaaccaact ccctctgatt ctcatacaca ggggtgtggc ttccattggc atctttgagt	720

73

ggccccaagt cgtacgcaga ttgtggactc agtacacagc ttgcgcaaac ctggacaatg 780  
 tggccatggc ccatcataca cctctacacc acctcatagc gacgttgaat atgagatcca 840  
 cccgtagtgc ccagctcata acatcctctc cattaagatt gaccacaggc aacttaccat 900  
 tgactaggac caagtccccc aaacacaaa attgagaaca gagcaacatg gtgccaaaca 960  
 tatcacagag aaatcaac 978

<210> 97  
 <211> 787  
 <212> DNA  
 <213> Homo sapien

<400> 97  
 acctggcaca aagcaaacia taaatattat tggtattggt gttataattg taaaatgaat 60  
 gacttcaaaa acatagtccc agtttggagg gattttgtga tgcagaatat ctaagtcata 120  
 gaaatagaag acaggtggaa taagtatatg ttcagagttt ttagatgtgt tgagtagaga 180  
 cggtaataat ggaagcatta aatacaaatg aaaatcacac cagatatccc tgaaattcaa 240  
 gcaaagaaag ttcacatgtg attcttgggc agcaagagaa aggactaggg ttatggcaat 300  
 gtgtggaaaa gttgaggctt gctaagggtt gagatctggt ggtagccctg gatcacatgg 360  
 ggtcagcacc aggcagtgcc tctgaaagcg gagagaggtc ctggacttcc cttgtgtata 420  
 acagttccta gtgtccaaca atgaggaaac ggtgaagcat ggttacaaaa ctgtgacaaa 480  
 acatatttac atctagcact gttaccactc accatgccaa acattggctg cacacgtgca 540  
 gcccttattt gtaattaaca tcaaaagact agatctgaag ccttcataa atgagagacc 600  
 attcatatgg cattcctgga aaaaacact gcacaggtag caaggctctc cactccctga 660  
 cgggttggtg ctgaacagtc agggattgtc ttgactagac ttctgatgct tctgcatctt 720  
 ctttctctt cccggaattc caaataacca attcatacca ttgtatttat gcttcgggta 780  
 acctagt 787

<210> 98  
 <211> 3670  
 <212> DNA  
 <213> Homo sapien

<220>  
 <221> misc\_feature  
 <222> (3416)..(3416)  
 <223> a, c, g or t

<400> 98

74

agcggacagc cgctccctcg ctctgctggg gcctccggac gcgcttccca cgcgggtctc	60
tggaacactc ggtccgaacg cagcctgct tgcactcaca ctgcggttca caccggagg	120
cgctctcgca ctacactgc cgctcacgcg cgctcacact cccccacgcg cgctccgctc	180
cggctccagc cccgcgcccc gcgaaggcgc aggcactgct gccgagagcg ccgagggggcc	240
ccgcggcctt cccatggcgg acctgagctt catcgaagat accgtcgct tccccgagaa	300
ggaagaggat gaggaggaag aagaggaggg tgtggagtgg ggctacgagg aagggtgtga	360
gtggggctcg gtgtttcctg atgctaattg ggaataccag tctcctatta acctaaactc	420
aagagaggct aggtatgacc cctcgctggt ggatgtccgc ctctcccaa attatgtggt	480
gtgccgagac tgtgaagtca ccaatgatgg acataccatt caggttatcc tgaagtcaaa	540
atcagttctt tcgggaggac cattgcctca agggcatgaa tttgaactgt acgaagtga	600
atttactggt ggaagagaaa accagcgtgg ttctgagcac acggttaatt tcaaagcttt	660
tcccatggag ctccatctga tccactggaa ctccactctg tttggcagca ttgatgaggc	720
tgtggggaag ccgcacggaa tcgccatcat tgctctgttt gttcagatag gaaaggaaca	780
tgttggttg aaggctgtga ctgaaatcct ocaagatatt cagtataagg ggaagtccaa	840
aacaatacct tgctttaatc ctaacacttt attaccagac cctctgctgc gggattactg	900
ggtgtatgaa ggctctctca ccatccacc ttgcagtga ggtgtcacct ggatattatt	960
ccgataccct ttaactatat ccagctaca gatagaagaa tttcgaaggc tgaggacaca	1020
tgttaagggg gcagaacttg tggaaggctg tgatgggatt ttgggagaca actttcggcc	1080
cactcagcct cttagtgaca gagtcattag agctgcattt cagtagccaa agaggacagg	1140
aacaagtctg tcttcatgag ggaggaagac aatggtccta taatgccctt ggataagaaa	1200
aggaaacttt tgagctgcac cttcagttta tcctcaaagc ctgcgttggt tgtcttcac	1260
taatccagct ttgatggaca tctgtgatgg ttgcctgtac acttgctgaa atgaaatatt	1320
agaaatggct gtatattcca aagaaacct atattatata tccacattac tgctgctagg	1380
attcatagtt gcacatactg tttattgctt atgtgtagaa ggaatgaaac tagtttccag	1440
agttgttatt aatatgaata tatatcatgt gttaatttg agaaaggaaa aatacattcc	1500
cggtgtagt agttcttcat ttctgtctc caacagaaaa ttactcatt ttagaactag	1560
tgtaatctt gataataaaa taagagtttt gattaagaac agcatagagc ttcaaatgc	1620
aaagtgaatg attagtaaaa ttatgtctca ttttattttt tcagcaccca taccacaatt	1680
aatattaggc tggattgcca tgggaaacat tttttggcat taatgcagca acataatact	1740
cactttaggt attactacat agttgaagga tttaactgaa tgtatggatc aaatttattt	1800



atttgacata ttcgaagctg tggtttaata ggaatttgag aaaggtgtaa gaaataggat 1860  
 aaaaagaagg tcagcaccat gtaccaggaa tagctttact ttccatacat agaaatataa 1920  
 atttagtggt atcctatatt acttttagtgt cgtacgcttt gtaagactta aatattttat 1980  
 tctattgatt ccactacttt ggtatgttaa gacattttctt taaagatgac caacaatattc 2040  
 cttatttttag gtgccactag cagatgtaag cgtatactta gttgccgtta gatgtgacag 2100  
 aatgagataa tttatgtaaa gcagtagagt acctggcaca aagcaaacaa taaatattat 2160  
 tgttattggt gttataattg taaaatgaat gacttcacaaa acatagtccc agtttggagg 2220  
 gatttgtgat gcagaatatc taagtcatag aaatagaaga caggtggaat aagtatatgt 2280  
 tcagagtttt tagatgtgtt gagtagagac ggtaataatg gaagcattaa atacaaatga 2340  
 aatcacacc agatatccct gaaattcaag caaagaaagt tcatcatgta ttcttgggca 2400  
 gcaagagaaa ggactagggt tatggcaatg tgtggaaaag ttgaggcttg ctaagggttg 2460  
 agatctgttg gtagccctgg atcacatggg gtcagcacca ggcagtgcct ctgaaagcgg 2520  
 agagagggtcc tggacttccc ttgtgtataa cagttcctag tgtccaacaa tgaggaaacg 2580  
 gtgaagcatg gttacaaaac tgtgacaaaa atatttacat ctagcactgt taccactcac 2640  
 atgccaacaa ttggctgcac acgtgcagcc ttatttgtaa ttaacatcaa aagactagat 2700  
 ctgaagcctt ccataaatga gaggccattc atatggcatt cctggaacaa aacactgcac 2760  
 aggtaccagc ctctccactc ctgaccgggt tgggtgctgaa cagtcaggga ttgttcttga 2820  
 actagacttc tgatgcttct tgcaatcttc ttctatcttt ccctgaaata cacaaaataa 2880  
 acaaatacaa taacaaatag taattaaatg actttcagga taacatctag ttgttcagac 2940  
 ttcacccttc acaggtgtgt gtgtatgtgt gtttatgtct gtatattgaa gcaatttgaa 3000  
 tttatttact gtatatttct tgagtaaaag actgaaatga actacttggt tcagatcatg 3060  
 gtgtccattg gtgacattgt ttggaggcat aatattcttt atatggaaaa tcctttaatt 3120  
 ccacagttag ttacctcaga ttcagaatat gaatactgtt tataatacgc tttttagga 3180  
 atgaattcga aaggtagtgt tcagtaaaca aaagcacaac aaactaatct cagagtctgc 3240  
 cctgatggct gtgataggga cagaaagcta aaccctactg ctgacgcgcc ccgcacattg 3300  
 ggcgcagaat ttccaagaa aacggggcaa atcaccgcca cggtcctaac tctgaactct 3360  
 atacgggcca tctgcctaa accactacaa ggcacgcacg ggaaaggact ctccgntcgc 3420  
 gactcgcaag cctacggccc ccgaacgaca ggcgcaccac gacaccaccg gcgcgtctac 3480  
 gagacatgat cagcgtcaag ggcacctgaa aaaacgatgc cccaactagt gcggcccgca 3540

76

accaggcaga cactaagctt gatagcacag cgactgcacc aagagctaata cagcacaca 3600  
 accaaagaca gaaactaccc actctatcac tacacggacg aactagaaa caacctgcaa 3660  
 ttgttactgc 3670

<210> 99  
 <211> 938  
 <212> DNA  
 <213> Homo sapien

<400> 99  
 ccacccccga cgacgacata ttaggggaac gggccactag atggctggc gagcgcgca 60  
 gtgtgatgga tgccgggca ggtacataat gttcagacct cctccatcct tttaaagtgc 120  
 tgctgcagta aataactagt ttgagtagaa ctatgctctg tctatctatt tggcacatgt 180  
 tctgctgctt ggggagtaag caagctaaag ggatgagaaa gaccacctcc ccctacctg 240  
 gaaattgcac tgcaaggcag ggcgagaatg gggtagctgg cagacctggc ctcttgttc 300  
 ccagtcttag ttatttcttg cagagattca gtattcagta aagaatagca ttcaattagt 360  
 caaaaaatat atatctaact tcttcttctt ccttcccatg aatcattgca cgtcattccc 420  
 taagctttct tctctttcca cctcatggcc tgctcagtct tccatccct accaatcaca 480  
 gactctcagc ctatagacgc agtcacagta tctcaactca tccgctctg cttcacacta 540  
 cattaacaat acctctcac tcacatacta cataactcca gctctagtct tccaaaattc 600  
 acctttcatg atgccactca gcatctcaa tacctttcat gggctctctg ctgccaaagg 660  
 ataacaggtc aaagtcatta gcctcaacag tgggcttcaa ccagccttgg gacctcagcc 720  
 catttatcca tcacagaggc tggtaactag tctcactgct caggctgtga gtgttcctga 780  
 tcttgtgac attctgtgct gtgctttaca tggaaacagg ctttctctc tctggcccat 840  
 tcgaatctc taatcaagcc catctgattc tgtacagaac acattttcaa gttcaattcc 900  
 ctggatgcgg ttgcgcgaaa agttgcttaa tgactggg 938

<210> 100  
 <211> 376  
 <212> DNA  
 <213> Homo sapien

<400> 100  
 tactcttggg tttcttctc caagactact ccttactcat atcagcaaata agcagctctt 60  
 ttcaagtgt cagtgtaaaa acctacaatt aatccttgat ttctcttca gtcagcctat 120  
 actaaatcaa tttcatttaa aatatctcgg ctactactct gcatctccac tgctaccatc 180  
 ggcctctcca gtcacattct ccaagagcac tctatctcat ttaaaagaca aaatctctgc 240

agtggcctgt gatgctcctt aatggcctac ataatccagc cctcaagcac ctccgtgatc 300  
 tctgtaaaac ttcccttgg tcaactgtgt tcagccacat taaccagctt gcataatttct 360  
 cacattcacc aagctt 376

<210> 101  
 <211> 3661  
 <212> DNA  
 <213> Homo sapien

<400> 101  
 ggacacaact caaccagta acagttagtc aatggctgtg gcaggctaaa tgtggctccc 60  
 aaatatgtcc atatcctaata cctacagcc tgtgaatatt accttatata gccaaagagga 120  
 ttttgcagat gtgattctga gattgagaga ttatgccaga ttatccaggt aggcccaaaa 180  
 tgtaatcacc acagtcctta taggagaggc aagaaagtca agtgtagaag gaggcgatag 240  
 aaggagagag ggatttgaag attaataggc tgcttgcttt gaagacagag ggaagggacc 300  
 atcaaccaga aataaacctc tagaagctgg aaaaggcatg gaaatagacc ctcccttaag 360  
 gtctctggag ggagtgcagc tttgatttct accgagtaaa attgattttg tacttcagac 420  
 ctccaaaact gtaagagaat gactgttggt ttaaaacat tgagtttgta gtaatttggt 480  
 gcagcagcca caagaaactg gtacaacatc tatatagaat tttttcagat aattgggagg 540  
 aaatttgaat atggatggca tattaatatt actgaatcag cattaaattt gtaggtgta 600  
 ataattgtgat tgtagctatt taggagaata tcctattttt aagagacatg ccaccatatt 660  
 tagggagaag tgccaacata tttgcagttt attttcaaat gggtcagagg ctgtctgtgt 720  
 acatgagaag acaaagataa ggcaaatgca gcaaaattgt aataattggt gaatccaggt 780  
 gaagggacta tggctggtct ttgtactttt ttttccaact tttctgtagg tttaaaattt 840  
 tcaaaaataaa aaatgggaaa tactttaaaa attgtaatca aagacattag tacagaaact 900  
 ttcataatgt attttatatt tacagtaaaa ttaatttatg taaattgata gaattttact 960  
 aatttcactc ccaagttaca ttaaaaggct tacatatggt tgataatagc atatgtaaac 1020  
 tagaactctg aatgatatcc attggtcata atacgtacta tgtagcggta atgggtgactt 1080  
 ttgtgattgc acaagtctag agatgcccc aatgacattg acttagacat ctgggttatc 1140  
 taaggctgaa actgaagttg aatagaagggt tttagtcaaa tactgagatg aaaactgagg 1200  
 cagtctggc gggggggagt gagtgtgtgt gtatatatac acacatagac atcatgcttc 1260  
 taaacattta cagaaagaaa gggtagatta tctacaaaaa aataagaatc agactgatat 1320  
 gagatcttac aaacctaacc cccttctctt tcctaaactc cagatttca tatttctgac 1380

ttcctatttg atatttacac ttcgatattt accaggagtc ttcaacattt tgttcaaaac 1440  
 agtactcttg gttttcttcc tccaagacta ctccctactc atatcagcaa atagcagctc 1500  
 ttttcaagtg ctcaagttaa aaacctacaa ttaatccttg atttctcttt cagtcagcct 1560  
 atactaaatc aatttcattt aaaatatctc ggctactact ctgcatctcc actgctacca 1620  
 tcggcctctc cagtcacatt ctccaagagc actctatctc atttaaaaga caaaatctct 1680  
 gcagtggcct gtgatgctcc ttaatggcct acataatcca gccctcaagc acctccgtga 1740  
 tctctgtaaa actttccctt ggctactgtg ctccagccac attaaccagc ttgcatattt 1800  
 ctacattca ccaagcttgt tcttgcttg gggcctttgt acttaccatg ttctgttctg 1860  
 agaatactct gcctcaagat atcctacaac tatcttactg tattcagctc tctgctcaag 1920  
 tattaactga tgaaacctgt catccctact ccactccatg ttctgcttta cttaacagca 1980  
 attgcacata tggcccccctg aataatatac atttagtcac ttatttttac ttatctgcta 2040  
 attaaaatgt agacttttcc tattctgttt actgctgtat tcccagcatg ttttatccga 2100  
 atgtgcagtg gtttcttttc ttctccctta tcgtgggaag tgatgtgcac aaatacacat 2160  
 aatggagcct gaatgtcata ttgctttcat acctgtgtga attttggtaa gaaaggaaaa 2220  
 gtagcgattg acaggtata taattacatt aagtcactct catagttagc tgtttattgc 2280  
 tttctgctc ttattctcag tccccaggac caaatgttga ccactacctt cccccacata 2340  
 taattagggt atttaccgaa cgccatgcag gtggctgtta aaaggaagat atatacttac 2400  
 cttataaact caacttttcc ctgttgtctt tctgtctcac ccctacctcc atgctttaaa 2460  
 ttaacttttc aggccttaggc cttatctctc agtagagcca tataaggat gtgtaaaagc 2520  
 aggaaaatgt ttctggggga tgaagctttg aaaagctttt ttttttttcc ttttggaat 2580  
 aaaataaggt agattcagca caatacctaa taactaaaaa atctgtttt aattgggtgg 2640  
 ggcagacagc aagtgtgtca tcttgaaga tactatttgg gattttatgt aggtacataa 2700  
 gagaaaaaag tgaacaaaag caaggggcta ccaggacgcc gcagtatgct taacatgtat 2760  
 tttctaagtt tgtattatgc ctttatcttg gtacttttat cttctgttct cacttgatct 2820  
 ttttgaaatg tattttaaat cctaataaaa atatataaag tctggaatta ataaaggatt 2880  
 aatgaaact tttgtatata tcaactgaaat tctcagaaaa aaggggggtg tggggagggg 2940  
 gaattgcctg gggtagtgag tgaaaattgt gaccaggttc ttactaagga atatggcaac 3000  
 tgcataatca aatgtcagtg gttaccaaac ttatgaatca cctggtgttg tgtcatagat 3060  
 tgtctatcct tgcctctcgc cccagtgat ttagatcagt ggaactatgt ggggtttaag 3120

79

```

aatatatacaa tatatatattg tatatatattg tgtgtctcga aagcttcagg gttaaataag 3180
ttttaactgt ttaggaaca ctattgtttt aggtatccag tctcaaagac gaaggccttt 3240
aaaacttact taatttttca ttacatttct tgcccagaaa attgtaaaat acccaacgat 3300
aacaatgggg aattgtctat cagcacttga ctaaaaagct ttactatcca tgacagcagc 3360
ctttgcatta ctcaattctg atggcattta acgtcttgaa acccagaaat aaatacctat 3420
agactcacag tacctgaaag gaataccaaa ttgagacaag agagctatat aaaccaaaaa 3480
ttgcttcaac cacagaatgg aggtctacag gtgcggaagg aaagtttata tggtagaggct 3540
tggtagcaaaa actattagga atattttcag gttactacac aattttgcga gctcaatatg 3600
cagttaacac tttttccctc gaatctcctg agcagattta cattgaccgg acccgtagca 3660
t 3661

```

```

<210> 102
<211> 698
<212> DNA
<213> Homo sapien

```

```

<400> 102
acatttccat ttccaccggc ttggagcaga gctgtcgagg agtgctattc taggatcctg 60
atgatgacca caagggcagt ttgtattcag ctgtccctgg gaacacttcc ctgaaagcgc 120
tcagggacat tttcatcagg cacagtgtct caggctacgg cactctgtat tgttccctgg 180
tggcttttagg gggctgggca tcgtagctga aataggacaa caggagatg gctgagtgtg 240
tttcccaact gccagatgac aacaggtcta tcagcataaa gtcatcatat aacttagaag 300
aaaccttacc ctcggtgaaa tctcccagca gatcagcaac gaaatggact aagcaacttc 360
ggtagaaaca catggggcta ggatataaac agttcatagg aaaggacacc tgatatcatt 420
aatgattagg gagagaaatt gggtagctaa cagcaggggt gagagagaaa ctttatagta 480
ttttcctctg tagcttttga attttaagac atatgaatgg attttttttt taattgtaat 540
taaagtataa tttttttaaa agagaaattt ggagtcattt aacttgtaag acaaaggcta 600
tcttgtaata agaatactgt tcttcctatt tgctctagat tttaagtttg gatgggctac 660
atgggtttctt agggcagaac cactcttata gactattt 698

```

```

<210> 103
<211> 1217
<212> DNA
<213> Homo sapien

```

```

<400> 103
acatttccat ttccaccggc ttggagcaga gctgtcgagg agtgctattc taggatcctg 60

```

80

```

atgatgacca caagggcagt ttgtattcag ctgtccctgg gaacacttcc ctgaaagcgc 120
tcagggacat tttcatcagg cacagtgtc caggctacgg cactctgtat tgttccctgg 180
tggcttttagg gggctgggca tcgtagctga aataggacaa caggagatg gtgagtgtgt 240
ttcccaactg cagatgacaa caggctcata agcataaagt catcatataa cttaaagaaa 300
ccttaccctc ggtgaaatct cccagcagat cagcaagaaa tagactaaca attcggtaga 360
aaaatggggc taggatataa acagttcata ggaaaggaca cctgatatca ttaatgatta 420
gggagagaaa ttgggtagct aacagcaggg gtgagagaga aactttatag tattttcctc 480
tgtagctttt gaattttaag acatatgaat ggattttttt tttaattgta attaaagtat 540
aattttttta aaagagaaat ttgggagtca tttaacttgt aagacaaagg ctatcttgta 600
ataagaatac tgttcttcct atttgctcta gattttaagt ttggatgggc atacatgggt 660
tttcttaggg cagaaccac tctactagac ctatttaacc ccatgacaga gcctagaagg 720
aacagtgta atagaagatg gcatttatgg caagaagggt gatcaagttc tccattagaa 780
tttgaaccag atctaagcc ttttcttccc ttgtttaaga acggcccggt atgttggtact 840
tcacgggcaa ggccaagtgg gatgcctgga atgagctgaa agggacttcc aaggaagatg 900
ccatgaaagc ttacatcaac aaagtagaag agctaaagaa aaaatacggg atatgagaga 960
ctggatttgg ttactgtgcc atgtgtttat cctaaactga gacaatgcct tgtttttttc 1020
taataccgtg gatggtggga attcgggaaa ataaccagtt aaaccagcta ctcaaggctg 1080
ctcaccatac ggctctaaca gattaggggc taaaacgatt actgactttc cttgagtagt 1140
ttttatctga aatcaattaa aagtgtattt gttactttaa aaaaaaaaaa aaaaaaaaaaag 1200
atctttaatt aagcgggt 1217

```

```

<210> 104
<211> 193
<212> DNA
<213> Homo sapien

```

```

<400> 104
ccgggcagggt acaatatgga tttcaaaata acgttcactg gtaatccttc ctgatgccaa 60
ttttaaaatg aagaccgtct aaatttttct gaccagttat tagttgccct gcctctcgga 120
aatgtgttta aacttttctt tcaattattt gatacctttt gcccaagaga ttactatctc 180
tctctttttt ttt 193

```

```

<210> 105
<211> 542

```

81

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 105

```

ggcgcgactt tttttttttt ttttttagtt atatatttaa tgaatcattt ttattgcaaa      60
gggtaaatta catgaaattg acaaaattta gtccatgtaa tatctatcaa aatacataca      120
tgtaagtgtg tgtatattta tatatgtata cagtacagtt ttcacaaaaa gcttcaacat      180
tcctaagaaa cacagacata gtcattctgg tacaatatgg atttaaaata agttcatggt      240
aatccttcct gatgccatt ttaaaatgaa gaccgtctaa atttttctga ccagttatta      300
gttgccctgc ctctcgaaa tgtgtttaaa cttttctttc aattatttga taccttttgc      360
ccaagagatt actatctctc tctttttttt ttttctttta agacagagtg ttgctctgtc      420
actcagggtg gagtgcagtg gcacaattcc tgatcactgc aacctctgcc tcccaggctc      480
aaacgatcct cccacctcag cctccccagt agctgggacc acaggcacat accaccaagc      540
tt                                                                                   542

```

&lt;210&gt; 106

&lt;211&gt; 715

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 106

```

ccgcccgggc aggtcctaaa tagaattcaa gattagacta aatgattttc agcagagcac      60
attcaagggt ttacattcta tgattgaaaa aaattttttg aaaacttttt atttcattct      120
ttcctgtagg attttgctac aaataacttt gggaatgaat aaagtggaaat ggtaactttc      180
cagtgggtca gaattgaatt agacttcttg tgactgtgat gtttggtttc cattgaaata      240
tatgaagtga gatgtcatat cctgaatata gtttgtcttc cccaattact tgatagcatg      300
tctgtcagcc agtaaagatt aagaacagag tttctctaaa ttccctccgat tattccacta      360
aggcacatta aaataactta ttttgggaaa ccagacatca cagatttctc catgaagtcc      420
taaattctct ttaaagtcag aataggtatc ttagttactg acagtattca ggtttttttc      480
tcccttggtg atatgtcatt ccatcagtga aaaaatattt tctccaagg gatatagaaa      540
ggatattctg taatacatca tcatcaatcc tttaacagta acagtctggc acttatcaca      600
aaaacgacca tttcttataa ccagaaagat atcttagatg tcttcacata tattttactat      660
gctgtagata aagatgcccg gggttatggg tccatttcat ggctggggtt acgtg          715

```

&lt;210&gt; 107

&lt;211&gt; 1716

&lt;212&gt; DNA

<213> Homo sapien

<220>

<221> misc\_feature

<222> (1594)..(1594)

<223> a, c, g or t

<400> 107

```

agactgcaat ttctgactaa agcttttaaat gccagggttaa acaggagaaa ctttttccac      60
tagaagaaaa tccttgctat ctatttttttc caatagaaga aaatcctgct atttatttta      120
tttgatgaat aaacaaattt attgcagtag cttaaaaaaa tttttttttt aaacagtctc      180
actctgtcgc ccaggctgga gtgaagcaat gtgatctcag ctactgcaa cctccacctc      240
ccgagtagct gggattacag acatgcacca ccaccctcag ctaatttttg tatttttagt      300
ggagacgggg tttcgccatg ttggccaggc tggctcttaa ctctggcct tacgtgatcc      360
gccccccctt ggccttccaa agtgtctgga ttacaggtgt gagccactgc acctggcctg      420
tagtagctta aaattttcct tgagaaaatt cctgacttta aaaataaacc ttatataagt      480
acaagtgatt gtgacaaatg acgtaaaaat ggcattcatg atgtctgaaa caagcctaaa      540
tagaattcaa gattagacta aatgattttc acaaagcaca ttcaaggttt tacattctat      600
gattgaaaaa aattttttga aaacttttta tttcattctt tcctgtagga ttttgctaca      660
aataactttg ggaatgaata aagtggaatg gtaactttcc agtggttcag aattgaatta      720
gacttcttgt gactgtgatg tttggtttcc attgaaatat atgaagtgag atgtcatatc      780
ctgaatatag tttgtcttcc ccaattactt gatagcatgt ctgtcagcca gtaaagatta      840
agaacagagt ttctctaaat tcctccgatt attccactaa ggcacattaa aatacttaat      900
tttgggaaac cagacatcac agatttctcc atgaagtcct aaatcttctt taaagtcaga      960
ataggtatct tagttactga cagtattcag gtttttttct cccttggtga tatgtcattc     1020
catcagtgaa aaaatatttt ctcccaggga taagaaagggt attctggtaa tacattatca     1080
tcaatcctta aacagtaaca gtcttggcac ttatcacaaa accgacccat ttcttataac     1140
cagaaagatt atcttagact gtccctcaca ttatacttta cctactgcct tgtaagaata     1200
agagttgctc actgtgttta ctgtgtgcc tccatattct ccattgcacc attggtgtat     1260
aacgttaaga gtttcattga atattatttt aagtattaca aaaggcagct tgcttcttaa     1320
tctatgcac tttgggggtt ttgaagaaat ttaattcttt gatgtaaaaa ggaactgtta     1380
aaaaagttgg aagctctgca cctgtgtata tatatatatt agcaataaag cagcatgggc     1440
tgagaatgca ctgaaaaaaaa aaatgctag tgacttcagc aagtcataat ctctctgcgg     1500

```



83

gtggaggggtc tcactgcat gtggatggcc gctggggctg accaggggtg tggtggcaga 1560  
 aggctggggc ggctgtggca gtttcttaaa atangacaac aatgacattt gccacattga 1620  
 tagacttttc ttttcacaaa agaagtctct gtagcacgtg gttgctgttg gtgcacttta 1680  
 cccacagtgg aacttctttc aaatagtctc aatcct 1716

&lt;210&gt; 108

&lt;211&gt; 666

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 108

tcgcgccga ggtacttaat aatgactgaa tttcatgttc ctacagtcac acatattcat 60  
 tagaagtttt atgttgttgg tctgatctga ttcttctttg tttgtgggtg gaacggcact 120  
 gagagaagta tagtttttta aacttgaaca tgttcagtag ttacattgcc ttagaaaacc 180  
 cagacacata gcagtggaaa tgaaagaaat ggcatcagaa gtgacttaat ttagcaattg 240  
 tgattcctct tgtaaaacaa aacaaaaaaa caatgccata ttttttgag aaaagttggc 300  
 aatatagggg ttctgtgtc tgtttcaca gaagactcat ttgttctttt gggggaacca 360  
 gtgccttaca gattttgtat atactgtaat tattcaggac tagggaacaa acaattgtat 420  
 tgtatttgtt acagattgta tatggctttg ttttaacatt cccctaaata aaatggcttc 480  
 attctccctt tggaaaaaaa catgactgtt atgttataaa acaaaaaaaa aaaaaaaaaa 540  
 aaaaaagggtg ggggtaccgg ggcaaaacgt gtcccggggg gaatggtttc ccggccca 600  
 aatccccac attgcgagaa aacgtgcga acaaaaaaaa aaaaaaacg aaaaaaaaaa 660  
 acaggg 666

&lt;210&gt; 109

&lt;211&gt; 1983

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 109

gaatttcgta atccttgaaa ttgaaaaaaa aaaaattgtg tttttaaaga gtgaaaacag 60  
 ttaggaaaca agtagaactg taatcagaac gctgcttcaa ttgatattaa aaataacctc 120  
 aataataatg taaagggtcc tttctcttgt gtcagttata ttcttaggga tagcctagaa 180  
 ggaatatatg gttagaacta agtgtgacta atcatctgag ccttgaagag aaacttcagt 240  
 gcctctaaac agatcatcta caaaacaaca ggtaaacatt tatgccagtt aagtgggtca 300  
 tgtttttgtt tcttgggttt ttccctaaatt taagtgggtg tgggcttacc ttgtagataa 360  
 aattatgttt tcttttttgt aaatacttga atgtggataa cgtcaaatca gaatattttg 420

tgaggaggtg atgatttgaa attaagctag atttctaggg aggtggtggt tccaatgaag	480
gatgggaaga aattaaaata gtcttcaaac ttcttcctta ttatatgttg ttgctttgga	540
aaagattggt cctatcctca atctaattta ttcactatta atatttttaa aacattcctg	600
agatacttaa aaagaccac ttagcgatta tagttgctca atgaaacaag aatttattta	660
tgcatagatt tttctctgta tcttaccaaa atccacttta cttagataac actaaattgt	720
tcttaaagac tactcatttc ccaataatcc tttatgattt caaaatttct agtggctcag	780
aagtgaattt tattttattt gtctttcact tgaataaatg agaaccaga aattaataat	840
gttgtttatt gcttactgtc aggactattt caaagactaa gaagagtttc ttctaacccc	900
ccctctcaa aggaatccta aattattagt tgtagataa gttttgtatg ctaagatatt	960
caggtttata gtttatgtat gtgtgtatat atataaatat atatgtatat ataaatatta	1020
tgttcagttt ggagtctggc acaactccat tatgtggatt agagagtaag atattatgga	1080
tgataaagta ctaaataaaa cataatattt atttataaaa gtgtgtagat tgttaaataca	1140
caaaaagagt gctatgacca ttatgtatga ggaaacaggc ctttgacctc ctggaaagca	1200
ctgctcaaaa gtcattagtg cccatttttg aattcccaa acagaaagct tcttagaaaa	1260
cacgctgaga ttttatttac aggaattctt ttgacacatt tcaattggtg tgtagtcaag	1320
tatagcaagt acttaataat gactgaattt catgttccta cagtcataca tattcattag	1380
aagttttatg ttgttggctt gatctgattc ttctttgttt gtgggtggaa cggcactgag	1440
agaagtatag ttttttaaac ttgaacatgt tcagtagtta cattgcctta gaaaaccag	1500
acacatagca gtggaaatga aagaaatggc atcagaagtg acttaattta gcaattgtga	1560
ttcctcttgt aaacaaaaac aaaaaaaca tgccatattt ttggagaaa agttggcaat	1620
ataggggttt cggtgtctgt ttcacaagaa gactcatttg ttcttttggg ggaaccagt	1680
ccttacagat tttgtatata ctgtaattat tcaggactag ggaacaaaca attgtattgt	1740
atgtgttaca gattgtatat ggctttgttt taacattccc ctaaataaaa tggcttcatt	1800
ctcccccttg aaaaaacat gactgttatg ttataaaaca aaaaaaaaaa aaaaaaaaaa	1860
aaaggtggg gtaccggggc aaacgtgtc ccggggggaa tggtttcccg gccacaaat	1920
ccccacatt gcgagaaaac cgtgcgaaca aaaaaaaaaa aaaaacgaaa aaaaaaaca	1980
ggg	1983

<210> 110  
 <211> 758  
 <212> DNA

85

&lt;213&gt; Homo sapien

&lt;400&gt; 110

```

aaaaaaaaacc acaacaaga gaggattgat tgataatatg gggcatgctt aatctaataca      60
tgctcgagcg gcgcagtagt gatggatcga gcggccgccg ggcaggtagc taacatatag      120
tagacagtgg agagtgggtc tctttcgttg tctcaggggc agacagatgg ggtgctggag      180
tcctctatca aagagtcaga gctctatccc agatgtgtaa tgaacgtggt cacagacata      240
ttgtcccatc accatttacc ttccctataa ccaactgtgc tccagccttg tagaatagac      300
acataggagc gcagcaatac gtctaaaaat aggagtgaga gagggcaggg catgcccggt      360
cttgtggtag aagaaaagaa tgtcaaagaa agcagctggg actaatgaac ttacattag      420
ccatattcca ttatttcagc ttaagtcaaa tgtcggctct catgaggcaa ctggctttga      480
caggagctac gctaattgtc cacttaccaa cctttaattt ctgggtaaaa gcagaaagag      540
aaaaactaat ggatttttca tttccagaa gagacaagaa tcaactacac tagtagtctg      600
tcagaacaaa agaaaacctg catccaatta caagaattat tactgtctct ttaataaata      660
accacattat taaaaaaaaa aaaaacaaaa aagggttggg ggtaccgggg ccaaggggtc      720
ccgggggggaa ttgtttcggc ccatatccat aaaaaaaa      758

```

&lt;210&gt; 111

&lt;211&gt; 3575

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 111

```

atgaaattac aactcaggat taagagtctc actcaaaacc gcacaactac atggaaactg      60
aacaacctgc tcctgaatga ctactgggta aataagaaaa ttaaggcaga aataaataag      120
ttctttgaaa ccattgagaa caaagacaca atgtaccaga acacagctaa agcagtgttc      180
agagggaaat tcatagcact aaatacccac atcagaaatt gggaaatacc taaaatcaac      240
gtgctaacat cacaattaaa agaactagag aagcgagagc aaacacattc aaaacaagaa      300
ataactaaga tcatagcaga actgaaggag atagagacac aaaaagccct tcaaaaaatc      360
agtgattcca ggagctgggt ttttgaaaag attaacaaaa cagatagact gctagccaga      420
ataataaaga agaaaagaga gaagaatcag atagacacaa taaaaaatga taaaggggat      480
atcaccacta accccacaga aatacaaact gccatcagag aatgctatca acacctctac      540
ataaataaac tagaaaatct agaagaaata ggccgggcgc agtgggtcac acctgtaatc      600
ccagcatttt gggaggccaa ggtgggcgga tcacctgagg tcaggagtgc gagaccagcc      660
tagccaacat ggtgaaaccc cgtctctact aaaattataa aaaattagcc ggggtgtagt      720

```

gtacacgcct gtagtcccag ttacttggga ggctgaggca tgagaattgc ttgaaccag	780
gaagtggagg tggaggtgag ccgaaattgt gccactgtac tccagcctgc aacagagtga	840
gacactgtca cacaaaaaag aaagaaatat cacaatatgt cacaataggc cgggcgcagt	900
ggctcacacc tgcagtccca gcactttggg aggccaaaggc agatggatca cctgaggtca	960
ggagtgtgag accagcctgg ccaacgtgac aaaaccagct ctactaaaaa taaaaaatt	1020
agccaggcgt gatggtgggc acctgtaatc ccagctactc aggaggctga gacatgagaa	1080
tcgcttgaac ccaggaggtg gagattgcac tgagctgaga tcctgccact gggctccagc	1140
ctgggtgaca gaatgagact ctgtctttaa aaaaaaaaaa aaaaaaaaaa aatcacata	1200
agtccatagg taaagatggg ggtacagaaa acaattaaat agaacaaaaa caactgtttc	1260
cttttcctgt gattcaagaa gggcttagat cttctactca gcatcctttt actaatgccc	1320
tccattggct ctacgcccac acatttcctt ttttatagct tattttgtaa tgctcctta	1380
attatccttt aatagaagcc accgctgata agctacctac actcatacag aagcattaat	1440
ataatgcccc agatgtactg tttcagggca aaaaggaaaa taatttccaa caaagtgggtg	1500
tgtgtctcac tgtcagatgc ttgcacttac acacggaatc gctgtgcatc cgacagaggc	1560
tgattggcac atggggcacg gggattgtca gctcaaacac cgtcagcagc gttgcccttg	1620
gaaatgggat ttcccagaac agtaaactg tctgtccttg atttacagag tagctacatt	1680
cctaggaaat ccagggtaca ttaaaactca ccatgttacc caggctggtc tcgaactcca	1740
ggcctcaagc aatcctccca catcagcttc ccagaatttt gggattacag gcatgagcca	1800
ccacaccag ccagaatatt ttatttctgt tagacacaga gcgttcgttg actcgtctgg	1860
gcgttagtgt taatattctg tacttgaagc aagcccacca agcggctgaa ctgggtggat	1920
aatggaaaat gtcctgtgga tttgggagtg agacaaaccg gcttgagtct aacctctcag	1980
ttagtctaag gctccaagct tgaaagggtt aaatgaagta ctatatttgt tttgtttcgt	2040
tttcgttttg tttgaggctt tgctctgttg ccaggtctgg agtgtagtgg cacaatctct	2100
gctcactgca acctccatct ccaggttca ggcgattctc ttgcctcagc ctccagagta	2160
gctgggatta cagggtgccg ccaccacacc cggctaagtt ttttttggtt tttttagtag	2220
acacagggtt tcacatgtt ggctagactg gtctcgaact cctgacctca agtgatccac	2280
ctgccttggc ctcccaaagt gctgggagta tgggtggtga gccaccacgc ctggcctaaa	2340
tgaagtacca catgaccgac cgaccgacct ggggaacata gcaagacccc atctctacaa	2400
aaatgtaaaa aataaaaatt agccgggtgt agtggtagat gcctgtaatc ctagatactc	2460

87

```

gggaggctaa ggcagaagga tcacttgagc ccaggagttc gaggctgcag tgagctgtga 2520
tcgtgccact gcactccatc ctgggtggca gagtgaggcc ctgtctcaaa ataaataatc 2580
cagtcccccc caagaaagga atgaagtgtc ataatgagaa aaatcctagt acctaacata 2640
tagtagacag tggagagtgg ttctctttcg tttctcaggg gcagacagat ggggtgctgg 2700
agtcctctat caaagagtca gagctctatc ccagatgtgt aatgaacgtg gtcacagaca 2760
tattgtccca ttaccattta ccttcctat aaccactgtg cctccagcct tgtagaatag 2820
acacatagga ggcagcaat acgtctaaaa ataggagtga gagagggcag ggcagcccg 2880
ttcttgtggg agaagaaaag aatgtcaaag aaagcagctg ggactaatga actttacatt 2940
agccatattc cattatttca gcttaagtca aatgtcggtc ctcatgaggc aactggcttt 3000
gacaggagct acgctaatta ccacttacca acctttaatt tctgggtaaa agcaaaagag 3060
aaaaactaat ggatttttca ttttccagag agacaagaat aaaataatag tagtctgtag 3120
aaaaaagaaa acctgcatca attacaagaa ttattaatgt atctttaata aataaccaca 3180
ttatttagct gtttaatttc ctaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3240
aaaaaaaaCa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3300
aggagggggg gggggcgaga aaaagagccg aggggggagc acagagcggg ccgccgcgca 3360
catatgaaaa aagcgaccca gaagaagaaa caaaaacca gcaagcgcaa acagaagaaa 3420
taagaaagag aaaaagttac gagacgaata gaaaggaaat aactacagga ccaacacggg 3480
acaaaccaa agcaaataaa caaagaaaat aagacagaca caagatgcca acgagctaac 3540
gcccggacaa tggaaacagg taaacaacat aaagc 3575

```

```

<210> 112
<211> 442
<212> DNA
<213> Homo sapien

```

```

<400> 112
actgagcagc tacggaagtg caaggcactg taggagtagg gtgagtatac tccccacaag 60
ggctcagggg caggcagggg acggtagaga taaaaacca cagaccatac acatagctgg 120
cactgtctct gagggttttg tgaggcacac aaatgcttag gagactagac gaagtaagac 180
aatgtctttg acatgaggca gaaatcaacg gaaagcatgc gcttttagaa catgtgtggg 240
actgtttttt ggtatcagca gactgaagag gcttttttaa cgtggaggga aggcaaactg 300
aggcatagag atgccaatac caggtcttgt caggaagaac agagtccaat ttggctgcag 360
gatagggcat atgtagggga ggggataaga ctggcatggg ggcagagggg gacttgaatg 420

```

88

tcaggtgaca gagtcaaagc tt

442

<210> 113  
 <211> 412  
 <212> DNA  
 <213> Homo sapien

<400> 113  
 tgtcatacta taaggcgaac tgggcctcta gatgcaattg ctcgagcggc gcaggtgatg 60  
 gatgttcgcg gcgaggtatc agaagctgtg atgtctgcct tgtagtcctg tgcttgttac 120  
 tgtaattttt tttttttttt tacgaagcac gtgactggac taatgtaagg cagatgacgt 180  
 gatctttaag actgctatat atatcagtct cttactctat aaggttttta attagaaaag 240  
 gcttatatgg ttaactacct tagactatat ctacagcagg gtctggtttg ccagaacaag 300  
 tttaaagtgg ctgtttatta agttggctat tttcagaatt gaaactataa gaccgccatt 360  
 tgacactgaa acttgcgatga atcctaaatt gcatcaatta tctatttgat aa 412

<210> 114  
 <211> 625  
 <212> DNA  
 <213> Homo sapien

<400> 114  
 gcaacaacaa ctgaatggct gtaatacatt aatgtatata gatgaattga gaagtcttct 60  
 agtgaaatgg ctcatatctt tgttcttggt ccagtcctgt tcagtttttg atcagtgcct 120  
 tgcaatatca cttgatcgac tcaacttaaca tttatacaag agtgcagagg cctcctcaga 180  
 gaatggatgg tagaaatgca ttgatgagag aacgtttatc tatctatctg tctatctatc 240  
 tatctatcta tctgtctcta tctaagaagt cataaaggct gagtctaata aggcaaaaaa 300  
 aaaaagaaaa aaaaaaaaag ctgtggcgat acccagggcc aaagcgtgat cccggcgcca 360  
 actgcgaaat ccgctcaciaa toccaacaac acccccacia ccccccccc agccccaaca 420  
 ccaacacctc acaaaaacct cacaacaccc ccaccacccc acacagccac cccctacca 480  
 cacaaccaca tcacaccacc accgccccac ccacaccaca cccccacac acactccgaa 540  
 caccacggcc cactccacac acccaccac caccagcacc aacacaccca cacaccaca 600  
 ccgcccacccc cacaccacac gcagc 625

<210> 115  
 <211> 378  
 <212> DNA  
 <213> Homo sapien

<400> 115

89

gcggcgcccg ggcaggtaca tagtgagat gcagtatata atttcaggct aggaaaatta 60  
gctactagta tgtatctgac agttcctaag agctaagagg cctaagaatg cagacgggga 120  
gaaaaaaaaac caaaacccaaa aaaaaagaca cctctccaat tgctgggagg gcctgggaat 180  
aggtgaagat caaaccacag tgggagagga gggtaaagat gtgagcttca agcgggtaat 240  
gggcaagcca cacctcccag ttcctaggag ggaatcgcca cggccgactt cagcattctc 300  
gtctttacta agacttaccc atagagaact acagcaggaa accgatttct tcattcattc 360  
tctttaaaaa gtatgaat 378

&lt;210&gt; 116

&lt;211&gt; 8905

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 116

atggcgcccg cgctggggcc ccagaaagt atcgctcagc tggagaacgc ggctaaagtt 60  
ctgatggtga ggacgcgcgc cccctcagac ccggggattc gcgggcccc ggctcgccct 120  
gccactccag gccttgctgc tcgctgggtt ggcgactggc aagggcctgc agggagcctg 180  
gaagtggagg aggaggtggc ggtggcgtgg cgcaggattc ttcagcctac tttcctcctg 240  
ccgtcgtccc ctccctccag gagctgtccc cttcccctgg ctgccagca cccagtcgg 300  
gcgtgggaat atagtgggtg agcaaagaga atttcttcac cttacaccct gccccacaga 360  
ctgggtcgca gagcaaggcg ccgggaagga gttgggggta tccccgcagg gcttcggggc 420  
tctcatatac tagtccttct gtctggaatg cttttcttcc ctgtcacttc atccttcagt 480  
tctctcagta gtcagtttct cagggaagcc ttccttagcc tgctgaaag tataccctgg 540  
gtgatagatt ggattggatt ggattggatc ggatcggatc ggatcggatt ggattatatt 600  
gtatttatatt ttaagagaca gggcagctgt caaaatggaa gttcagggtc actagaggtt 660  
ggcacatgtc tccagggtaa acacatgagt gcttgcattc atctttggat ccctgcgttc 720  
gcttctgttt tagcttttga tgattcctta atttcttctg ccacagccat aatggaagca 780  
gttgtccgag agtggattct cttggaaaaa ggtagcatcg agtctctgcy aacattcctt 840  
ttaacctatg tcttaciaaag gcccaacctt caaaagtatg ttogggaaca gattctacta 900  
gcagtagcag taattgtaaa aagaggatca ttagataaat caattgactg caaaagcatt 960  
tttcatgaag tcagccagtt gattagtagt ggcaatccca ctgtgcaaac tctggcctgt 1020  
tctattctga ctgcgctatt gagtgaattt tcaagttcaa gtaaaactag caacattgga 1080  
ttgagcatgg aattccatgg taactgcaaa aagagttttt caggaagaag accttcgtca 1140

90

gatcttcatg ttaactgttg aagttctgca ggagttcagc aggcgggaaa acctcaatgc	1200
tcagatgtct tcagtatttc agcgttacct tgcactcgcc aatcaagtct tgagctggaa	1260
ctttcttctt ccaaatttgg gcagacatta tatagctatg tttgaatcct cgcaaaatgt	1320
gctgttgaag ccaacagagt cctgcgggag actcttcttg acagcagagt tatggagctt	1380
ttcttcacag tacatcgaaa aatccgagaa gcattcagat atggcaccaa gattctctgc	1440
agtgccttgc ccagttagct tctcttcatg gacctatctt cccagatgaa ggatcacaag	1500
ttgattatct agcacacttc attgagggat tactgaatac tatcaatgga attgaaatag	1560
aagattctga agctgtgggg atctccagca ttatcagcaa cctgataacc gtgttccac	1620
gaaatgtttt aactgccatt ccaagtgaac ttttctctc ctttgtaac tgctcacac	1680
acctcacttg ttcttttggg cgaagtgtg cattggaaga agtgcctgat aaagatgaca	1740
tggtatacat ggaagcatat gataaattgt tggagtcctg gttaactttg gttcaagatg	1800
acaaacattt ccataaaggc ttttttacc aacatgcagt tcaagttttc aattcctata	1860
ttcagtgcc ctagctgct ccagatggca caagaaattt gactgccaat ggtgtggcct	1920
ctcgtgagga ggaagaaata agtgaacttc aagaggatga tcgagaccag ttttctgatc	1980
aactggccag tgtaggaatg ctaggaagaa ttgctgcaga aactgtata cctcttctga	2040
caagtttatt agaagaaaga gtaacaagac tccatggtca gttacaacga catcagcaac	2100
agttacttgc ttcaccgggt tcaagcactg ttgacaacaa aatgcttgat gatctctatg	2160
aagatattca ctggcttatt ttagttacag gctacctctt agctgatgat actcaggag	2220
agactccgct aatacctcca gaaataatgg aatattccat taagcattca tctgaagttg	2280
acattaatac aacacttcaa attttgggat ctccaggaga aaaggcttct tccatcccag	2340
ggtacaacag aacagattct gtgattagc tgttgtctgc cattctcaga gtttcagaag	2400
ttgaatctcg agcaataaga gcagatctca ctcatctact aagtccccag atgggcaaag	2460
atattgtttg gtttttaaaa cgctgggcaa agacttatct cctggtggat gaaaaactgt	2520
atgatcagat aagtctgcc ttcagtacag cgttcggagc agatacagag ggttctcagt	2580
ggataattgg ctaccttta caaaaagtca tcagtaacct ctacgtctgg agtagtgagc	2640
aggaccttgc aatgacact gtgcagctcc ttgtcacttt ggtggaaaga agagaaaggg	2700
caaacttagt aattcaatgt gagaactggt ggaatttagc taagcagttt gcaagccgaa	2760
gcccacctct taatttcttg tcaagtcctg tgcagaggac attgatgaag gctctagtct	2820
taggaggttt tgcacatatg gacacagaaa ccaaacagca gtattggaca gaggttcttc	2880
agccacttca gcagcattc ttaagagtga taaaccaaga aaacttccag cagatgtgtc	2940



agcaagagga agtcaagcag gaaatcactg ccacactaga ggcctgtgtt ggcattgctg 3000  
 aggctaccca gattgacaac gtagcaatcc tgtttaattt tttaattggac ttccttacca 3060  
 attgcattgg attgatggaa gtttacaaga ataccacaga gactgtcaat ctcatatag 3120  
 aagtttttgt tgaagttgca cataaacaga tatgctatct tggagagtcc aaagctatga 3180  
 acttatatga agcctgcctt actttgttgc aagtgtattc taagaataat ttagggcggc 3240  
 aaagaataga tgttacagca gaagaagagc aataccaaga cctgcttctc attatggaac 3300  
 ttcttactaa cctgctgtca aaagaattca tagatttcag tgatacagat gaagtgttta 3360  
 gaggacatga gccagggtcaa gcagcaaaca gatctgtgtc agcagcggat gttgtgttgt 3420  
 atggagtaaa cctaattctg cccttgatgt cacaggatct ctgaagttt ccaacccttt 3480  
 gtaatcagta ctacaaatta atcacattta tctgtgagat ttttctgaa aaaataccac 3540  
 agcttcctga ggatctgttt aaaagtctga tgtactccct agaattagga atgacatcaa 3600  
 tgagttcgga ggtttgccag ctttgccctgg aggccttgac accgttagct gaacagtgtg 3660  
 caaaagcaca agaaacagac tcaccacttt ttctagcaac acggcacttt cttaagctgg 3720  
 tttttgatat gctggttttg caaaagcaca acacagagat gaccactgct gctggcgaag 3780  
 ctttctacac gttggtgtgt ttgcaccagg ctgaatatc tgaactggtc gaaacattac 3840  
 tatcaagtca gcaagaccca gttatttacc agagattagc agatgccttc aacaagctca 3900  
 ctgcaagcag cactcctcct acgctggatc ggaagcagaa gatggccttc ttaaagagtt 3960  
 tagaagaatt tatggcaaat gttggtgtgt tcctttgtgt aaaataaaca acagaacttt 4020  
 atgcttaatt tagatccttt ctgcaaagtg cactgaattg ctgaaagttg acttgagctc 4080  
 tgcctattc ctcatgcat ttggccattt tggattttgg agagcctgaa actttgatat 4140  
 gtatgtaata cagtgaaca ggagaggtca acttggcctc agcttctgct gtttaagtgtt 4200  
 agccacaatc tgtcatatat atgtctttta gattctgaat ggtgatttaa aattttcaaa 4260  
 atgaaattcc atatatgtgc aaacagatat gggcaccacg aaatacatat gcagtgcctt 4320  
 ttttctttt aacatagggtg gctagccaaa gtttagaatt ttgtcatta aatatgaaat 4380  
 ggatatatgc taggcagtgt ttctcaaaat ctccacagat cgcctgcctc acttgaggag 4440  
 ctggtgaaaa ggcagattct taggccaac tgtagacctt cagagtcaga atgtctggtt 4500  
 gttgggcca ggagtcttca tgttaataag cttctccctt tcgtcaccct aaaagttttg 4560  
 aatcaatgaa agagacattg aaaactctta agaggttttg tgctttctag ctttctctcc 4620  
 ctttgatgat tgggttttat aattcagcag gaaggggaaa catcatcagg ggtttgttgg 4680

ctttttctta gcttgctttc ttgcttgctt gctttcttgc ttttcttgct ttctgtctct	4740
ctctttcttt tctctctctc tctcacatca acccagtgc gcagggtttg tgtaatacaa	4800
gtcactaatc atactctgat gcctgaactt gaggaggaaa atacatgtat atttttgttc	4860
cgtaaaaata accttaggaa ctgtagccat ttcattgcct taattttaag aggaaaatac	4920
aaaaacagct gatttgtttt agtaagaaac cacgtcttga tgcttcagag ttgggttagg	4980
gtgttagctg ctatgaacct gttgcccctt tcgatcgtgt atttatgtag gtttatcagt	5040
gaaatgaaag gcttgtttcc gtctagtcta actttttgag tgtgtttcta tccagccaca	5100
tagcccatat ctactctaaa tggcttgctt aagcaataat tattttaaag gatgtgaatc	5160
actgattcac acagactatt gcacgttggg gcattagggg caataattct tatccagaca	5220
tgggagccag tgaatttaat ttcagagatt aaaaattcac tttagatcct ctagtgtgat	5280
ctcttaatca ggatttttat acagctgccg ggctccccta attcagtgtg ccagcttaca	5340
atgtggaaat gaaagctaatt ttatacacag caggcatatg aaactccact cattgcagta	5400
ctttcacagc acagtgcag gtagaggact ctggcacagg tgcactcatg aaactctgct	5460
tccaccatgt tcttgacacc tatctattaa accattctgc aaatacgggt tttctacctg	5520
attgcatata gcatatgtgt cattacatgt gatgctgtgc aaaactttgt ataattctgt	5580
gttattaaca gttaacaaaa ctggagcatc tgaattacat ccaacctgtg catgtgatgt	5640
taggtagatg tgaatgcagg gccttgggcc ataacttaca tttctctcaa tttgattagc	5700
tttgagtca aattaagggg aagcaaaaaac atcttgaaaa gactgctagg aaggaaatta	5760
atatcagtca tccagaagta cacgtttctg tattttaaaa aatactttga tgcatttatt	5820
tttaggtgtt ttttttttcc ccttaaaaaa ctgaagtga tatgcagcag taatctattt	5880
gttttgcatg gttcttggtg ttttgtgttt ccagatccc tcaagcttcc tcagctgttg	5940
cgaattatgt gtatctgtgt gtgtgctaag tacagtctct ttaccaaagg gcactgaaac	6000
acacaattga ctggacaggt ccacgcgcca tgacaaaact ataatcaagt tattaact	6060
aaagaggagt gggaaaggaa tgccttggtg agtaaaaagg catctatatt taataacttt	6120
tatccagatg gcaacatatt tgcaaaattt gccagatcc tattacaata ctaaaaatag	6180
aaaatttcac ctccatattc ctgaggtgta atttcattag actagtttta gtttaaaaag	6240
accttcttca gattggacca aataatactt ataagatcag cagaatgttg aatattagct	6300
cactgggggtg gggagaagcc actaccattt tttaggtgat ggggatgcc ctgagttgca	6360
acggctagac cttttcaggg tggttgtgtc catgtttgcc tgattggatg cttattcact	6420
ttgtgttttc ttttgtttta ttttgtccaa ttttgtcttt agctgtgttt attaaacttc	6480

ccggtcttgt	tttgttttaa	tgctcttggc	ccagtgggtg	tcaagaacac	tggcttaatt	6540
caagtcagtt	gatttttttt	ctattaaaac	tgttggttaa	atatttttta	aaacaaaaac	6600
attatttgtg	ccctctttta	tatatgtcaa	agggacactg	tcaagtattt	cattttttaga	6660
tttttgtttt	ataaaatttc	tgttggtcat	atagtatcct	ttaacctcta	gttttccata	6720
catcctttgt	ttgtttctca	ttttattttc	cttgacccat	ttatttccca	aggcacaatc	6780
actaaagact	ttgtactttc	acagtctgtt	aatgtggtag	cacctgtaac	tgtgttcttg	6840
ttctgtttaa	aggattgatt	tgcttttata	gtccttgtgc	tggatgagtg	gctgcctcag	6900
tagcaaaact	acctgacagt	atttgacagt	gtcctttcca	gcaccattat	ttgggtcttt	6960
caggggtggc	atctctgtta	gaagacagta	gcatgttaac	atcactgcat	tgagtttttg	7020
tctggtgtaa	agtatgactt	ttaatgtaaa	caaactgcag	gtttttttca	aactaatttt	7080
aagaatttag	tcttatttcg	ttgtaaactg	tgtatcta	tattattacat	tactctgttc	7140
agatgggatg	gttactacca	cttgtccatg	attttcat	gttttcaag	tatctatctc	7200
atcccccc	agtcagcatt	atttaacact	ccccttaact	gtccttgaac	tttctctttt	7260
aacaaaaatg	tcaagtcttt	acagttgtaa	tatcaccatg	tttcccat	ctgttaatac	7320
ttctatgaac	ccctaaagta	ttgaaggga	ctagctgtca	gtttcaagga	ttacaagttt	7380
gagtctocta	gtattcaaca	tcattctgaa	ccctgaaata	atatttttct	ctgttaaaca	7440
atttttatct	gtttgccacc	tctgttggtt	gaggtgggtg	tcaattgacc	ttactaagtt	7500
agctgtcttt	gatgaggaat	tattgttatt	ggttcctgaa	taaaacatta	accttttaag	7560
tcagaagga	cctcgggtact	tcttaagggt	tgtttgtgtt	ttctaaaacc	agagaataag	7620
gaactgattt	ggctatgagg	tttaacatta	taattttctg	taagctttcc	cacaaaaaaa	7680
cattgttgat	ttgaggatat	aataatgttt	taatcttttt	aaaatataag	tggttattct	7740
ctgacttggt	aactatgttc	tgaaaacact	gcatttaaga	atttttaaaa	attgggtttc	7800
taaaattaaa	atgtccaaat	taggcata	gctgagctca	aattgatgtg	aaatgccatg	7860
gttccagttg	aattttaagc	atattttcat	ttagatataa	aatatatgaa	gtatgctttg	7920
ttgattatag	tgagaacca	tgacatagtt	aaccaaagaa	tatgtttggt	tcaaataaaa	7980
atagaagctt	aatactgggc	attcatactt	tttaaagaga	atgaatgaag	aaatcggttt	8040
cctgctgtag	ttctctatgg	gtaagtctta	gtaaagacga	gaatgctgaa	gtcggccgtg	8100
gcgattccct	cctaggaact	gggaggtgtg	gcttgcccat	tacctgcttg	aagctcacat	8160
ctttaccctc	ctctcccact	gtggtttgat	cttcacctat	tcccaggccc	tcccagcaat	8220

94

tggagaggtg tctttttttt ttggtttttg ttttttttct ccccgctctgc attcttaggc 8280  
 ctcttagcta ttaggaactg tcagatacat actagtagct aattttccta gcctgaaatt 8340  
 atatactgca tctgcactat gtacctacta gggatctgac ctcaagtgtt ttctgagccc 8400  
 aggcttcctg gtgtggtgtc ttttaccaca taaaattatt acaaattgca aatgttgga 8460  
 ttgtgatttg attatctgta caaagaaaga agctctatgc agtgagtttg tggtttaatg 8520  
 gtcacaaaaa tggtagcact gctaccactc agcacgtgta aaatttttta aatttataaa 8580  
 tattaataatt ttaaaacttac actaagactt ttcagtttta tttaaagacc cagggatgag 8640  
 tgtactgttt aaatatattac ctctattaac ataactaatg aaggataaaa attgcattta 8700  
 gtttttcaga agatgctgca atatgatttt aggaaataag gctatgtatt gagccagtta 8760  
 taggctgaat atcaggttga taaaatttta tttgtatttt taaaattcat aaatgggagt 8820  
 taaaatgtgt cttttcacta aatattttta ttacaaaaaa aaaaaaaaaa aaaaaaaaaa 8880  
 aaaaaaaaaa aaaaaaactg cggcc 8905

<210> 117  
 <211> 827  
 <212> DNA  
 <213> Homo sapien

<400> 117  
 tcgcgccga ggtaccctgc atcactgcc a tgggtgtgct attctcatct caacatagaa 60  
 ttgggtgggtt ctctaagggt tgcaggaac ctctaaaaag atgtgattct ttgggagggg 120  
 atatttga aa ttccaacttc cattccccct agcaaaagga agcagctgct gtttaagggt 180  
 tttatctgag ccactttaaa gatgaatcca tgggtattact ctggatacta gccattcctt 240  
 aggattttaa ggtcacattt tttcctgga tgctttatgt cccacctcc acctgagccc 300  
 tcatcctctg ttccctacta tactcccaac ttctactctt tgttttatcc acctatccct 360  
 attacctgac cttttgtctt cctgtctcc catccttggg gggacatgca gccctgtggt 420  
 catggttctg atgacatcat cagggcagcc ctctgccca ggtattatgg cctgtcagca 480  
 ttccctgtgc cctccaaacc ttaggcctag aatgcggagc tgccaacata acattcaccc 540  
 ttttgaacag atggagtcag gcacactaac acagccttct gtcctcaata acacagccat 600  
 tattgccact tggctcagtc gtcaatgtaa accctcagag tcagctgaac tatttttaggc 660  
 caaacatact gtttttgtaa agtatttttc attataaat ctataagaca gttctattta 720  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aggctggggc gaaccggggc caacggctcc 780  
 cgggggaaat tgtttccgc caaattcccc caaaaaatgg caaacg 827

<210> 118  
 <211> 6470  
 <212> DNA  
 <213> Homo sapien

<400> 118  
 ggctccctgg tagctatagc agccgcggcg gttaagtatg cggcgccagg agctgctaaa 60  
 tgtgaacaat aatgtcttgg aagagaaatt atttttcagg gggtcgtggg agtgtacaag 120  
 ggatgtttgc acctcgaagc tcaacctcca tagccccag caaaggcctc agcaatgagc 180  
 cagggcaaaa cagctgcttc ctcaacagtg ccttcgaggt tttgtggcac ttggatatct 240  
 tccgacgtag ctttaggcag cttacaactc acaagtgcac gggagattcc tgcactcttt 300  
 gcgctctcaa ggggaatcttt aaccagtttc agtgtagtag tgaaaaagtg cttccatctg 360  
 acactctccg cagtgtctctg gcaaagactt tccaggatga acaacgtttc cagctgggaa 420  
 ttatggatga tgctgcagag tgctttgaaa acctcctgat gagaattcac ttccacattg 480  
 ctgatgaaac caaaggagat atatgtactg cccaacactg catttcccat cagaaatttg 540  
 caatgacatt gtttgagcag tgtgtatgta ctagctgtgg tgccacttct gatccgtgc 600  
 ctttcatcca gatggtacat tatactctcca ccacttcctt ttgcaatcag gctatttgta 660  
 tgctggaaaag acgagagaaa ccttcaccaa gcatgttttg tgagctgctg cagaatgcca 720  
 gcaccatggg ggatctgcgg aactgtccaa gcaactgtgg agagaggatc aggattcgcc 780  
 gtgtgttgat gaatgctcca cagattatca cgattgggct ggtatgggac tcagaccact 840  
 cagacttagc agaagatggt atccacagcc tgggaacctg ccttaagctg ggtgatctgt 900  
 ttttcagagt gacggatgac cgggccaagc aatctgaact gtacttagtt ggaatgatct 960  
 gttactatgg caaacattat tctacattct tttttcaaac aaagattcgc aaatggatgt 1020  
 attttgatga tgctcatgtc aaggagattg ggcccaaagt gaaggatgtg gtgaccaaatt 1080  
 gcatcaaggg gcattatcag cccctgctgc tgctttatgc agatccccag ggtacccccag 1140  
 tttccacca ggacctgcct cccaagctg agttccagtc atacagcagg acatgctacg 1200  
 acagtgaaga ttcaggacac ctgactgata gtgaatgtaa tcagaaacac acatccaaga 1260  
 aagggtcact gatagagcgc aagaggagct ctggtcgggt taggagggaa ggcgatgagc 1320  
 cccaggcctc gggataccac agtgaaggag aaacactgaa agagaagcag gctcctagaa 1380  
 atgcctccaa accatccagc agcaccaaca ggctgagaga ttttaaagag acagtcagca 1440  
 atatgatcca taacagacca tccctggctt ctcagaccaa tgtaggctct cactgcaggg 1500  
 gcagaggagg agaccagcct gacaaaaaac ctctaggac cctgccttta cactctcgtg 1560

actgggaaat agagagtacc agcagtgagt caaaatccag ttcttccagc aagtatcgtc	1620
ccacatggag acccaaacga gaatctctga atattgacag tatctttagt aaggacaaaa	1680
ggaagcactg tggctatacc cagcttagcc ccttttctga ggattcagct aaagaattta	1740
taccagatga accaagcaag ccaccttctt acgacattaa atttggtgga ccaagccccc	1800
agtacaagcg ctggggccca gcacggccag gctctcacct tttagagcag ccccccgac	1860
taatccagcg aatggaatct ggctatgaaa gcagtgagag gaacagcagc agccctgtca	1920
gcctggatgc agccctgcct gagagctcaa atgtctacag ggatccaagt gctaagagat	1980
cagctgggtt ggttccttcc tggcgctata tcccaaagtc gcacagcagt agcatcctgg	2040
aggtagactc cacagcatcc atgggtggct ggacaaagag tcagccttct tctggtgagg	2100
agatatcttc taaaagtga ctggatgaat tgcaggaaga ggtggccagg agggcgagg	2160
aacaggaact tcgaagaaaa cgggagaagg agttagaggc agcgaaaggg tttaaccctc	2220
atcctagccg ctcatggac ttggatgaac tgcagaatca ggggaggagt gacggctttg	2280
agaggtccct gcaagaggca gagtcagtgt ttgaagagtc actacatctg gaacagaaag	2340
gagactgtgc tgcagctttg gctctctgta atgaagctat ctctaaacta agacttgccc	2400
tgcattggtgc cagctgtagc acgcacagca gagccctagt cgataagaag ttgcaaatca	2460
gtattcgaaa agcacggagc ctgcaggatc gcattgcagca gcagcaatca ccacagcagc	2520
cgtcgcagcc ctacgcctgc ctcccaacac aggcggggac tctctctcag ccaacaagtg	2580
aacagcctat cccgctccaa gtattgttaa gccaaagggc ccaactggaa tccggcatgg	2640
atacagagtt tggggccagt tctttcttcc attcacctgc ttcttgccat gagtcaact	2700
catcactatc tccagagtca tctgccccac agcacagctc ccccagtaga tctgccttga	2760
agcttctgac ttcggttgaa gtagacaaca ttgaaccctc tgcattccac aggcaagggt	2820
tacctaaagc accaggggtg actgagaaga attctcatca tagttgggag ccattggatg	2880
ccccagaggg taagctgcaa ggctctaggt gtgacaacag cagttgcagc aagctccctc	2940
cacaagaagg aagaggcatt gctcaagaac agctgttcca agaaaagaag gatcctgcta	3000
accctccccc ggtgatgcct ggaatagcca cctctgagag gggatgatga cacagcctag	3060
gctgtagtcc ttcaaattca tcagctcagc ccagccttcc cctgtataga acctgccacc	3120
ccataatgcc tgttgcttct tcatttgtgc ttactgtcc tgatcctgtg cagaaaaacta	3180
accaatgcct ccaaggccaa agcctcaaaa ctctattgac tttaaaagtg gacagaggca	3240
gtgaggagac ctataggcca gagtttccca gcacaaaggg gcttgccgt tctctggctg	3300
agcagttcca gaggatgcag ggtgtctcca tgagggatag tacaggtttc aaggatagaa	3360

gtttgtcagg tagtctaagg aagaactctt ccccttctga ttctaagcct cctttctcac 3420  
 agggtaaga gaaaggccac tggccatggg caaagcaaca atcctctctg gagggggggg 3480  
 atagaccact ttcttgggaa gagtccactg aacattcttc tcttgctta aactctgggc 3540  
 tgcctaattg tgaaacttct agcggaggac agcccagggtt ggcagagcca gacatatacc 3600  
 aagagaagct gtccaagtg agagatgtta ggtctaagga tctgggcagc agtactgact 3660  
 tggggacttc cttgcctttg gattcctggg tgaatatcac aaggttctgt gattctcagc 3720  
 ttaagcatgg ggcacctagg ccaggaatga agtcctcccc tcatgattcc catacgtgtg 3780  
 taacctatcc agagagaaat cacatccttt tgcattccaca ttggaaccaa gacacagagc 3840  
 aggagacctc agaattggag tctctgtatc aggccagtct tcaggcttct caagctggct 3900  
 gttctggatg ggggcagcag gataccgcct ggcacccact tagccaaaca ggctctgcag 3960  
 atggcatggg gaggaggttg cactcagccc atgatcctgg tctctcaaag acttcaacag 4020  
 cagaaatgga gcatggtctc catgaagcca gaacagtgcg tacttctcag gctacacctt 4080  
 gccgaggcct cagcaggag tgtggggagg atgagcagta cagtgcagag aatttacgtc 4140  
 gcatctcacg cagtctcagt ggcaccgttg tctcagagag ggaggaagct ccggtttctt 4200  
 cccacagttt tgattcatca aacgtgagga agcctttgga aaccgggcac cgttgttcca 4260  
 gctcctcttc cctccctgtc atccatgacc cttctgtgtt tctcctcggg cccaactct 4320  
 accttccccca accacagttc ctgtccccag atgtcctgat gccaccatg gcaggggagc 4380  
 ccaatagact cccaggaact tcaaggagtg tccagcagtt tctggctatg tgtgacaggg 4440  
 gtgaaacttc ccaagggggc aagtacacag gaaggacttt gaactaccag agcctcccc 4500  
 atcgctccag aacagacaac tcctgggcac cctggtcaga gaccaaccag catattggga 4560  
 ccagattcct gactactcca ggggtgaatc ctcaactaac ctacactgc acactaccag 4620  
 aaagaagcaa gggccttcag gttcctcaca ctacgtcctg gagtgatctt ttccattcac 4680  
 cctcccaccc tcccattgtt catcctgtgt acccaccatc tagcagtctt catgtacccc 4740  
 tgaggtcagc ttggaattca gatcctgttc cagggtcccc aaccctggg cctcgaagag 4800  
 tagatatgcc cccagatgat gactggaggc aaagcagtta tgctccccc tctggacaca 4860  
 ggagaacagt gggagagggg tttctgtttg ttctatcaga tgctcccaga agagagcaga 4920  
 tcagggttag agtcctgcag cacagtcaat ggtaaagggt attcctttcc tttcctggag 4980  
 ctacaccttt ctttgtaaaa ctgtactgtg ggcggggcgc ggtggctcac acctgtaac 5040  
 ccagcacttt gggaggctga ggcgggtgga tcacgaggtc aggagattga gaccatcctg 5100

98

gccaacatgg tgaaaccccg tctctaccaa aatacaaaaa attagccagg cgtgacgggtg 5160  
cgtgcctgta gtcccaacta ctcggaaggc tgaggcagga gaattgcttg aaccggggag 5220  
gcagagggttg cagtgaagccg agatcgacc actgcactcc agcttggtgca tagagtgaga 5280  
ctccatctca aaaaacaaaa caaaacaaca acaaaataaa ctactgtggc agcgttggtgta 5340  
ccctgcatca ctgccatggg tgtgctattc tcatctcaac atagaattgg tgggttctcc 5400  
taagggtgtc aggaacctct aaaaagatgt gattctttgg gaggggatat ttgaaattcc 5460  
aacttccatt cccctagca aaaggaagca gctgctgttt aagggtttta tctgagccac 5520  
tttaaagatg aatccatggg attactctgg atactagcca ttccttagga ttttaagggtc 5580  
acattttatt cctggatgct ttatgtcccc acctccacct gagccctcat cctctgttcc 5640  
ctactatact cccaacttct actctttgtt ttatccacct atccctatta cctgacctt 5700  
tgtcttcct gtctcccatc cttgggggga catgtagccc tgtggtcattg gttctgatga 5760  
catcatcagg gcagccccc tgcccaggta ttatggcctg tcagcattcc ctgtgcctc 5820  
caaaccttag gcctagaatg cggagctgcc aacataacat tcacctttt gaacagatgg 5880  
agtcaggcac actaacacag ccttctgtcc tcaataacac agccattatt gccacttgct 5940  
cagtcgtcaa tgtaaaccct cagagtcagc tgaactattt taggccaac atactgtttt 6000  
tgtaaagtat ttttcattaa taaatctata agacagttct atttaaaaa aaaaaaaaaa 6060  
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaacaaaaa aaaaaaaaaa aaaaaaaaaa 6120  
aaacaggtgg gggccgcgcg cgggcgcgcc ccgagagaa aatttccaca aacaccgtg 6180  
ggggggcggc gggcgcccca agtgagtgc agagaaagaa agacgaggag cacaacagga 6240  
ggtccgtcct ccagaagaaa acaaccgct gcggcacaga acaaaggagg tggcgggggg 6300  
tgcgtccac cagcaaat aagaaaaccc cgcggggggg ggaaaaacag cagacgagtg 6360  
tcgtgaagaa caacaaccca caggagagag gcctcgtgga caaggcacac agggggtgct 6420  
cacaaaacaa gggggtacaa agaaggagac gcaagaaaac ataattgccc 6470

&lt;210&gt; 119

&lt;211&gt; 435

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 119

gtataatcat ataggcgc at ggttctctaa tgctgctcga gcggcgctg tgatggatgc 60  
gtggcgcggc gaggtacctc tcaacactga gaactgtagt agttgaaacc actgttctag 120  
tgggcagtta gaacagttgt tttcccgctc ttgttcccca cagagctgcc caagttatta 180



99

tctgctcctg ggggttgacc atctgtttta tgacagttat gatattgttg tttaaaaaaa 240  
 atccaaattg ttactttgat ttatatgac taactctgaa tcacggaagt attactatga 300  
 tgttcaaaac tctgattgac tctacttgc ttaaaaactc tcagatccct tctgcattta 360  
 tcatcagaga tcggtaaaga tgacaacaag caggtctaaa gttctgagat gttagcacat 420  
 acccttttca caatt 435

<210> 120  
 <211> 1262  
 <212> DNA  
 <213> Homo sapien

<400> 120  
 ggccgagttt tttttttttt tttttttttt tgtttttttt tttttttttt tttttttttt 60  
 tgttttagat atgttgcttt tattcaaaag aataaaatgc ttgacaaact ctttaaacac 120  
 aaggtttgaa ccaaaccacc agtcttctac aacaactctg tgaggtaggt atctgcatag 180  
 ccacaaggga tccacatagt cctttcttcc cttgtacctc tcaaactctg agaattgtag 240  
 tagttgaaac cactgttcta gtgggcagtt agaacagttg ttttccccgt cttgttcccc 300  
 acagagctgc ccaagttatt atctgctcct ggggttgacc catctgtttt atgacagtta 360  
 tgatattgtt gtttaaaaaa aatccaaatt gttactttga ttatatgat ctaactctga 420  
 atcacggaag tattactatg atgttcaaaa ctctgattga ctctacttgc tttaaaaact 480  
 ctcatgccct ttctgcattt atcatcagag atcggtaaag atgacaacaa gcaggtctaa 540  
 agttctgaga tgttagcaca tacccttttc acaatttagg aagctttaag atcatttagt 600  
 atttttttat gttacaaaat ttggtacaat acacctcttt caggaaagtc ttagtagtaa 660  
 ctccaaatat tataattatt gtaaccagaa ttgtgacctc tggagcagaa tgcattgcaca 720  
 caaaataaaa tcctgtcaaa aaatgacatc accattcccc cacaccaa atgtgaattgg 780  
 taggaaatgc atttccagtc tggtagatgg cagtgtgaca aactcctact cactcgcttt 840  
 tcaagttggt gactgcagct gaaatgtttt tctgtgatgt atgccaccct tttacctatt 900  
 tgatttgga atgtagaatt cggattcatg tcatctccac agacctttcc tcttaggagt 960  
 gcctaagctg tcttactctg atggagggtat aatgtagcac gaaagacttc caaagaacca 1020  
 gtttctctct tgctgttccct cttacaactc ttcacgtcta tctaaacatt ctatgcagga 1080  
 gtctactaa gaaattttgg tgtaatgcc ctttgatcag ttatttgttg tatgacttca 1140  
 ttcaaaaaca ctttcatcaa tagcatgggg attgtatcta tgaaaggga gttggtgtcc 1200  
 tgcgttcctc acaaaattat ccaaaggata aaatgaaaag tatgtgagaa acctgcttta 1260

100

at

1262

<210> 121  
<211> 562  
<212> DNA  
<213> Homo sapien

<400> 121  
ggtaccaact tgagtgcctc ctaaaagtgt aaccttgggg gcggggatac agaaggatga 60  
tgctgacaat ggaattttaa aacaaacagc aacattttgt ggtgtctaca ggcgtggggg 120  
tggaggagct gcagcgtcac catgggaaca aaagtctccc acgcatctca ggcccagga 180  
atctttaaag agggagagtg ggcattgggag gaggacttaa gctattagtc atattttatt 240  
tcgaaaacta gatcttaagt aactgtagca aaatgttaac aattcttacc ttggaatacc 300  
ggttacatgg gattcatgtt actctatfff ttcattcatgt gcaaatatff tcatatfftg 360  
acaattaaaa ctaaatagta gctttttata aaagtggcat atgcactgaa gtataatgtg 420  
ctaatttggg attcgtttta ataaaacagc tttcttatac aaaaaaaaaa aaaaaaaaaa 480  
aaaagggttg gggaacaag ggcaaaagg gttcccgagg ggaaatggtt accgggtcga 540  
aatctcacia ttggagaaaa ac 562

<210> 122  
<211> 695  
<212> DNA  
<213> Homo sapien

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> a, c, g or t

<400> 122  
ctggagcatg gtntgcagga gtgcaagact gcaagcctcc tccacggcca ccaactccagg 60  
cctggataaa gaattcgtgg catatttcag ggaacagaat gtcccctggg gcgaaagggg 120  
atgaagtcac tctacttgta ccaacttgag tgcctcctaa aagtgttaacc ttgggggcgg 180  
ggatacagaa ggatgatgct gacaatggaa tttaaaaaca aacagcaaca ttttgtggtg 240  
tctacaggcg tgggggtgga ggagctgcag cgtcaccatg ggaacaaaag tctcccacgc 300  
atctcaggcc cgaggaatct ttaaagaggg agagtgggca tgggaggagg acttaagcta 360  
ttagtcatat tttatttcga aaactagatc ttaagtaact gtagcaaaat gtaacaatt 420  
cttaccttgg aataccggtt acatgggatt atgttactct attttttcat catgtgaaat 480  
atcttatatt ttgacaatta aaactaaata gtagcttttt ataaaagtgg catatgcact 540

101

gaagtataat gtgctaattt gggattcggt taaataaaac agctttctta gaataaaaaa 600  
 aaaaaaaaaa aaaaaaaggt tgggggaaac aagggcaaaa ggggttcccg gggggaaatg 660  
 gttaccgggt cgaaatttca caattggaga aaaac 695

<210> 123  
 <211> 386  
 <212> DNA  
 <213> Homo sapien

<400> 123  
 aaccctggc caggcccagc tgccacaccc tttctgggag aagcatggcc tacagaatga 60  
 agagggggac caggaacccc tgtgggagag gcttagacct gaagcagtgc ccactctggc 120  
 tctctctgcc ttggctgact gggttcctgg accatgtgca tttcactggg ccatgggata 180  
 tacatctcct tgcaccccca gctggtctga tccctgccag ggccccctcc tctctgctca 240  
 tggctctcag gtggcctgat catggaaagt aaggagttag gcattacctt ctgggagtga 300  
 accctgactc catcccccta ttgccaccct aaccaatcat gcaaacttct ccctccctgg 360  
 ggtaattcaa cagttaaaag aagctt 386

<210> 124  
 <211> 654  
 <212> DNA  
 <213> Homo sapien

<400> 124  
 atgataaacc acctcagccc ccaccaagcc gccgcacccg tagaccagac cccaaggacc 60  
 ctggccacca tgggcccagag agcattacct tcatctctgg ctctgtgag ccggcccttg 120  
 agtccccac ctgctgcctg ctctggcgac cctgggtgtg ggagtgggtgc cgggctgect 180  
 tctgttccg ccgctgccgg gattgcctcc agcgtgtgg aggccgtgtg cggggatgca 240  
 gccctgcct gtctactgag gactcccctg aggggactgc tgaagccaac tggccaagg 300  
 agcacaatgg agtgccccc agccctgac gtgcagcccc ccgccggcgg gatggccagg 360  
 cgggctgcaa gtcaaccatg ggcagcagct tcagctaccc cgatgttaag ctcaaaggca 420  
 tccctgtgta tccctaccga gaggccacct cccagcccc tgatgcggac tctgtctgca 480  
 aggagccact ggccgatccc ccaccagcg agcacagcct gccagcacc ttgcccagta 540  
 gtctctgtgg ctccgaggag tactattctt tccatgagtc ggacctggac ctgccggaga 600  
 tgggcagtgg ctccatgtcg agccgagaaa ttgatgtgct catcttcaag aagc 654

<210> 125

102

<211> 684  
 <212> DNA  
 <213> Homo sapien

<400> 125  
 acatgcagat gtgcatgtta cagagataaa gtgatcgaga caaggactga ctgggtatag 60  
 aaggaagaca gactcctgtc ttcactccta aatgcagttc tttggaatca ccctactgtg 120  
 atgggcgtag tagggagcca tcagctagga agaaacgtgg gagatgtgaa ttccaagagt 180  
 tgcctggaca gggcaagtca tgttagcgtg ggtcacactt ccaagatatt taaagcaaat 240  
 acaaaacaga acagaggatt caaacgcaa gtatgggaga tttaggccct gcagaggcag 300  
 accattcctt agtatctcac aaagcagagt aatactggag gcagagtagg ggggtggttg 360  
 agagcagtta gtaccaataa caatgaagtc tgtgtttgat ctgatcgata ctttcagtc 420  
 ccgaatcaaa gatatggaga agcagaagaa ggagggcatt gtttgcaaag aggacaaaaa 480  
 gcagtccctg tgagaacttc ctatccaggt tccggtggag gaggagggtg ctggtgatct 540  
 ctgtcctaac gatgaagact gggctattca caggcagctc tctgccctca gtggtcaggc 600  
 gtgcacattt ggtctgcgcc acataacatt ctgaagcttg ggtatcatgg tcatagtgtt 660  
 ccgtgtgaat gtatcgtcac atcc 684

<210> 126  
 <211> 2671  
 <212> DNA  
 <213> Homo sapien

<400> 126  
 ctgccgaaga gttcaaaaca gaagagcaag atgcctcagg gagtatagaa tttggtgtat 60  
 cttttcctga tagggaatca tcatctatgg aaacatccat cgaacaaaaa gcaactgaaa 120  
 cttctcacac agagggaatt actgccattg aggagagctg ggagtctatg tttaacgatg 180  
 atggtgactg cctggatcca cgtcttctac aagagttatc agggaatacc aagagcagag 240  
 agagcatcca ggaacctaga tctgattact acaatcatga agttcctgat attgacctca 300  
 gtgattgtga attcccacat gtcattgaaa tttatgactt tccccaaaga tttcgtactg 360  
 aagaccttct acggggtttc tgcagttatc aaaagaaagg atttgatatt aaatgggtgg 420  
 atgatacaca tgccttagga gtattctcca gtccaattac agctcgtgat gcgttgggta 480  
 ttaaaccacac catggtgaag attcgtccct tgtcacaggc cacaagagca gccaaaggcca 540  
 aagctagagc ttatgctgag ttcctccagc cagcaaagga gcgtcctgag acttcagcag 600  
 ccctagccag aaggtagtc atcagtgcc ttgggggttcg aagtaagcag agcaaaaccg 660  
 aacgagaagc agagctcaag aaactgcaag aagccagaga gagaaagcgg ttggaagcca 720

agcaacggga agacatctgg gaaggcagag accagtctac agtttgaaca tcaactcaatg	780
aaagggataa ttccatgaat cagaaaatgt ttccatagcc ttcagataag atgacccctc	840
cagagctcta tgtacatgca gatgtgcatg ttaaagagat aaagtgatcg agacaaggac	900
tgactgggta tagaaggaag acagactcct gtcttcactc ctaaagcag ttctttggaa	960
tcaccctact gtggtgggcg tagtagggag ccatacagcta ggaagaaacg tgggagatgt	1020
gaattccaag agttgcctgg acagggcaag tcatgttagc gtgggtcaca cttccaagat	1080
atttaaagca aatacaaac agaacagagg attcaaaccg caagtatggg agatttaggc	1140
cctgcagagg cagaccattc cttagtatct cacaagcag agtaatactg gaggcagagt	1200
agggggtggt tggagagcag ttagtaccaa taacaatgaa gtctgtgttt gatctgatcg	1260
atactttcca gtccgaatc aaagatatgg agaagcagaa gaaggagggc attgtttgca	1320
aagaggacaa aaagcagtcc ctgtgagaac ttccatcca gggtccggtg gaggaggagg	1380
ttgctggtga tctctgttcc taacgatgaa gactgggcct attcacagca gctctctgcc	1440
ctcagtggtc aggcgtgcaa ttttggctctg cgccacataa ccattctgaa gcttttaggc	1500
gttgagagg aagttggggg agtggttagaa ctgttcccaa ttaatgggag ctctgttgtt	1560
gagcgagaag aaaaaaaga tgaagaatga gaacgcagac aagttactta agagtgaana	1620
gcaaatgaag aagtctgaga aaaagagcaa gcaagagaaa gagaagagca agaagaaaa	1680
aggaggtaaa acagaacagg atggctatca gaaaccacc acaaacact tcacgcagag	1740
tcccaagaag tcagtggccg acctgctggg gtcccttgaa ggcaaacgaa gactccttct	1800
gatcactgct cccaaggctg agaacaatat gtatgtgcaa caacgtgatg aatatctgga	1860
aagtttctgc aagatggcta ccaggaaaat ctctgtgatc accatcttcg gccctgtcaa	1920
caacagcacc atgaaaatcg accactttca gctagataat gagaagccca tgcgagtggg	1980
ggatgatgaa gacttggtag accagcgtct catcagcgag ctgaggaaaag agtacggaat	2040
gacctacaat gacttcttca tgggtgctaac agatgtggat ctgagagtca agcaatacta	2100
tgaggtagca ataacaatga agtctgtgtt tgatctgatc gatactttcc agtcccgaa	2160
caaagatatg gagaagcaga agaaggagg cattgtttgc aaagaggaca aaaagcagtc	2220
cctggagaac ttccatcca gggtccggtg gaggaggagg ttgctggtga tctctgctcc	2280
taacgatgaa gactgggcct attcacagca gctctctgcc ctcagtggtc aggcgtgcac	2340
attgggtctgg ggccttacc ttctgaagct taagcgtgag cacggactgg gggcccggtc	2400
aactggcccc attaaggagc cccgagataa cgagaaacgt acaccccatg gtgaaaaaca	2460

104

ccgcacaaat ccacggaccc ggagacaacc caggccaggc gcaaaaagca agaccacacg 2520  
 gatatcacc c aaggcagcga gaagggacca cacacacacc cgcacaacag gacacccaag 2580  
 cggcgccaca acagtcacga caccacaagg ccacgaagca acacacagaa acatacacag 2640  
 cagcacacgg ccatacaacc gcccacacag c 2671

<210> 127  
 <211> 420  
 <212> DNA  
 <213> Homo sapien

<400> 127  
 acggggccgca gtgttgatgg atgcggcgag gtaactctct ctcccttaag agttatgagt 60  
 tatcaagagg agacttctta aagacagcaa cgcaattctt gtaacttggtg taaatagccc 120  
 catctttcag agtgatacca tttctacatt tgataatgcc tgtattcctg taggatgtat 180  
 atagtttagg ggattttttt ttggttgggg ttttggtttt ttagaagggtc aatatgtctg 240  
 gttttattta tgtgcttgaa aaagatcatt tgaaaaaat aaatacattt tcaaccacaa 300  
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa ggcgcggggg ggaacccggg gccagagcg 360  
 ggccccgggg ggcgaattgg gttctcccgg cccacattcc cccaaaatat tggcacacag 420

<210> 128  
 <211> 2269  
 <212> DNA  
 <213> Homo sapien

<400> 128  
 taccgaggag ggaacaagct acatgctatt ttgtttgtag tattgtggaa cagtcttgtt 60  
 atggagtgcc agcttagagg ttgttgcaaa ctgtctaga agtgagagca tgggtttttt 120  
 tagccctttg agagtctaca tctaataaac attcttgctc acccataaat aacgtcaagc 180  
 ctcaatgtca ccgtcacgtt gggatactct ttctcatctg gcacccctaga caggacaagg 240  
 ttggttacct ttccttccat gaacatgaa cctgtgacgg catcattcat cctgacttca 300  
 ccaagctccg cctgtgggtg aggccagagc tcccactggc aattttttaga agagccagag 360  
 gctccctgct tcctctagaa ataacagttc aggggtgaagc atggagggtt tcagttccca 420  
 gacaatggaa ccatttagag acaacacagt tggacatttc cactttttcc ttgattcctg 480  
 gaagtccagt gggttctgca gctgaaaaag ccctgggtcc cagcagcaga gagacaggac 540  
 agaggggatg cttgggcggg gagggacggt aacctgcaga acagattcca tttttataga 600  
 acgagtacac gtttgctaaa acagtcctgc tttcccagac tggattccca ccacagggac 660  
 agtcggaact caggactagc tccagcgaca tctttcctcc gaattcaagc cttctatcac 720

105

```

aatgtcaaaa cagctattta taaagccatt ttcattgtac ttgataacag cacgagtc 780
aaaactttta gaaataaaat aggacattgg cttgattgaa aagagggact ttttaaaaat 840
tgttctttcg tcagaagcct tttggatgac ttacaatagc tctgatgaag ataccacccc 900
agcgtcagtc caataggtca gtgagtttca acaggcatcc atccctccca tgaagggatt 960
ctggatgatgg gaagtttctg taatgacagg aaagcattga ccctcattga ttgtcaactt 1020
tggatattagc catgaaagac aggatgctca ttgggtgttc tgtagagtga ggaatgctgc 1080
ctattccctc ccagaacgtc tgacccaggg gtgtgtgttg aggagccctg ggggaaatgg 1140
accaagtttt cccacagagc agtattaggg tgaagagcag gtgactggta ggccccagct 1200
cccatcatte cctcccaaag ccattttgtt cagttgtctca tccacgctgg attccagaga 1260
gttttccaat ttgggaagcc atgagaaagg tttttaaatc ttgggaagat ggagagaggg 1320
acataggata gttgactoca acatgacagg aagaggctgg agattgggaa ttggccatca 1380
accaagcctg tagtagtaaa gccatggtcc cgcattggaa ttacttgggg aacttataca 1440
gttctgatac ccaggctctc ctagaccagt tcaaccaatt ctaggtgggg gactcaggca 1500
tcagtgtgtt tcgtagctcc ccgggtgttt tcctgtgca gccgagcttg ggaaactgcc 1560
atgctttttg gatgtcaagg cgctgttggg ggctgggtgt gacagcacag agccagggtg 1620
tcttgtggaa accacagcca cgggtttgcc actggctcag catggcctca ctgccagtcc 1680
cagcctgggt gagggacaag atggtttctc ttgggagttc ctgagtggag cacccttcca 1740
ggctttttga aagccagctg atctgtggag ccttggttaag ggactcaata cgggtgtttg 1800
atattgatgt ttttccttga gactgtcttg tccatcaata aagatggagg atgtctctc 1860
tttgaacccc gcttccccac cagtactctc tctcccttag agtttatgag ttattcaagg 1920
aggagacttc ttaaagacag caacgcaatt cttgtaactt gtgtaaatag ccccatcttt 1980
cagagtata ccatttctac atttgataat gcctgtatcc ctgtaggatg tatatagttt 2040
aggggatttt tttttgttt ggtttgttt tttagaagtc aatatgtctg gttttattta 2100
ttgcttgaaa aagatcattt gaaaaaata aatacatttt caacaaaaa aaaaaaaaaa 2160
aaaaaaaaa aaaaaaaaaa ggcgcggggg gaaccggggg ccagagcgg gccccggggg 2220
gcgaattggg ttctccggc ccacattccc ccaaatatt ggcacacag 2269

```

&lt;210&gt; 129

&lt;211&gt; 750

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

106

&lt;400&gt; 129

```

gccgcccggg caggtaacca agtttcagtt acacaggagg catgagattg atctagtgc 60
aaaaatgatg agtataataa ataataatgc actgtatatt ttgaaattgc taaaagtaga 120
tttaaaattg atttacatac atattttaca tatttataaa gcacatgcaa tatgttgta 180
catgtataga atgtgcaacg atcgagtcag ggtatctgtg gtatccacca ctttgagcat 240
ttatcgattc tatatgtcag gaacatttca agttatctgt tctagcaagg aaatataaaa 300
tacatttata tgttgactat ggcctatcta catgttgcaa ctaaacta gattttactt 360
cctttccaac tgtgggtttg tttcatttca ccacctctt ttcattccct ttctcaccca 420
cacactatgc cgggcctcag gcatatacta ttctactgtc tgtctctgta agcgattatc 480
agtttttagct tccacatatg agagaatgca tgcaaagtgc tgtctttcca tgcctgggtc 540
tatttcactt aagcaaatg acctccgctg tccatccatg ttatttatat taccacaacta 600
gtgttcataa aactagtata tacaccacat agtataccac agaaacggac cactgcggat 660
aaacaggatt tctggtocac acttttgtcc catacgggac cgtggggcaa tctgattacg 720
cgcacagcaa gagcaacca gtaagaaaca 750

```

&lt;210&gt; 130

&lt;211&gt; 738

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 130

```

gcgtgggcgc ggccgaggta ctgtgaatta cggatgctct ttgaaggaaa gaaatatcga 60
ttctaattgtt cttcagaagt tctggcaggg ataagcagga catcgactgg aacgtatgct 120
aaatgaaagc agacaaattt ctattttctt acctgagcaa atattttatt gaaactgctt 180
atgtatgccca aaggagccca caacttcagc tacacaactt tttgtattga aagaactcat 240
actttttgtg gcttttattt cacatttaat ttaaagtgc ttttagcact aaaatgccta 300
gaagatttta ctccagacct ataaggaaat gtttagtttt tatgaaaaat gacaagtcga 360
tggttaaact tctcatgtct ttggtgcttt ggccctaata gcactggaca acaccagcag 420
cacatggaaa catatttttg gaagcaaac ttaatttta tataacgtat gctatggaga 480
gctaagacaa ttaaggact acttggtttc tttttttttt cttataaaaa tggaatccac 540
tgtgttgaag actcttgata ttcattgtgt tgtctaacca ttttttggtt tataattaga 600
ataaaatata gttgtgataa tgggtcatcg atggattttg tttggaaagc tacatcttat 660
ttgtgaaatg ttttttaaaa tcagagtaac tatcaactga ttcagctttt tgttggtttg 720
ttcttggtat aatacttg 738

```



<210> 131  
 <211> 1875  
 <212> DNA  
 <213> Homo sapien

<400> 131  
 tggcaacgat ctggaccgct acaaccgct aagctccagc gccttgtgcg caacgcgctg 60  
 gcgcacgtgg tgccaaggag cgcgagctga gctggcgcac tcggagagtt tcgccgcctg 120  
 tgccgctacg gcaagcgcga gttcaagatc ggcggcgagc tgcgcacg cgcaagcagccc 180  
 taccggctgc agattcagct gtcggcgagc cgcagccaca cgctcgagtt ccagagctcta 240  
 gaggacctga tcatgggaga agcgacgcaa cgaccagat cgggcgcgcg gcccgctgctg 300  
 caggagctcg ccacgcacct gcaccggcg gagccggagg agggcgacag caacgtggcg 360  
 cggactacgc cgctcccg gcgccccct gcgcccagct ccgaggagga ggacggagag 420  
 gcagtggcac actgatgggc gagctgagcg cagagctgcg aaggggaaact gtttgagta 480  
 gcagccgctg ctccctttct ccctctcttc ctccctcttt tgccactgtc tgggccccat 540  
 ctgggattcc tgggcccctt ggaaaagagt tggtgaaatg cgcagccggc tgtggacggg 600  
 ggaggaggaa ggggacagag ggagcaggaa taagactgta gaactgtttt gtactgtgaa 660  
 ttacggatgc tctttgaagg aaagaaatat cgattcta gttcttcaga agttctggca 720  
 gggataagca ggacatcgac tggaactgt gctaaatgaa agcagacaaa tttctatttt 780  
 cttacctgag caaatatttt gttgaaactg cttatgtatg tcaaaggagc ccacaacttc 840  
 agctacacaa ctttttgtat tgaaagaact catacttttt gtagctttta tttcacattt 900  
 aatttaaagt gacttttagc actaaaatgc ctagaagatt ttactccaga cctataagga 960  
 aatgtttagt ttttatgaaa aatgacaagt cgatgggtta acttctcatg tctttggtgc 1020  
 tttggcccta atagcactgg acaacaccac gaccacatgg aaacatattt ttggaagcaa 1080  
 aactttaatt ttatataacg tatgctatgg agagctaaga caatttaagg actacttggt 1140  
 ttctattttt tttcttaata aaatggaatc cactgtgttg aagactcttg atatcatgtg 1200  
 cttgtctaac cttttttgt tttataaatt agaataaaat atagttgtga taatggtcat 1260  
 cgaatggatt tgtttgaaa gctacatctt atttgtgaaa tgttttttaa atcagagtaa 1320  
 ctatcaactg attcagcttt ttgttgtttt gttcttggct ataatacttg tgactcatga 1380  
 agaattatgt tgacaaacag gataaattcc acatgcattt ttttcccag tgagttgtat 1440  
 aaactttatt tttgttgaa gttgtatggt aaatcaatgt tacattctta tatcacttct 1500  
 tgagaaggaa gttccgattt gaaattgtat catttccttc aaaatgaagg gcagtgtcta 1560

108

gttaaataaa agattgatga tatcttttaa gccaaaaaaa aaaaaaaaaa aaaaaaaaaa 1620  
 aaaaaaacga accaaaccaa taaaaacaag aagcacacag accgaacacc acacacacaa 1680  
 gccaccagag ctacataac gcgcgggcaa acatccacac ggccacacac agcaaccac 1740  
 tatgagagcc accccgcgga acaaaagacc ccacacacaa ccagagacaa gaaacctgcg 1800  
 , agccacgccc tccacacca caaccacgaa tagtcacctc agtaacaaaa caaacacaga 1860  
 cggaggcgcc gacaa 1875

<210> 132  
 <211> 828  
 <212> DNA  
 <213> Homo sapien

<400> 132  
 tggtcgcggc cgaggtacaa taggtctctt gaatttatct ctctgtcta attgaaattt 60  
 gtatcccttg accaacaatct tcccagtcac acccccatcc ctctggtaac catcattcta 120  
 ctctagttgt atgagttcaa tttttttaga ttccatttat aagtatttta attaatatct 180  
 ttatcctctt tccagataat tcaaggacct tagcatttta actctagtca actgtaatat 240  
 tacattocat cgtattgcag tattttagtc ttcttctatt aagccttcca aattggatat 300  
 tagcattatt gtggttggtt cacattagca ttattgtggt tgtttcagat agtcaatatt 360  
 gatgcagatt tacctgaata ttacccatga ttaccatcat tccttcttct tacttagatt 420  
 tccatcatcc ttcttcttga aatataattt ttaaaaggct cattgaagaa gttctgttga 480  
 tggtaaatac agttttactt tctttgaaaa tatctttatt ttgccacat cagttatttt 540  
 attgttcagt attaagaaaa cctaattcct ggtgtttctt cccatcattg ttgatattga 600  
 gttgtgtgcc atcaggcaaa tgtcattact ttttagatat tctaaacctg ttgtttcttt 660  
 aagtaagtac attgtctccc ccttaatctg ttctccttcg taatgtttta ttattgtct 720  
 cactattatg gattctggac aggtttcttc tgggtccttc tttcaggttg ctattctcta 780  
 ttcagggtgtg tttatctgct atttatcatc cctccagttt tttccttg 828

<210> 133  
 <211> 1023  
 <212> DNA  
 <213> Homo sapien

<400> 133  
 tggtcgcggc cgaggtacaa taggtctctt gaatttatct ctctgtcta attgaaattt 60  
 gtatcccttg accaacaatct tcccagtcac acccccatcc ctctggtaac catcattcta 120

109

```

ctctagttgt atgagttcaa tttttttaga ttccatttat aagtgattta attaatatct 180
ttatcctctt tccagataat tcaaggacct tagcatttta actctagtca actgtaatat 240
tacattccat cgtattgcag tatttttagtc ttcttctatt aagccttcca aattggatat 300
tagcattatt gtggttggtt cacattagca ttattgtggt tgtttcagat agtcaatatt 360
gatgcagatt tacctgaata ttacccatgg attaccatgc attccttctt tctacttaga 420
tttccatcat ccttcttctt gaaatataat ttttaaagg tccattgaag aagtgtctgt 480
tgatggtaaa tacagtttta ctttctgttg aaaatatctt tattttgccc acatcagtta 540
ttttattggt cagtgattaa gaaaacctaa ttctgtggtt ttcttcccat cattgttgat 600
attgagttgt gtgccatcag gcaaagtca ttacttttta gatattctaa actgttggtt 660
gctttaagta agtacattgt gctcccctta atctgttctc ttcgtaatgt tttatttatt 720
tgtctcacta taatgaattc tggacaggtt tctcttggtc tttctttgca gtttgtaaat 780
tctctattca gctgtatcta atctgtctatt taattcatcc atcaagtatt ttttccctag 840
tattttgttt taataatttt atttactatt tctagatttt tttctaataca tcttggtctt 900
tgtcatagta tcttcttctt tatatacatt ttatttatgt atctgataac attaataact 960
taaacccttg taagttataa gtatgttttt agttttggtg ctgatttggt tcaaataaac 1020
ata 1023

```

```

<210> 134
<211> 757
<212> DNA
<213> Homo sapien

```

```

<400> 134
gagcgccgcc cgggcaggta ccttcgtgcc cctcagtagt tgttttagcc taatgtagag 60
tcaatctagg acttataatt attcatcatg attttgagta gattgtaatc atcaagaatt 120
tttcatagat cgtttacttc caattgaatt tagctcagaa gtgattgctt tctctttatt 180
tgagatagga gctctcgac tgctgccagg ctaggagtg aagcggcat gatcgctggc 240
tactagcaa cctctgcctc cggggttgaa gcagatatac ccctgacctc aagcctctg 300
cagtagctag ggactacagg tagttcatcg cttgtcctta gcttgaaac taggatgcac 360
aaacacatgg gttattatac tcgtacacgg agctggtcac acaacggaac tagactctct 420
ctccaaatgt gataccacac agacaacact cagaactacc ttcgagcctt acttaagatc 480
atcccttcac tgatctaaca aacttacaaa cattaatata accagatact gcgtctcgac 540
tattgcacgg caaatcaaaa tacaacaggt tctccactaa agaccagggt gtgacatgct 600

```

110

ctagagatca acagaacaat ctaatcctga cctcaccgcc aactatgatg acacgatggc 660  
 cgctggccca cacaggaagg ccgacacggg ccgcgctcaa agaccacca tgtccggacc 720  
 tagcctaaaa aaaactcacg ccccgccgcc cctacct 757

<210> 135  
 <211> 1513  
 <212> DNA  
 <213> Homo sapien

<400> 135  
 gcgggagcct gggcggcgag ccgggtgtga gctgcctgaa aatgcactcg gatgccgccg 60  
 ctgtcaattht tcagctgaac tctcatctct caaactggc aaatattcat aagatctacc 120  
 acaccttaa taagctgaac ctaacagaag acattggcca agacgatcac caaacaggaa 180  
 gtctgcggtc ttgcagttct tcagactgct ttaataaagt gatgccacca aggaaaaaga 240  
 gaagacctgc ctctggagat gatttatctg ccaagaaaag tagacatgat agcatgtata 300  
 gaaaatatga ttcgactaga ataaagactg aagaagaagc cttttcaagt aaaagggtgct 360  
 tggaaatggt ctatgaatat gcaggaaactg atgatgttgt aggccctgaa ggcattggaga 420  
 aattttgtga agacattggt gttgaaccag aaaacgtgag tcaaacttac tgagttgggt 480  
 gaatcagttg gttgtttttc atacttaaat ctttgttctt tagcaaataa atagaataat 540  
 taaaaagtag tggatatgta gtttttatga agcagtctaa gaaataagtt ctaattctag 600  
 tttgacttat aagcagattc tccattcttg taagtatat ggtgtaacta cagttatttt 660  
 ttctctcatt taatttcttg tatgtaaaag gtacagtaag ccagatgctt acaaaatggg 720  
 gtggccacat gtgcctacaa tgacggatca actggaggcc acattgtacg ctgtgtacct 780  
 tcgtgcccct cagtagttgt tttagcctaa tgtagagtca atctaggact tataattatt 840  
 catcatgatt ttgagtagat tgtaatcatc aagaattttt catagatcgt ttacttccaa 900  
 ttgaatttag ctcagaagtg attgcttttt tttttttgag ataggagctc tcgcaactgtc 960  
 gccaggctag gagtgaagc ggtcatgac gtccgctcac tagcaacctc tgcctcccg 1020  
 gttgaagcag atatacccct gacctcaagc ctctgcagc agctaggagc tacaggtagt 1080  
 tcatcgcttg tccttagctt ggaaactagg atgcacaaac acatgggtta ttatactcgt 1140  
 acacggagct ggtcacacaa cggaactaga ctctctctcc aaatgtgata ccacacagac 1200  
 aacactcaga actaccttcg agccttactt aagatcatcc cttcactgat ctaacaaact 1260  
 tacaacatt aatacaacca gatactgcgt ctgcactatt gcacggcaaa tcaaaaataca 1320  
 acaggttctc cactaaagac caggtggtga catgtcctag agatcaacag aacaatctaa 1380

111

tcctgaccct cagccaact atgatgacac gatggccgct ggccacaca ggaaggccga 1440  
 caggggccgc gctcaaagac caccatgtc cggacctagc ctaaaaaaa ctcacgcccc 1500  
 gccgccccta cct 1513

<210> 136  
 <211> 738  
 <212> DNA  
 <213> Homo sapien

<400> 136  
 gcgtggtcgc ggcgaggtag caacccacgc acaccccaac agcctttcct cggccccctc 60  
 ctcaggcctc ctaattactc tttctcagcc tggagtgtgg ggccgttacc gtcctcttcc 120  
 cccttctcct tccatactgc acttaacctt gctggaagat ttaatgatgg agatttaggg 180  
 caactgtggc tgcttgggac ccttccttgg gaccaaagga acttaaaacc caatacctga 240  
 cactggaatg aaatccaagt ttttaaatac cacctttcaa tctctcacag atctcacatc 300  
 tatcttaaaa tactcagcct cactccttaa ctgagtgtct gcctgagagg gagaaaagtt 360  
 ccatttttaa aacgtattca ctttactgat tactgtgcaa ttgaattaa gtcacgattc 420  
 tttagtcatt gaggtcgaga atctcagatt caaattgtca gagaccatga tttagaagtc 480  
 taccaaacac ccagtttcct tccactgttt tagggtaaca ggaaaacatg agattggggg 540  
 ggtgtccgct attaaatgga accacacatc atgaaattca attctcatgt taagacattc 600  
 tgtattgtgg gatgtcaaaa gtatctcca aaactttcgt ttgacctgtc agagtgggga 660  
 tggttactcc ctatacttca gtttgtttca caagcttggc gtaaccaggc atagtgttcc 720  
 gtgtgaatgt tcgtccac 738

<210> 137  
 <211> 1350  
 <212> DNA  
 <213> Homo sapien

<400> 137  
 atggttatgg agaagcccag tccgctgctt gtagggcggg agtttgtgag gcaatattat 60  
 actttgctga ataaagctcc ggaatattta cacagggttt atggcaggaa ttcttcttat 120  
 gttcatgggtg gagtagatgc tagtggaag cccagggaag ctgtttatgg ccaaaatgat 180  
 atacaccaca aagtattatc tctgaacttc agtgaatgtc atactaaaat tcgtcatgtg 240  
 gatgctcatg caaccttgag tgatggagta gttgtccagg tcatgggttt gctgtctaac 300  
 agtggacaac cagaaagaaa gtttatgcaa acctttgttc tggctcctga aggatctgtt 360  
 ccaaataaat tttatgttca caatgatatg tttcgttatg aagatgaagt gtttgggtgat 420

112

```

tctgagcctg aacttgatga agaatcagaa gatgaagtag aagaggaaca agaagaaaga 480
caaccatctc ctgaacctgt gcaagaaaat gctaacagtg gttactatga agctcacctc 540
gtgactaatg gcatagagga gcctttggaa gaatcctctc atgaacctga acctgagcca 600
gaatctgaaa caaagactga agagctgaaa ccacaagtgg aggagaagaa cttagaagaa 660
ctagaggaga aatctactac tcctcctccg gcagaacctg tttctctgcc acaagaacca 720
ccaaagccaa gagtgaagc taaaccagaa gttcaatctc agccacctcg tgtgcgtgaa 780
caacgacctg gagaacgacc tggttttcct cctagaggac caagaccagg cagaggagat 840
atggaacaga atgactctga caaccgtaga ataattcgct atccagatag tcatcaactt 900
tttgttggtg acttgccaca tgatattgat gaaaatgagc taaaggaatt ctcatgagt 960
tttgaaaacg ttgtggaact tcgcatcaat accaaggggtg ttgggggaaa gcttccaaat 1020
tttggttttg tggtttttga tgactctgaa ccagttcaga gaatcttaat tgcaaaaccg 1080
attatgtttc gaggggaagt acgtttaaat gtggaagaga aaaaaacaag agctgcaaga 1140
gagcgagaaa ccagaggtgg tggatgatgat cgcagggata ttaggcgcaa tgatcgaggt 1200
cccgtggtc cacgtggaat tgtgggtggt ggaatgatgc gtgatcgtga tggaagagga 1260
cctcctccaa ggggtggcat ggcacagaaa cttggctctg gaagaggaac cgggcaaatg 1320
gagggccgct tcacaggaca gcgtcgctga 1350

```

```

<210> 138
<211> 569
<212> DNA
<213> Homo sapien

```

```

<220>
<221> misc_feature
<222> (509)..(509)
<223> a, c, g or t

```

```

<400> 138
cgccccgggca ggtcgcccat gtgctgtgat gtcagtgagc gggcggagtt caggctggtc 60
agtgccaggt gtccttctc ccacccgaga acagtggcca ggttgctcct caggcacctc 120
gggcaactgc cccttcctt ccagtggggc ctgacctggc taccgagctt ggcagctaat 180
aggcggggcc ctcagcattc acgctcctga gctgctttat caaactagga ttgttcccc 240
aggtctaaga aaaccatcca ttactgcaa agttagtatt tactgcggat gggctaggag 300
ttagaggaag agagtgactc aaatcacaac acctcctgga cgaagctgga agcggattaa 360
aataccgggc ctaatttcag aacaacaaaa aaaaaagaaa aaaaaaaaaa agcgcgggcc 420

```

113

ggaacccagg ggccaaaagg gtgggtcccg gggggggaaa tctggttacc gcggcccaaa 480  
 attccccaaa aaatttgagg gggccaaang caccgcgctc tctgcccccc ccacgcccgc 540  
 cccccccccc acaacccatc gccgccccg 569

<210> 139  
 <211> 739  
 <212> DNA  
 <213> Homo sapien

<400> 139  
 tatatcacta taggggactg ggtcctctag atgctgctcg agcggccgca gtgtgatgga 60  
 tccgggcagg tactgcctgg ttttacaaga attaatgcag tttcacagtg aagcatgtaa 120  
 gatattgaat tttagagaca atagaccaga tacctttcta atotcatttt attcattaat 180  
 gtcaaataat accattttta aaaatatggt gcttatttgt ctagcaagta acctatagaa 240  
 aagtattatt ttatacaaaa agatgattag gtcacataaa ggaattggaa tcttaagttt 300  
 aaaatacact tctgttttta gccagaaggg agaaacgatg gttggattta tgccattttt 360  
 caattaaaaa ccatgtggta ctacttgaag cagtttctga gtaaattggag gtgttttaag 420  
 atttgtatta ttctctccca atgactagat agtagtattt tacaatggag acttaaaagt 480  
 tttttgtgtt ttattctttc gcttttctat gccctcaatc caaagaacac cagaaatata 540  
 cttgtagtgc gaaaacttgg gtttatcact cgcacaaagg aatgacacac accatggggc 600  
 actctggagc ctctcaataa aaggatgttt caaaggaaca acaacaaaaa aaaaaaaaaa 660  
 aaaacgttgg gggaaacaca gggcacaaag tgtcccgggg gaaattgttt tccgccacaa 720  
 tccaaaattc acaaaaacc 739

<210> 140  
 <211> 1131  
 <212> DNA  
 <213> Homo sapien

<400> 140  
 aagttgatag tatatccacc acctccagct aaggagggca tctctgttac caatgaggac 60  
 ctgcactgtc taaatgaagg agaattttta aatgatgtta ttatagactt ttatttgaaa 120  
 tacttggtgc ttgaaaaact gaagaaggaa gacgctgacc gaattcatat attcagttct 180  
 tttttctata aacgccttaa tcagagagag aggagaaatc atgaaacaac taatctgtca 240  
 atacagcaaa aacggcatgg gagagtaaaa acatggaccc ggcacgtaga tatttttgag 300  
 aaggatttta tttttgtacc ccttaatgaa gcgtgagtaa gaatttcctt taaaggaaaa 360

114

tcttttaaadc atgtaaatga tgacaatttt taaataatga gtatgagggtg aagaattcat 420  
 ttttaaacat ctttctgaaa tctcttgtgt atattcatat ttgtactgcc tgttttacaa 480  
 gaattaatgc agtttcacag tgaagcatgt aagatattga attttagaga caatagacca 540  
 gatacctttc taatctcatt ttattcatta atgtcaaata ataccatttt taaaaaatg 600  
 gtgcttattt gtctagcaag taacctatag aaaagtatta ttttatacaa aaagatgatt 660  
 aggtcacata aaggaattgg aatcttaagt ttaaaataca cttctgtttt tagccagaag 720  
 ggagaaacga tgggtggatt tatgccattt ttcaattaaa aaccatgtgg tactacttga 780  
 agcagtttct gagtaaatgg aggtgtttta agatttgtat tattctctcc caatgactag 840  
 atagtagtat tttacaatgg agacttaaaa gttttttgtg ttttattctt tcgcttttct 900  
 atgccctcaa tccaaagaac accagaaata cacttgtagt cggaaaactt gggtttatca 960  
 cttgcatcaa ggaatgacac acaccatggg ccactctgga gcctctcaat aaaaggatgt 1020  
 ttcaaaggaa caacaacaaa aaaaaaaaaa aaaaaacgtt gggggaaaca cagggcacia 1080  
 agtgtcccgg gggaaattgt tttccgccac aatccaaaat tcacaaaaac c 1131

<210> 141  
 <211> 887  
 <212> DNA  
 <213> Homo sapien

<400> 141  
 gcgtggccgc ggccgaggta cactgaatta ttcacagtaa tcgcttggtt ggggaaaggg 60  
 ttagtaaatg ccaaaggaaa taccacaga aatctctac acagcttaga tgttgtgctg 120  
 gcatttaagg cccatgagtg atggccatt ctgcagcttt tcatgccatg cctttccttt 180  
 gtgtgggggt ccacagatca gagtctgtct gtggcatcga cttccttatg tcctcattgt 240  
 tcccacccat tgctgggatg tccacgttgg acttctcaaa agtggcccaa gaatctaagt 300  
 gcaaaatctg tttggatttt tacaattttt tctaatctt ttacagtctt ggtcattcct 360  
 atttcaactg caattttttt caatgacttg cctggtgtga atattttttt aaagcatcca 420  
 gtattaaaca aaaaaattta aacagctaaa aaaaaaaac aaaaaacaaa cggctgggag 480  
 aaaccagggc tcaataccgg ctcccgtgg tgctgaacac tggatatactc cgcgggtcac 540  
 caattcccaa ccacaacata cgggcgagac aaggctgcac gcaaccggc acgcgcagtgt 600  
 cgaggacac gtcacggagc caagaacggg cagcaggacc acagagaacc agacgcaggc 660  
 cgcgcacgtg gagcggagggt gtagaacga cagccgccgc gccgtgggca gcggccatgg 720  
 cgcacacggg ccgacacgga agcggagccg cagcgacagc gagcagcacg cggggcgagc 780



115

gcgcggcgag gaggggagcg gcgcggggaa cggacgctgc agagaggcgg agggcggcga 840  
 gccgcggcgc ggccgagccg aaggcgaccg caagcggcgg cggcggc 887

<210> 142  
 <211> 2086  
 <212> DNA  
 <213> Homo sapien

<400> 142  
 cgagccaaga attcggcacg aaaaacaaat acttcctgat cgatcccttg tcttgtttag 60  
 tatgtctcct gaccattttt taccctaaca tttgtgttct tttcccgaga agggaaatca 120  
 acttctatcc tatctctacc cagcagagggc cctgcccga ctttacacac aaaaccatct 180  
 aactttttga tattctaaat gggggaaacc cctattttat aaccctcggg tacttttaat 240  
 ctttagatga ggaactagag gagccactat gtctctctca gcaccatgat ttatgcctta 300  
 gctaaggcct tcacttgggg aagggaaga aggttggttt caagcctgtg gcctcctgtc 360  
 actccccacc cctggaaggc ccttcacttt tgggtgatgc ctagaggcct catggacagc 420  
 agtcccttct gacaccagc gagatatcat ctgggagggt cgcagccctc agttccctc 480  
 atggctctct ctttcacttc cctccatgac accacctcat cgagttgaag atgttattga 540  
 tgagtgcagt ggggtgtatag tgtcctccca aaattcatgt caccacagaa attcagaatg 600  
 caaccttatc tggaaataga atctttgcaa atgtgattag ttaagatgaa atcatactga 660  
 gttaggatga acctgaaatc caatcactgg tgtccttgta agaggaaagg tcacaaagag 720  
 acagaggaga tacacagagg agcccatgta atgatgggta cggagactga cgtggcaca 780  
 ctataagcca aggaatgcca ggaaggcca gctagcagaa gctagggaaa aacacagagg 840  
 gattctcccc tggagccttt ggaggagggt tggccctgct gacaccttgg ttctggactt 900  
 ctggcccca gaactgtgag aaaataaatt tctgtggttt aagccacaca gtttgtggtg 960  
 ctctgacttc gtgagctttt ctgccatct gacagcgctt gcctgccttc ctccctgccc 1020  
 accgtcctcc cgcccgtcc cagaccctcc tcgtcctca tccactcca ctctgtgag 1080  
 tgtcctcca caccatggct gcaatccca ccttaagctg gggactcca aaccgcgact 1140  
 tccccacagg gctcaggagg cttttctcca gccagcctca catttgact catgttctc 1200  
 ccccatgcca cctcagcta cgctgaatta ttcacagtaa tcgcttggtt ggggaaaagg 1260  
 ttagtaaatg ccaaaggaaa taccacaga aatctctac acagcttaga tgttggtgctg 1320  
 gcatttaagg cccatgagt atggtccatt ctgcagcttt tcatgccatg ctttctctt 1380  
 gtgtgggggt ccacagatca gagtctgtct gtggcatcga cttccttatg tctcattgt 1440

116

```

tcccacccat tgctgggatg tccacgttgg actttctcaaa agtggccaag aatctaagtg 1500
caaaatctgt ttggattttt acaatttttt cctaattcttt tacagtcttg gtcatttcta 1560
tttcaactgc aatttttttc aatgacttgc ctggtgtgaa tattttttta aagcatccag 1620
tattaaacaa aaaaatttaa acagctaaaa aaaaaaaca aaaaacaaac ggctgggcga 1680
aaccagggct caataccggc tcccgtggg gctgaacact ggtatactcc gcggttcacc 1740
aattccaac cacaacatac gggcgagaca aggtgcacg caaccggca cgcgcatgtc 1800
gcaggacacg tcacggagcc aagaacgggc agcaggacca cagagaacca gacgcaggcc 1860
gcgcacgtgg agcggagggg tagaaccgac agccgccgcg ccgtgggcag cggccatggc 1920
gcacacgggc cgacacggaa gcggagccgc agcgacagcg agcagcacgc ggggcgacgg 1980
cgcggcgagg aggggagcgg cgcggggaac ggacgctgca gagaggcgga gggcggcgag 2040
ccgcggcgcg gccgagccga aggcgaccgc aagcggcggc ggcggc 2086

```

```

<210> 143
<211> 676
<212> DNA
<213> Homo sapien

```

```

<400> 143
gccgccgggc aggtactaaa taaaatgcaa aacatgtcac atcactcttc ttcattgggtt 60
catgtcctct gtgggtcagg tcttcacat gtagagtaga ggtagggat gttcacacct 120
tcaatgacaa cctacacatt tctgctcaa caggtccaaa attgttccta ggtttcaaag 180
ttgtgttttg tttgtttttt tcctttttct tttttttttt ttttttttga gaagtggagt 240
ttggctctgg ttggccccgg tgtggagtgt gcaaggggcg gtgatctgcg gttcaccaac 300
aaacctcgtg gtctccgcg gtttacaagg gcgattatc cgtggcctac aggcctcgcg 360
agtatagccg tgggatataa tagggcagtg gcgcacacca gtgcccagac ttaatttgtg 420
ggtattttta ggtagaagaa gcgggggtct cccccctt tgtgtgggtc tcgaggcgct 480
ggactctggg aggcctcgcg tggaaacctc gaggggtgat ctcacacctg tgcgcttggg 540
ggccttccca caaaagggtg gcctgggggg atttaccagg gcgtggcaga agcccaaact 600
atgtgggccc gggcgcacac aggggggttt cccaaaaggg tttttttaac cgggtattaaa 660
aagagggttt cgctag 676

```

```

<210> 144
<211> 1260
<212> DNA
<213> Homo sapien

```

117

&lt;400&gt; 144

taaacataca cacatcaaaa ataactcagc cacatgcaac aatacagaga atcttaaaga	60
catagtatga gcaaaataat cagtacacac aaaattccac ttatacaaag ctcaaaaaca	120
aaattaagca atatttttta gaaatgact tataaatgat gactgaccca ctatcaagga	180
aagtatttaa cattgctctg aaagttctgg aaattcttga ttttcctttc tcaatttcta	240
cacccatcac cagcccgagt cttccccaac tcactaaaca gcaccgcat ccatttagca	300
tttcaagcca gtgagaagtc atccttaatt ctgctttttc attaatttcc ctacttctaa	360
tctattacgt gtcttattag atctaagatc aatatatttc ctgaatatgt ctatttatgt	420
ccatttccaa cactaccact gaagtctaag ccattgtcac ctttctttct ggattactgc	480
aatagcctca cagcttccac tcttgaccac atacactcca ttctgcactc agccctcata	540
gtgatcatta taaaggataa aatgggtgtg ccagttagct cagttgggta gatcatggta	600
ctaataaaat gcaaaacatg tcacatcact cttcttcatg gggtcatgtc ctctgtgggt	660
caggctcttc acatgtagag tagaggtagg gtatgttcac acctcaatg acaactacac	720
atttctgctc caacaggctc aaaattgttc ctaggtttca aagttgttgt ttgtttgttt	780
ttttcctttt tctttttttt tttttttttt ggagaagtgg agttttggct ctgggtggcc	840
caggcggtga gtgtgcaagt ggcgggtgat tgcgggtcac caacaaacct cgtgggtcctc	900
cgcggtttac aaggcgatt attccgtggc ctacaggcct cgcgagtata gccgtgggat	960
ataatagggc agtggcgcac accagtgcc gagcttaatt tgtgggtatt ttaaggtaga	1020
agaagcgggg ttctctcccc cctttgtgtg ggtctcgagg gcgtggactc tgggaggcct	1080
cgcgtggaac cctcgagggg tgatctcaca cctgtgcgct tgggggcctt cccacaaaag	1140
gtgggcctgg ggggatttac caggcggtgg cagaagccca aactatgtgg gccggggcgc	1200
acacaggggg gtttcccaaa agggttttt taaccggtat taaaaagagg gtttcgctag	1260

&lt;210&gt; 145

&lt;211&gt; 433

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 145

cggccgccgg gcaggtactg gtggttggtt tcattagtgg atcacacaca gggttgtact	60
tggcttgtaa aatgggtgcct cggatagggt gagtttgat aagtatgat gtatgtatga	120
gttatagcaa aattaagtag attgaatcaa gtccatgcaa aagcagtaaa acagttatta	180
attgttaatt ttttaaaaat taaaacgtta ataaaacagt ttgtaatgtt ttgctagtgt	240
cttttataaa atgatgtaag ttacagtgga agtcttcaca ggacttgtgt ctttcttgga	300

118

actattgaaa tgtaatttag gatgatttga tcttccatct caagttgtca acatggctgt 360  
 gtcattctgg cttacatatg ttttatttaa caaaattcta gtcaagggat aaggccttaa 420  
 tgaagacaag ctt 433

<210> 146  
 <211> 1791  
 <212> DNA  
 <213> Homo sapien

<400> 146  
 ggaatgaaca aacaaacaaa aatccttgct ctctgggtgc ttacatttta gttgggagag 60  
 ggacaaacaa gataaggga atacatacct tagttaagaa caagtgccac agaggaaaag 120  
 ccaggctgag gcagtgggtg tgaacatttt atacagggat gtccagaatc agggcctttga 180  
 agaaagccct gaaggcagcg tgtaccgagc aggaatgccc tgtggaggct gagcatttag 240  
 gaagtgggaa cagccggtgc ggaggtcctg gagggtgagg ggtgtcaaga aggccagcat 300  
 ggctggagca gaaagcaggg cggggagggtg ggggaccagc tcacagggtgc ctagagccag 360  
 aatgagaagg gcttcttggc tggattacag gcgtgagcca ctggaacctg gccttgTTTT 420  
 gctttatttt ttctcttaca tgaagtaaag cgcttgggtc aaacacacaa aaatactgcc 480  
 ttgtactggt ggttggttct attagtggat cacacacagt gttctacttg gcttgtaaaa 540  
 tgggtgccttg gatagggtga gtttgataa gtatgtatgt atgtatgagt tatagcaaaa 600  
 ttaagtagat tgaatcaagt ccatgcaaaa gcaataaaac agttttaatt ttttaatttt 660  
 taaaaatta aaactttaat aaaacagttt ttaatttttt gctaggttct tttaaaaaat 720  
 gatgtaactt acatggaagt cttcacagga cttttttctt tcctggaact attgaaatgt 780  
 aatttaggat gatttgatct tccatctcaa gttgtcaaca tggctgtgtc attctggctt 840  
 acatatgttt tatttaacaa aattctagtc aagggataag ggcataatga agacaagctt 900  
 cagttatgaa agtacaaact atttgtgtga ttaattttta aaaatgacat taagaagccc 960  
 attgtaaaat aatatttgca gtcaaatggt ttttcttgct gtaagtcttg ttgtagctat 1020  
 gtttagggta gtggttctca tctaccttg agtgcataag acttacctag caggcttggt 1080  
 taaaaagttc agattcctag ctttgtacct agggattgcc tcagggtgga tgggctgtgg 1140  
 tcctggagtc atcactttta taaatagtgg ttcagagacc acagagagag actgcttcat 1200  
 cgaatgggaa gtaccaagga gaaagtacaa ttcagtattg tctggaggca agtggacact 1260  
 ttgtacctga ggtttagaat aggtggtctc ttgccagtac aatccccagg cgttttctgt 1320  
 gtccagaagt agtaagaatg cctttaattc agaggattat ctaagctctt taaagctggt 1380

119

```

tttctccatt tgtcatagtg ccttctctga aaaatgaatg tacaggtatc ctattttcta 1440
atgtaattag gatTTTTTaa aagcaatttt gatagttttt cttttaaaaa gtaaaattca 1500
gcactgtgac ttgaaccccc aaatctttca catacaggtg aaacattaag ccacaaataa 1560
atatgacaga aagaagaaaa gatactattc ctgtcattag ggactagtag ccattaactt 1620
gaaccgactc ggcaagggtg caacatttct tggcacatcg tgcacacact atgttttgac 1680
acgaggactt cccacttata aacaccggac cggggaatat ttcacatcgt ttaagtaatg 1740
caccccgggc aaaaaggaga aaccctcatt caaaaaatct atcgccgtct a 1791

```

```

<210> 147
<211> 349
<212> DNA
<213> Homo sapien

```

```

<400> 147
ggaatgatcg atactatagg ggcattggtc atctaataca tgctcgagcg cgcgccagtt 60
gtgatggatg cgtggtcgcg gccgagggtc acgtttagct gagtataatt ttaaatagcc 120
ctatgtgaca agtggctact ttattggaca gtgtagatct aagattaatt cctcaactgt 180
tttgactca acaaagacat acctctgagt tggcaaccag cagggtggat aacgggccag 240
tggtgataaa atcaaagaat aggtaatgaa acaatcatcc agttaacaat cagcaagggt 300
cttcagagcc taattaatgt ttaattctaa ataaattgca acaattaag 349

```

```

<210> 148
<211> 848
<212> DNA
<213> Homo sapien

```

```

<400> 148
agctgggatt acagacgccc accaccacac ccagctaatt ttgtatttt tagtagagat 60
ggggtttcac catgttggtc gggctggtct tgaactccta acctcgtgat cctcctgcct 120
cagcctccca aagtgcaggg attacaggtg tgagccaactg cgcgcgacat cccatttaac 180
tttctgtctc tgtgactctg atgactctag gaacctcata taagtgaat aatataggat 240
ttattctttt ttaaaaaatt tattttgaga tggagtctca ctctgtcact caggctggag 300
tgcatgact cgatctcggc tcaactgcaac ctccgccttc ctggcttaag caatttttgt 360
gcctcagcct cccaagtatc tgagattaca ggcgtgtgcc accacacca gctatttttt 420
attttttatt tttagtagaa gatgggggtt cgccatgttg gccggactgg tctggaactc 480
ctggcctcaa gtggtcctcc cacctcggtc tctcaaagtg ctgggattac aggcgtgagc 540

```

120

caccacgttt agctgagtat aatttttaa atgcccctatgt gacaagtggc tacttttattg 600  
gacagtgtag atctaagatt aattcctcaa ctgttttgca ctcaacaaag acatacctct 660  
gagttggcaa ccagcagggg ggataacggg ccagtgggtga taaaatcaaa gaataggtaa 720  
tgaaacaatc atccagttaa caatcagcaa ggttcttcag agcctaatta atgtttaatt 780  
ctaaataaat tgcaacaatt aagaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 840  
actcggtc 848

<210> 149  
<211> 414  
<212> DNA  
<213> Homo sapien

<400> 149  
cagtggtacg cgcgacgcag gtaccacagc tcccagtgcc cattacctct atcatggatg 60  
ctgggtgact ttgggaagtc accacctctt cccaagcctg tttcccatat cacagatgtg 120  
gggccatggc ctgatgatg gtctccacag gtctttccac ctctgtgagt ccaagtcagg 180  
tcaatcagca aggacccaat ctctgaccct gggtcagctc ctccagaacca acccccagca 240  
tctctaaagc aaaagcctca cctcaagggc tgctcagaag agagcacctt cagcatgagt 300  
tgttgctgga aggatcta atagctgtgtt tcttgggaag tgggtgcttta cttagccctg 360  
tggaacaact ctctatgcat ctgtgtgagc agatgatcat tgtattacct tta 414

<210> 150  
<211> 2088  
<212> DNA  
<213> Homo sapien

<400> 150  
ggcggcagtg atacatgttg gcaggctggc cttgatcctg actcaagtga tccgcgcct 60  
caacctocca aggtgctggg attacaggtg tgagccacca cacttgtgca gtatatcctc 120  
agtatgaaga tatttttata ttctgtgtt ctctggcttc agagtttcac ctgcccacac 180  
agggctcgtt gctggcaact ggacttcccc ataagccttg ggtatcctgt gatgggctgt 240  
gtctccctga agattgtctg gcttgccac ttctccgtgc atgactctgg gtgtgagtct 300  
gtctaggaac aggagggaaa gttggactca gacagaaatc agatgcttcc atgtattcag 360  
ggcgcgcatt gtgagcagtg gagtatgagc cttgagggcc tcatgggtgc agggcaggct 420  
tcctgcaga tgggtggcag cccctggtag aatgtggat ttctctggaa tctagaagtg 480  
ccatatttta gtggaaaggc atcagggtg tttgacagtg tgcgtcttcc caatcccatg 540  
ttcctccatt cgtgtgtctg ttataaaact gagtgaaggc tgctatgacc tgtgttact 600

121

```

ctggttacag ggaggtgcaa accattctgt ctcccagcct ttcttctctc tttgtgtgct 660
cccagcactt ccttcttttc taacatggcc tggagagagt ctctctctcc ttgtctctgt 720
ctcttaataa tagtttttaa cgtggacatc tcttccttgg tacagtgggt tttaaatcct 780
gagaagaacc aagtcagggt ttttaaagca gactaaaagc atgaaattgc tttcagaaga 840
atgtatatca tcgggaaaag tttgggggca gagtggggga atcaggcttt attcaaaaga 900
aacagttgaa aacatggact ttttctaccc aatgccatt tcacgactcc tctgagacta 960
attgggaaac ggggaaattc ttggaatttt ttttttaaga aacttttttg tgtttttttt 1020
aatttttagt cacttattag tgaaacctca ttttagatct gacattggtg gatagatgga 1080
tttaggcaaa tatgatgcgt ttgtggggaa tccacgtggt tgacgttaga acctcccttc 1140
tgcagactgt tgctgtcat ctaagcgaat tggaaatgct gagcttccat aagtcagctg 1200
agttttaaag gtaaactgta tggctgaagt agtaaagcac ctgaccacaa aacctcttgt 1260
aaaaacagcc ctgagtaggt atttccaggg ctccacaaag ttgcttatgg gaatcctgag 1320
ctgcttttca ccatctcaag aagcctaaga agttatatat ttaatcaggt agacaaaaca 1380
gttcaaagca taagggtccat ggtggtggaa aatggatgca agtgattcta agtttgtgga 1440
tttgtggata gcagagggat cgggacctct tggaggaacc ctgggtacca agctcccagg 1500
cccttctctc atcatggatg ctgggtgact ttgggaagtc accacctctt cccaagcctg 1560
tttcccatat cacagatgtg gggccatggc ctcgatgatg gtctccacag gtctttccac 1620
ctctgtgagt ccaagtcagg tcaatcagca aggaccatc tctgccctgg gtcagctcct 1680
cagaaccaac cccagcatc tctaaagcaa aagcctcacc tcaagggctg ctcagaagag 1740
agcaccttca gcatgagttg ttgctggaag atctaataag ctgtgtttcc tgggaagtgg 1800
tgctttactt agcctgtgg acaacttctc tatgcatctg tgtgagcaga tgatcattgt 1860
attacctttt atcggtagta agcttggaag aataatttaa gaatacaatg gagaaatgta 1920
aataagtatc tatgtaaatt tgtttaaaat aaactgaatg tatttaaatg tccatttata 1980
tgttctttta tgtaacatgt agtttaataa agttcctgtt tatgagagtc atgtttcatc 2040
tcagcttctt ccaaaaaaaaa aaaaaaaaaa agatctttta ttaagcgg 2088

```

```

<210> 151
<211> 509
<212> DNA
<213> Homo sapien

```

```

<400> 151
cggactcccc ccgcggaacgc gctggcttcg cgtatcgggt tacttccttt ataaaaattt 60

```

122

ttataacttta tgtggaaatg ggatctcact atgttgctca gacttgctct gaactcctgt 120  
 tatagcacca cctcttacia gtgttgggca gctccgcttc tctcacttgt ctggaattct 180  
 aaggcacttc cctgaagtgc tcatcctgag ctaatatggg atagggtgg agagagaaca 240  
 gaggtggata gcatgccaga atgaggtggg aagggtggga tcagcagcct ttgggaagga 300  
 aagaagtatg agtcccaggg tattaacaag gtggaggggc aataaaattt attacatatt 360  
 gggattcata ctaaatgagt agatttttagc ttctcttgcc acaataaaca aaaaaaatgc 420  
 cacaacacca cacaacaaaa aaagggtgcg ggaaccaggg ccaaacgtcc ccgggtgaat 480  
 gtttcccgcc atcaaattaa aacacacag 509

<210> 152  
 <211> 560  
 <212> DNA  
 <213> Homo sapien

<400> 152  
 ccagcctggg taacagatgt gagaccctgt ctgttaagag aatcagaaaa gagagagaaa 60  
 gctagactta gctccaagtc tggagctttt ggggttttct tcctttataa aaatttttta 120  
 acttatgtgg aaatggggtc tcaactatgtt gctcagactt gtcttgaact cctgggttagc 180  
 accacctctt acaagtgttg ggcagctccg cttctctcac ttgtctggaa ttctaaggca 240  
 cttccctgaa gtgctcatcc tgagctaata tgggataggg ctggagagag aacagaggtg 300  
 gatagctgcc agaatgaggt gggaaggtgg ggatcagcag cctttgggaa ggaaagaagt 360  
 atgagtccca gggattataa aggtggaggg gcaataaaat ttattacata tgggattcat 420  
 actaaatgag tagatttttag cttctcttgc cacaataaac aaaaaaatg ccacaacacc 480  
 acacacaaaa aaaagggtgcg gggaaccagg gccaaacgtc ccgggtgaa tgtttccgc 540  
 catcaaatta aaacacacag 560

<210> 153  
 <211> 577  
 <212> DNA  
 <213> Homo sapien

<400> 153  
 tgatgatata tggggcatgg tcctctagat gctgctcgag cggcgcagtg tgatggatgc 60  
 gtggtcgcgg cgaggtacca cctgttcatt ggggaactgt gggaaacgga gccaacggac 120  
 ctaagtgcct tttgacagtg agtttcatac catttcagta gtgtatttct ttcttaattct 180  
 gaataaacca gtatgatact ctcagacaca gaagaataaa gggagcagat cattaacgtt 240



123

ttcttttttaa acctttatga tgacttcctt atgaattact gaacgaacac tggaatggga 300  
 ctgaggatc ctgaggacat ctctcaactc tggccttagt tccccctctg taaaattagg 360  
 gtgccaacta aatgatctac aaggtcctt ccagcgccgc cattctgtaa ttacatcatg 420  
 tgtaactgta ttaaacatac acaagtgact gccaggcatg ggaatgtaac ttccgagtaa 480  
 atgctttggg ttgttcagaa tacactatga acttctttcc aaagacgggt tgtggtaaat 540  
 agtggatatt ttgattataa gaaatagagt ttccttg 577

<210> 154  
 <211> 1138  
 <212> DNA  
 <213> Homo sapien

<400> 154  
 aagaaattcg gcacgaggaa agtgctggga ttacaagcat gagcccagcg cctggctgta 60  
 tctttcattt tacccaagtc actttacca agtaagtaat taggggaaag cctgagtctt 120  
 gtaccacctg ttcatattggg gaactgtggg aaacggagcc aacggaccta agtgcccttt 180  
 gacagtgagt ttcataccat ttcagtagtg tatttctttc ttaatctgaa taaaccagaa 240  
 tgatactctc agcacagaag aataaaggga gcgagtcatt aacgttttct ttttaaacct 300  
 ttatgatgac ttcttatga attactgaac gaacactgga atgggactca ggtatcctga 360  
 ggacatctct caactctggc cttagtcccc cctctgtaaa attaggggtgc caactaaatg 420  
 atctacaagg tcccttcag cgccgccatt ctgtaattac atcatgtgta actgtattaa 480  
 acatacacia gtgactgcca ggcattggga tgtaacttcc gagtaaatgc tttggtttgt 540  
 tcagaataca ctatgaactt ctttccaaag acgggtgtg gtaaatagtg gatattttga 600  
 ttataagaaa tagagtttcc ttgaagcttt agctggagat acagcaatag tgtgggtgtc 660  
 ctacaaatat cacagtgtat tcaaacatat ttttctatca aaaatcattt ttgtaaaagc 720  
 tgtgtgtttt tatccaactt gtgataataa atgttcttta ttttagaata aaaaaaaaaa 780  
 aaaaaaaaaa aaagaaaaaa aaaggaaata aaaaaaaaaa acaggagaca aagacaacgg 840  
 cggcacgcaa caaccacatc gcggaaggcg acaagcgaac aaccagccc gagctcgtga 900  
 aggcgagcca acatgaagga gcgcactatc caagacagg agctgacata acagaagaga 960  
 acaaaaacaa gagacaagta gaacaaaaac aaagagaaga caggacacac gagaaaagca 1020  
 ggtgtaatca gacgaacgac gcgacaaaca gagagacgtg caagcataaa atagcaacaa 1080  
 ccaagagaca gcgacggaca cacgaagcaa gacgagcgac gccgagcaca gcagggat 1138

<210> 155

124

<211> 800  
 <212> DNA  
 <213> Homo sapien

<400> 155  
 cgtggtcgcc ggccgagggt gccataggcc ccagaccaa ctagaccacc agcatgttca 60  
 tgtccagacc tcggcagtgg cgtgcactgc ttgtgcacct cagttcctcc agtgttggtt 120  
 tgtttgtttt ttaattcagc atcctgctgg ttttactttc caagcaagat ctgttgcgac 180  
 tcccaaatgc gttttaatga gtcctcctt atttgccttt cttcttacgt attttggtgt 240  
 atttaaagat tgtgcaggag atattctaga aggcattaat ggtttgcatt caaacgatg 300  
 tggtttgctc aagttatttt ctgtctttat tactgagacg gattaatctc cttatttttt 360  
 tcttgatgat ttgaagttgt aacagttgtc cagctattgc ttaataaaat tttgcagatc 420  
 aaaaaaaaaa aaaaaaaaaa aaaaaagggt gggggtaacc agggccaaga ggggtccctc 480  
 ggggtcgaca attgggtcac cgggtccat caatttcccc acaaacataa tacaggacat 540  
 aggcacacac agcaaacgca cacagcacca agacagacaa ctacggcgag ctaaggacgc 600  
 agagaagacg cggcaacgcg gaacgccccg agcaaggccg aggcaacaca ggagaggggc 660  
 agcgcacgac ggccggagca cgagcaggaa agcaacgaag agagacaacg gacacacgcg 720  
 agggcgaaga gaagagagca ggaacgacag gacaagcaca caaacgagcg gcaacagcag 780  
 acccagacga aacagcgcg 800

<210> 156  
 <211> 4632  
 <212> DNA  
 <213> Homo sapien

<400> 156  
 atgtatgcag cagtggaaca tgggcctgtg ctttgcagtg actccaacat cctgtgcctg 60  
 tcctggaagg ggcgtgtccc caagagttag aaggagaagc ctgtgtgcag gagacgctac 120  
 tatgaggaag gctggctggc cacgggcaac gggcgaggag tggttggggg gactttcacc 180  
 tctagtcaact gtcgcaggga caggagtact ccacagagga taaatttcaa cctccggggc 240  
 cacaatagcg aggttggtgt ggtgaggtgg aatgagccct accagaaact ggccacgtgc 300  
 gatgcggacg gaggcataatt cgtgtggatt cagtacgagg gcaggtggtc tgtggagctg 360  
 gtcaacgacc gcggggcgca ggtgagtgat ttcacgtgga gccatgatgg aactcaagca 420  
 cttatttcct atcgagatgg gtttgcctg gttgggtctg tcagtggaca aagacactgg 480  
 tcatccgaaa tcaacttga aagtcaaatt acgtgtggca tatggactcc tgacgaccaa 540  
 caggtgctgt ttggcacggc cgatgggcag gtgattgtca tggattgcc aaggcagaatg 600

ctggcccacg	tcctottgca	cgagtcagac	gggtgcctcg	gcatgtcctg	gaactaccgg	660
atcttcctgg	tggaggacag	cagcgagagc	gacacggact	cagatgacta	cgccccctccc	720
caagatggtc	cggcagcata	tcccatccca	gtgcagaaca	tcaagcctct	gtccaccgtc	780
agcttcacct	cgggagacat	cagcttaatg	aacaactacg	atgacttgtc	tcccacggtc	840
atccgctcag	ggctgaaaga	ggtaggtagc	cagtgggtga	cacaggggga	cttgctggca	900
gtcgtgga	tggaaacggc	gaccagctt	ggtagcttc	ccaatggccc	ccttctgaag	960
agtgccatgg	tcaagttcta	caatgttcgt	ggggagcaca	tcttcacact	ggacactctc	1020
gtgcagcgcc	ccatcatctc	catctgctgg	ggcacccggg	attcgaggct	gttgatggca	1080
tcaggaccag	ccctgtacgt	ggtagctgtg	gagcaccggg	tgtccagcct	gcagctgctg	1140
tgccagcagg	ccatcgccag	caccttgctg	gaggacaagg	acgtcagcaa	gctgactctg	1200
cccccccgcc	tctgtccta	cctctccact	gccttcaccc	ccaccatcaa	gcccccaatt	1260
ccagatccga	acaacatgag	agactttgtc	agctacccat	cagccggcaa	cgagcggctg	1320
cactgcacca	tgaagcgcac	agaggacgac	cgggaggtgg	gcggcccgtg	ctacacgctc	1380
tacctggagt	acctgggcgg	gcttggtccc	atcctcaaag	ggcggcgcat	cagcaagctg	1440
cggccagagt	tcgtcatcat	ggaccgcggg	acagatagca	aaccagatga	aatctatggg	1500
aacagcttga	tttctactgt	gatcgacagc	tgcaactgct	cagactccag	tgacattgag	1560
ctgagtgatg	actgggctgc	caagaaatct	cccaaaatct	ccagagctag	caaatacccc	1620
aaactcccaa	ggatcagcat	tgaggcccg	aagtcaccca	agctgccccg	ggctgctcag	1680
gagctctccc	ggccccacg	gttgcctctg	cgcaagccct	ctgtgggctc	gccagcctg	1740
actcggagag	agtttccttt	tgaagacatc	actcagcaca	actatcttgc	tcaggtcacg	1800
tctaatactc	ggggaaccaa	atttaagatt	gtgggcttgg	ctgctttcct	gccaaccaac	1860
ctcgggtcag	taatctataa	aaccagcctc	ctgcatctcc	agccgcggca	gatgaccatt	1920
tatctcccag	aagttcggaa	aatttccatg	gactatatta	atttacctgt	cttcaaccca	1980
aatgttttca	gtgaagatga	agatgattta	ccagtgcagc	gagcatctgg	tgtccctgag	2040
aacagcccac	cttgtagcgt	gaacatccct	attgcaccca	tccacagctc	ggctcaggct	2100
atgtccccca	cgcagagcat	agggctgggtg	cagtccctac	tggccaatca	gaatgtgcag	2160
ctagatgtcc	tgaccaacca	gacgacagct	gtagggacag	cagaacatgc	aggtgacagg	2220
tgccacccag	taaccaggt	ctccaaccgg	tactccaatc	ctggacaggt	gattttcggg	2280
agcgtggaaa	tgggcgcgat	cattcagaac	ccccctccac	tgtccctgcc	tccccgcgcg	2340

126

caggggcca	tgcagctgtc	cacggtgggc	catggagacc	gagaccacga	acacctgcag	2400
aagtcagcca	aggccctgcg	gccaacaccg	cagctggcag	ctgaggggga	cgcagtggtc	2460
tttagtgccc	cccaggaggt	ccaggtgacg	aagataaacc	ctccaccccc	gtaccacagga	2520
accatccccg	ctgcccccac	cacagcagca	ccccgcgcc	ctctgccgcc	cccacagccc	2580
ccagtggatg	tgtgcttgaa	gaagggcgac	ttctccctct	acccacgctc	agtgcactac	2640
cagaccccc	tgggctatga	gaggatcacc	accttcgaca	gcagtggcaa	cgtggaggag	2700
gtgtgccggc	cccgaccccg	gatgetgtgc	tcccagaaca	cctacacctt	ccccggcccc	2760
ggtagctctg	ccaccttgag	gtcacggcc	actgagaaga	aggtccctca	gcctgcagc	2820
agtgcacccc	tgaaccgctt	gaccgtccct	cgctactcca	tccccaccgg	ggacccaccc	2880
ccgtatcctg	aaattgccag	ccagctggcc	caggggcggg	gggctgcccc	gaggtccgac	2940
aatagcctca	tccacgctac	cctgcggagg	aacaaccgtg	aggctacgct	caagatggcc	3000
cagctggccg	acagcccgcg	ggcccccttg	cagcccctgg	ccaagtccaa	gggcggggccc	3060
gggggggtgg	tgacacagct	cccagcgccg	ccccacctg	ccctgtacac	ctgcagtcag	3120
tgcagtggca	cagggcccag	ctcacagccc	ggagcctccc	tggcccatac	cgccagcgcc	3180
tcccgttg	cctcccagtc	ctcctacagc	ctcctgagcc	cacccgacag	cgcccgcgac	3240
cgcaccgact	acgtcaactc	ggccttcacg	gaggacgagg	ccctgtccca	gcactgtcag	3300
cttgagaagc	ccttgaggca	ccctcccctg	cctgaagctg	ctgtcacctt	gaaacggcca	3360
cccccttacc	agtgggaccc	catgctgggt	gaggacgttt	gggttcctca	agaaaggaca	3420
gcacagactt	cagggcccaa	ccccttaaaa	ctgtcctctc	tgatgctgag	tcagggccag	3480
cacctggacg	tgtcccgact	gcccttcac	tcccccaagt	ctcctgccag	ccccactgcc	3540
actttccaaa	caggctatgg	gatgggagtg	ccatatccag	gaagctataa	caacccccct	3600
ttgcctggag	tgaggctcc	ctgctctccc	aaagatgcc	tgtccccaac	gcagtttgca	3660
caacaggagc	ctgctgtggt	ccttcagccg	ctgtacccac	ccagcctctc	ctattgcacc	3720
ctgcccccca	tgtacccagg	aagcagcacg	tgctctagtt	tacagctgcc	acctgtcgcc	3780
ttgcatccat	ggagttocta	cagcgcctgc	cgcgccatgc	agaaccccc	gggcaactctc	3840
ccccaaagc	cacacttggt	ggtggagaag	ccccttggtg	ccccaccacc	tgccgacctc	3900
caaagccact	tgggcacaga	ggtgatggta	gagactgcag	acaacttcca	ggaagtcctc	3960
tccctgaccg	aaagcccagt	ccccagcg	acagaaaaat	ttggaaagaa	gaaccggaag	4020
cgcctggaca	gccgagcaga	agaaggcagc	gttcaggcca	tactgaggg	caaagtgaag	4080
aaggaggcta	ggactttgag	tgactttaat	tccctaactc	ccagcccaca	cctggggaga	4140

127

gagaagaaga aagtgaagag tcagaaagac caactgaagt caaagaagtt gaataagaca 4200  
 aacgagttcc aggacagctc cgagagcgag cctgagctgt tcatcagcgg ggatgagctc 4260  
 atgaaccaga gccagggcag cagaaagggc tggaaaagca agcgctcccc acggggccgcc 4320  
 ggcgagctgg aggaggccaa gtgccggcgg gccagtgaga aggaggacgg gcggctgggc 4380  
 agccaaggct tcgtgtacgt gatggccaac aagcagccgc tgtggaacga ggccaccag 4440  
 gtctaccagc tggacttcgg ggggcgggtg acccaggagt ccgccaagaa cttccagatt 4500  
 gagttagagg ggcggcaggt gatgcagttt ggacggattg atggcagtcg gtacattcta 4560  
 gacttcagat atccgttctc agccgtgcag gcctttgcag ttgccctggc caacgtgact 4620  
 cagcgctca aa 4632

<210> 157  
 <211> 998  
 <212> DNA  
 <213> Homo sapien

<400> 157  
 tgctgctcga gcgcgcgcag tgtgatggat ccgccccggc aggtaccttt tcctctcaca 60  
 ttggcagaat agcacgcact agatgcctga ccttgagctc tagtctcccc gtttaaactc 120  
 taccttgggc agtaacgaca attattcctc attcaagtaa tttcaatgct gaaactgaac 180  
 tctattacta atgccttcca atcagagttc ctgatgggga tgccctgtggg atggcccact 240  
 aacctggggg acctaggcta gcatggggtg agttgggtaa ggaagatgat gcgttagttc 300  
 ctgatagatg ctacgagatg tagtttgga tttcagttgt tgtccagtta tgattttcac 360  
 tgggggttct gcagtcacag caagctgtgt atgaactagc tgtactagtg gatgacacac 420  
 tataactaat caaactagac taaagacaca ctgaaaatct gcgttataac taacaagata 480  
 tcactcatct gacacataac caccattaca ccttatggta cgtcaggatt cataaatagt 540  
 actgctctga atgacttatg ggaaatggtg ccactcaaaa gcaacttcct aacttgagga 600  
 ataactcctt tgtagtttac tttctgggtac tgggttggtgc cttgtatcgg gatacagcta 660  
 tattcttagc tcaaagtctt cttttggaga gcacagtagt tatcctactg gtgagactga 720  
 gaacctgagc tcatgagagg ccattccttc ctgggtgtcg gaccagggct ctgtgtcagg 780  
 aaaaaccttc tgggtgacct ttgtagactc gtttcagggt gattccctct tatcttcga 840  
 gagtagaatt cgcagtcggg ggcctttccc ttcacccgta actcgcccc tctgggcagg 900  
 ggcgggggtg cggctcttaa cgctggctcc ggggttgggg ggccccgggc ccgcaacgcg 960  
 ggttttgggc gggtcgcgcc cctccctcca acgggccc 998

<210> 158  
 <211> 766  
 <212> DNA  
 <213> Homo sapien

<400> 158  
 gggatgatcg ctactatag ggcgctggc actagatgca tgccgagcgg cgccaggtga 60  
 tggatcgagc ggccgcccgg gcaggtacat gttcatgaat ttgtgctgaa taattacttg 120  
 agtgtgaaat tggtatgta tgcgatatat agtagtcaaa tatagaagat aatgcaaaac 180  
 aatttaaagt gattgtagca gtccgctgta ttctacagca gcaggattgt aggagatta 240  
 ctgtagtctt cacagcgagc agcatgtgag attggccagt ccgctcaaat tcgtgccaat 300  
 acttggtata tgctatcttg tcaatttcta gacattctgg agagtgtgta gtacttgctc 360  
 atcttggaca aattacactt aatagttatg tatccatttc tctaattttg ataacatttt 420  
 acataagttt atcgttatga gatatgttct ttattttgaa gtgcttattg tccattttac 480  
 attgggtcat ctgttattga attgtaaaaca ttccctgaat atttaaatat gagtgccttg 540  
 tcagtttttg tcacaaatat cctcgttttt tcactttttg cccttttatt attctgaaaa 600  
 tgccaagtga ttaaaattaa ttttactatt gttcaataaa caaaacaaaa aaaaaaaaaa 660  
 aaaaacacaa aaaaacaaaa gcgcgggggg taaccggggg cccaaggggg tccccggggg 720  
 acattggtct ccccggtcac aattcccccc aatcgacaa cagggc 766

<210> 159  
 <211> 1400  
 <212> DNA  
 <213> Homo sapien

<400> 159  
 ctatgattag cttattagc tttgtggtt atatgcatca gaaagagtaa gacttaattt 60  
 tgtgtggaac aaataccctg gtgtagcatg tttcattaga atttgtttat agagatattg 120  
 ccatagaaaa gttatTTTT attagtaaag aatgctttgt atttccttg tggcttctaa 180  
 gtaccctttt ttggttatta tacctttatc cataagtatc tttaaattatt acaaaaatta 240  
 catattcttt taaatatttt aaagatttat tatattcatt taggttttaa tccactttta 300  
 attttttaga tgaaaagtaa gagaaaagta tataaatcat gagcaciaat tgaactaacc 360  
 aaggtaacaa tcaatctgct caagaaattg agcatcacca ccacctctc ctgcactgtc 420  
 caaatcagca ccccgactt ccaaagcaaa tgttactcac tacactgact tctaacacaa 480  
 tagacttggt ttgtctgtt tcaactatac aaaaatgaat catagagtat gtgttggttt 540

129

gtatctggct cctttcacta aaatttttgggt ttataaaatt catccatgtg gttgaacaca 600  
 gttgtagatt gttcatttta attgttttac agtattttatt gtgtgactaa aacactactt 660  
 atttattcta taattgacag actttgggtt gcttttgctt tgggagtata aacattttta 720  
 tatctatgct ttaggtacat gttcatgaat ttgtgctgaa taattacttg agtgtgaaat 780  
 tgttatgtta tgcgatatat agtagtcaaa tatagaagat aatgcaaaac aatttaaagt 840  
 gattgtagca gtttgctgta ttctacagca gcagattgta gcagattact gtattctaca 900  
 gcagcagcat gtgagattgc cagttgctca aattcgtgcc aatacttgggt attttttattc 960  
 ttttaatttt agacattctg gagagtgtgt agtaattttt catcttggaa aattacatta 1020  
 aattagtatc catttctcta attttgataa cattttcata agtttattgt tattagatat 1080  
 tttctttatt ttgaagtgtt tattgtccat ttacattgg gtcattctgtt attgaattgt 1140  
 aaacattcct tgaatattta aatatgagt cttggtcagt tttgtcaca aatatcctct 1200  
 tttttcactt tttgcccttt tattattctg aaaatgccaa ttgattaaaa ttaattttac 1260  
 tattgttcaa taaacaaaac aaaaaaaaaa aaaaaaaac acaaaaaaac aaaagcgcg 1320  
 ggggtaaccg ggggcccaag ggggtccccg ggggacattg gtctcccccg tcacaattcc 1380  
 cccaatcgc acaacagggc 1400

&lt;210&gt; 160

&lt;211&gt; 556

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 160

acctattcac cattccaacg tgaagaagct ctgcatgtag gaaagaataa ttaacacact 60  
 tatagtctac tgcccatgta aggatcagct ccggctaaga ggccaaagat gggtgacatc 120  
 gtcattgctct gccttttatt tttctttct taccactta gcttcctaat tggaggaagg 180  
 aggcgtggta aaggatatg aagactatgg tttaattaga ccagaaaaca ctgtcataat 240  
 ctctgggctg cagtcagaat gtccagtttt gtctttgggc caagataagg gcagtgggat 300  
 ttatgatgtg ttgtttatag tctgaaacta ctctgggtgat caccaggggc agtttcttta 360  
 atcgatgggt tccaagctgg cctaagtaca tttaagtaga gactgggctg ataaacatga 420  
 ccagacgaga cataaagacc ctgttgggaa tgacattgaa ctctcaaagt caagatttct 480  
 tacacaaatc tatcagctgg agaataatga gaggcagctg tggatatatgt gtgcaaataa 540  
 ggacattatg aagctt 556

&lt;210&gt; 161

130

<211> 1327  
 <212> DNA  
 <213> Homo sapien

<400> 161  
 ggaagacctg attgggaata gtcgaaagcc ttgatatgtg caaagaaaga accatttgat 60  
 caacccagtt cttaatacag gatactaact taaaatatag actcaagtta tacgataaatt 120  
 caaacattta ttgtatttat actattctat atgtactttt ccaggaacca ggaatacaaaa 180  
 actgacatgt tctctgtaca gaggtcaga ctagtagaga acagttaggt acgccgttaa 240  
 ttataaacta atatgtatca tcaattatgg gtttttatgg gggtttgga ggtggaaggg 300  
 accagggaga gatgatgagt gatgatgggt atgtagtctt taggaggatg caattataac 360  
 attgctcttc ctttcacgca ccacatgatt tagcaagtac ttcattatgg ctccaccatt 420  
 aacatggcca atggcttctg gatactcaca gtccaggcac agtttctctt gaagattttt 480  
 tacctctccc atctttaaga aattgtctgg atgtccatga aagatgetga cacttgatt 540  
 aattcattaa aaaacaccac cccctccctg aaataaacta aaaagtaatg aattcataga 600  
 aaaaaatttc accaagattg aaactagaga atatacctag acttgcaact tgagctttga 660  
 gaaatgtgta cctattcacc attccaacgt gaagaagctc tgcagtagga aaaataatta 720  
 acacacttat agtctactgc ccatgtaagg atcagctccg gctaagaggc caaagatggg 780  
 tgacatcggt atgctctgcc tttatttttt ctttcttacc cacttagctt cctaattgga 840  
 ggaaggaggc gtggtaaagg tatatgaaga ctatggttta attagaccag aaaacactgt 900  
 cataatctct ggggtcatca gaatgtccag ttttgtcttt gggccaagat aagggcagtg 960  
 ggatttatga tgtgttggtt atagtctgaa actactctgg tgatcaccag ggtcagtttc 1020  
 tttaatgatg gtttccaact ggcctaatac attaaagtaag actggctgat aacatgacca 1080  
 gacagacata aagacctgt tgggaatgac attgaactct caaagtcaag atttcttaca 1140  
 caaatctatc agctggagaa aatgaaggca gtgtggtata tgtgtgcaaa taaggacatt 1200  
 atgaagctta aatatggaat gtctcttgga ccccgatgt catctgtatt ctctttttct 1260  
 tcttgtaacta tatcctttgc ctgtaaataa aagggtttatt tgaaaaaaaa aaaaaaaaaa 1320  
 gatcggc 1327

<210> 162  
 <211> 318  
 <212> DNA  
 <213> Homo sapien

<400> 162  
 gggtctccta aatgtcttaa cccatgttta tcttggtctg ctattccatg agcaaagaga 60



131

ataaagcaca aagctgtgag agtattaaat atggacacta gatttacatt tccaacaaga 120  
aattcatctc cctccaaagt cccagaccag ggctagaatg tggttcattt ttaacaatca 180  
aagtggcaag atctgttttg tgatcactgt aaaacaggaa acacagtaat gccttcattg 240  
tgaggtgcta aaaggtcaag cttgggtaac aatgtccata gctgttcttg tgaatgtttc 300  
gtcaatcaaa tagtgaaa 318

<210> 163  
<211> 1042  
<212> DNA  
<213> Homo sapien

<400> 163  
acagtctggt tctctcttca cccccagaac aaaaatcgaa cttctggttg gacagtgtca 60  
gatgtcactg aggtgacccc agcctgtttg cagttccaag tcttccgtgt aggcgtcact 120  
gctactggaa cttttagatg gaggagcctg tatgatgatg tcctgaacat ttctatcctt 180  
tctcacaca gagggaaagt actgggaata tcagagacaa gctattatta aacaagtgtc 240  
tctagtccaa gacatctcct gtggcagggg aatgaggggg caggctgtat cagtgatatt 300  
tttataaact ctggtttttag aaaaaattct tcagatggac gcattatttt aagacttta 360  
cattttccaa aaccaactga atcttatccc ctccatttat cccctccag acacttctaa 420  
tcaaggtcac catctccaac ttccccata gacagtaaaa atatggctgg agaattctac 480  
tgtaatagaa aaccaaggag atatggtaat ttgacagtgt gtttccttcc catccactag 540  
acaagaatac cccctcccat tcttctctcc cctcagtcac cagaatgaag tgggctggaa 600  
aacagttggt ctggttcctt tatagagact gattcccaca ttggatactg cctggaggcc 660  
ttggggatga atgagaagtt ctgctgggtt ggatcagtag cagaagcagg taacacatca 720  
gggaaccggt cagcctaaga taggagggga cagaaaatga tgaaagagtt tctgatacat 780  
ttatcagcta aattgctatg gtcaccccca tgtctcctgt aatgtccaac actaaggaat 840  
taaactaagt aaactacaac ctttgtgtct tgccttgacc ttggaccaat ggaatatact 900  
tcttatttca tattcagtgg ataagcaaat ctgcttcac cctgccttaa ctactcaag 960  
gtctctgtga tgcactccag agttttcctc cttccctgca tagtcttctc ctccctagct 1020  
gcctttcaaa ttggtgaaaa tg 1042

<210> 164  
<211> 1120  
<212> DNA  
<213> Homo sapien

<400> 164  
 gccgcctttt tttttttttt ttttttagaca agaaattatt ttagtccttt agtacagtct 60  
 gtttcctcct tcacccccag aacaaaaatc gaacttcttg ttggacagcg tcagatgtca 120  
 ctgaggtgac ccagcctgt ttgcagttcc aagtcttccg ttagggcgtc actgctactg 180  
 gaactttgta gatgaggagc ctgtatgatg atgtcctgaa catttctatc ctttcctcac 240  
 acagagggaa gctactggga atatcagaga caagctatta ttaaacaagt gtctctagtc 300  
 caagacatct cctgtggcag ggaaatgagg gggcaggctg tatcagtgat atttttataa 360  
 actctggttt tagaaaaaat tcttcagatg gacgcattat tttaagactt taacattttc 420  
 caaaaccaac tgaatcttat cccctccatt tatccccctc cagacacttc taatcaaggt 480  
 caccatctcc aacttcccc atagacaata aaaatatggc tggagaattc tactgtaata 540  
 gaaaaccaag gagatatagt aatttgacag tgtgtttcct ttccatccac tagacaagaa 600  
 taccctctcc cattctttcc tccctcagt caccagaatg aaggggctgg aaaacggttg 660  
 tctggttcct tttagagctg attccccatt ggatactgcc tggaggcctt ggggatgaat 720  
 gagaagttct gcagtttgga tcagtagcag aagcaggtaa cacatcaggg aaccggtcag 780  
 cctaagatag gaggggacag aaaatgatga aagagtttct gatacattta tcagctaaat 840  
 tgctatggtc acccccatgt ctctgtaat gtccaaacct aaggaattaa ctaagtaaac 900  
 taaaaccttt gtgttcttgc tctgacctg gacaatggaa ttcttcttat tttcattcag 960  
 tggatagcaa atctgcttct tccctgcctt aactcactca aggtctctgt gatgcactcc 1020  
 agagttttcc tccttccctg catagtcttc tccctccctag ctgcctttca aattggtgaa 1080  
 aatgaagctt caggattatg aaaactagta cttaatgaag 1120

<210> 165  
 <211> 810  
 <212> DNA  
 <213> Homo sapien

<400> 165  
 agatcatgct cgagcggcgc agtgtgatgg attggtcgcg gccgaggtag ttttttatgg 60  
 cttacatctg tgcctggtcg gccatcaagt ctgggtgccg ctgtttgaga tttggggctg 120  
 tttcctgcaa ctgatctctg ctacagataa ggcttccctc ctggaggcca aagccctggt 180  
 taacgttaag agctctatga tgatgcaaac ttacagaggc atcacctaac ataacaaaaa 240  
 cctccccaga accagaacct gttttttcac caaaacctt ccgctgcttg aataagaatg 300  
 tcttttcctt tcctaccaac tttgatgccg ctggccactg tgacataact tttacttagc 360

133

ggggtaaatac atagatggat tacttgaact gccaacacaa gactgctgga cgagggacag 420  
 agctggatat gttagacaaa gatatacgaa cgacttggcg taatcactgg tcaatagctg 480  
 acaccatgat gtgaaaagta gtaatcacgg ctcaacagta ccaacacaag atacagaaga 540  
 caggagaaga ggaacaggaa aagaagaaac aacagagcac aaagagagaa caagcacaca 600  
 acagacgaag gccacaagag cgaaggagga cgggacgcag caccagcaac agaggaacgg 660  
 cacgcacaga agaacacaga caagaaaacg agaagaaacc acacgcacaa cttagccagaa 720  
 tcagagacag aaaacgcgaa gacaggaggc agaagcagaa acacaagaaa accgaacacc 780  
 aaaacaggca gcacaaacac gaagagaaaag 810

<210> 166  
 <211> 601  
 <212> DNA  
 <213> Homo sapien

<400> 166  
 gaagtataac tatatgggag aatgggtcct tagatgcagg ctcgagcggc gcagtgtgat 60  
 ggatccgccc gggcaggtac tcaggtgtta tatgattttc tgagctgaat aagtgcgagg 120  
 agcagattat taagatctgc cattctgaaa cgctggtcct tttctccttc ctatagtga 180  
 ccataaaatt ctgttgatca gattatatta catacatttg ggggagtgga gggacatgag 240  
 ttaagtagcc cttcatgtat ttataatctc ttttctactg aatcaaatga cttagccatg 300  
 accctgaatg gacctgtttt acttcaagtg agatgtctgc cttttatgaa ttgtatatgt 360  
 gaatagagtt cgggggttgc caaaaatgca tacatgtatg taagtaaaat tttttatgaa 420  
 gtagtctgtc aaatgtatca taaagtttat ttttctttta tacgtaaata attaaaaata 480  
 atcacatatt ttgaaaaaa aaaaaaaaaa aaaaaagggt ggggggtatc tcggggccaa 540  
 aaggggtccc gggggggaat tggttttccg gttcaaattt ccacaaattt gggagaaaat 600  
 a 601

<210> 167  
 <211> 1035  
 <212> DNA  
 <213> Homo sapien

<400> 167  
 tggtcgcggc gaggtactgt aaatgtgatg gaaaacattg atgagaattt attggcagtt 60  
 cagattgtgt tttcccaact taggctcttt attaattggg taaggttttc tccaaaaagg 120  
 gcatttcaac aatgggaatt attttaaatt ggttaaacca gtgggcacag attacttata 180  
 ttccttctct gctttgtgac tcaccagcag taacacacac aatccacatc ttgtgcacct 240



This page is not part of  
the pamphlet!

**WO 02-064611**

**4/5**

Date: 22 aug 2002

Destination: Agent

Address:



134

```

caaatgaaca gacttggttt ccttgcttcc ttgacatttc catgactgtt tcacatacaa 300
actattgggt gaggtttttc agctgttacc gacccaagtc ctgctgtctc tgtgtgggtcc 360
tacaaaaact gtccattccc acccctttgc tttgccattt gcaagagtct ggaattgtca 420
ggtctcagct tcgaaaagtc ctgggtccac tgacaggaca cattcttttag tgggaattaa 480
gacctacaaa gtctagtttg tatgtaggta tgaaggggaat tttttaataa aagtggaaaa 540
gctgtgaaca gcattagaac tctgtctatt tcttaatttt aaaatatgct gatatgcctt 600
aaactgtagt tgtagatcct tgtcattttg ctgtttgaaa ataaccaatg tgttttctaa 660
aactgtcgtg taatctactt tcattgttaa tgcagaattg tcatatatgt aagccgcatg 720
ttagacattt gtctttttta aactaaagta attgtattga tgtgaagcat atcatttttt 780
caaatatgaa agtgatcact tagcaacatg cttggtaatt tggcatctgt taaggtagga 840
gagtggtgaa cagataatct atgcatatat cactagtgcc aagacataaa gcgggggaaa 900
atatattttt acccaaacat taaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaggc 960
tgggggtaac cgggggccaaa ggggtcccgg ggtgaattgg tttccgctc aaattcccc 1020
atttttgggc aaacc 1035

```

```

<210> 168
<211> 1666
<212> DNA
<213> Homo sapien

```

```

<400> 168
ctgggtgatg aagtgagact ctccaaaaaa aaaaagaaat tattaatccc tgcctgtgct 60
ctacatagcc tcatgggcat cattggatag ctgagagggc ccttgattct ggcaaggcaa 120
ataaagccag aatgagaaat taccatcttc tactagagaa aaccaagaga aaaattttta 180
tgctaggatg cctttatgac cacttaattt ttaaatctta gttaaatggt ctctccctgg 240
tgctaactgc tgacagtggc cacctctttt ttggggattg aggggcctac ataactagct 300
ggccttacct catatctttt gttcaaacat aataccatct ttttgcttct tctgaacttt 360
agatctccat aacacatgta ctgtagaatg tgatggaaaa gcattgatga gaatttattg 420
gcagttcaga ttgtgttttc ccaacttagg ctctttatta attggttaag gttttctcca 480
aaaagggcat ttcaacaatg ggaattatct aatgtaacag tgggcacaga ttacttatct 540
tcttctctg ctttgtgact caccagcagt aacacacaca atccacatct tgtgcacctc 600
aatgaacag acttggtttc cttgctttct tgacatttcc atgactgttt cacatacaaa 660
ctattgggtg aggtttttca gctgttaccg acccacgtcc tgctgtctct gtgtggtcct 720

```

135

acaaaaactg tccattccca cccctttgct ttgccatttg caagagtctg gaattgtcag 780  
 gtctcagctt cgaaaagtcc tggttccact gacaggacac attcttttagt gggaattaag 840  
 acctacaaag tctagtttgt atgtaggtat gaagggaatt ttttaataa attgaaaagc 900  
 tgtgaacagc attagaactt tgtctatttc ttaattttaa aatatgctga tatgccttaa 960  
 actgtagttg tagatccttg tcattttgct gtttgaaaat aaccaatgtg ttttctaaaa 1020  
 ctgtcgtgta atctactttc attgttaatg cagaattgtc atatatgtaa gctgcatgtt 1080  
 agacatttgt cttttttaaa ctaaagtaat tgtattgatg tgaagcatat cattttttca 1140  
 aatatgaaag tgatcactta gcaacatgct tggtaatttg gcatctgtta aggtaggaga 1200  
 gtggtgaaca gataatctat gcatatatca ctagtgccaa gacataaagc gggggaaaat 1260  
 atatttttac ccaaacatta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa caactgtgtt 1320  
 cggcgcgctt gtggccccgg aagaagagtc ttctcgtaga accatcgtgg tttgggcca 1380  
 gcggggcccc aggaggtagg gtgccacacg ggccaaaagc gtgtcccagg agacaccgg 1440  
 gggcactaga acaacttagg gtgtgtgagg aatattttcg ctcaccccat gttacaaaaa 1500  
 caaccgcgca gagggggcaa acagcaacag ggtttctgtg aaacaacaac ccccaaatgg 1560  
 agggaaagtc tcgagaagga catacaggga aagcctaata caacagaggg aagatccaa 1620  
 ggaaaagcac tatcatataa ataattatcg ccgccggctg tgcggg 1666

<210> 169  
 <211> 633  
 <212> DNA  
 <213> Homo sapien

<400> 169  
 aaaacaacac ggaatgtcta cgactaacta tagggcccct ggtgtatcta gatgcatgct 60  
 cgagccggcc gccatgatgt gactggatgt cgcggccgag gtacagagta tgtagtgggc 120  
 atctgttgaa tgaatgcttt tcccagtacg cacgtgtatt catacaatat taatataatt 180  
 agtcccctgg gcttacagat aaaaatgaaa cgcacacacg tgcccagctg cagtgagacc 240  
 cagggtgttc tctccacccc ctagtgggtc cctgggcagg tctttttttt ttggtaaacac 300  
 tcaccaggtc tgttctgtag tcaatcatgt gatggactgt gtcgggtgaac tgtgcaggac 360  
 actgtttctca tagtggtcat tagcgacaga gtaaactatg ttgccatgca agggttattt 420  
 ggcatctgca ttttaagtga aatgttgaat caatgaaaag gtgttgatta agcagtagtt 480  
 gtagatatgc taagtttttc aaattactaa tatcaagtgg agatggtttt tactttataa 540  
 gggatttgct ttggtgatag cataaataat gggtttccct ttttggtaac tgtaacatta 600



136

attggctggc aactttggta ttcccataga ctg

633

&lt;210&gt; 170

&lt;211&gt; 563

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 170

gggaaggaag acatataggg cggaatgggt cctagatgca tgtcgagcgg cgcagtgatga 60

tggatcgggc ccgggcaggt acaaaaaata ggataaatgc ttgttttttt atttagcaat 120

gtccaaaata atgaattgat ttcccgagta tcctctaaag gtaaccaggg atttttttta 180

tttaattatc ttgaaccac atatttaaata atacgtagta tgctacaaac cattgcagtt 240

aagtaccttt attgatgctt gagttgcca ctttttcttt tttttttttt ggagacagag 300

cctcgctctg tcaccagggc tggagtgcag ggcgctcatc ttgactcac ttgcaacctt 360

ccttccttcc gtggggtgca ggcagattct cctgtgcctt acagcctccg agtttggtg 420

ggatttacag ggcattgttg caagtttccc acattttcag tgagaaattc ctcaattggc 480

ctccgtgagt ggtttgaaa ttgacccag aattcttgga gtgggtgtat tagctatcta 540

tggctggtgt aacaaattga cct 563

&lt;210&gt; 171

&lt;211&gt; 682

&lt;212&gt; DNA

&lt;213&gt; Homo sapien

&lt;400&gt; 171

gaaaagggtg gcagcaggtg cacgtgttat cagcctgac atctatcacc tgatggtttt 60

agcaatacct aaatccgtga tatcatcaga ggttgcaaaa tgatgagatt cagggttttt 120

ttttacataa ttattggtca gaattattct gcaaatagct tctctttaac agtattcggt 180

taccttgaaa tacaggttgt acaaaaaata ggataaatgc ttgttttttt atttagcaat 240

gtccaaaata atgaattgat ttcccgatc cctctaaagg taaccaggga ttttttttat 300

ttaattatct tgaaccaca tatttaaata tacgtagtat gctacaaacc attgcagtta 360

atacctttat tgatgcttga gttgcccact tttttctttt tttttttttg gagacagagc 420

ctcgctctgt caccagggc ggagtgcagg ggcgctcatc ttgactcact tgcaaccttc 480

cttccttccg tggggtgcag gcagattctc ctgtgcctta cagcctccga gtttggtgg 540

gatttacagg gcattgttgc aagtttccca cattttcagt gagaaattcc tcaattggcc 600

tccgtgagtg gtttggaat tgacccaga attcttgag tgggtgtatt agctatctat 660

137

ggctggtgta acaaattgac ct

682

<210> 172  
 <211> 75  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 172

Met Gly Pro Arg Ser Arg Leu Trp Pro Ser Ser Pro Leu Trp Leu Val  
 1 5 10 15

Gln Pro Leu Cys Thr Pro Gly Val Phe Thr Pro Gly Ala Asp Ser Ser  
 20 25 30

His Cys Ser Ser Phe Leu Arg Glu Ile Thr Val Val Ile Ala Ala Gly  
 35 40 45

Ala Asn Arg Leu Gly Leu Val Ser Cys Ala Phe Gly Gln Leu Leu Thr  
 50 55 60

Arg Ser Ser Leu Lys Gln Trp Gly Gly Pro His  
 65 70 75

<210> 173  
 <211> 38  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 173

Met Phe Pro Arg Leu Asp Ser Thr Ser Trp Pro Gln Gly Ile Leu Trp  
 1 5 10 15

Ala Trp Thr Pro Lys Pro Leu Arg Leu Glu Val Cys Glu Pro Pro Ser  
 20 25 30

Leu Pro Ser Leu Trp Ser  
 35

<210> 174  
 <211> 52  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 174

Met Thr Leu Phe Ile Arg Cys Cys Thr Asn Tyr Gly Asn Leu Cys Gln  
 1 5 10 15

Tyr Phe Asn Val Cys Trp Ile Ile Thr Asp Ile Phe Ile Ile Leu Met  
20 25 30

Ser Thr Asn Leu Phe Ile Leu Ile Ala Arg Val Ser Leu Gly Ser Lys  
35 40 45

His His Leu Gly  
50

```
<210> 175
<211> 37
<212> PRT
<213> Homo sapien
```

<400> 175

Met Ala Gly Ser Gly Lys Val Pro Ile Thr Thr Thr Tyr Lys Pro Pro  
1 5 10 15

Thr Asn Ser Asn Ala Ile His Leu Pro Thr Pro Ile Ile Arg Lys Ala  
20 25 30

Gly Phe Thr Gly Ile  
35

```
<210> 176
<211> 88
<212> PRT
<213> Homo sapien
```

<400> 176

Met Gly Leu Thr Leu Lys Ser Leu Cys Asp Ser Lys Met Asn Cys Gln  
1 5 10 15

Ser Asn Val Pro Leu Met Lys Asp Pro Ile Thr Leu Gln His Val Cys

Ile Gln Arg Thr Tyr Leu Arg Leu Ser Phe Gly His Gly Gly Arg Leu  
35 40 45

Leu Leu Lys Thr Tyr Gln Ser Pro Leu Trp Arg Ser Ala Asp Arg Pro  
50 55 60

His Asp Leu Gly Asn Gly Leu Leu Val Ile Trp Asp Cys Leu Gly Leu  
65 70 75 80

139

Cys Asn Gly Thr Trp Gly Gln Asn  
85

<210> 177  
<211> 61  
<212> PRT  
<213> Homo sapien

<400> 177

Met Asp His Lys Ser Ala Asn His Ser Ser Ala Leu Leu Lys Met Leu  
1 5 10 15

Leu Ala Gly Gly Met Ser Leu Pro Glu Val Pro Glu Gly Leu Thr Pro  
20 25 30

Thr Pro Ser Ser Gln Thr His Leu Ser Lys Gly Lys Gly Arg Asn Leu  
35 40 45

Glu Lys Ser Tyr Phe His Asn His Ser Leu Arg Glu Pro  
50 55 60

<210> 178  
<211> 198  
<212> PRT  
<213> Homo sapien

<400> 178

Met Thr Pro Ile His Leu Ile Cys Ser Pro Ser His Glu Leu Gln Asp  
1 5 10 15

Thr Thr His Pro Gln Pro Gln Arg Glu Cys Gln Arg Phe Ser Thr His  
20 25 30

Gly Ala Gln Thr Thr Gln Cys Ala Thr His His His Pro Tyr Ile Ser  
35 40 45

Gly Ala Ala Thr Arg Thr Tyr Leu Arg His Val Ala Pro Asp Tyr Ser  
50 55 60

Ala Pro Leu Met Ala Pro Pro Thr Asn Thr Arg Leu Ala Pro Ala Ser  
65 70 75 80

Leu Gln Pro Thr His Leu Arg Pro Pro Leu Ala Arg His Pro Leu Thr  
85 90 95

Ala Asp Cys Arg Thr His Gln Leu Thr Asp Thr Arg Pro Leu His Pro

140

100

105

110

Arg Pro Ile Thr Ser Arg Thr Pro Gln Pro Leu Pro Ser His Thr His  
 115 120 125

Gly Leu His His Thr Arg Pro Pro His Thr Ala Thr Gly Cys Pro Tyr  
 130 135 140

Leu Ser Thr Ser Arg Pro Leu Pro Pro Leu His Thr Arg Ser Ile His  
 145 150 155 160

Pro Asp Asn Pro His Cys Thr Thr Pro His His Ser Pro Ser Lys Pro  
 165 170 175

Ser Thr Thr Thr His Gln Gln Ser Pro Ala Pro Thr Pro Asn Lys Pro  
 180 185 190

His Pro Arg Arg Ala Ser  
 195

<210> 179  
 <211> 20  
 <212> PRT  
 <213> Homo sapien

<400> 179

Met Ile Gly Ile Thr Trp Cys Phe Glu Leu Ile His Pro Thr Leu Glu  
 1 5 10 15

Leu Thr Ala Thr  
 20

<210> 180  
 <211> 107  
 <212> PRT  
 <213> Homo sapien

<400> 180

Met Gly Ala Ser Gly Pro Glu Arg Glu Asp Arg Asn Ser Glu Asn Gly  
 1 5 10 15

Val Glu Lys Lys Asn Val Lys Glu Leu His Glu Glu His Met Ala Glu  
 20 25 30

Lys Lys Glu Leu Gln Glu Glu Asn Gln Arg Leu Gln Gly Leu Pro Val  
 35 40 45

141

Ser Gly Ser Glu Glu Gly Arg Leu Pro Val Pro Ser Ala Arg Ser Ser  
 50 55 60

Thr Leu Arg Ala Ser Cys Arg Asn Glu Leu Gly Ser Leu Leu Pro Gly  
 65 70 75 80

Gly Glu Thr Ser Leu Gly Leu Lys Glu Gly His Arg Thr Lys Gly Ala  
 85 90 95

Arg Gly Gly His Arg Glu Asp Pro Gln Glu Lys  
 100 105

<210> 181  
 <211> 27  
 <212> PRT  
 <213> Homo sapien

<400> 181

Met Ser Thr His Ser Val His Ser Thr Gly Leu Pro Phe Tyr Lys Leu  
 1 5 10 15

Ser Leu Thr Ser Leu Ser Ser Met Thr Leu Val  
 20 25

<210> 182  
 <211> 40  
 <212> PRT  
 <213> Homo sapien

<400> 182

Cys Phe Glu Lys Met Leu Asn Arg Leu Gly Ala Val Ala His Val Cys  
 1 5 10 15

Asn Pro Ser Thr Leu Gly Gly Arg Gly Gly Trp Ile Met Arg Ser Gly  
 20 25 30

Val Arg Asp Gln Pro Gly Gln His  
 35 40

<210> 183  
 <211> 26  
 <212> PRT  
 <213> Homo sapien

<400> 183

142

Met Arg Lys Gln Ala Phe Asp Leu Leu Glu Ser Thr Ala Gln Lys Ser  
 1 5 10 15

Leu Val Pro Ile Phe Glu Phe Pro Lys Gln  
 20 25

<210> 184  
 <211> 39  
 <212> PRT  
 <213> Homo sapien

<400> 184

Met Lys Glu Glu Gly Arg Leu Leu Thr Val Ala Glu Gly Arg Gln Gly  
 1 5 10 15

Pro Ser Cys Ser Ser His Ile Asn Ser Lys Lys Pro Ser Gln Gln Asn  
 20 25 30

Lys Ser Ile Phe Asn Ser Ser  
 35

<210> 185  
 <211> 76  
 <212> PRT  
 <213> Homo sapien

<400> 185

Met Val Glu Pro Ala Leu Ser Gly Cys Gln Gln Arg Lys Gly Gly Tyr  
 1 5 10 15

Ser Ser Glu Arg Gln Ser Gln Pro Thr Gln Gly Gly Gln Gly Val Arg  
 20 25 30

Pro Gln Thr Tyr Ser Pro Ala Asp Leu Thr Val Arg Pro Ser Cys Ser  
 35 40 45

Gly Thr Gly Asn Ala Gln Ala Glu Ile Ala Leu Leu His Thr Tyr Asn  
 50 55 60

Thr Thr Leu Glu Asn Asn Leu Glu Trp Phe Thr Leu  
 65 70 75

<210> 186  
 <211> 35  
 <212> PRT  
 <213> Homo sapien

143

&lt;400&gt; 186

Met Arg Gln Pro Cys Leu Ala Ile Pro Glu Ala Ser Ala Ser Leu Ile  
 1 5 10 15

Cys Arg Cys His Arg His Phe Thr Tyr Ser His Leu Met Ala Arg Phe  
 20 25 30

Leu Leu Leu  
 35

&lt;210&gt; 187

&lt;211&gt; 76

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 187

Met Phe Phe Ala Leu Met Gly Ile Cys Pro Gly Thr Leu Pro Pro Gly  
 1 5 10 15

Pro Pro Leu Pro Arg Trp Pro Pro Pro Val Phe Cys Phe Phe Phe  
 20 25 30

Phe Phe Gly Phe Phe Phe Cys Cys Phe Thr Val Lys Leu Phe Ile Glu  
 35 40 45

Gln Ile Glu Asp Asn Asp Ile Cys Phe Tyr Tyr Arg Ser Leu Pro Ser  
 50 55 60

Ser Tyr Ile Ile Asp Thr Tyr Tyr Glu Thr Cys Ile  
 65 70 75

&lt;210&gt; 188

&lt;211&gt; 173

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 188

Met Ile Gly Cys Ser Leu Leu Val Ala Cys Leu Cys Cys Leu Val Gln  
 1 5 10 15

Ser Phe Arg Ala Met Phe Ser Cys Phe Ser Gly Leu Ser Leu Cys Leu  
 20 25 30

Met Leu Pro Leu Trp Cys Val Cys Pro Thr Val Cys Ala Phe Phe Cys  
 35 40 45



144

Gly Tyr Leu Leu Phe Phe Ser Leu Arg His Ala Ala Cys Gly Cys Leu  
 50 55 60

Leu Val Cys Leu Ser Cys Leu Ala Leu Pro Ser Gly Pro Ile Leu Ser  
 65 70 75 80

Phe Ser Phe Cys Leu Arg Val Val Ser Ser Val Arg Val Ala Cys Ala  
 85 90 95

Arg Ser Ala Ala Val Leu Leu Leu Arg Gly Val Pro Pro Pro Ser Leu  
 100 105 110

Arg Thr Leu Ser Leu Ile Ala Ser Thr Ala Thr Arg Leu Ser Phe Val  
 115 120 125

Phe Leu Phe Ser Leu Pro Arg Gly Leu Leu Cys Val Gly Gly Ser Gly  
 130 135 140

Ser Val Leu Gly Ser Leu Val Arg Arg Ala Gln Ser Val Gly Leu Arg  
 145 150 155 160

Asp Phe Val Ser Val Leu Gln Val Val Leu Thr Cys Leu  
 165 170

<210> 189  
 <211> 29  
 <212> PRT  
 <213> Homo sapien

<400> 189

Met Val Leu Tyr Ser Glu Gly His Gln His Gly Pro His Leu Leu Asn  
 1 5 10 15

Met Glu Asn Gln Asn Leu Asn Glu Leu Pro Leu Lys Gly  
 20 25

<210> 190  
 <211> 122  
 <212> PRT  
 <213> Homo sapien

<400> 190

Phe Phe Ala Asp Glu Val Ser Arg Leu Ser Pro Gly Leu Glu Cys Ser  
 1 5 10 15

145

Gly Val Ile Ser Ala His Cys Asn Phe His Leu Leu Gly Ser Ser Ser  
                   20                  25                  30

Ser Pro Ala Ser Ala Ser Gln Val Ala Glu Ile Thr Gly Ala Cys His  
                   35                  40                  45

Pro Thr Trp Leu Ile Phe Val Ile Leu Val Glu Thr Gly Phe His His  
                   50                  55                  60,

Val Gly Gln Ala Asp Ala Leu Leu Thr Ser Gly Asp Pro Pro Phe Ser  
                   65                  70                  75                  80

Ala Pro Lys Val Leu Gly Ile Thr Gly Val Ser His Arg Ala Arg Pro  
                   85                  90                  95

Ala Asn Thr Phe Ala Leu Thr Thr Leu Gly Leu Leu Tyr Lys Ile Val  
                   100                  105                  110

Met Ile Ala Met Glu Val Leu Pro Val Pro  
                   115                  120

<210> 191  
 <211> 11  
 <212> PRT  
 <213> Homo sapien

<400> 191

Met Trp Arg Ala Lys Gln Tyr Asp Leu Gln Thr  
                   1                  5                  10

<210> 192  
 <211> 28  
 <212> PRT  
 <213> Homo sapien

<400> 192

Met Met Phe Ser Leu Ser Gln Lys Gly Ser Ala Ala Val Gln Ser Pro  
                   1                  5                  10                  15

Ser Thr Leu Ser Thr Pro Thr Phe Ser Ile Ser Tyr  
                   20                  25

<210> 193  
 <211> 48  
 <212> PRT  
 <213> Homo sapien

146

&lt;400&gt; 193

Met Asp Ser Gly Ala Arg Ala Gly Lys Pro Leu Leu Asp Pro Val Cys  
 1 5 10 15

Leu Pro Ala Trp Ser Leu Cys Leu Gln Pro Cys Leu Tyr Ser Ser Leu  
 20 25 30

Pro Pro His Gln Pro Pro Leu Ala Ser Pro Tyr Arg Leu Ser Lys Lys  
 35 40 45

&lt;210&gt; 194

&lt;211&gt; 1138

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 194

Met Gly Asp Phe Ala Ala Pro Ala Ala Ala Asn Gly Ser Ser Ile  
 1 5 10 15

Cys Ile Asn Ser Ser Leu Asn Ser Ser Leu Gly Gly Ala Gly Ile Gly  
 20 25 30

Val Asn Asn Thr Pro Asn Ser Thr Pro Ala Ala Pro Ser Ser Asn His  
 35 40 45

Pro Ala Ala Gly Gly Cys Gly Gly Ser Gly Gly Pro Gly Gly Gly Ser  
 50 55 60

Ala Ala Val Pro Lys His Ser Thr Val Val Glu Arg Leu Arg Gln Arg  
 65 70 75 80

Ile Glu Gly Cys Arg Arg His His Val Asn Cys Glu Asn Arg Tyr Gln  
 85 90 95

Gln Ala Gln Val Glu Gln Leu Glu Leu Glu Arg Arg Asp Thr Val Ser  
 100 105 110

Leu Tyr Gln Arg Thr Leu Glu Gln Arg Ala Lys Lys Ser Gly Ala Gly  
 115 120 125

Thr Gly Lys Gln Gln His Pro Ser Lys Pro Gln Gln Asp Ala Glu Ala  
 130 135 140

Ala Ser Ala Glu Gln Arg Asn His Thr Leu Ile Met Leu Gln Glu Thr  
 145 150 155 160

147

Val Lys Arg Lys Leu Glu Gly Ala Arg Ser Pro Leu Asn Gly Asp Gln  
 165 170 175

Gln Asn Gly Ala Cys Asp Gly Asn Phe Ser Pro Thr Ser Lys Arg Ile  
 180 185 190

Arg Lys Asp Ile Ser Ala Gly Met Glu Ala Ile Asn Asn Leu Pro Ser  
 195 200 205

Asn Met Pro Leu Pro Ser Ala Ser Pro Leu His Gln Leu Asp Leu Lys  
 210 215 220

Pro Ser Leu Pro Leu Gln Asn Ser Gly Thr His Thr Pro Gly Leu Leu  
 225 230 235 240

Glu Asp Leu Ser Lys Asn Gly Arg Leu Pro Glu Ile Lys Leu Pro Val  
 245 250 255

Asn Gly Cys Ser Asp Leu Glu Asp Ser Phe Thr Ile Leu Gln Ser Lys  
 260 265 270

Asp Leu Lys Gln Glu Pro Leu Asp Asp Pro Thr Cys Ile Asp Thr Ser  
 275 280 285

Glu Thr Ser Leu Ser Asn Gln Asn Lys Leu Phe Ser Asp Ile Asn Leu  
 290 295 300

Asn Asp Gln Glu Trp Gln Glu Leu Ile Asp Glu Leu Ala Asn Thr Val  
 305 310 315 320

Pro Glu Asp Asp Ile Gln Asp Leu Phe Asn Glu Asp Phe Glu Glu Lys  
 325 330 335

Lys Glu Pro Glu Phe Ser Gln Pro Ala Thr Glu Thr Pro Leu Ser Gln  
 340 345 350

Glu Ser Ala Ser Val Lys Ser Asp Pro Ser His Ser Pro Phe Ala His  
 355 360 365

Val Ser Met Gly Ser Pro Gln Ala Arg Pro Ser Ser Ser Gly Pro Pro  
 370 375 380

Phe Ser Thr Val Ser Thr Ala Thr Ser Leu Pro Ser Val Ala Ser Thr

385						390						395					400
Pro	Ala	Ala	Pro	Asn	Pro	Ala	Ser	Ser	Pro	Ala	Asn	Cys	Ala	Val	Gln		
				405					410					415			
Ser	Pro	Gln	Thr	Pro	Asn	Gln	Ala	His	Thr	Pro	Gly	Gln	Ala	Pro	Pro		
			420					425					430				
Arg	Pro	Gly	Asn	Gly	Tyr	Leu	Leu	Asn	Pro	Ala	Ala	Val	Thr	Val	Ala		
		435					440					445					
Gly	Ser	Ala	Ser	Gly	Pro	Val	Ala	Val	Pro	Ser	Ser	Asp	Met	Ser	Pro		
	450					455						460					
Ala	Glu	Gln	Leu	Lys	Gln	Met	Ala	Ala	Gln	Gln	Gln	Gln	Arg	Ala	Lys		
465					470					475					480		
Leu	Met	Gln	Gln	Lys	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln		
				485					490						495		
Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	His	Ser		
				500				505						510			
Asn	Gln	Thr	Ser	Asn	Trp	Ser	Pro	Leu	Gly	Pro	Pro	Ser	Ser	Pro	Tyr		
		515					520					525					
Gly	Ala	Ala	Phe	Thr	Ala	Glu	Lys	Pro	Asn	Ser	Pro	Met	Met	Tyr	Pro		
	530					535					540						
Gln	Ala	Phe	Asn	Asn	Gln	Asn	Pro	Ile	Val	Pro	Pro	Met	Ala	Asn	Asn		
545					550					555					560		
Leu	Gln	Lys	Thr	Thr	Met	Asn	Asn	Tyr	Leu	Pro	Gln	Asn	His	Met	Asn		
				565					570					575			
Met	Ile	Asn	Gln	Gln	Pro	Asn	Asn	Leu	Gly	Thr	Asn	Ser	Leu	Asn	Lys		
			580					585					590				
Gln	His	Asn	Ile	Leu	Thr	Tyr	Gly	Asn	Thr	Lys	Pro	Leu	Thr	His	Phe		
		595					600					605					
Asn	Ala	Asp	Leu	Ser	Gln	Arg	Met	Thr	Pro	Pro	Val	Ala	Asn	Pro	Asn		
610						615						620					

149

Lys Asn Pro Leu Met Pro Tyr Ile Gln Gln Gln Gln Gln Gln Gln  
 625 630 635 640

Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Pro Pro Pro Pro Gln Leu  
 645 650 655

Gln Ala Pro Arg Ala His Leu Ser Glu Asp Gln Lys Arg Leu Leu Leu  
 660 665 670

Met Lys Gln Lys Gly Val Met Asn Gln Pro Met Ala Tyr Ala Ala Leu  
 675 680 685

Pro Ser His Gly Gln Glu Gln His Pro Val Gly Leu Pro Arg Thr Thr  
 690 695 700

Gly Pro Met Gln Ser Ser Val Pro Pro Gly Ser Gly Gly Met Val Ser  
 705 710 715 720

Gly Ala Ser Pro Ala Gly Pro Gly Phe Leu Gly Ser Gln Pro Gln Ala  
 725 730 735

Ala Ile Met Lys Gln Met Leu Ile Asp Gln Arg Ala Gln Leu Ile Glu  
 740 745 750

Gln Gln Lys Gln Gln Phe Leu Arg Glu Gln Arg Gln Gln Gln Gln  
 755 760 765

Gln Gln Gln Gln Ile Leu Ala Glu Gln Gln Leu Gln Gln Ser His Leu  
 770 775 780

Pro Arg Gln His Leu Gln Pro Gln Arg Asn Pro Tyr Pro Val Gln Gln  
 785 790 795 800

Val Asn Gln Phe Gln Gly Ser Pro Gln Asp Ile Ala Ala Val Arg Ser  
 805 810 815

Gln Ala Ala Leu Gln Ser Met Arg Thr Ser Arg Leu Met Ala Gln Asn  
 820 825 830

Ala Gly Met Met Gly Ile Gly Pro Ser Gln Asn Pro Gly Thr Met Ala  
 835 840 845

Thr Ala Ala Ala Gln Ser Glu Met Gly Leu Ala Pro Tyr Ser Thr Thr  
 850 855 860

150

Pro Thr Ser Gln Pro Gly Met Tyr Asn Met Ser Thr Gly Met Thr Gln  
 865 870 875 880

Met Leu Gln His Pro Asn Gln Ser Gly Met Ser Ile Thr His Asn Gln  
 885 890 895

Ala Gln Gly Pro Arg Gln Pro Ala Ser Gly Gln Gly Val Gly Met Val  
 900 905 910

Ser Gly Phe Gly Gln Ser Met Leu Val Asn Ser Ala Ile Thr Gln Gln  
 915 920 925

His Pro Gln Met Lys Gly Pro Val Gly Gln Ala Leu Pro Arg Pro Gln  
 930 935 940

Ala Pro Pro Arg Leu Gln Ser Leu Met Gly Thr Val Gln Gln Gly Ala  
 945 950 955 960

Gln Ser Trp Gln Gln Arg Ser Leu Gln Gly Met Pro Gly Arg Thr Ser  
 965 970 975

Gly Glu Leu Gly Pro Phe Asn Asn Gly Ala Ser Tyr Pro Leu Gln Ala  
 980 985 990

Gly Gln Pro Arg Leu Thr Lys Gln His Phe Pro Gln Gly Leu Ser Gln  
 995 1000 1005

Ser Val Val Asp Ala Asn Thr Gly Thr Val Arg Thr Leu Asn Pro  
 1010 1015 1020

Ala Ala Met Gly Arg Gln Met Met Pro Ser Leu Pro Gly Gln Gln  
 1025 1030 1035

Gly Thr Ser Gln Ala Arg Pro Met Val Met Ser Gly Leu Ser Gln  
 1040 1045 1050

Gly Val Pro Gly Met Pro Ala Phe Ser Gln Pro Pro Ala Gln Gln  
 1055 1060 1065

Gln Ile Pro Ser Gly Ser Phe Ala Pro Ser Ser Gln Ser Gln Ala  
 1070 1075 1080

Tyr Glu Arg Asn Ala Pro Gln Asp Val Ser Tyr Asn Tyr Ser Gly  
 1085 1090 1095

151

Asp Gly Ala Gly Gly Ser Phe Pro Gly Leu Pro Asp Gly Ala Asp  
 1100 1105 1110

Leu Val Asp Ser Ile Ile Lys Gly Gly Pro Gly Asp Glu Trp Met  
 1115 1120 1125

Gln Glu Leu Asp Glu Leu Phe Gly Asn Pro  
 1130 1135

<210> 195  
 <211> 30  
 <212> PRT  
 <213> Homo sapien

<400> 195

Met Gln Leu Pro Leu Ser His Lys Arg Lys Lys Gln Tyr Ser Phe Tyr  
 1 5 10 15

Val Phe Asp Thr Asn Ile Lys His Asn Ser Val Leu Val His  
 20 25 30

<210> 196  
 <211> 46  
 <212> PRT  
 <213> Homo sapien

<400> 196

Met Lys Ile Tyr Phe Lys Ile Leu Leu Met Phe Leu Lys Lys Tyr Phe  
 1 5 10 15

Leu Arg Phe His Leu Met Lys Thr Met Lys Tyr Ser Val Phe Tyr Ser  
 20 25 30

Thr Thr Arg Gln Met Trp Ser Ile Pro Phe Val Phe Phe Phe  
 35 40 45

<210> 197  
 <211> 18  
 <212> PRT  
 <213> Homo sapien

<400> 197

Met Leu Glu Ala Gly Ile Ser Phe Lys Val Arg Leu Gln Lys Trp Lys  
 1 5 10 15



152

Gln Ile

<210> 198  
 <211> 132  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 198

Met Phe Tyr Ser Ile Leu Ala Met Leu Arg Asp Arg Gly Ala Leu Gln  
 1 5 10 15

Asp Leu Met Asn Met Leu Glu Leu Asp Ser Ser Gly His Leu Asp Gly  
 20 25 30

Pro Gly Gly Ala Ile Leu Lys Lys Leu Gln Gln Asp Ser Asn His Ala  
 35 40 45

Trp Phe Asn Pro Lys Asp Pro Ile Leu Tyr Leu Leu Glu Ala Ile Met  
 50 55 60

Val Leu Ser Asp Phe Gln His Asp Leu Leu Ala Cys Ser Met Glu Lys  
 65 70 75 80

Arg Ile Leu Leu Gln Gln Gln Glu Leu Val Arg Ser Ile Leu Glu Pro  
 85 90 95

Asn Phe Arg Tyr Pro Trp Ser Ile Pro Phe Thr Leu Lys Pro Glu Leu  
 100 105 110

Leu Ala Pro Leu Gln Ser Glu Gly Leu Ala Ser Pro Met Ala Ala Gly  
 115 120 125

Gly Val Trp Pro  
 130

<210> 199  
 <211> 226  
 <212> PRT  
 <213> Homo sapien

&lt;400&gt; 199

Pro Pro Lys His Leu Lys Ser Lys Phe Gly Gly Met Arg Lys Ala Asp  
 1 5 10 15

Asp Asp Leu Ile Leu Leu Leu Gly Arg Ile Glu Glu Pro Phe Trp Gln

153

20

25

30

Asn Phe Lys His Leu Gln Glu Val Phe Gln Lys Ile Lys Thr Leu  
 35 40 45

Ala Gln Leu Ser Lys Asp Val Gln Asp Val Met Phe Tyr Ser Ile Leu  
 50 55 60

Ala Met Leu Arg Asp Arg Gly Ala Leu Gln Asp Leu Met Asn Met Leu  
 65 70 75 80

Glu Leu Asp Ser Ser Gly His Leu Asp Gly Pro Gly Gly Ala Ile Leu  
 85 90 95

Lys Lys Leu Gln Gln Asp Ser Asn His Ala Trp Phe Asn Pro Lys Asp  
 100 105 110

Pro Ile Leu Tyr Leu Leu Glu Ala Ile Met Val Leu Ser Asp Phe Gln  
 115 120 125

His Asp Leu Leu Ala Cys Ser Met Glu Lys Arg Ile Leu Leu Gln Gln  
 130 135 140

Gln Glu Leu Val Arg Ser Ile Leu Glu Pro Asn Phe Arg Tyr Pro Trp  
 145 150 155 160

Ser Ile Pro Phe Thr Leu Lys Pro Glu Leu Leu Ala Pro Leu Gln Ser  
 165 170 175

Glu Gly Leu Ala Ile Thr Tyr Gly Leu Leu Glu Glu Cys Gly Leu Arg  
 180 185 190

Thr Glu Leu Asp Asn Pro Arg Ser Thr Trp Asp Val Glu Ala Lys Met  
 195 200 205

Pro Leu Ser Ala Leu Tyr Gly Thr Leu Ser Leu Leu Gln Gln Leu Ala  
 210 215 220

Glu Ala  
 225

&lt;210&gt; 200

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

154

&lt;400&gt; 200

Met Ala Lys His Lys Gly Gly Tyr Gly Lys Tyr Trp Val Thr Leu Ile  
 1 5 10 15

Ile Gly Leu Asn Ala Thr Asn Asn Ile Ile Ile Val Leu Thr Tyr Phe  
 20 25 30

Phe Arg Leu Leu Ser  
 35

&lt;210&gt; 201

&lt;211&gt; 28

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 201

Met Val His Lys Ser Tyr Phe Thr Thr Leu Ser Leu Val Ile Leu Gly  
 1 5 10 15

Val Trp Pro Cys Lys Ala Ser Ser Gln Arg Phe Cys  
 20 25

&lt;210&gt; 202

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 202

Met Gly Ser Val Cys Val Cys Phe His Arg Ser Thr Thr Ser Glu Val  
 1 5 10 15

Ser Leu His Leu Cys Ile Phe Thr Ser Gln Gly Gln Gly Pro Gly Asn  
 20 25 30

Leu Arg Gly Ser His Ser Phe Ser Leu Pro Gln Thr Met Pro Leu Pro  
 35 40 45

Pro Ile Ser Leu Gly Gln Glu Ser Gly Phe Cys Phe Pro Tyr Phe Phe  
 50 55 60

Phe Pro Arg His Trp Glu Ala Ser Gly Glu Gln His Gln  
 65 70 75

&lt;210&gt; 203

&lt;211&gt; 70

155

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 203

Met Gly Pro Pro Leu Pro Leu Gly Gly Trp Ser Ser Asp Leu Leu Ala  
 1 5 10 15

Gln Lys Val Leu Phe Phe His Leu Leu Cys Leu Asn Glu Ser Ser Trp  
 20 25 30

Thr Tyr Thr Pro Leu Ser Asp Glu Arg Ala Arg Leu Arg Arg Cys Ala  
 35 40 45

Gly His Leu Leu Arg Ile His Val Gly Ser Ala Ala Pro Gly Gly Gly  
 50 55 60

Ser Thr Ser Ala Ala Thr  
 65 70

&lt;210&gt; 204

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 204

Met Ser Lys Lys Lys Asp Gln Asp Leu Cys Leu Lys Ile Glu Met His  
 1 5 10 15

Thr Ala Ala Ala Gln Lys Leu Arg Pro Ala Ser Lys Leu His Glu Ala  
 20 25 30

Leu Val Lys Thr Asp  
 35

&lt;210&gt; 205

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 205

Met Pro Ser Val Ala Gln Gly Pro Val Pro Trp His Leu Gly Ser Arg  
 1 5 10 15

Ser Ala Val Ala Val Phe Glu Phe Leu Val Met Phe Glu Gln Arg Pro  
 20 25 30

156

Tyr Val Cys Ile Leu His Trp Ala Pro Gln Ile Thr Trp Pro Ile Leu  
           35                          40                          45

Arg Arg Gly Val Ser His Leu Gln Ser Pro Lys Ser Pro Leu Glu Val  
           50                          55                          60

Phe Leu Asn Glu Arg Thr Glu Ala Phe Leu Lys Ser Ser Val Gly Glu  
       65                          70                          75                          80

Thr Val His His His Thr Gln  
                           85

&lt;210&gt; 206

&lt;211&gt; 46

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 206

Met Ser Pro Gly Thr Ala Met Ala Leu Gly Ala Pro Thr Leu Phe Phe  
       1                          5                          10                          15

Phe Phe Phe Phe Phe Phe Tyr Asn Gln Pro Ile Arg Asp Leu Ser  
                           20                          25                          30

Ile Asn Lys Pro Leu Phe Ile Ile Arg Asn Trp Leu Thr Gln  
           35                          40                          45

&lt;210&gt; 207

&lt;211&gt; 91

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 207

Met Ser Ser Pro Gln Ser Ile Glu His Asn His Asp Ser His Glu Leu  
       1                          5                          10                          15

Pro Thr Pro Pro Ala Ala Ser Ala Gln Arg Glu Ser Pro Leu Gln Val  
           20                          25                          30

Cys Leu Ile Ala Glu Pro Ile Phe Phe Leu Pro Gly Gln Gln Leu Leu  
           35                          40                          45

Ser Ser Met Ser Arg His Trp Cys Ser Leu Gly Trp Ala Pro Val Thr  
       50                          55                          60

Pro Met Glu Ile Leu Asp Gly Cys Tyr Arg Thr Gly Leu Asp Val Arg

157

65

70

75

80

Gly Leu Gly Asn Gly Ala Gln Glu Ser Ser Ser  
                                     85                                    90

&lt;210&gt; 208

&lt;211&gt; 87

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 208

Met Cys Val Arg Asn Ser Met Phe Lys Lys Glu Ile Ile Gln Arg Val  
   1                                    5                                    10                                    15

Thr Asn His Gly Ser Val Gly His Trp Thr Lys Leu Gly Phe Trp Thr  
                                     20                                    25                                    30

Phe Leu Pro Asn Ile Asn Phe Ala Leu Ala Ser Val Tyr Thr His Thr  
                                     35                                    40                                    45

His Thr Thr Thr Asn Thr Thr Gln Thr Thr Phe Trp Ala Asn Thr Thr  
   50                                    55                                    60

Arg Arg Gln Arg Arg Leu Pro Gly Leu Lys Leu Gly Ser Leu Pro Ala  
   65                                    70                                    75                                    80

Pro Gln Phe Ser Gln Gln Leu  
                                     85

&lt;210&gt; 209

&lt;211&gt; 55

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 209

Met Thr Cys Phe Arg Glu Cys Leu Leu Val Tyr Leu Tyr Ser Ile Cys  
   1                                    5                                    10                                    15

Leu Leu Asn Ser Leu His Lys Leu Glu Leu Leu Ser Arg Arg Leu Arg  
                                     20                                    25                                    30

Glu Cys Lys Tyr Val Thr His Lys Met His Trp Ser Met Val Asn Lys  
                                     35                                    40                                    45

Thr Asn His Phe Gly Leu Val  
   50                                    55

158

<210> 210  
 <211> 58  
 <212> PRT  
 <213> Homo sapien

<400> 210

Met Val Ile Phe Tyr Ser Ser Pro Ser Gln Asp Ser Ala Leu Ile Tyr  
 1 5 10 15

Tyr Ile Pro Phe Ile Leu Leu Tyr Arg Leu Leu Ser Glu Thr His Val  
 20 25 30

Gln Ile Arg Asp Lys Ile Leu Lys His Ile Thr Pro Ser Leu Val Phe  
 35 40 45

Ser Ile Gln Ile Leu Arg Asn Ser Cys Tyr  
 50 55

<210> 211  
 <211> 37  
 <212> PRT  
 <213> Homo sapien

<400> 211

Met Asn Leu Tyr Leu Lys Met Lys Thr Ile Pro Lys Lys Thr Cys Met  
 1 5 10 15

Ser Lys Thr Glu Leu Phe Leu Pro Phe Thr Pro Lys Tyr Leu Lys Leu  
 20 25 30

Asn Leu Ser His Phe  
 35

<210> 212  
 <211> 99  
 <212> PRT  
 <213> Homo sapien

<400> 212

Phe Phe Phe Phe Leu Arg Trp Ser Leu Ala Leu Ser Pro Arg Leu Glu  
 1 5 10 15

Cys Ser Gly Val Ile Ser Thr His Cys Asn Leu Cys Phe Pro Gly Ser  
 20 25 30

159

Ser Asp Ser Arg Ala Ser Pro Thr Phe Gln Val Ala Trp Ile Thr Gly  
 35 40 45

Val Arg His His Ser Trp Leu Ile Phe Val Leu Leu Val Glu Thr Gly  
 50 55 60

Phe His His Val Val Gln Ala Val Glu Leu Leu Thr Ser Arg Asp Pro  
 65 70 75 80

Pro Ala Ser Ala Ser Gln Ser Ala Ala Ile Ile Gly Val Asn His Cys  
 85 90 95

Ala Arg Pro

<210> 213  
 <211> 43  
 <212> PRT  
 <213> Homo sapien

<400> 213

Met Gln Glu Phe Thr Trp Leu Phe Glu Lys Glu Asn Phe Lys Val Ser  
 1 5 10 15

Gly Trp Thr Glu Ser His Glu Ala Arg Ser Leu Leu Thr Ala Arg Ser  
 20 25 30

Leu Glu Lys Gln Val Ser Gly Ser Phe Thr Ser  
 35 40

<210> 214  
 <211> 61  
 <212> PRT  
 <213> Homo sapien

<400> 214

Met Ala Val Asp Phe Tyr Asn Phe Val Thr Lys Leu Val Val Thr Thr  
 1 5 10 15

Gly Tyr Leu Arg Ile Ser Phe Leu Ala Tyr Lys Phe Phe Ser Phe Pro  
 20 25 30

Phe Leu Asp Ser Leu Ser Leu Cys Cys Pro Gly Leu Glu Cys Ser Gly  
 35 40 45

Val Ile Pro Ala His Tyr Asn Leu Tyr Leu Pro Gly Arg



160

50

55

60

<210> 215  
 <211> 127  
 <212> PRT  
 <213> Homo sapien

<400> 215

Ser Gln Asn<sup>1</sup> Ile Phe Phe Gly Val Ala Ile Phe Phe Phe Ser Phe Phe  
 1 5 10 15

Arg Gln Ser Leu Ser Leu Val Ala Gln Ala Arg Val Gln Trp Arg Asp  
 20 25 30

Pro Gly Ser Leu Gln Pro Leu Pro Pro Gly Phe Lys Arg Phe Leu Gly  
 35 40 45

Leu Ser Leu Pro Ser Ser Ala Gly Tyr Arg Arg Ala Pro Pro Pro Cys  
 50 55 60

Pro Ala Leu Leu Tyr Phe Ala Val Glu Thr Gly Phe His His Val Gly  
 65 70 75 80

Gln Ala Gly Leu Glu Leu Leu Thr Ser Gly Asn Pro Ala Ala Ser Ala  
 85 90 95

Ser Gln Ser Ala Gly Ile Thr Gly Thr Ser His Cys Thr Gln Pro Tyr  
 100 105 110

Tyr His Lys Ser Ser Ala Cys Trp Tyr Leu Ile Arg Phe Tyr Leu  
 115 120 125

<210> 216  
 <211> 13  
 <212> PRT  
 <213> Homo sapien

<400> 216

Met Glu Cys Ser Ser Leu Ala Glu Phe Lys Pro Val Phe  
 1 5 10

<210> 217  
 <211> 100  
 <212> PRT  
 <213> Homo sapien

<400> 217

161

Pro Gln Gln Thr Leu Lys Arg Ile Gln Gln Val Leu Ile Lys Cys Cys  
 1 5 10 15

Leu Ala Phe Tyr Leu Phe Leu Phe Phe Phe Phe Leu Arg Trp Ser Leu  
 20 25 30

Ala Leu Leu Pro Ser Leu Lys Cys Ser Gly Val Ile Ser Ala His Cys  
 35 40 45

Asn Leu Arg Leu Pro Gly Leu Gly Asp Ser Leu Ala Ser Ala Ser Arg  
 50 55 60

Val Ala Gly Met Thr Thr Gly Thr Cys His His Ala Gln Leu Ile Phe  
 65 70 75 80

Val Phe Leu Val Glu Thr Gly Phe Cys Val Ser Gln Asp Gly Leu Asp  
 85 90 95

Leu Leu Ile Ser  
 100

<210> 218  
 <211> 46  
 <212> PRT  
 <213> Homo sapien

<400> 218

Met Glu Gly Gly Glu Met Ser Thr Gln Val Glu Asn Arg Ser Glu Gly  
 1 5 10 15

Thr Ile Pro Ile Gln Thr Thr Cys Lys Ser His Asn Lys Ala Pro His  
 20 25 30

Cys Thr Glu Leu Arg His Lys Gln Arg Phe Pro Thr Asp Gly  
 35 40 45

<210> 219  
 <211> 72  
 <212> PRT  
 <213> Homo sapien

<400> 219

Ile Ser Phe Ile Phe Phe Ser Glu Ala Cys Gln Val Glu Val Arg Leu  
 1 5 10 15

162

Leu Leu Ala Tyr Asn Ser Ser Ala Arg Ile Pro Lys Cys Pro Trp Met  
 20 25 30

Glu Gly Gly Glu Met Ser Pro Gln Val Glu Thr Ser Ile Glu Gly Thr  
 35 40 45

Ile Pro Phe Ser Lys Pro Val Lys Val Tyr Ile Met Pro Lys Pro Ala  
 50 55 60

Arg Arg Pro Lys Pro Ala Arg Arg  
 65 70

<210> 220  
 <211> 41  
 <212> PRT  
 <213> Homo sapien

<400> 220

Met Glu Cys Lys Val Ile Lys Cys Ser Cys Phe His Leu Glu Gly Cys  
 1 5 10 15

Gly Pro Glu Gly Lys Arg Ser Pro Lys Tyr Pro Pro Pro Trp Cys Ser  
 20 25 30

Ser Leu Cys Leu Val Pro Ala Arg Ala  
 35 40

<210> 221  
 <211> 30  
 <212> PRT  
 <213> Homo sapien

<400> 221

Met Asn Ser Phe Gly Tyr Met Thr Pro Ser Lys Phe Phe Lys Lys Glu  
 1 5 10 15

Ile Thr Phe Lys Thr Thr Tyr Ile Phe Cys Phe Cys Leu Arg  
 20 25 30

<210> 222  
 <211> 22  
 <212> PRT  
 <213> Homo sapien

<400> 222

Met Leu Gln Ile Gly His Leu Leu Ser Met His Ser Leu Asp Lys Asn  
 1 5 10 15

163

Ile Gly Gln Val Gly Met  
20

<210> 223  
<211> 18  
<212> PRT  
<213> Homo sapien

<400> 223

Met Ser Asp Arg Val Val Ala Leu Leu Glu Val Phe Phe Pro Phe Gln  
1 5 10 15

Arg Glu

<210> 224  
<211> 133  
<212> PRT  
<213> Homo sapien

<400> 224

Met Gly Asn Ser Ile Asp Thr Val Arg Tyr Gly Lys Glu Ser Asp Leu  
1 5 10 15

Gly Asp Val Ser Glu Glu His Gly Glu Trp Asn Lys Glu Ser Ser Asn  
20 25 30

Asn Glu Gln Asp Asn Ser Leu Leu Glu Gln Tyr Leu Thr Ser Val Gln  
35 40 45

Gln Leu Glu Asp Ala Asp Glu Arg Thr Asn Phe Asp Thr Glu Thr Arg  
50 55 60

Asp Ser Lys Leu His Ile Ala Cys Phe Pro Val Gln Leu Asp Thr Leu  
65 70 75 80

Ser Asp Gly Ala Ser Val Asp Glu Ser His Gly Ile Ser Pro Pro Leu  
85 90 95

Gln Gly Glu Ile Ser Gln Thr Gln Glu Asn Ser Lys Leu Asn Ala Glu  
100 105 110

Val Gln Gly Gln Gln Pro Glu Cys Asp Ser Thr Phe Gln Leu Leu His  
115 120 125

164

Val Gly Val Thr Val  
130

<210> 225  
<211> 50  
<212> PRT  
<213> Homo sapien

<400> 225

Met Arg Asn Ser Ser Pro Ile Leu Thr Pro Ala Leu Phe Ser Phe His  
1 5 10 15

Met Tyr Ile Gly Pro Leu Ile Arg Ile Phe Lys Lys Phe Pro Arg Pro  
20 25 30

Pro Asn Leu Thr Ile Asp Asp Pro Leu Ser Leu Phe Arg Arg Asn Tyr  
35 40 45

Ile Gly  
50

<210> 226  
<211> 43  
<212> PRT  
<213> Homo sapien

<400> 226

Met His Ser Phe Phe Leu Ser Met Leu Cys Pro Glu Ala Leu Arg Val  
1 5 10 15

Leu Leu Lys Gln Ala Ala Gly Leu Leu Arg Glu Ile Lys Gly Phe Ile  
20 25 30

Ser Thr Thr Arg Cys Gln Asn Leu His Phe Glu  
35 40

<210> 227  
<211> 99  
<212> PRT  
<213> Homo sapien

<400> 227

Met Leu Glu Arg Arg Ser Val Met Asp Arg Arg Arg Ala Gly Asn Ser  
1 5 10 15

Pro Pro Arg Ile Glu Lys Cys Leu Leu Gly Arg Glu Glu Gly Glu Ala

165

20

25

30

Gly Ala Gly Pro Ser Pro Gly Ser Leu Leu Gly Pro Gln Lys Ala Leu  
 35 40 45

Asn Gln Ala Pro Ser Leu Gln Gly Lys Pro Arg Pro Gln Pro Asp Asn  
 50 55 60

Leu Glu Gly Arg Lys Ser Gln Thr Leu Gly Leu Phe Phe Gly Gly Ile  
 65 70 75 80

Ile Gly Phe Phe Phe Met Phe Leu Leu Glu Phe Cys Leu Leu Ala  
 85 90 95

Asn Ser Val

<210> 228

<211> 44

<212> PRT

<213> Homo sapien

<400> 228

Met Lys Ser Ile Gln Leu Lys Phe Ser Tyr Ile Ile Glu Pro Gln Leu  
 1 5 10 15

Asn Gly Met Asn Gly Ile Gly Asn Leu Leu Glu Met Ile Phe Met Ile  
 20 25 30

Thr Phe Val Val Ile Pro Phe Ser Trp Leu Arg Phe  
 35 40

<210> 229

<211> 41

<212> PRT

<213> Homo sapien

<400> 229

Tyr Phe Pro Leu Gln Ile Trp Ile Ser Glu Asp Ser Asn Asn Ile Glu  
 1 5 10 15

Ala Val Asn Gln Trp Lys Glu Thr Val Ile Asn Pro Glu Lys Val Val  
 20 25 30

Ile Arg Trp His Lys Leu Asn Pro Ser  
 35 40

166

<210> 230  
 <211> 48  
 <212> PRT  
 <213> Homo sapien

<400> 230

Met Leu Lys Gly His Tyr Gln Tyr Gly Met Glu Asp Leu Ser Phe His  
 1 5 10 15

Thr Phe Ser Ser Ser Phe Leu Asn Phe Leu Leu Leu Phe Leu Leu Ser  
 20 25 30

Cys Met Val Ala Pro Phe Pro Phe Leu Leu Ser Val Pro Ser Lys Gln  
 35 40 45

<210> 231  
 <211> 108  
 <212> PRT  
 <213> Homo sapien

<400> 231

Phe Leu Lys Arg Gln Ser Ile Ser Leu Leu Pro Gln Leu Glu Cys Ser  
 1 5 10 15

Gly Thr Ile Ile Val His His Thr Leu Glu Leu Leu Gly Lys Gly Ser  
 20 25 30

Ser Leu Ala Ser Ala Ser Gln Val Ala Arg Tyr Thr Gly Met Cys Tyr  
 35 40 45

His Ala Trp Leu Ile Lys Lys Ile Phe Leu Glu Met Arg Ser Cys Cys  
 50 55 60

Val Ala Gln Ala Gly Leu Lys Leu Leu Gly Ser Asn Asn Pro Pro Thr  
 65 70 75 80

Leu Ala Ser Gln Ser Ala Gly Ile Thr Gly Val Ser His Ser Thr Ala  
 85 90 95

Pro Tyr Leu Gln Ile Leu Asn Gln Ala Ile Ala Ile  
 100 105

<210> 232  
 <211> 64  
 <212> PRT

167

&lt;213&gt; Homo sapien

&lt;400&gt; 232

Met Ser Pro Arg Ala Pro Phe Ala Pro Gly Cys Pro Gln Pro Leu Val  
 1 5 10 15

Val Phe Tyr Val Cys Phe Phe Phe Phe Leu Ile Phe Cys Phe Val Lys  
 20 25 30

Lys His His Tyr Met Phe Leu Tyr Pro Arg Leu Lys Thr Phe Gly Asn  
 35 40 45

Leu Ile Ser Asn Ile Lys Ile Gln Ile Lys Thr His Ser Thr Ile Pro  
 50 55 60

&lt;210&gt; 233

&lt;211&gt; 35

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 233

Met Cys Val Asn Ala Ser Thr Val Gly Gln Met Cys Glu Asn Glu Leu  
 1 5 10 15

Lys His Met Leu Arg Ile Lys Val Asn Arg Arg Asn Phe Glu Arg Phe  
 20 25 30

Pro Leu Met  
 35

&lt;210&gt; 234

&lt;211&gt; 72

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 234

Met Asn Ile Phe Pro Trp Ala Gly Gly Pro Trp Ser Leu Pro Gln Ala  
 1 5 10 15

Arg Tyr Arg Ala Pro Ala Cys Ala Pro Thr Asn His Gly Lys Gln Arg  
 20 25 30

Arg Pro Pro His Leu Lys Ser Trp Pro Val Val Val Ser Ser Val Phe  
 35 40 45

Leu Leu Ser Glu Gln Asn Val Leu Lys Leu Glu Leu Thr Lys Val Lys



168

50

55

60

Ser Ser Lys Thr Thr Tyr Ala Thr  
65 70

<210> 235  
<211> 1163  
<212> PRT  
<213> Homo sapien

<400> 235

Met Asp Arg Asn Arg Glu Ala Glu Met Glu Leu Arg Arg Gly Pro Ser  
1 5 10 15

Pro Thr Arg Ala Gly Arg Gly His Glu Val Asp Gly Asp Lys Ala Thr  
20 25 30

Cys His Thr Cys Cys Ile Cys Gly Lys Ser Phe Pro Phe Gln Ser Ser  
35 40 45

Leu Ser Gln His Met Arg Lys His Thr Gly Glu Lys Pro Tyr Lys Cys  
50 55 60

Pro Tyr Cys Asp His Arg Ala Ser Gln Lys Gly Asn Leu Lys Ile His  
65 70 75 80

Ile Arg Ser His Arg Thr Gly Thr Leu Ile Gln Gly His Glu Pro Glu  
85 90 95

Ala Gly Glu Ala Pro Leu Gly Glu Met Arg Ala Ser Glu Gly Leu Asp  
100 105 110

Ala Cys Ala Ser Pro Thr Lys Ser Ala Ser Ala Cys Asn Arg Leu Leu  
115 120 125

Asn Gly Ala Ser Gln Ala Asp Gly Ala Arg Val Leu Asn Gly Ala Ser  
130 135 140

Gln Ala Asp Ser Gly Arg Val Leu Leu Arg Ser Ser Lys Lys Gly Ala  
145 150 155 160

Glu Gly Ser Ala Cys Ala Pro Gly Glu Ala Lys Ala Ala Val Gln Cys  
165 170 175

Ser Phe Cys Lys Ser Gln Phe Glu Arg Lys Lys Asp Leu Glu Leu His

169

180

185

190

Val His Gln Ala His Lys Pro Phe Lys Cys Arg Leu Cys Ser Tyr Ala  
 195 200 205

Thr Leu Arg Glu Glu Ser Leu Leu Ser His Ile Glu Arg Asp His Ile  
 210 215 220

Thr Ala Gln Gly Pro Gly Ser Gly Glu Ala Cys Val Glu Asn Gly Lys  
 225 230 235 240

Pro Glu Leu Ser Pro Gly Glu Phe Pro Cys Glu Val Cys Gly Gln Ala  
 245 250 255

Phe Ser Gln Thr Trp Phe Leu Lys Ala His Met Lys Lys His Arg Gly  
 260 265 270

Ser Phe Asp His Gly Cys His Ile Cys Gly Arg Arg Phe Lys Glu Pro  
 275 280 285

Trp Phe Leu Lys Asn His Met Lys Ala His Gly Pro Lys Thr Gly Ser  
 290 295 300

Lys Asn Arg Pro Lys Ser Glu Leu Asp Pro Ile Ala Thr Ile Asn Asn  
 305 310 315 320

Val Val Gln Glu Glu Val Ile Val Ala Gly Leu Ser Leu Tyr Glu Val  
 325 330 335

Cys Ala Lys Cys Gly Asn Leu Phe Thr Asn Leu Asp Ser Leu Asn Ala  
 340 345 350

His Asn Ala Ile His Arg Arg Val Glu Ala Ser Arg Thr Arg Ala Pro  
 355 360 365

Ala Glu Glu Gly Ala Glu Gly Pro Ser Asp Thr Lys Gln Phe Phe Leu  
 370 375 380

Gln Cys Leu Asn Leu Arg Pro Ser Ala Ala Gly Asp Ser Cys Pro Gly  
 385 390 395 400

Thr Gln Ala Gly Arg Arg Val Ala Glu Leu Asp Pro Val Asn Ser Tyr  
 405 410 415

170

Gln Ala Trp Gln Leu Ala Thr Arg Gly Lys Val Ala Glu Pro Ala Glu  
 420 425 430

Tyr Leu Lys Tyr Gly Ala Trp Asp Glu Ala Leu Ala Gly Asp Val Ala  
 435 440 445

Phe Asp Lys Asp Arg Arg Glu Tyr Val Leu Val Ser Gln Glu Lys Arg  
 450 455 460

Lys Arg Glu Gln Asp Ala Pro Ala Ala Gln Gly Pro Pro Arg Lys Arg  
 465 470 475 480

Ala Ser Gly Pro Gly Asp Pro Ala Pro Ala Gly His Leu Asp Pro Arg  
 485 490 495

Ser Ala Ala Arg Pro Asn Arg Arg Ala Ala Ala Thr Thr Gly Gln Gly  
 500 505 510

Lys Ser Ser Glu Cys Phe Glu Cys Gly Lys Ile Phe Arg Thr Tyr His  
 515 520 525

Gln Met Val Leu His Ser Arg Val His Arg Arg Ala Arg Arg Glu Arg  
 530 535 540

Asp Ser Asp Gly Asp Arg Ala Ala Arg Ala Arg Cys Gly Ser Leu Ser  
 545 550 555 560

Glu Gly Asp Ser Ala Ser Gln Pro Ser Ser Pro Gly Ser Ala Cys Ala  
 565 570 575

Ala Ala Asp Ser Pro Gly Ser Gly Leu Ala Asp Glu Ala Ala Glu Asp  
 580 585 590

Ser Gly Glu Glu Gly Ala Pro Glu Pro Ala Pro Gly Gly Gln Pro Arg  
 595 600 605

Arg Cys Cys Phe Ser Glu Glu Val Thr Ser Thr Glu Leu Ser Ser Gly  
 610 615 620

Asp Gln Ser His Lys Met Gly Asp Asn Ala Ser Glu Arg Asp Thr Gly  
 625 630 635 640

Glu Ser Lys Ala Gly Ile Ala Ala Ser Val Ser Ile Leu Glu Asn Ser  
 645 650 655

171

Ser Arg Glu Thr Ser Arg Arg Gln Glu Gln His Arg Phe Ser Met Asp  
 660 665 670

Leu Lys Met Pro Ala Phe His Pro Lys Gln Glu Val Pro Val Pro Gly  
 675 680 685

Asp Gly Val Glu Phe Pro Ser Ser Thr Gly Ala Glu Gly Gln Thr Gly  
 690 695 700

His Pro Ala Glu Lys Leu Ser Asp Leu His Asn Lys Glu His Ser Gly  
 705 710 715 720

Gly Gly Lys Arg Ala Leu Ala Pro Asp Leu Met Pro Leu Asp Leu Ser  
 725 730 735

Ala Arg Ser Thr Arg Asp Asp Pro Ser Asn Lys Glu Thr Ala Ser Ser  
 740 745 750

Leu Gln Ala Ala Leu Val Val His Pro Cys Pro Tyr Cys Ser His Lys  
 755 760 765

Thr Tyr Tyr Pro Glu Val Leu Trp Met His Lys Arg Ile Trp His Arg  
 770 775 780

Val Ser Cys Asn Ser Val Ala Pro Pro Trp Ile Gln Pro Asn Gly Tyr  
 785 790 795 800

Lys Ser Ile Arg Ser Asn Leu Val Phe Leu Ser Arg Ser Gly Arg Thr  
 805 810 815

Gly Pro Pro Pro Ala Leu Gly Gly Lys Glu Cys Gln Pro Leu Leu Leu  
 820 825 830

Ala Arg Phe Thr Arg Thr Gln Val Pro Gly Gly Met Pro Gly Ser Lys  
 835 840 845

Ser Gly Ser Ser Pro Leu Gly Val Val Thr Lys Ala Ala Ser Met Pro  
 850 855 860

Lys Asn Lys Glu Ser His Ser Gly Gly Pro Cys Ala Leu Trp Ala Pro  
 865 870 875 880

Gly Pro Asp Gly Tyr Arg Gln Thr Lys Pro Cys His Gly Gln Glu Pro  
 885 890 895

172

His Gly Ala Ala Thr Gln Gly Pro Leu Ala Lys Pro Arg Gln Glu Ala  
 900 905 910

Ser Ser Lys Pro Val Pro Ala Pro Gly Gly Gly Gly Phe Ser Arg Ser  
 915 920 925

Ala Thr Pro Thr Pro Thr Val Ile Ala Arg Ala Gly Ala Gln Pro Ser  
 930 935 940

Ala Asn Ser Lys Pro Val Glu Lys Phe Gly Val Pro Pro Ala Gly Ala  
 945 950 955 960

Gly Phe Ala Pro Thr Asn Lys His Ser Ala Pro Asp Ser Leu Lys Ala  
 965 970 975

Lys Phe Ser Ala Gln Pro Gln Gly Pro Pro Pro Ala Lys Gly Glu Gly  
 980 985 990

Gly Ala Pro Pro Leu Pro Pro Arg Glu Pro Pro Ser Lys Ala Ala Gln  
 995 1000 1005

Glu Leu Arg Thr Leu Ala Thr Cys Ala Ala Gly Ser Arg Gly Asp  
 1010 1015 1020

Ala Ala Leu Gln Ala Gln Pro Gly Val Ala Gly Ala Pro Pro Val  
 1025 1030 1035

Leu His Ser Ile Lys Gln Glu Pro Val Ala Glu Gly His Glu Lys  
 1040 1045 1050

Arg Leu Asp Ile Leu Asn Ile Phe Lys Thr Tyr Ile Pro Lys Asp  
 1055 1060 1065

Phe Ala Thr Leu Tyr Gln Gly Trp Gly Val Ser Gly Pro Gly Leu  
 1070 1075 1080

Glu His Arg Gly Thr Leu Arg Thr Gln Ala Arg Pro Gly Glu Phe  
 1085 1090 1095

Val Cys Ile Glu Cys Gly Lys Ser Phe His Gln Pro Gly His Leu  
 1100 1105 1110

Arg Ala His Met Arg Ala His Ser Val Val Phe Glu Ser Asp Gly

173

1115

1120

1125

Pro Arg Gly Ser Glu Val His Thr Thr Ser Ala Asp Ala Pro Lys  
 1130 1135 1140

Gln Gly Arg Asp His Ser Asn Thr Gly Thr Val Gln Thr Val Pro  
 1145 1150 1155

Leu Arg Lys Gly Thr  
 1160

<210> 236  
 <211> 55  
 <212> PRT  
 <213> Homo sapien

<400> 236

Met Cys Val Phe Cys Gly Phe Phe Cys Ser Arg Phe Val Arg Glu Met  
 1 5 10 15

Trp Gly Asn Phe Gly Pro Lys Thr Asn Phe Thr Pro Gly Thr Pro Phe  
 20 25 30

Cys Pro Trp Leu Ser Pro Asn Leu Phe Cys Leu Val Val Val Trp Phe  
 35 40 45

Tyr Arg Leu Leu Ile Phe Tyr  
 50 55

<210> 237  
 <211> 156  
 <212> PRT  
 <213> Homo sapien

<400> 237

Met Pro Met Glu Gly His Thr Leu Cys Met Arg Ile Arg Gly Ser Trp  
 1 5 10 15

Leu Ala Ala Arg Leu Pro Val Met Pro Phe Glu Gly Asp Val Gly Pro  
 20 25 30

Trp Val Arg Met Lys Val Phe Ile Cys His Ser Ser Ser Pro Gln Val  
 35 40 45

Ala Ile His Leu Gly Gly Gly Arg Glu Gly Ser Ala Leu Ala Ile Val  
 50 55 60

174

Tyr Pro Ala Ser Leu Arg Phe Ile Asp Leu His Lys Arg Leu Cys Ser  
65 70 75 80

Gly Lys Gly Arg Gly Pro Gln Lys Gly Ala Trp Gln Asp Arg Trp Met  
85 90 95

Leu Tyr Gly His Met Glu Ile Thr Pro Ser Ser Leu Ala Pro Ala Ser  
100 105 110

Ala Ser Arg Pro Leu His Gly Val Arg Cys Phe Cys Ala Cys Cys Pro  
115 120 125

Thr Ser Leu His Ser Arg Ala Leu Ile Asn His Phe Asp Pro Pro Leu  
130 135 140

Ala Glu Gly Ser Pro Leu Tyr Arg Val Gln Ser Leu  
145 150 155

<210> 238  
<211> 86  
<212> PRT  
<213> Homo sapien

<400> 238

Met Met Asn Phe Leu Cys Leu Asn Phe Arg Asp Ile Trp Cys Asp Phe  
1 5 10 15

His Leu Tyr Leu Met Leu Pro Leu Leu Pro Ser Leu Leu Asn Thr Ser  
20 25 30

Lys Asn Ser Glu His Ile Leu Ile Pro Pro Val Phe Tyr Phe Tyr Asp  
35 40 45

Leu Asp Ile Leu His His Lys Ile Pro Pro Asn Trp Asp Tyr Val Phe  
50 55 60

Glu Val Ile His Phe Thr Ile Ile Thr Thr Ile Thr Ile Ile Phe Ile  
65 70 75 80

Val Cys Phe Val Pro Gly  
85

<210> 239  
<211> 289

175

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 239

Ala Asp Leu Ser Phe Ile Glu Asp Thr Val Ala Phe Pro Glu Lys Glu  
 1 5 10 15

Glu Asp Glu Glu Glu Glu Glu Gly Val Glu Trp Gly Tyr Glu Glu  
 20 25 30

Gly Val Glu Trp Gly Leu Val Phe Pro Asp Ala Asn Gly Glu Tyr Gln  
 35 40 45

Ser Pro Ile Asn Leu Asn Ser Arg Glu Ala Arg Tyr Asp Pro Ser Leu  
 50 55 60

Leu Asp Val Arg Leu Ser Pro Asn Tyr Val Val Cys Arg Asp Cys Glu  
 65 70 75 80

Val Thr Asn Asp Gly His Thr Ile Gln Val Ile Leu Lys Ser Lys Ser  
 85 90 95

Val Leu Ser Gly Gly Pro Leu Pro Gln Gly His Glu Phe Glu Leu Tyr  
 100 105 110

Glu Val Arg Phe His Trp Gly Arg Glu Asn Gln Arg Gly Ser Glu His  
 115 120 125

Thr Val Asn Phe Lys Ala Phe Pro Met Glu Leu His Leu Ile His Trp  
 130 135 140

Asn Ser Thr Leu Phe Gly Ser Ile Asp Glu Ala Val Gly Lys Pro His  
 145 150 155 160

Gly Ile Ala Ile Ile Ala Leu Phe Val Gln Ile Gly Lys Glu His Val  
 165 170 175

Gly Leu Lys Ala Val Thr Glu Ile Leu Gln Asp Ile Gln Tyr Lys Gly  
 180 185 190

Lys Ser Lys Thr Ile Pro Cys Phe Asn Pro Asn Thr Leu Leu Pro Asp  
 195 200 205

Pro Leu Leu Arg Asp Tyr Trp Val Tyr Glu Gly Ser Leu Thr Ile Pro  
 210 215 220



This page is not part of  
the pamphlet!

**WO 02-064611**

**5/5**

Date: 22 aug 2002

Destination: Agent

Address:



176

Pro Cys Ser Glu Gly Val Thr Trp Ile Leu Phe Arg Tyr Pro Leu Thr  
 225 230 235 240

Ile Ser Gln Leu Gln Ile Glu Glu Phe Arg Arg Leu Arg Thr His Val  
 245 250 255

Lys Gly Ala Glu Leu Val Glu Gly Cys Asp Gly Ile Leu Gly Asp Asn  
 260 265 270

Phe Arg Pro Thr Gln Pro Leu Ser Asp Arg Val Ile Arg Ala Ala Phe  
 275 280 285

Gln

<210> 240  
 <211> 59  
 <212> PRT  
 <213> Homo sapien

<400> 240

Met Cys Gln Ile Asp Arg Gln Asp Leu Val Leu Leu Lys Leu Val Ile  
 1 5 10 15

Tyr Cys Ser Arg His Leu Lys Gly Trp Arg Arg Ser Glu His Tyr Val  
 20 25 30

Pro Ala Arg Ala Ser Ile Thr Leu Arg Arg Ser Thr Ser His Leu Val  
 35 40 45

Ala Arg Ser Pro Asn Met Ser Ser Ser Gly Val  
 50 55

<210> 241  
 <211> 41  
 <212> PRT  
 <213> Homo sapien

<400> 241

Met Leu Leu Asn Gly Leu His Asn Pro Ala Leu Lys His Leu Arg Asp  
 1 5 10 15

Leu Cys Lys Thr Phe Pro Trp Ser Leu Cys Phe Ser His Ile Asn Gln  
 20 25 30

177

Leu Ala Tyr Phe Ser His Ser Pro Ser  
           35                          40

<210> 242  
 <211> 80  
 <212> PRT  
 <213> Homo sapien

<400> 242

Met Asn Cys Leu Tyr Pro Ser Pro Met Cys Phe Tyr Arg Ser Cys Leu  
   1                  5                  10                  15

Val His Phe Val Ala Asp Leu Leu Gly Asp Phe Thr Glu Gly Lys Val  
           20                          25                          30

Ser Ser Lys Leu Tyr Asp Asp Phe Met Leu Ile Asp Leu Leu Ser Ser  
           35                          40                          45

Gly Ser Trp Glu Thr His Ser Ala Ile Ser Leu Leu Ser Tyr Phe Ser  
   50                          55                          60

Tyr Asp Ala Gln Pro Pro Lys Ala Thr Arg Glu Gln Tyr Arg Val Pro  
   65                          70                          75                          80

<210> 243  
 <211> 45  
 <212> PRT  
 <213> Homo sapien

<400> 243

Glu Arg Pro Gly Met Leu Asp Phe Thr Gly Lys Ala Lys Trp Asp Ala  
   1                  5                  10                  15

Trp Asn Glu Leu Lys Gly Thr Ser Lys Glu Asp Ala Met Lys Ala Tyr  
           20                          25                          30

Ile Asn Lys Val Glu Glu Leu Lys Lys Lys Tyr Gly Ile  
           35                          40                          45

<210> 244  
 <211> 24  
 <212> PRT  
 <213> Homo sapien

<400> 244

Met Cys Leu Asn Phe Ser Phe Asn Tyr Leu Ile Pro Phe Ala Gln Glu

178

1                      5                      10                      15

Ile Thr Ile Ser Leu Phe Phe Phe  
20

<210> 245  
<211> 69  
<212> PRT  
<213> Homo sapien

<400> 245

Leu Phe Phe Gln Leu Phe Asp Thr Phe Cys Pro Arg Asp Tyr Tyr Leu  
1                      5                      10                      15

Ser Leu Phe Phe Phe Ser Phe Lys Thr Glu Cys Cys Ser Val Thr Gln  
20                      25                      30

Val Gly Val Gln Trp His Asn Ser Ala Ser Leu Gln Pro Leu Pro Pro  
35                      40                      45

Arg Leu Lys Arg Ser Ser His Leu Ser Leu Pro Ser Ser Trp Asp His  
50                      55                      60

Arg His Ile Pro Pro  
65

<210> 246  
<211> 39  
<212> PRT  
<213> Homo sapien

<400> 246

Met Glu Thr Lys His His Ser His Lys Lys Ser Asn Ser Ile Leu Asn  
1                      5                      10                      15

His Trp Lys Val Thr Ile Pro Leu Tyr Ser Phe Pro Lys Leu Phe Val  
20                      25                      30

Ala Lys Ser Tyr Arg Lys Glu  
35

<210> 247  
<211> 93  
<212> PRT  
<213> Homo sapien

<400> 247

179

Leu Leu Gln Ala Leu Lys Lys Ile Phe Phe Leu Asn Ser Leu Thr Leu  
 1 5 10 15

Ser Pro Arg Leu Glu Ala Ser Asn Val Ile Ser Ala His Cys Asn Leu  
 20 25 30

His Ser Arg Val Ala Gly Ile Thr Asp Met His His His Pro Gln Leu  
 35 40 45

Ile Phe Val Phe Leu Val Glu Thr Gly Phe Arg His Val Gly Gln Ala  
 50 55 60

Gly Leu Ala Leu Leu Ala Leu Arg Asp Pro Pro Pro Leu Ala Phe Gln  
 65 70 75 80

Ser Ala Gly Ile Thr Gly Val Ser His Cys Thr Trp Pro  
 85 90

<210> 248  
 <211> 51  
 <212> PRT  
 <213> Homo sapien

<400> 248

Met Phe Phe Phe Phe Val Phe Phe Phe Phe Leu Phe Ala Arg Phe Ser  
 1 5 10 15

Arg Asn Val Gly Asp Leu Trp Ala Gly Lys Pro Phe Pro Pro Gly His  
 20 25 30

Val Leu Pro Arg Tyr Pro His Leu Phe Phe Phe Phe Phe Phe Phe Cys  
 35 40 45

Phe Ile Thr  
 50

<210> 249  
 <211> 62  
 <212> PRT  
 <213> Homo sapien

<400> 249

Met Asn Phe Thr Leu Ala Ile Phe His Tyr Phe Ser Leu Ser Gln Met  
 1 5 10 15

180

Ser Val Leu Met Arg Gln Leu Ala Leu Thr Gly Ala Thr Leu Met Cys  
 20 25 30

His Leu Pro Thr Phe Asn Phe Trp Val Lys Ala Glu Arg Glu Lys Leu  
 35 40 45

Met Asp Phe Ser Phe Ser Arg Arg Asp Lys Asn Gln Leu His  
 50 55 60

<210> 250

<211> 190

<212> PRT

<213> Homo sapien

<400> 250

Met Lys Leu Gln Leu Arg Ile Lys Ser Leu Thr Gln Asn Arg Thr Thr  
 1 5 10 15

Thr Trp Lys Leu Asn Asn Leu Leu Leu Asn Asp Tyr Trp Val Asn Lys  
 20 25 30

Lys Ile Lys Ala Glu Ile Asn Lys Phe Phe Glu Thr Ile Glu Asn Lys  
 35 40 45

Asp Thr Met Tyr Gln Asn Thr Ala Lys Ala Val Phe Arg Gly Lys Phe  
 50 55 60

Ile Ala Leu Asn Thr His Ile Arg Asn Trp Glu Ile Pro Lys Ile Asn  
 65 70 75 80

Val Leu Thr Ser Gln Leu Lys Glu Leu Glu Lys Arg Glu Gln Thr His  
 85 90 95

Ser Lys Gln Glu Ile Thr Lys Ile Ile Ala Glu Leu Lys Glu Ile Glu  
 100 105 110

Thr Gln Lys Ala Leu Gln Lys Ile Ser Asp Ser Arg Ser Trp Phe Phe  
 115 120 125

Glu Lys Ile Asn Lys Thr Asp Arg Leu Leu Ala Arg Ile Ile Lys Lys  
 130 135 140

Lys Arg Glu Lys Asn Gln Ile Asp Thr Ile Lys Asn Asp Lys Gly Asp  
 145 150 155 160

181

Ile Thr Thr Asn Pro Thr Glu Ile Gln Thr Ala Ile Arg Glu Cys Tyr  
 165 170 175

Gln His Leu Tyr Ile Asn Lys Leu Glu Asn Leu Glu Glu Ile  
 180 185 190

<210> 251  
 <211> 132  
 <212> PRT  
 <213> Homo sapien

<400> 251

Met Pro Val Leu Ser Pro Pro Leu His Met Pro Tyr Pro Ala Ala Lys  
 1 5 10 15

Leu Asp Ser Val Leu Pro Asp Lys Thr Trp Tyr Trp His Leu Tyr Ala  
 20 25 30

Ser Val Cys Leu Pro Ser Thr Phe Lys Lys Pro Leu Gln Ser Ala Asp  
 35 40 45

Thr Lys Lys Gln Ser His Thr Cys Ser Lys Ser Ala Cys Phe Pro Leu  
 50 55 60

Ile Ser Ala Ser Cys Gln Arg His Cys Leu Thr Ser Ser Ser Leu Leu  
 65 70 75 80

Ser Ile Cys Val Pro His Lys Thr Leu Arg Asp Ser Ala Ser Tyr Val  
 85 90 95

Tyr Gly Leu Trp Val Phe Ile Ser Thr Val Pro Cys Leu Thr Leu Ser  
 100 105 110

Pro Cys Gly Glu Tyr Thr His Pro Thr Pro Thr Val Pro Cys Thr Ser  
 115 120 125

Val Ala Ala Gln  
 130

<210> 252  
 <211> 30  
 <212> PRT  
 <213> Homo sapien

<400> 252

Met Gln Phe Arg Ile His Ala Ser Phe Ser Val Lys Trp Arg Ser Tyr



1                      5                      10                      15

```
<210> 253
<211> 49
<212> PRT
<213> Homo sapien'
```

Trp

```
<210> 254
<211> 54
<212> PRT
<213> Homo sapien
```

Ser Ser Pro Thr Val Val  
50

```
<210> 255
<211> 1088
<212> PRT
<213> Homo sapien
```

<400> 255

183

Asp Asp Ser Leu Ile Ser Ser Ala Thr Ala Ile Met Glu Ala Val Val  
 1 5 10 15  
 Arg Glu Trp Ile Leu Leu Glu Lys Gly Ser Ile Glu Ser Leu Arg Thr  
 20 25 30  
 Phe Leu Leu Thr Tyr Val Leu Gln Arg Pro Asn Leu Gln Lys Tyr Val  
 35 40 45  
 Arg Glu Gln Ile Leu Leu Ala Val Ala Val Ile Val Lys Arg Gly Ser  
 50 55 60  
 Leu Asp Lys Ser Ile Asp Cys Lys Ser Ile Phe His Glu Val Ser Gln  
 65 70 75 80  
 Leu Ile Ser Ser Gly Asn Pro Thr Val Gln Thr Leu Ala Cys Ser Ile  
 85 90 95  
 Leu Thr Ala Leu Leu Ser Glu Phe Ser Ser Ser Ser Lys Thr Ser Asn  
 100 105 110  
 Ile Gly Leu Ser Met Glu Phe His Gly Asn Cys Lys Arg Val Phe Gln  
 115 120 125  
 Glu Glu Asp Leu Arg Gln Ile Phe Met Leu Thr Val Glu Val Leu Gln  
 130 135 140  
 Glu Phe Ser Arg Arg Glu Asn Leu Asn Ala Gln Met Ser Ser Val Phe  
 145 150 155 160  
 Gln Arg Tyr Leu Ala Leu Ala Asn Gln Val Leu Ser Trp Asn Phe Leu  
 165 170 175  
 Pro Pro Asn Leu Gly Arg His Tyr Ile Ala Met Phe Glu Ser Ser Gln  
 180 185 190  
 Asn Val Leu Leu Lys Pro Thr Glu Ser Leu Arg Glu Thr Leu Leu Asp  
 195 200 205  
 Ser Arg Val Met Glu Leu Phe Phe Thr Val His Arg Lys Ile Arg Glu  
 210 215 220  
 His Ser Asp Met Ala Gln Asp Ser Leu Gln Cys Leu Ala Gln Leu Ala  
 225 230 235 240

184

Ser Leu His Gly Pro Ile Phe Pro Asp Glu Gly Ser Gln Val Asp Tyr  
 245 250 255

Leu Ala His Phe Ile Glu Gly Leu Leu Asn Thr Ile Asn Gly Ile Glu  
 260 265 270

Ile Glu Asp Ser Glu Ala Val Gly Ile Ser Ser Ile Ile Ser Asn Leu  
 275 280 285

Ile Thr Val Phe Pro Arg Asn Val Leu Thr Ala Ile Pro Ser Glu Leu  
 290 295 300

Phe Ser Ser Phe Val Asn Cys Leu Thr His Leu Thr Cys Ser Phe Gly  
 305 310 315 320

Arg Ser Ala Ala Leu Glu Glu Val Leu Asp Lys Asp Asp Met Val Tyr  
 325 330 335

Met Glu Ala Tyr Asp Lys Leu Leu Glu Ser Trp Leu Thr Leu Val Gln  
 340 345 350

Asp Asp Lys His Phe His Lys Gly Phe Phe Thr Gln His Ala Val Gln  
 355 360 365

Val Phe Asn Ser Tyr Ile Gln Cys His Leu Ala Ala Pro Asp Gly Thr  
 370 375 380

Arg Asn Leu Thr Ala Asn Gly Val Ala Ser Arg Glu Glu Glu Glu Ile  
 385 390 395 400

Ser Glu Leu Gln Glu Asp Asp Arg Asp Gln Phe Ser Asp Gln Leu Ala  
 405 410 415

Ser Val Gly Met Leu Gly Arg Ile Ala Ala Glu His Cys Ile Pro Leu  
 420 425 430

Leu Thr Ser Leu Leu Glu Glu Arg Val Thr Arg Leu His Gly Gln Leu  
 435 440 445

Gln Arg His Gln Gln Gln Leu Leu Ala Ser Pro Gly Ser Ser Thr Val  
 450 455 460

Asp Asn Lys Met Leu Asp Asp Leu Tyr Glu Asp Ile His Trp Leu Ile

185

465                                      470                                      475                                      480  
 Leu Val Thr Gly Tyr Leu Leu Ala Asp Asp Thr Gln Gly Glu Thr Pro  
    485                                      490                                      495  
 Leu Ile Pro Pro Glu Ile Met Glu Tyr Ser Ile Lys His Ser Ser Glu  
    500                                      505                                      510  
 Val Asp Ile Asn Thr Thr Leu Gln Ile Leu Gly Ser Pro Gly Glu Lys  
    515                                      520                                      525  
 Ala Ser Ser Ile Pro Gly Tyr Asn Arg Thr Asp Ser Val Ile Arg Leu  
    530                                      535                                      540  
 Leu Ser Ala Ile Leu Arg Val Ser Glu Val Glu Ser Arg Ala Ile Arg  
 545                                      550                                      555                                      560  
 Ala Asp Leu Thr His Leu Leu Ser Pro Gln Met Gly Lys Asp Ile Val  
    565                                      570                                      575  
 Trp Phe Leu Lys Arg Trp Ala Lys Thr Tyr Leu Leu Val Asp Glu Lys  
    580                                      585                                      590  
 Leu Tyr Asp Gln Ile Ser Leu Pro Phe Ser Thr Ala Phe Gly Ala Asp  
    595                                      600                                      605  
 Thr Glu Gly Ser Gln Trp Ile Ile Gly Tyr Leu Leu Gln Lys Val Ile  
    610                                      615                                      620  
 Ser Asn Leu Ser Val Trp Ser Ser Glu Gln Asp Leu Ala Asn Asp Thr  
 625                                      630                                      635                                      640  
 Val Gln Leu Leu Val Thr Leu Val Glu Arg Arg Glu Arg Ala Asn Leu  
    645                                      650                                      655  
 Val Ile Gln Cys Glu Asn Trp Trp Asn Leu Ala Lys Gln Phe Ala Ser  
    660                                      665                                      670  
 Arg Ser Pro Pro Leu Asn Phe Leu Ser Ser Pro Val Gln Arg Thr Leu  
    675                                      680                                      685  
 Met Lys Ala Leu Val Leu Gly Gly Phe Ala His Met Asp Thr Glu Thr  
    690                                      695                                      700

186

Lys Gln Gln Tyr Trp Thr Glu Val Leu Gln Pro Leu Gln Gln Arg Phe  
 705 710 715 720

Leu Arg Val Ile Asn Gln Glu Asn Phe Gln Gln Met Cys Gln Gln Glu  
 725 730 735

Glu Val Lys Gln Glu Ile Thr Ala Thr Leu Glu Ala Leu Cys Gly Ile  
 740 745 750

Ala Glu Ala Thr Gln Ile Asp Asn Val Ala Ile Leu Phe Asn Phe Leu  
 755 760 765

Met Asp Phe Leu Thr Asn Cys Ile Gly Leu Met Glu Val Tyr Lys Asn  
 770 775 780

Thr Pro Glu Thr Val Asn Leu Ile Ile Glu Val Phe Val Glu Val Ala  
 785 790 795 800

His Lys Gln Ile Cys Tyr Leu Gly Glu Ser Lys Ala Met Asn Leu Tyr  
 805 810 815

Glu Ala Cys Leu Thr Leu Leu Gln Val Tyr Ser Lys Asn Asn Leu Gly  
 820 825 830

Arg Gln Arg Ile Asp Val Thr Ala Glu Glu Glu Gln Tyr Gln Asp Leu  
 835 840 845

Leu Leu Ile Met Glu Leu Leu Thr Asn Leu Leu Ser Lys Glu Phe Ile  
 850 855 860

Asp Phe Ser Asp Thr Asp Glu Val Phe Arg Gly His Glu Pro Gly Gln  
 865 870 875 880

Ala Ala Asn Arg Ser Val Ser Ala Ala Asp Val Val Leu Tyr Gly Val  
 885 890 895

Asn Leu Ile Leu Pro Leu Met Ser Gln Asp Leu Leu Lys Phe Pro Thr  
 900 905 910

Leu Cys Asn Gln Tyr Tyr Lys Leu Ile Thr Phe Ile Cys Glu Ile Phe  
 915 920 925

Pro Glu Lys Ile Pro Gln Leu Pro Glu Asp Leu Phe Lys Ser Leu Met  
 930 935 940

187

Tyr Ser Leu Glu Leu Gly Met Thr Ser Met Ser Ser Glu Val Cys Gln  
 945 950 955 960

Leu Cys Leu Glu Ala Leu Thr Pro Leu Ala Glu Gln Cys Ala Lys Ala  
 965 970 975

Gln Glu Thr Asp Ser Pro Leu Phe Leu Ala Thr Arg His Phe Leu Lys  
 980 985 990

Leu Val Phe Asp Met Leu Val Leu Gln Lys His Asn Thr Glu Met Thr  
 995 1000 1005

Thr Ala Ala Gly Glu Ala Phe Tyr Thr Leu Val Cys Leu His Gln  
 1010 1015 1020

Ala Glu Tyr Ser Glu Leu Val Glu Thr Leu Leu Ser Ser Gln Gln  
 1025 1030 1035

Asp Pro Val Ile Tyr Gln Arg Leu Ala Asp Ala Phe Asn Lys Leu  
 1040 1045 1050

Thr Ala Ser Ser Thr Pro Pro Thr Leu Asp Arg Lys Gln Lys Met  
 1055 1060 1065

Ala Phe Leu Lys Ser Leu Glu Glu Phe Met Ala Asn Val Gly Gly  
 1070 1075 1080

Leu Leu Cys Val Lys  
 1085

<210> 256  
 <211> 78  
 <212> PRT  
 <213> Homo sapien

<400> 256

Met Val Leu Met Thr Ser Ser Gly Gln Pro Ser Cys Pro Gly Ile Met  
 1 5 10 15

Ala Cys Gln His Ser Leu Cys Pro Pro Asn Leu Arg Pro Arg Met Arg  
 20 25 30

Ser Cys Gln His Asn Ile His Pro Phe Glu Gln Met Glu Ser Gly Thr  
 35 40 45

188

Leu Thr Gln Pro Ser Val Leu Asn Asn Thr Ala Ile Ile Ala Thr Trp.  
 50 55 60

Leu Ser Arg Gln Cys Lys Pro Ser Glu Ser Ala Glu Leu Phe  
 65 70 75

<210> 257

<211> 595

<212> PRT

<213> Homo sapien

<400> 257

Val Gln Lys Thr Asn Gln Cys Leu Gln Gly Gln Ser Leu Lys Thr Ser  
 1 5 10 15

Leu Thr Leu Lys Val Asp Arg Gly Ser Glu Glu Thr Tyr Arg Pro Glu  
 20 25 30

Phe Pro Ser Thr Lys Gly Leu Val Arg Ser Leu Ala Glu Gln Phe Gln  
 35 40 45

Arg Met Gln Gly Val Ser Met Arg Asp Ser Thr Gly Phe Lys Asp Arg  
 50 55 60

Ser Leu Ser Gly Ser Leu Arg Lys Asn Ser Ser Pro Ser Asp Ser Lys  
 65 70 75 80

Pro Pro Phe Ser Gln Gly Gln Glu Lys Gly His Trp Pro Trp Ala Lys  
 85 90 95

Gln Gln Ser Ser Leu Glu Gly Gly Asp Arg Pro Leu Ser Trp Glu Glu  
 100 105 110

Ser Thr Glu His Ser Ser Leu Ala Leu Asn Ser Gly Leu Pro Asn Gly  
 115 120 125

Glu Thr Ser Ser Gly Gly Gln Pro Arg Leu Ala Glu Pro Asp Ile Tyr  
 130 135 140

Gln Glu Lys Leu Ser Gln Val Arg Asp Val Arg Ser Lys Asp Leu Gly  
 145 150 155 160

Ser Ser Thr Asp Leu Gly Thr Ser Leu Pro Leu Asp Ser Trp Val Asn  
 165 170 175

189

Ile Thr Arg Phe Cys Asp Ser Gln Leu Lys His Gly Ala Pro Arg Pro  
 180 185 190

Gly Met Lys Ser Ser Pro His Asp Ser His Thr Cys Val Thr Tyr Pro  
 195 200 205

Glu Arg Asn His Ile Leu Leu His Pro His Trp Asn Gln Asp Thr Glu  
 210 215 220

Gln Glu Thr Ser Glu Leu Glu Ser Leu Tyr Gln Ala Ser Leu Gln Ala  
 225 230 235 240

Ser Gln Ala Gly Cys Ser Gly Trp Gly Gln Gln Asp Thr Ala Trp His  
 245 250 255

Pro Leu Ser Gln Thr Gly Ser Ala Asp Gly Met Gly Arg Arg Leu His  
 260 265 270

Ser Ala His Asp Pro Gly Leu Ser Lys Thr Ser Thr Ala Glu Met Glu  
 275 280 285

His Gly Leu His Glu Ala Arg Thr Val Arg Thr Ser Gln Ala Thr Pro  
 290 295 300

Cys Arg Gly Leu Ser Arg Glu Cys Gly Glu Asp Glu Gln Tyr Ser Ala  
 305 310 315 320

Glu Asn Leu Arg Arg Ile Ser Arg Ser Leu Ser Gly Thr Val Val Ser  
 325 330 335

Glu Arg Glu Glu Ala Pro Val Ser Ser His Ser Phe Asp Ser Ser Asn  
 340 345 350

Val Arg Lys Pro Leu Glu Thr Gly His Arg Cys Ser Ser Ser Ser  
 355 360 365

Leu Pro Val Ile His Asp Pro Ser Val Phe Leu Leu Gly Pro Gln Leu  
 370 375 380

Tyr Leu Pro Gln Pro Gln Phe Leu Ser Pro Asp Val Leu Met Pro Thr  
 385 390 395 400

Met Ala Gly Glu Pro Asn Arg Leu Pro Gly Thr Ser Arg Ser Val Gln  
 405 410 415



190

Gln Phe Leu Ala Met Cys Asp Arg Gly Glu Thr Ser Gln Gly Ala Lys  
 420 425 430

Tyr Thr Gly Arg Thr Leu Asn Tyr Gln Ser Leu Pro His Arg Ser Arg  
 435 440 445

Thr Asp Asn Ser Trp Ala Pro Trp Ser Glu Thr Asn Gln His Ile Gly  
 450 455 460

Thr Arg Phe Leu Thr Thr Pro Gly Cys Asn Pro Gln Leu Thr Tyr Thr  
 465 470 475 480

Ala Thr Leu Pro Glu Arg Ser Lys Gly Leu Gln Val Pro His Thr Gln  
 485 490 495

Ser Trp Ser Asp Leu Phe His Ser Pro Ser His Pro Pro Ile Val His  
 500 505 510

Pro Val Tyr Pro Pro Ser Ser Ser Leu His Val Pro Leu Arg Ser Ala  
 515 520 525

Trp Asn Ser Asp Pro Val Pro Gly Ser Arg Thr Pro Gly Pro Arg Arg  
 530 535 540

Val Asp Met Pro Pro Asp Asp Asp Trp Arg Gln Ser Ser Tyr Ala Ser  
 545 550 555 560

His Ser Gly His Arg Arg Thr Val Gly Glu Gly Phe Leu Phe Val Leu  
 565 570 575

Ser Asp Ala Pro Arg Arg Glu Gln Ile Arg Ala Arg Val Leu Gln His  
 580 585 590

Ser Gln Trp  
 595

<210> 258

<211> 55

<212> PRT

<213> Homo sapien

<400> 258

Met Thr Val Met Ile Leu Leu Phe Lys Lys Asn Pro Asn Cys Tyr Phe  
 1 5 10 15

191

Asp Leu Tyr Asp Leu Thr Leu Asn His Gly Ser Ile Thr Met Met Phe  
 20 25 30

Lys Thr Leu Ile Asp Ser Thr Cys Phe Lys Asn Ser Gln Ile Pro Ser  
 35 40 45

Ala Phe Ile Ile Arg Asp Arg  
 50 55

<210> 259  
 <211> 43  
 <212> PRT  
 <213> Homo sapien

<400> 259

Met Met Leu Thr Met Glu Phe Lys Asn Lys Gln Gln His Phe Val Val  
 1 5 10 15

Ser Thr Gly Val Gly Val Glu Glu Leu Gln Arg His His Gly Asn Lys  
 20 25 30

Ser Leu Pro Arg Ile Ser Gly Pro Arg Asn Leu  
 35 40

<210> 260  
 <211> 75  
 <212> PRT  
 <213> Homo sapien

<400> 260

Met Ala Tyr Arg Met Lys Arg Gly Thr Arg Asn Pro Cys Gly Arg Gly  
 1 5 10 15

Leu Asp Leu Lys Gln Cys Pro Leu Trp Leu Leu Leu Pro Trp Leu Thr  
 20 25 30

Gly Phe Leu Asp His Val His Phe Thr Gly Pro Trp Asp Leu His Leu  
 35 40 45

Leu Ala Ser Pro Ala Gly Leu Ile Pro Ala Arg Ala Pro Ser Phe Leu  
 50 55 60

Leu Met Val Phe Arg Trp Pro Asp His Gly Lys  
 65 70 75

192

<210> 261  
 <211> 218  
 <212> PRT  
 <213> Homo sapien

<400> 261

Met Ile Asn His Leu Ser Pro His Gln Ala Ala Ala Pro Val Asp Gln  
 1 5 10 15

Thr Pro Arg Thr Leu Ala Thr Met Gly Gln Arg Ala Leu Pro Ser Ser  
 20 25 30

Leu Ala Leu Leu Ser Arg Pro Leu Ser Pro Pro Pro Ala Ala Cys Ser  
 35 40 45

Gly Asp Pro Gly Cys Gly Ser Gly Ala Gly Leu Pro Ser Ala Ser Ala  
 50 55 60

Ala Ala Gly Ile Ala Ser Ser Ala Val Glu Ala Val Cys Gly Asp Ala  
 65 70 75 80

Ala Pro Ala Cys Leu Leu Arg Thr Pro Leu Arg Gly Leu Leu Lys Pro  
 85 90 95

Thr Gly Pro Arg Ser Thr Met Glu Cys Pro Pro Ala Leu Ile Val Gln  
 100 105 110

Pro Pro Ala Gly Gly Met Ala Arg Arg Ala Ala Ser Gln Pro Trp Ala  
 115 120 125

Ala Ala Ser Ala Thr Pro Met Leu Ser Ser Lys Ala Ser Leu Cys Ile  
 130 135 140

Pro Thr Glu Arg Pro Pro Pro Gln Pro Leu Met Arg Thr Pro Ala Ala  
 145 150 155 160

Arg Ser His Trp Pro Ile Pro His Pro Ala Ser Thr Ala Cys Pro Ala  
 165 170 175

Pro Leu Pro Val Val Leu Val Ala Pro Arg Ser Thr Ile Leu Ser Met  
 180 185 190

Ser Arg Thr Trp Thr Cys Arg Arg Trp Ala Val Ala Pro Cys Arg Ala  
 195 200 205

193

Glu Lys Leu Met Cys Ser Ser Ser Arg Ser  
 210 215

<210> 262  
 <211> 104  
 <212> PRT  
 <213> Homo sapien

<400> 262

Met Pro Ser Phe Phe Cys Phe Ser Ile Ser Leu Ile Arg Asp Trp Lys  
 1 5 10 15

Val Ser Ile Arg Ser Asn Thr Asp Phe Ile Val Ile Gly Thr Asn Cys  
 20 25 30

Ser Pro Thr Thr Pro Tyr Ser Ala Ser Ser Ile Thr Leu Leu Cys Glu  
 35 40 45

Ile Leu Arg Asn Gly Leu Pro Leu Gln Gly Leu Asn Leu Pro Tyr Leu  
 50 55 60

Arg Phe Glu Ser Ser Val Leu Phe Cys Ile Cys Phe Lys Tyr Leu Gly  
 65 70 75 80

Ser Val Thr His Ala Asn Met Thr Cys Pro Val Gln Ala Thr Leu Gly  
 85 90 95

Ile His Ile Ser His Val Ser Ser  
 100

<210> 263  
 <211> 260  
 <212> PRT  
 <213> Homo sapien

<400> 263

Glu Lys Lys Lys Lys Met Lys Asn Glu Asn Ala Asp Lys Leu Leu Lys  
 1 5 10 15

Ser Glu Lys Gln Met Lys Lys Ser Glu Lys Lys Ser Lys Gln Glu Lys  
 20 25 30

Glu Lys Ser Lys Lys Lys Lys Gly Gly Lys Thr Glu Gln Asp Gly Tyr  
 35 40 45

194

Gln Lys Pro Thr Asn Lys His Phe Thr Gln Ser Pro Lys Lys Ser Val  
 50 55 60

Ala Asp Leu Leu Gly Ser Phe Glu Gly Lys Arg Arg Leu Leu Leu Ile  
 65 70 75 80

Thr Ala Pro Lys Ala Glu Asn Asn Met Tyr Val Gln Gln Arg Asp Glu  
 85 90 95

Tyr Leu Glu Ser Phe Cys Lys Met Ala Thr Arg Lys Ile Ser Val Ile  
 100 105 110

Thr Ile Phe Gly Pro Val Asn Asn Ser Thr Met Lys Ile Asp His Phe  
 115 120 125

Gln Leu Asp Asn Glu Lys Pro Met Arg Val Val Asp Asp Glu Asp Leu  
 130 135 140

Val Asp Gln Arg Leu Ile Ser Glu Leu Arg Lys Glu Tyr Gly Met Thr  
 145 150 155 160

Tyr Asn Asp Phe Phe Met Val Leu Thr Asp Val Asp Leu Arg Val Lys  
 165 170 175

Gln Tyr Tyr Glu Val Pro Ile Thr Met Lys Ser Val Phe Asp Leu Ile  
 180 185 190

Asp Thr Phe Gln Ser Arg Ile Lys Asp Met Glu Lys Gln Lys Lys Glu  
 195 200 205

Gly Ile Val Cys Lys Glu Asp Lys Lys Gln Ser Leu Glu Asn Phe Leu  
 210 215 220

Ser Arg Phe Arg Trp Arg Arg Arg Leu Leu Val Ile Ser Ala Pro Asn  
 225 230 235 240

Asp Glu Asp Trp Ala Tyr Ser Gln Gln Leu Ser Ala Leu Ser Gly Gln  
 245 250 255

Ala Cys Thr Leu  
 260

<210> 264

<211> 62

<212> PRT

195

&lt;213&gt; Homo sapien

&lt;400&gt; 264

Met Ser Gly Phe Ile Tyr Val Leu Glu Lys Asp His Leu Lys Lys Ile  
 1 5 10 15

Asn Thr Phe Ser Thr Thr Lys Lys Lys Lys Lys Lys Lys Lys Lys  
 20 25 30

Arg Arg Gly Gly Glu Pro Gly Ala Gln Ser Gly Pro Arg Gly Ala Asn  
 35 40 45

Trp Val Leu Pro Ala His Ile Pro Pro Lys Tyr Trp His Thr  
 50 55 60

&lt;210&gt; 265

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 265

Met Leu Gln Leu Asn Thr Arg Phe Tyr Phe Leu Ser Asn Cys Gly Phe  
 1 5 10 15

Val Phe Ile Tyr His Pro Leu Phe Ile Pro Phe Leu Thr His Thr Leu  
 20 25 30

Cys Arg Ala Ser Gly Ile Tyr Tyr Ser Thr Val Cys Leu Cys Lys Arg  
 35 40 45

Leu Ser Val Leu Ala Ser Thr Tyr Glu Arg Met His Ala Lys Phe Cys  
 50 55 60

Leu Ser Met Pro Gly Leu Ile Ser Leu Lys Gln Asn Asp Leu Arg Val  
 65 70 75 80

Pro Ser Met Leu Phe Ile Leu Pro Asn  
 85

&lt;210&gt; 266

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 266

Met Thr Ser Arg Trp Leu Asn Phe Ser Cys Leu Trp Cys Phe Gly Pro

1                      5                      10                      15

Asn Ser Thr Gly Gln His His Asp His Met Glu Thr Tyr Phe Trp Lys

20                      25                      30

```
<210> 267
<211> 111
<212> PRT
<213> Homo sapien
```

Asn Asp Leu Asp Arg Tyr Asn Pro Leu Ser Ser Gln Arg Leu Val Arg  
1 5 10 15

His Ser Glu Ser Phe Ala Ala Leu Cys Arg Tyr Gly Lys Arg Glu Phe  
35 40 45

Ile Gln Leu Ser Ala Gln Arg Ser His Thr Leu Glu Phe Gln Ser Leu  
65 70 75 80

Glu Asp Leu Ile Met Gly Glu Ala Thr Gln Arg Pro Arg Ser Gly Ala  
85 90 95

Arg Pro Val Leu Gln Glu Leu Ala Thr His Leu His Pro Ala Glu  
100 105 110

```
<210> 268
<211> 60
<212> PRT
<213> Homo sapien
```

Met Val Asn Thr Val Leu Leu Ser Leu Lys Ile Ser Leu Phe Cys Pro  
1 5 10 15

His Gln Leu Phe Tyr Cys Ser Val Leu Arg Lys Pro Asn Ser Cys Val  
20 25 30

His Tyr Phe Leu Asp Ile Leu Asn Leu Leu Phe Leu  
50 55 60

```
<210> 269
<211> 72
<212> PRT
<213> Homo sapien
```

<400> 269

Met Cys Leu Cys Ile Leu Val Ser Lys Leu Arg Thr Ser Asp Glu Leu  
1 5 10 15

Pro	Val	Val	Pro	Ser	Tyr	Cys	Arg	Arg	Leu	Glu	Val	Arg	Gly	Ile	Ser
			20					25					30		

Ala Ser Thr Arg Glu Ala Glu Val Ala Ser Glu Pro Thr Ile Met Thr  
35 40 45

Ala Cys Thr Pro Ser Leu Ala Thr Val Arg Glu Leu Leu Ser Gln Ile  
50 55 60

Lys Arg Lys Gln Ser Leu Leu Ser  
65 70

```
<210> 270
<211> 152
<212> PRT
<213> Homo sapien
```

<400> 270

Gly Ser Leu Gly Gly Glu Pro Gly Val Ser Cys Leu Lys Met His Ser  
1 5 10 15

Asp Ala Ala Ala Val Asn Phe Gln Leu Asn Ser His Leu Ser Thr Leu  
20 25 30

Ala Asn Ile His Lys Ile Tyr His Thr Leu Asn Lys Leu Asn Leu Thr  
35 40 45

Glu Asp Ile Gly Gln Asp Asp His Gln Thr Gly Ser Leu Arg Ser Cys  
50 55 60



198

Ser Ser Ser Asp Cys Phe Asn Lys Val Met Pro Pro Arg Lys Lys Arg  
65 70 75 80

Arg Pro Ala Ser Gly Asp Asp Leu Ser Ala Lys Lys Ser Arg His Asp  
85 90 95

Ser Met Tyr Arg Lys Tyr Asp Ser Thr Arg Ile Lys Thr Glu Glu Glu  
100 105 110

Ala Phe Ser Ser Lys Arg Cys Leu Glu Trp Phe Tyr Glu Tyr Ala Gly  
115 120 125

Thr Asp Asp Val Val Gly Pro Glu Gly Met Glu Lys Phe Cys Glu Asp  
130 135 140

Ile Gly Val Glu Pro Glu Asn Val  
145 150

<210> 271  
<211> 52  
<212> PRT  
<213> Homo sapien

<400> 271

Met Glu Pro His Ile Met Lys Phe Asn Ser His Val Lys Thr Phe Cys  
1 5 10 15

Ile Val Gly Cys Gln Lys Tyr Leu Pro Lys Leu Ser Phe Asp Leu Ser  
20 25 30

Glu Trp Gly Trp Leu Leu Pro Ile Leu Gln Phe Val Ser Gln Ala Trp  
35 40 45

Arg Asn Gln Ala  
50

<210> 272  
<211> 449  
<212> PRT  
<213> Homo sapien

<400> 272

Met Val Met Glu Lys Pro Ser Pro Leu Leu Val Gly Arg Glu Phe Val  
1 5 10 15

199

Arg Gln Tyr Tyr Thr Leu Leu Asn Lys Ala Pro Glu Tyr Leu His Arg  
 20 25 30

Phe Tyr Gly Arg Asn Ser Ser Tyr Val His Gly Gly Val Asp Ala Ser  
 35 40 45

Gly Lys Pro Gln Glu Ala Val Tyr Gly Gln Asn Asp Ile His His Lys  
 50 55 60

Val Leu Ser Leu Asn Phe Ser Glu Cys His Thr Lys Ile Arg His Val  
 65 70 75 80

Asp Ala His Ala Thr Leu Ser Asp Gly Val Val Val Gln Val Met Gly  
 85 90 95

Leu Leu Ser Asn Ser Gly Gln Pro Glu Arg Lys Phe Met Gln Thr Phe  
 100 105 110

Val Leu Ala Pro Glu Gly Ser Val Pro Asn Lys Phe Tyr Val His Asn  
 115 120 125

Asp Met Phe Arg Tyr Glu Asp Glu Val Phe Gly Asp Ser Glu Pro Glu  
 130 135 140

Leu Asp Glu Glu Ser Glu Asp Glu Val Glu Glu Glu Gln Glu Glu Arg  
 145 150 155 160

Gln Pro Ser Pro Glu Pro Val Gln Glu Asn Ala Asn Ser Gly Tyr Tyr  
 165 170 175

Glu Ala His Pro Val Thr Asn Gly Ile Glu Glu Pro Leu Glu Glu Ser  
 180 185 190

Ser His Glu Pro Glu Pro Glu Pro Glu Ser Glu Thr Lys Thr Glu Glu  
 195 200 205

Leu Lys Pro Gln Val Glu Glu Lys Asn Leu Glu Glu Leu Glu Glu Lys  
 210 215 220

Ser Thr Thr Pro Pro Pro Ala Glu Pro Val Ser Leu Pro Gln Glu Pro  
 225 230 235 240

Pro Lys Pro Arg Val Glu Ala Lys Pro Glu Val Gln Ser Gln Pro Pro  
 245 250 255

200

Arg Val Arg Glu Gln Arg Pro Arg Glu Arg Pro Gly Phe Pro Pro Arg.  
                   260                                  265                                  270

Gly Pro Arg Pro Gly Arg Gly Asp Met Glu Gln Asn Asp Ser Asp Asn  
                   275                                  280                                  285

Arg Arg Ile Ile Arg Tyr Pro Asp Ser His Gln Leu Phe Val Gly Asn  
                   290                                  295                                  300

Leu Pro His Asp Ile Asp Glu Asn Glu Leu Lys Glu Phe Phe Met Ser  
                   305                                  310                                  315                                  320

Phe Gly Asn Val Val Glu Leu Arg Ile Asn Thr Lys Gly Val Gly Gly  
                                   325                                  330                                  335

Lys Leu Pro Asn Phe Gly Phe Val Val Phe Asp Asp Ser Glu Pro Val  
                                   340                                  345                                  350

Gln Arg Ile Leu Ile Ala Lys Pro Ile Met Phe Arg Gly Glu Val Arg  
                   355                                  360                                  365

Leu Asn Val Glu Glu Lys Lys Thr Arg Ala Ala Arg Glu Arg Glu Thr  
                   370                                  375                                  380

Arg Gly Gly Gly Asp Asp Arg Arg Asp Ile Arg Arg Asn Asp Arg Gly  
                   385                                  390                                  395                                  400

Pro Gly Gly Pro Arg Gly Ile Val Gly Gly Gly Met Met Arg Asp Arg  
                                   405                                  410                                  415

Asp Gly Arg Gly Pro Pro Pro Arg Gly Gly Met Ala Gln Lys Leu Gly  
                                   420                                  425                                  430

Ser Gly Arg Gly Thr Gly Gln Met Glu Gly Arg Phe Thr Gly Gln Arg  
                   435                                  440                                  445

Arg

&lt;210&gt; 273

&lt;211&gt; 63

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 273

201

Met Cys Cys Asp Val Ser Glu Arg Ala Glu Phe Arg Leu Val Ser Ala  
 1 5 10 15

Arg Cys Ser Phe Ser His Pro Arg Thr Val Ala Arg Leu Leu Leu Arg  
 20 25 30

His Pro Gly Gln Leu Pro Leu Pro Phe Gln Trp Gly Leu Thr Trp Leu  
 35 40 45

Pro Ser Leu Ala Ala Asn Arg Arg Ala Pro Gln His Ser Arg Ser  
 50 55 60

<210> 274

<211> 60

<212> PRT

<213> Homo sapien

<400> 274

Met Asp Pro Gly Arg Tyr Cys Leu Val Leu Gln Glu Leu Met Gln Phe  
 1 5 10 15

His Ser Glu Ala Cys Lys Ile Leu Asn Phe Arg Asp Asn Arg Pro Asp  
 20 25 30

Thr Phe Leu Ile Ser Phe Tyr Ser Leu Met Ser Asn Asn Thr Ile Phe  
 35 40 45

Lys Asn Met Val Leu Ile Cys Leu Ala Ser Asn Leu  
 50 55 60

<210> 275

<211> 111

<212> PRT

<213> Homo sapien

<400> 275

Lys Leu Ile Val Tyr Pro Pro Pro Pro Ala Lys Gly Gly Ile Ser Val  
 1 5 10 15

Thr Asn Glu Asp Leu His Cys Leu Asn Glu Gly Glu Phe Leu Asn Asp  
 20 25 30

Val Ile Ile Asp Phe Tyr Leu Lys Tyr Leu Val Leu Glu Lys Leu Lys  
 35 40 45

202

Lys Glu Asp Ala Asp Arg Ile His Ile Phe Ser Ser Phe Phe Tyr Lys  
 50 55 60

Arg Leu Asn Gln Arg Glu Arg Arg Asn His Glu Thr Thr Asn Leu Ser  
 65 70 75 80

Ile Gln Gln Lys Arg His Gly Arg Val Lys Thr Trp Thr Arg His Val  
 85 90 95

Asp Ile Phe Glu Lys Asp Phe Ile Phe Val Pro Leu Asn Glu Ala  
 100 105 110

<210> 276

<211> 97

<212> PRT

<213> Homo sapien

<400> 276

Met Ser Gln Asp Thr Ser Arg Ser Gln Glu Arg Ala Ala Gly Pro Gln  
 1 5 10 15

Arg Thr Arg Arg Arg Pro Arg Thr Trp Ser Gly Gly Val Glu Pro Thr  
 20 25 30

Ala Ala Ala Pro Trp Ala Ala Ala Met Ala His Thr Gly Arg His Gly  
 35 40 45

Ser Gly Ala Ala Ala Thr Ala Ser Ser Thr Arg Gly Asp Gly Ala Ala  
 50 55 60

Arg Arg Gly Ala Ala Arg Gly Thr Asp Ala Ala Glu Arg Arg Arg Ala  
 65 70 75 80

Ala Ser Arg Gly Ala Ala Glu Pro Lys Ala Thr Ala Ser Gly Gly Gly  
 85 90 95

Gly

<210> 277

<211> 76

<212> PRT

<213> Homo sapien

<400> 277

Met Gly Ser Cys Pro Leu Trp Val Arg Ser Ser Thr Cys Arg Val Glu

1                      5                      10                      15

Leu Phe Phe Phe Lys Lys Phe Ile Leu Arg Trp Ser Leu Thr Leu Ser  
1 5 10 15

Leu Arg Leu Glu Cys Ser Asp Ser Ile Ser Ala His Cys Asn Leu Arg  
20 25 30

Leu Pro Gly Leu Ser Asn Phe Cys Ala Ser Ala Ser Gln Val Ser Glu  
35 40 45

Ile Thr Gly Val Cys His His Thr Gln Leu Phe Phe Ile Phe Tyr Phe  
50 55 60

Ala Ala Lys Met Gly Phe Arg His Val Gly Arg Thr Gly Leu Glu Leu  
65 70 75 80

Leu Ala Ser Ser Gly Pro Pro Thr Ser Ala Ser Gln Ser Ala Gly Ile  
85 90 95

Thr Gly Val Ser His  
100

```
<210> 281
<211> 43
<212> PRT
<213> Homo sapien
```

<400> 281

Met Trp Gly His Gly Leu Asp Asp Gly Leu His Arg Ser Phe His Leu  
1 5 10 15

Cys Glu Ser Lys Ser Gly Gln Ser Ala Arg Thr Gln Ser Leu Thr Leu  
20 25 30

Gly Gln Leu Leu Arg Thr Asn Pro Gln His Leu  
35 40

```
<210> 282
<211> 46
<212> PRT
<213> Homo sapien
```

<400> 282

Met Ala Gly Asn Ile His Pro Gly Thr Phe Gly Pro Gly Ser Pro His  
1 5 10 15

Leu Phe Phe Leu Cys Gly Val Val Ala Phe Phe Leu Phe Ile Val Ala  
20 25 30

205

Arg Glu Ala Lys Ile Tyr Ser Phe Ser Met Asn Pro Asn Met  
           35                          40                          45

<210> 283  
 <211> 70  
 <212> PRT  
 <213> Homo sapien

<400> 283

Met Pro Gly Ser His Leu Cys Met Phe Asn Thr Val Thr His Asp Val  
 1                          5                          10                          15

Ile Thr Glu Trp Arg Arg Trp Lys Gly Pro Cys Arg Ser Phe Ser Trp  
                           20                          25                          30

His Pro Asn Phe Thr Glu Gly Glu Leu Arg Pro Glu Leu Arg Asp Val  
           35                          40                          45

Leu Arg Ile Pro Glu Ser His Ser Ser Val Arg Ser Val Ile His Lys  
       50                          55                          60

Glu Val Ile Ile Lys Val  
 65                          70

<210> 284  
 <211> 49  
 <212> PRT  
 <213> Homo sapien

<400> 284

Met Ser Ser Ser Leu Phe Ala Phe Leu Leu Thr Tyr Phe Val Val Phe  
 1                          5                          10                          15

Lys Asp Cys Ala Gly Asp Ile Leu Glu Gly Ile Asn Gly Leu His Ser  
           20                          25                          30

Lys Arg Cys Gly Leu Ser Lys Leu Phe Ser Val Phe Ile Thr Glu Thr  
       35                          40                          45

Asp

<210> 285  
 <211> 1544  
 <212> PRT  
 <213> Homo sapien



206

&lt;400&gt; 285

Met Tyr Ala Ala Val Glu His Gly Pro Val Leu Cys Ser Asp Ser Asn  
 1 5 10 15

Ile Leu Cys Leu Ser Trp Lys Gly Arg Val Pro Lys Ser Glu Lys Glu  
 20 25 30

Lys Pro Val Cys Arg Arg Arg Tyr Tyr Glu Glu Gly Trp Leu Ala Thr  
 35 40 45

Gly Asn Gly Arg Gly Val Val Gly Val Thr Phe Thr Ser Ser His Cys  
 50 55 60

Arg Arg Asp Arg Ser Thr Pro Gln Arg Ile Asn Phe Asn Leu Arg Gly  
 65 70 75 80

His Asn Ser Glu Val Val Leu Val Arg Trp Asn Glu Pro Tyr Gln Lys  
 85 90 95

Leu Ala Thr Cys Asp Ala Asp Gly Gly Ile Phe Val Trp Ile Gln Tyr  
 100 105 110

Glu Gly Arg Trp Ser Val Glu Leu Val Asn Asp Arg Gly Ala Gln Val  
 115 120 125

Ser Asp Phe Thr Trp Ser His Asp Gly Thr Gln Ala Leu Ile Ser Tyr  
 130 135 140

Arg Asp Gly Phe Val Leu Val Gly Ser Val Ser Gly Gln Arg His Trp  
 145 150 155 160

Ser Ser Glu Ile Asn Leu Glu Ser Gln Ile Thr Cys Gly Ile Trp Thr  
 165 170 175

Pro Asp Asp Gln Gln Val Leu Phe Gly Thr Ala Asp Gly Gln Val Ile  
 180 185 190

Val Met Asp Cys His Gly Arg Met Leu Ala His Val Leu Leu His Glu  
 195 200 205

Ser Asp Gly Val Leu Gly Met Ser Trp Asn Tyr Pro Ile Phe Leu Val  
 210 215 220

Glu Asp Ser Ser Glu Ser Asp Thr Asp Ser Asp Asp Tyr Ala Pro Pro

207

225		230		235		240
Gln Asp Gly Pro	Ala Ala Tyr Pro	Ile Pro Val Gln	Asn Ile Lys Pro			
	245	250	255			
Leu Leu Thr Val	Ser Phe Thr Ser	Gly Asp Ile Ser	Leu Met Asn Asn			
	260	265	270			
Tyr Asp Asp Leu	Ser Pro Thr Val	Ile Arg Ser Gly	Leu Lys Glu Val			
	275	280	285			
Val Ala Gln Trp	Cys Thr Gln Gly	Asp Leu Leu Ala	Val Ala Gly Met			
	290	295	300			
Glu Arg Gln Thr	Gln Leu Gly Glu	Leu Pro Asn Gly	Pro Leu Leu Lys			
	305	310	315	320		
Ser Ala Met Val	Lys Phe Tyr Asn	Val Arg Gly Glu	His Ile Phe Thr			
	325	330	335			
Leu Asp Thr Leu	Val Gln Arg Pro	Ile Ile Ser Ile	Cys Trp Gly His			
	340	345	350			
Arg Asp Ser Arg	Leu Leu Met Ala	Ser Gly Pro Ala	Leu Tyr Val Val			
	355	360	365			
Arg Val Glu His	Arg Val Ser Ser	Leu Gln Leu Leu	Cys Gln Gln Ala			
	370	375	380			
Ile Ala Ser Thr	Leu Arg Glu Asp	Lys Asp Val Ser	Lys Leu Thr Leu			
	385	390	395	400		
Pro Pro Arg Leu	Cys Ser Tyr Leu	Ser Thr Ala Phe	Ile Pro Thr Ile			
	405	410	415			
Lys Pro Pro Ile	Pro Asp Pro Asn	Asn Met Arg Asp	Phe Val Ser Tyr			
	420	425	430			
Pro Ser Ala Gly	Asn Glu Arg Leu	His Cys Thr Met	Lys Arg Thr Glu			
	435	440	445			
Asp Asp Pro Glu	Val Gly Gly Pro	Cys Tyr Thr Leu	Tyr Leu Glu Tyr			
	450	455	460			

208

Leu Gly Gly Leu Val Pro Ile Leu Lys Gly Arg Arg Ile Ser Lys Leu  
 465 470 475 480

Arg Pro Glu Phe Val Ile Met Asp Pro Arg Thr Asp Ser Lys Pro Asp  
 485 490 495

Glu Ile Tyr Gly Asn Ser Leu Ile Ser Thr Val Ile Asp Ser Cys Asn  
 500 505 510

Cys Ser Asp Ser Ser Asp Ile Glu Leu Ser Asp Asp Trp Ala Ala Lys  
 515 520 525

Lys Ser Pro Lys Ile Ser Arg Ala Ser Lys Ser Pro Lys Leu Pro Arg  
 530 535 540

Ile Ser Ile Glu Ala Arg Lys Ser Pro Lys Leu Pro Arg Ala Ala Gln  
 545 550 555 560

Glu Leu Ser Arg Ser Pro Arg Leu Pro Leu Arg Lys Pro Ser Val Gly  
 565 570 575

Ser Pro Ser Leu Thr Arg Arg Glu Phe Pro Phe Glu Asp Ile Thr Gln  
 580 585 590

His Asn Tyr Leu Ala Gln Val Thr Ser Asn Ile Trp Gly Thr Lys Phe  
 595 600 605

Lys Ile Val Gly Leu Ala Ala Phe Leu Pro Thr Asn Leu Gly Ala Val  
 610 615 620

Ile Tyr Lys Thr Ser Leu Leu His Leu Gln Pro Arg Gln Met Thr Ile  
 625 630 635 640

Tyr Leu Pro Glu Val Arg Lys Ile Ser Met Asp Tyr Ile Asn Leu Pro  
 645 650 655

Val Phe Asn Pro Asn Val Phe Ser Glu Asp Glu Asp Asp Leu Pro Val  
 660 665 670

Thr Gly Ala Ser Gly Val Pro Glu Asn Ser Pro Pro Cys Thr Val Asn  
 675 680 685

Ile Pro Ile Ala Pro Ile His Ser Ser Ala Gln Ala Met Ser Pro Thr  
 690 695 700

209

Gln Ser Ile Gly Leu Val Gln Ser Leu Leu Ala Asn Gln Asn Val Gln  
 705 710 715 720

Leu Asp Val Leu Thr Asn Gln Thr Thr Ala Val Gly Thr Ala Glu His  
 725 730 735

Ala Gly Asp Arg Cys His Pro Val Thr Gln Val Ser Asn Arg Tyr Ser  
 740 745 750

Asn Pro Gly Gln Val Ile Phe Gly Ser Val Glu Met Gly Arg Ile Ile  
 755 760 765

Gln Asn Pro Pro Pro Leu Ser Leu Pro Pro Pro Pro Gln Gly Pro Met  
 770 775 780

Gln Leu Ser Thr Val Gly His Gly Asp Arg Asp His Glu His Leu Gln  
 785 790 795 800

Lys Ser Ala Lys Ala Leu Arg Pro Thr Pro Gln Leu Ala Ala Glu Gly  
 805 810 815

Asp Ala Val Val Phe Ser Ala Pro Gln Glu Val Gln Val Thr Lys Ile  
 820 825 830

Asn Pro Pro Pro Pro Tyr Pro Gly Thr Ile Pro Ala Ala Pro Thr Thr  
 835 840 845

Ala Ala Pro Pro Pro Pro Leu Pro Pro Pro Gln Pro Pro Val Asp Val  
 850 855 860

Cys Leu Lys Lys Gly Asp Phe Ser Leu Tyr Pro Thr Ser Val His Tyr  
 865 870 875 880

Gln Thr Pro Leu Gly Tyr Glu Arg Ile Thr Thr Phe Asp Ser Ser Gly  
 885 890 895

Asn Val Glu Glu Val Cys Arg Pro Arg Thr Arg Met Leu Cys Ser Gln  
 900 905 910

Asn Thr Tyr Thr Leu Pro Gly Pro Gly Ser Ser Ala Thr Leu Arg Leu  
 915 920 925

Thr Ala Thr Glu Lys Lys Val Pro Gln Pro Cys Ser Ser Ala Thr Leu  
 930 935 940

210

Asn Arg Leu Thr Val Pro Arg Tyr Ser Ile Pro Thr Gly Asp Pro Pro  
 945 950 955 960

Pro Tyr Pro Glu Ile Ala Ser Gln Leu Ala Gln Gly Arg Gly Ala Ala  
 965 970 975

Gln Arg Ser Asp Asn Ser Leu Ile His Ala Thr Leu Arg Arg Asn Asn  
 980 985 990

Arg Glu Ala Thr Leu Lys Met Ala Gln Leu Ala Asp Ser Pro Arg Ala  
 995 1000 1005

Pro Leu Gln Pro Leu Ala Lys Ser Lys Gly Gly Pro Gly Gly Val  
 1010 1015 1020

Val Thr Gln Leu Pro Ala Arg Pro Pro Pro Ala Leu Tyr Thr Cys  
 1025 1030 1035

Ser Gln Cys Ser Gly Thr Gly Pro Ser Ser Gln Pro Gly Ala Ser  
 1040 1045 1050

Leu Ala His Thr Ala Ser Ala Ser Pro Leu Ala Ser Gln Ser Ser  
 1055 1060 1065

Tyr Ser Leu Leu Ser Pro Pro Asp Ser Ala Arg Asp Arg Thr Asp  
 1070 1075 1080

Tyr Val Asn Ser Ala Phe Thr Glu Asp Glu Ala Leu Ser Gln His  
 1085 1090 1095

Cys Gln Leu Glu Lys Pro Leu Arg His Pro Pro Leu Pro Glu Ala  
 1100 1105 1110

Ala Val Thr Leu Lys Arg Pro Pro Pro Tyr Gln Trp Asp Pro Met  
 1115 1120 1125

Leu Gly Glu Asp Val Trp Val Pro Gln Glu Arg Thr Ala Gln Thr  
 1130 1135 1140

Ser Gly Pro Asn Pro Leu Lys Leu Ser Ser Leu Met Leu Ser Gln  
 1145 1150 1155

Gly Gln His Leu Asp Val Ser Arg Leu Pro Phe Ile Ser Pro Lys

211

1160	1165	1170
Ser Pro Ala Ser Pro Thr	Ala Thr Phe Gln Thr	Gly Tyr Gly Met
1175	1180	1185
Gly Val Pro Tyr Pro Gly	Ser Tyr Asn Asn Pro	Pro Leu Pro Gly
1190	1195	1200
Val Gln Ala Pro Cys Ser	Pro Lys Asp Ala Leu	Ser Pro Thr Gln
1205	1210	1215
Phe Ala Gln Gln Glu Pro	Ala Val Val Leu Gln	Pro Leu Tyr Pro
1220	1225	1230
Pro Ser Leu Ser Tyr Cys	Thr Leu Pro Pro Met	Tyr Pro Gly Ser
1235	1240	1245
Ser Thr Cys Ser Ser Leu	Gln Leu Pro Pro Val	Ala Leu His Pro
1250	1255	1260
Trp Ser Ser Tyr Ser Ala	Cys Pro Pro Met Gln	Asn Pro Gln Gly
1265	1270	1275
Thr Leu Pro Pro Lys Pro	His Leu Val Val Glu	Lys Pro Leu Val
1280	1285	1290
Ser Pro Pro Pro Ala Asp	Leu Gln Ser His Leu	Gly Thr Glu Val
1295	1300	1305
Met Val Glu Thr Ala Asp	Asn Phe Gln Glu Val	Leu Ser Leu Thr
1310	1315	1320
Glu Ser Pro Val Pro Gln	Arg Thr Glu Lys Phe	Gly Lys Lys Asn
1325	1330	1335
Arg Lys Arg Leu Asp Ser	Arg Ala Glu Glu Gly	Ser Val Gln Ala
1340	1345	1350
Ile Thr Glu Gly Lys Val	Lys Lys Glu Ala Arg	Thr Leu Ser Asp
1355	1360	1365
Phe Asn Ser Leu Ile Ser	Ser Pro His Leu Gly	Arg Glu Lys Lys
1370	1375	1380

212

Lys Val Lys Ser Gln Lys Asp Gln Leu Lys Ser Lys Lys Leu Asn  
 1385 1390 1395

Lys Thr Asn Glu Phe Gln Asp Ser Ser Glu Ser Glu Pro Glu Leu  
 1400 1405 1410

Phe Ile Ser Gly Asp Glu Leu Met Asn Gln Ser Gln Gly Ser Arg  
 1415 1420 1425

Lys Gly Trp Lys Ser Lys Arg Ser Pro Arg Ala Ala Gly Glu Leu  
 1430 1435 1440

Glu Glu Ala Lys Cys Arg Arg Ala Ser Glu Lys Glu Asp Gly Arg  
 1445 1450 1455

Leu Gly Ser Gln Gly Phe Val Tyr Val Met Ala Asn Lys Gln Pro  
 1460 1465 1470

Leu Trp Asn Glu Ala Thr Gln Val Tyr Gln Leu Asp Phe Gly Gly  
 1475 1480 1485

Arg Val Thr Gln Glu Ser Ala Lys Asn Phe Gln Ile Glu Leu Glu  
 1490 1495 1500

Gly Arg Gln Val Met Gln Phe Gly Arg Ile Asp Gly Ser Ala Tyr  
 1505 1510 1515

Ile Leu Asp Phe Gln Tyr Pro Phe Ser Ala Val Gln Ala Phe Ala  
 1520 1525 1530

Val Ala Leu Ala Asn Val Thr Gln Arg Leu Lys  
 1535 1540

<210> 286  
 <211> 56  
 <212> PRT  
 <213> Homo sapien

<400> 286

Met Gly Asn Gly Ala Thr Gln Lys Gln Leu Pro Asn Leu Arg Asn Asn  
 1 5 10 15

Ser Phe Val Val Tyr Phe Leu Val Leu Val Gly Ala Leu Tyr Arg Asp  
 20 25 30

213

Thr Ala Ile Phe Leu Ala Gln Met Ser Leu Leu Glu Ser Thr Val Val  
35 40 45

Ile Leu Leu Val Arg Leu Arg Thr  
50 55

<210> 287  
<211> 77  
<212> PRT  
<213> Homo sapien

<400> 287

Met Leu Leu Ala Val Arg Thr Thr Val Ile Cys Leu Gln Ser Cys Cys  
1 5 10 15

Cys Arg Ile Gln Arg Thr Ala Thr Ile Thr Leu Asn Cys Phe Ala Leu  
20 25 30

Ser Ser Ile Phe Asp Tyr Tyr Ile Ser His Asn Ile Thr Ile Ser His  
35 40 45

Ser Ser Asn Tyr Ser Ala Gln Ile His Glu His Val Pro Ala Arg Ala  
50 55 60

Ala Ala Arg Ser Ile Thr Trp Arg Arg Ser Ala Cys Ile  
65 70 75

<210> 288  
<211> 45  
<212> PRT  
<213> Homo sapien

<400> 288

Met Tyr Leu Gly Gln Leu Gly Asn His Arg Leu Lys Lys Leu Thr Leu  
1 5 10 15

Val Ile Thr Arg Val Val Ser Asp Tyr Lys Gln His Ile Ile Asn Pro  
20 25 30

Thr Ala Leu Ile Leu Ala Gln Arg Gln Asn Trp Thr Phe  
35 40 45

<210> 289  
<211> 44  
<212> PRT  
<213> Homo sapien



214

&lt;400&gt; 289

Met Lys Ala Leu Leu Cys Phe Leu Phe Tyr Ser Asp His Gln Thr Asp  
 1 5 10 15

Leu Ala Thr Leu Ile Val Lys Asn Glu Pro His Ser Ser Pro Gly Leu  
 20 25 30

Gly Leu Trp Arg Glu Met Asn Phe Leu Leu Glu Met  
 35 40

&lt;210&gt; 290

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 290

Met Phe Arg Thr Ser Ser Tyr Arg Leu Leu Ile Tyr Lys Val Pro Val  
 1 5 10 15

Ala Val Thr Pro Thr Arg Lys Thr Trp Asn Cys Lys Gln Ala Gly Val  
 20 25 30

Thr Ser Val Thr Ser Asp Thr Val Gln Pro Glu Val Arg Phe Leu Phe  
 35 40 45

Trp Gly  
 50

&lt;210&gt; 291

&lt;211&gt; 44

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 291

Met Ser Gln Trp Pro Val Ala Ser Lys Leu Val Gly Lys Glu Lys Thr  
 1 5 10 15

Phe Leu Phe Lys Gln Arg Lys Gly Phe Gly Glu Lys Thr Gly Ser Gly  
 20 25 30

Ser Gly Glu Val Phe Val Met Leu Gly Asp Arg Leu  
 35 40

&lt;210&gt; 292

&lt;211&gt; 61

&lt;212&gt; PRT

215

&lt;213&gt; Homo sapien

&lt;400&gt; 292

Met Val His Tyr Arg Lys Glu Lys Lys Thr Ser Val Ser Glu Trp Gln  
 1 5 10 15

Ile Leu Ile Ile Cys Ser Ser His Leu Phe Ser Ser Glu Asn His Ile  
 20 25 30

Thr Pro Glu Tyr Leu Pro Gly Arg Ile His His Thr Ala Pro Leu Glu  
 35 40 45

Pro Ala Ser Lys Asp Pro Phe Ala His Ile Val Ile Leu  
 50 55 60

&lt;210&gt; 293

&lt;211&gt; 112

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 293

Met Gly Ile Ile Leu Asn Trp Leu Asn Gln Trp Ala Gln Ile Thr Tyr  
 1 5 10 15

Leu Pro Ser Leu Leu Cys Asp Ser Pro Ala Val Thr His Thr Ile His  
 20 25 30

Ile Leu Cys Thr Ser Asn Glu Gln Thr Trp Phe Pro Cys Phe Leu Asp  
 35 40 45

Ile Ser Met Thr Val Ser His Thr Asn Tyr Trp Val Arg Phe Phe Ser  
 50 55 60

Cys Tyr Arg Pro Thr Ser Cys Cys Leu Cys Val Val Leu Gln Lys Leu  
 65 70 75 80

Ser Ile Pro Thr Pro Leu Leu Cys His Leu Gln Glu Ser Gly Ile Val  
 85 90 95

Arg Ser Gln Leu Arg Lys Val Leu Val Pro Leu Thr Gly His Ile Leu  
 100 105 110

&lt;210&gt; 294

&lt;211&gt; 55

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

216

&lt;400&gt; 294

Met Arg Phe Ile Phe Ile Cys Lys Pro Arg Gly Leu Ile Ile Leu Ile  
 1 5 10 15

Leu Tyr Glu Tyr Thr Cys Val Leu Gly Lys Ala Phe Ile Gln Gln Met  
 20 25 30

Pro Thr Thr Tyr Ser Val Pro Arg Pro Arg His Pro Val Thr Ser Trp  
 35 40 45

Arg Pro Ala Arg Ala Cys Ile  
 50 55

&lt;210&gt; 295

&lt;211&gt; 77

&lt;212&gt; PRT

&lt;213&gt; Homo sapien

&lt;400&gt; 295

Met Leu Glu Leu Pro Thr Phe Ser Phe Phe Phe Phe Gly Asp Arg Ala  
 1 5 10 15

Ser Leu Cys His Pro Gly Trp Ser Ala Gly Ala Ser Ser Leu Thr His  
 20 25 30

Leu Gln Pro Ser Phe Leu Pro Trp Gly Ala Gly Arg Phe Ser Cys Ala  
 35 40 45

Leu Gln Pro Pro Ser Leu Ala Gly Ile Tyr Arg Ala Leu Leu Gln Val  
 50 55 60

Ser His Ile Phe Ser Glu Lys Phe Leu Asn Trp Pro Pro  
 65 70 75



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US02/04197

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/02, 21/04

US CL : 536/23.1, 24.3

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Search the USPTOs database of nucleic acid and protein sequences.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	VINCENT et al. Oligonucleotides as short as 7-mers can be used for PCR amplification. DNA and Cell Biology. 1994, Vol. 13, No. 1, pages 75-82, note the octomer in the legend of Figure 5 and the heptamer in the legend of Figure 5 and compare to positions 60-67 of SEQ ID NO: 1.	1-5 and 7-8
X	SOMMER et al. Minimal homology requirements for PCR primers. Nucleic Acids Research. 1989, Vol. 17, No. 16, page 6749, note the first primer listed in Table I and compare the 3 nucleotides on its 3' end to the complementary nucleotides at positions 252-254 of SEQ ID NO: 1.	1-5 and 7-8

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:		"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

31 MAY 2002

Date of mailing of the international search report

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-8230

Authorized officer

ETHAN WHISENANT, PH.D.

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US02/04197**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-5 and 7-8, SEQ ID NO: 1

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

1. This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

I. Claim(s) 1-5, 7-8, drawn to polynucleotides, vectors comprising the polynucleotide, methods of introducing the polynucleotide to host cells, and host cells comprising the polynucleotide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

II. Claim(s) 10-11, drawn to an isolated polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

III. Claim(s) 12, drawn to antibodies. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

IV. Claim(s) 9, drawn to a method of synthesizing a polypeptide, classified in class 435, subclass 69.1. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

V. Claim(s) 6 and 14, drawn to a diagnostic method of using the polynucleotide of Claim 1. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VI. Claim(s) 13-14, drawn to a diagnostic method of using a polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VII. Claim(s) 15, drawn to a kit for determining the presence of the nucleic acid molecule of claim 1 or the polypeptide of Claim 11. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

VIII. Claim(s) 16, drawn to a therapeutic method of using a polypeptide. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

IX. Claim(s) 17, drawn to a vaccine comprising the polypeptide of Claim 11 or a polynucleotide encoding said polypeptide of Claim 11. This group comprises at least 171 different embodiments. See the requirement to elect a single sequence below.

2. Sequence Election Requirement Applicable to All Groups

In addition, each Group detailed above reads on distinct sequences. Each sequence is distinct because they are unrelated sequences, and a further restriction is applied to each Group. For an selected Group drawn to amino acid sequences, the Applicants must elect a single amino acid sequence. For an elected Group drawn to nucleotide sequences, the Applicants must elect one nucleic acid sequence.

Examination will be restricted to only the elected sequence.

3. The inventions listed as Groups I-IX do not relate to a single

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/04197

general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature(s).

The claims as drawn are related to each other because of the product i.e. the isolated nucleic acid molecule of Claim 1. However, since the isolated nucleic acid molecule of Claim 1, as claimed, is known, the claims are no longer linked by a special technical feature, because, by definition, the special technical feature must distinguish over the prior art. Without the special technical feature the claims lack unity.